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CHAPTER 1 
 
General introduction 
 
  
7 
 
Malaria 
Malaria is one of the world's chief causes of morbidity and mortality by infectious diseases. The disease is a 
major problem with a significant impact on public health and socio-economic welfare worldwide. Nearly half of 
the world’s population is at risk of malaria and in 2016, roughly 200 million clinical cases and nearly half a 
million deaths were attributed to malaria (1). Children under five years of age are particularly susceptible to 
malaria infection, illness and death, but other risk groups including non-immune adults such as pregnant 
women or travelers from non-endemic areas are also affected by the disease. Malaria burden is most severe in 
the Sub-Saharan African region with 90% and 92% of malaria cases and deaths occurring, respectively (1). 
Although a significant decrease in malaria mortality rates has been observed in the last 15 years among others 
due to diagnosis-based treatment and improved availability and use of insecticide-treated bed nets and indoor 
residual spraying (1), malaria control efforts are threatened by the emergence of drug-resistant parasites (2) 
and insecticide-resistant mosquitoes (3).  
 
Plasmodium life cycle 
Malaria is an Anopheles mosquito-borne infectious disease that is caused by protozoan parasites of the 
Plasmodium genus. Six species are known to infect humans: P. falciparum, P. vivax, P. ovale, P. malariae, P. 
knowlesi and P. cynomolgi, of which P. falciparum is the most lethal  species. Plasmodia are characterized by a 
complex multi-stage life cycle in the human host (Figure 1): infection is initiated upon deposition of sporozoites 
into the skin during a blood meal by female infected Anopheles mosquitoes. Within hours after an initial 
mosquito bite, the majority of sporozoites enter the blood circulation (4) and migrate via the skin and blood 
vessels to the liver by gliding motility which is characterized by spiral movements (5, 6), and crossing cell 
barriers by breaching host cell membranes (7). Sporozoites in the blood first cross Kupffer cells that are located 
throughout the sinusoidal lining before traversing several hepatocytes until ultimately infecting a final 
hepatocyte (8, 9). Plasmodium parasites have developed several strategies to suppress hepatocyte function 
while preventing apoptosis, ensuring parasite survival and development inside hepatocytes (10). After a 
maturation and replication step in the liver of approximately 7 days for P. falciparum, thousands of merozoites 
progress to invade erythrocytes and further replicate into both asexual and sexual stages (11). The blood-stage 
cycle is followed by the uptake of emerging sexual stage parasites by mosquitoes, followed by further spread 
and transmission of malaria (12). While the initial liver-stage is asymptomatic, the cyclic blood-stage triggers 
systemic inflammation and is responsible for the clinical symptoms of malaria such as fever, headache, fatigue 
and myalgia. More advanced complications caused by Plasmodium falciparum infection include neurological 
deficits, severe anemia, cerebral malaria, respiratory distress and organ failure, which may ultimately lead to 
death. 
 
Naturally acquired immunity against malaria 
Individuals living in malaria-endemic areas routinely experience multiple malaria infections and slowly acquire 
immunity against clinical malaria upon parasite exposure. This naturally acquired immunity appears to wane in 
the absence of ongoing Plasmodium falciparum exposure (13). Developed anti-parasite immunity is mainly 
directed against blood-stage parasites, limits blood-stage parasitaemia and protects individuals who are 
routinely exposed to Plasmodium infection from clinical disease (14). Malaria infection occurs rarely in infants, 
most likely due to the acquisition of maternal antibodies or passively acquired maternal antibodies to infants 
(15). In contrast to adults, young children are less efficient to acquire protective immunity, explaining why the 
majority of children of less than five years old have symptomatic Plasmodium infection (16, 17). While partial 
immunity against the parasite can be acquired through natural exposure, Plasmodium infection carriers 
without clinical symptoms but with very low parasite densities in the blood allow further spread of malaria 
(13). This is a major hurdle for malaria elimination. Failure to develop naturally acquired sterile immunity in 
combination with the emergence of drug-resistant parasites (2) and insecticide-resistant mosquitoes (3) 
underscore the need for a highly effective vaccine. 
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Figure 1. Plasmodium parasite life cycle.  
Reprinted by permission from Elsevier Ltd (A. Teo et al, Functional antibodies and protection against blood-stage malaria, 
Trends in Parasitology, 2016 November; 32 (11): 887-898. https://doi.org/10.1016/j.pt.2016.07.003) 
 
Rationale for a pre-erythrocytic vaccine  
An ideal malaria vaccine would optimally target the clinically silent pre-erythrocytic stage, encompassing 
sporozoites and liver-stage parasites, thereby preventing the development of disease-causing blood-stages 
and transmission of malaria parasites. Parasite pre-erythrocytic stages constitute an attractive target for 
vaccine-induced immune responses, because of the low number of parasites and infected host cells as 
compared to erythrocytic stages (18). Although this may also be a major challenge, because one single infected 
hepatocyte may already cause breakthrough infection. Additionally, these stages allow a larger time window 
for the induction of protective immune responses, since they last for approximately 7 days in contrast to the 
48-hour cyclic blood-stages (19). Despite substantial efforts, vaccine development is hampered by the 
complexity of Plasmodium parasites and their interaction with the human immune system (20). Plasmodium 
parasites have a multi-stage life cycle and the many different strains show great genetic and antigenic 
diversity, enabling parasites to evade host immune responses and thus, increasing parasite survival (21-23). 
Additionally, parasites may interfere with the host immune response by modulating various effectors of the 
immune system, such as induction of regulatory T-cells or atypical memory B-cells with a phenotype similar to 
exhausted cells (24-30). A major stumble block for the development of an effective vaccine is our incomplete 
understanding of protective immune responses to malaria, both in terms of relevant effector immune 
mechanisms and target antigens.  
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Controlled Human Malaria Infection model 
Further enhancing our understanding of protective anti-malarial immune responses can be achieved by means 
of the controlled human malaria infection (CHMI) model (31). The development of this model in human 
subjects is an important and powerful tool in malaria vaccine development, enabling investigators to assess 
the efficacy of pre-clinical vaccines or anti-malarial therapeutic strategies in small groups of healthy malaria-
naive human individuals prior to testing these approaches in malaria-endemic areas (32). Malaria-naive 
individuals are exposed to Plasmodium sporozoites via the natural route of infection by infectious mosquito 
bites (33-38) or with an inoculum of blood-stage parasites (39-41) or sporozoites (42-44). Study subjects are 
followed up intensely after infection and immediately treated once parasites are detected in the blood. Since 
this experimental human challenge model is carried out in volunteers without any history of malaria and a 
controlled environment, the CHMI model is an invaluable model to further elucidate effector mechanisms of 
protective immunity induced against Plasmodium infection (31). 
 
Pre-erythrocytic subunit vaccination approaches 
The most advanced subunit vaccine candidate to date is the RTS,S subunit vaccine (Mosquirix, 
GlaxoSmithKline) which is based on a major Plasmodium falciparum sporozoite surface protein, the 
circumsporozoite protein (CSP), and is fused to hepatitis B virus surface antigen virus-like particles (45). RTS,S 
vaccination has shown to elicit strong CSP-specific antibody titers and CD4+ T-cell responses that were 
associated with RTS,S-induced protection (46-49). The RTS,S vaccine induced protection in the majority of 
volunteers in a controlled human malaria infection (CHMI) model following challenge by infectious mosquito 
bites (46-48), however, delayed parasitaemia was developed in most volunteers upon a re-challenge with 
infectious mosquito bites, five to six months after the initial challenge (50, 51). Phase III field trials with the 
RTS,S subunit vaccine conferred only modest, rapidly waning protection within one year against clinical disease 
in infants, children and adults living in highly malaria-endemic areas (52-56). Other subunit vaccination 
approaches, for instance a combination of CSP and thrombospondin-related adhesion protein (TRAP) or a 
single recombinant liver-stage antigen-1 (LSA-1)-based vaccine failed to provide protection in the majority of 
CHMI volunteers (57, 58). 
 
Whole parasite vaccination approaches 
Since generating long-lasting and protective anti-malarial immunity with subunit vaccines has been met with 
limited success, a multi-pronged immune response that targets many parasite antigens might be a more 
promising approach for malaria vaccine development (23). This has risen an interest in whole parasite 
vaccination approaches, exposing the host to a broad range of parasite antigens. In contrast to subunit 
vaccination, sterile immunity against Plasmodium falciparum malaria can be achieved experimentally by whole 
parasite immunization with intact, attenuated sporozoites in animal models and human volunteers. Several 
whole parasite vaccination approaches have been applied, amongst other attenuation of sporozoites by 
radiation, genetic modification or co-administration of anti-malarial drugs. 
 
Radiation attenuated sporozoites (RAS) 
Live sporozoites can be attenuated by exposure to gamma irradiation, which causes random mutations and 
double-strand breaks in the parasite DNA (59). Radiation attenuated sporozoites can still invade hepatocytes 
following infection, but arrest early during intra-hepatic development and do not lead to blood-stage infection 
(60, 61). Immunization with radiation attenuated live sporozoites has shown to induce protection against 
subsequent malaria infection in rodents (62), non-human primates (63, 64) and more importantly, also in 
human subjects (65-67). Immunization with RAS induced about 90% protection in human subjects after 
exposure to bites of more than 1,000 Plasmodium falciparum-infected and irradiated mosquitoes (67) or a 
total dose of intravenously injected 675,000 cryopreserved sporozoites (44). RAS-induced protection is most 
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likely mediated by a combination of several effector mechanisms, such as antibody responses, CD4+ and CD8+ 
T-cell responses targeting sporozoite and liver-stage antigens (68-73). 
 
Genetically attenuated parasites (GAP) 
Next to radiation attenuation, live sporozoites can be attenuated by targeted deletion of specific genes or a 
combination of genes (74). Genetically attenuated rodent or human malaria pre-erythrocytic parasites have 
shown to arrest at different stages during liver-stage (75-81) and induced sterile protection in rodent models 
of malaria (75, 76, 82). In a Phase I trial, human subjects were exposed to mosquitoes infected with a 
Plasmodium falciparum double knock-out GAP vaccine candidate, leading to breakthrough infection in one out 
of six volunteers (83). However, in a recent Phase I safety trial, a triple knock-out Plasmodium falciparum GAP 
did not cause breakthrough infection in humans after exposure to bites from 150-200 infected mosquitoes 
(84). Further clinical testing of newly developed GAPs are currently underway. 
 
Chemoprophylaxis and sporozoites (CPS) 
While immunization with RAS requires bites of at least 1,000 infected mosquitoes and GAP still has a long way 
to go, a ground-breaking highly efficient immunization regimen has been established that induces long-lasting 
sterile immunity in malaria-naive individuals by exposure to only 30-45 P. falciparum-infected mosquito bites 
(85-87) or 150,000 intravenously injected cryopreserved sporozoites (88), while receiving a prophylactic 
regimen of chloroquine (ChemoProphylaxis and Sporozoites; CPS). Chloroquine is a potent malaria drug that 
efficiently eliminates erythrocytic parasites (89). In contrast to RAS and early-stage GAP, CPS-immunization 
allows full liver-stage maturation and development of early asexual blood-stage parasites, thus exposing the 
immune system to a broad range of antigens. This may also explain the high and unprecedented efficacy of this 
model. CPS-induced protective immunity is mediated by immune responses directed against pre-erythrocytic 
rather than blood-stage parasites (41). In previous CPS-immunization trials, cellular responses to both blood-
stage parasites and sporozoites were observed (87, 90). Further delineation of cellular responses revealed a 
role for ƴδ T-cells, Th1 and cytotoxic CD4+ and CD8+ T-cell responses in CPS-induced immunity (86, 91). With 
respect to humoral immune responses, protein microarray analysis of antibody responses identified CSP and 
LSA-1 as antigens that are predominantly recognized by CPS-immunized volunteers (92). Moreover, memory B-
cells and antibodies to CSP and LSA-1 have found to be efficiently induced after CPS-immunization (93). The 
CPS immunization regimen provides important proof that sterile protection against Plasmodium falciparum 
malaria by a reasonable immunization dose is feasible. This model is therefore an invaluable tool to 
systematically delineate mechanisms of sterile pre-erythrocytic immunity to malaria.  
 
Pre-erythrocytic antibody-mediated immunity towards malaria 
Anti-malarial cellular immune responses involve the induction of memory CD8+ cytotoxic and interferon-
gamma (IFN-ƴ)-producing T-cells, depending on CD4+ T-cell help (94-96). These cells mediate inhibition of 
parasite growth and development inside hepatocytes (97), and activate macrophages by IFN-ƴ secretion, 
resulting in enhanced phagocytosis and killing of Plasmodium-infected erythrocytes (98, 99). Additionally, CD4+ 
T-cells have shown to reduce blood-stage parasite growth in vitro (99, 100), and CD4+ T-cell help is essential for 
Plasmodium-specific antibody-mediated immune responses (101). Although these studies do not prove that 
cell-mediated immune responses contribute to protective anti-malarial immunity, they might play a role in 
controlling parasite growth. With respect to anti-malarial humoral immune responses, many studies have 
attempted to establish correlations between levels of antibodies specific to merozoite antigens and protective 
immunity against clinical disease (102, 103). Antibodies recognizing merozoite or blood-stage antigens, such as 
parasite erythrocyte invasion ligands (erythrocyte binding antigens; EBAs (104)), P. falciparum reticulocyte-
binding homologue proteins (PfRh (105)), rhoptry neck protein 2 (RON2; (106)), merozoite surface protein-1 
(MSP-1; (103, 107)), merozoite surface protein-3 (MSP-3; (103)), apical membrane antigen-1 (AMA-1;(103)) 
have shown to be associated with a reduced risk of clinical malaria.  
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However, while the focus of blood-stage immunity has long been on antibody titers and standardized 
reference assays, these assays are often poorly or inconsistently predictive of protective immunity to malaria 
(108). Correlates of protection against malaria are difficult to assess for any mechanism in the field among 
others due to a huge parasite strain diversity and variation in exposure. Nevertheless, studies have shown that 
anti-malarial protection is more strongly associated with anti-merozoite IgG subclass-specific antibody 
responses, particularly IgG3 responses (109-111). This suggests that antibody functional effector mechanisms 
may be important in anti-malarial immunity and protection from Plasmodium malaria infection. While 
functional antibody-mediated assays may be more difficult and less well-established than simple 
measurements of malaria-specific antibody levels, they might be more relevant in terms of determining the 
quality of the humoral immune response, e.g. with respect to epitope specificity, antibody avidity and isotype, 
and their possible association with anti-malarial protection. Measurements of the presence of or levels of 
functional antibodies targeting Plasmodium blood-stage parasites may be better correlates of protective 
immunity (112). Indeed, historic passive transfer studies have demonstrated a key role for antibodies in 
controlling blood-stage parasites during natural Plasmodium falciparum infection and reducing clinical 
symptoms of malaria (113-115), as confirmed in animal models of malaria (116-118). Antibodies targeting 
blood-stage malaria have a broad range of specificities and possible functions (112). They may recognize 
specific antigens or parasite-infected erythrocytes, prevent adhesion of merozoites to vascular endothelium 
and block merozoite interactions with erythrocyte receptors (119-122). Additionally, anti-malarial antibodies 
have shown to prevent invasion of merozoites into erythrocytes (123), inhibit blood-stage parasite growth in 
vitro (105, 124-128), and interact with the complement system, a system consisting of heat-sensitive, soluble 
and cell-surface associated proteins that are involved in pathogen opsonization, recruitment of phagocytes, 
and pathogen lysis via downstream C3 complement protein deposition (129). The complement system has 
recently shown to play a key role in antibody-mediated inhibition of Plasmodium falciparum merozoite 
invasion by reducing Plasmodium falciparum blood-stage replication and preventing clinical disease (130). In 
addition, antibodies may also contribute to fragment crystallizable (Fc)-receptor-mediated opsonization and 
phagocytosis of merozoites by phagocytes, or Fc-receptor-mediated lysis by natural killer T-cells, a process also 
known as antibody-dependent cell-mediated cytotoxicity (131). Indeed, opsonization followed by phagocytosis 
has previously shown to be important in malaria for efficient merozoite clearance (130, 132-135), and 
antibodies targeting infected erythrocytes have shown to interact with Fc-receptors of monocytes, resulting in 
the release of soluble factors and inhibition of parasite growth (136). Monocyte-mediated opsonic 
phagocytosis of merozoites by antibodies has been associated with protection in longitudinal studies from 
Kenya (137) and Papua New Guinea (135). Additionally, merozoite-specific antibodies have shown to promote 
neutrophil respiratory burst in the presence of active complement (134), and neutrophil respiratory burst has 
been found to be associated with protection from clinical malaria (138). Last but not least, merozoite-
opsonizing antibodies have a strong strain-transcending component (139). 
 
With respect to antibody-mediated immunity towards Plasmodium pre-erythrocytic stages, it is less clear 
whether this might also play a role in anti-malarial immune responses. While naturally acquired and whole 
parasite immunization-induced antibodies have shown to recognize various pre-erythrocytic antigens, such as 
CSP, thrombospondin-related adhesive protein (TRAP) and liver-stage antigen-1 (LSA-1) (92, 140-143), in 
contrast to blood-stage immunity, the functional importance of antibodies in parasite pre-erythrocytic 
immunity is less well established. There are currently no functional correlates of pre-erythrocytic protection 
and hence, it is important to understand the relevance of pre-erythrocytic antibodies in protective immunity 
against Plasmodium falciparum malaria and which antibody functions are most important in protection. More 
knowledge is required on the functional capacity of antibodies to interfere with the sporozoite journey from 
the skin to the liver and by which effector mechanisms they interact with Plasmodium pre-erythrocytic stages. 
Antibodies may target the cell-free Plasmodium sporozoite stage and prevent its invasion into the hepatocyte 
by different mechanisms, such as direct neutralization of sporozoites by inhibition of gliding motility and 
hepatocyte traversal or invasion, complement-mediated cytotoxicity, opsonization and phagocytosis of 
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sporozoites by phagocytes, or antibody-dependent cell-mediated cytotoxicity. Antibodies targeting the 
sporozoites might lower initial liver parasite load and thus, complement T-cell mediated immune responses 
targeting infected hepatocytes. CSP-specific antibodies have shown to immobilize sporozoites in vitro (144, 
145), opsonize sporozoites (146), and RAS immunization-induced antibodies immobilized Plasmodium berghei 
sporozoites inoculated into mouse skin (147). Furthermore, antibodies from malaria-exposed individuals have 
shown to reduce sporozoite invasion of hepatocytes in vitro (148-150). Taken together, these data suggest that 
functional pre-erythrocytic antibody responses may have a protective effect on Plasmodium malaria infection. 
However, it is yet unknown how anti-malarial antibodies may interfere with Plasmodium sporozoite infectivity 
by e.g. direct neutralization, opsonization, complement fixation on sporozoites, or killing of sporozoites, and 
their relevance in anti-malarial protection. Understanding the exact role of functional antibodies in pre-
erythrocytic immunity may help to further improve our knowledge of what exactly induces protective 
immunity against Plasmodium malaria sporozoites and liver-stage parasites. While natural Plasmodium 
exposure and whole parasite immunization have been shown to induce antibodies to Plasmodium malaria pre-
erythrocytic antigens (87, 92, 93, 140-143), immune effector mechanisms of these antibodies have not yet 
been explored. This thesis aims to address the possible functional contribution of antibodies to protective pre-
erythrocytic immunity induced by whole parasite immunization or natural exposure to Plasmodium infection. 
It aims to unravel possible immune effector mechanisms by which these antibodies may interact with 
homologous and heterologous sporozoites, and how important the CSP protein is for whole parasite 
immunization-induced protective immunity towards Plasmodium pre-erythrocytic stages. 
 
Aims and outline of this thesis 
The overall aim of this thesis is to improve our understanding of pre-erythrocytic functional antibody-mediated 
responses towards Plasmodium falciparum malaria by using the ChemoProphylaxis and Sporozoite 
immunization regimen and samples from naturally exposed individuals.  
 
In Chapter 2, the aim is to optimize and evaluate an in vitro assay allowing us to assess the inhibitory effect of 
antibodies on human hepatocyte traversal by Plasmodium sporozoites. In Chapter 3, we will study whether 
CPS-immunization induces antibodies that are functionally active and capable of neutralizing homologous 
sporozoite infectivity in vitro and in a liver-chimeric mouse model in vivo. In Chapter 4, the aim is to assess 
whether CPS-immunization induces cross-species protection upon a primary challenge infection with two 
genetically and geographically distinct Plasmodium falciparum parasite strains. Besides, we will assess whether 
CPS-induced functional antibodies have strain-transcending neutralizing activity and are capable of inhibiting in 
vitro heterologous sporozoites. In Chapter 5, we will further explore the importance of the complement 
system as an additional immune effector mechanism by which CPS-induced antibodies may further interfere 
with sporozoite infectivity in vitro. In Chapter 6, the aim is to characterize the importance of antibodies 
targeting CSP for CPS-induced antibody-mediated immunity by assessing the effect of depletion of CSP-specific 
antibodies on neutralization of sporozoite infectivity in vitro and liver-stage infection in vivo in a liver-chimeric 
mouse model. In Chapter 7, we will investigate whether malaria-exposed schoolchildren from Burkina Faso can 
acquire (functional) antibody-mediated responses towards Plasmodium sporozoites. In Chapter 8, we will 
further explore the contribution of the complement system to naturally acquired Plasmodium pre-erythrocytic 
antibody-mediated immunity. The findings of this thesis and future avenues for further research will be 
summarized and discussed in Chapter 9. 
  
13 
 
References 
1. (WHO) WHO. World malaria report 2017. WHO; 2017 November 2017.  Contract No.: ISBN 978 92 4 
156552 3. 
2. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin 
resistance in Plasmodium falciparum malaria. The New England journal of medicine. 2014;371(5):411-23. 
3. Hemingway J, Ranson H. Insecticide resistance in insect vectors of human disease. Annual review of 
entomology. 2000;45:371-91. 
4. Yamauchi LM, Coppi A, Snounou G, Sinnis P. Plasmodium sporozoites trickle out of the injection site. 
Cell Microbiol. 2007;9(5):1215-22. 
5. Stewart MJ, Vanderberg JP. Malaria sporozoites leave behind trails of circumsporozoite protein during 
gliding motility. J Protozool. 1988;35(3):389-93. 
6. Amino R, Thiberge S, Shorte S, Frischknecht F, Menard R. Quantitative imaging of Plasmodium 
sporozoites in the mammalian host. Comptes rendus biologies. 2006;329(11):858-62. 
7. Mota MM, Pradel G, Vanderberg JP, Hafalla JC, Frevert U, Nussenzweig RS, et al. Migration of 
Plasmodium sporozoites through cells before infection. Science. 2001;291(5501):141-4. 
8. Frevert U, Engelmann S, Zougbede S, Stange J, Ng B, Matuschewski K, et al. Intravital observation of 
Plasmodium berghei sporozoite infection of the liver. PLoS Biol. 2005;3(6):e192. 
9. Amino R, Giovannini D, Thiberge S, Gueirard P, Boisson B, Dubremetz JF, et al. Host cell traversal is 
important for progression of the malaria parasite through the dermis to the liver. Cell host & microbe. 
2008;3(2):88-96. 
10. Zheng H, Tan Z, Xu W. Immune evasion strategies of pre-erythrocytic malaria parasites. Mediators 
Inflamm. 2014;2014:362605. 
11. Menard R, Tavares J, Cockburn I, Markus M, Zavala F, Amino R. Looking under the skin: the first steps 
in malarial infection and immunity. Nat Rev Microbiol. 2013;11(10):701-12. 
12. Prudencio M, Rodriguez A, Mota MM. The silent path to thousands of merozoites: the Plasmodium 
liver stage. Nat Rev Microbiol. 2006;4(11):849-56. 
13. Doolan DL, Dobano C, Baird JK. Acquired immunity to malaria. Clin Microbiol Rev. 2009;22(1):13-36, 
Table of Contents. 
14. Carneiro I, Roca-Feltrer A, Griffin JT, Smith L, Tanner M, Schellenberg JA, et al. Age-patterns of malaria 
vary with severity, transmission intensity and seasonality in sub-Saharan Africa: a systematic review and 
pooled analysis. PLoS One. 2010;5(2):e8988. 
15. Riley EM, Wagner GE, Akanmori BD, Koram KA. Do maternally acquired antibodies protect infants 
from malaria infection? Parasite Immunol. 2001;23(2):51-9. 
16. Baird JK, Purnomo, Basri H, Bangs MJ, Andersen EM, Jones TR, et al. Age-specific prevalence of 
Plasmodium falciparum among six populations with limited histories of exposure to endemic malaria. Am J 
Trop Med Hyg. 1993;49(6):707-19. 
17. Baird JK. Host age as a determinant of naturally acquired immunity to Plasmodium falciparum. 
Parasitol Today. 1995;11(3):105-11. 
18. Kappe SH, Vaughan AM, Boddey JA, Cowman AF. That was then but this is now: malaria research in 
the time of an eradication agenda. Science. 2010;328(5980):862-6. 
19. Crompton PD, Pierce SK, Miller LH. Advances and challenges in malaria vaccine development. J Clin 
Invest. 2010;120(12):4168-78. 
20. Riley EM, Stewart VA. Immune mechanisms in malaria: new insights in vaccine development. Nature 
medicine. 2013;19(2):168-78. 
21. Mercereau-Puijalon O, Fandeur T, Guillotte M, Bonnefoy S. Parasite features impeding malaria 
immunity: antigenic diversity, antigenic variation and poor immunogenicity. Res Immunol. 1991;142(8):690-7. 
22. Rasti N, Wahlgren M, Chen Q. Molecular aspects of malaria pathogenesis. FEMS Immunol Med 
Microbiol. 2004;41(1):9-26. 
23. Casares S, Richie TL. Immune evasion by malaria parasites: a challenge for vaccine development. Curr 
Opin Immunol. 2009;21(3):321-30. 
24. Kemp K, Akanmori BD, Adabayeri V, Goka BQ, Kurtzhals JA, Behr C, et al. Cytokine production and 
apoptosis among T cells from patients under treatment for Plasmodium falciparum malaria. Clin Exp Immunol. 
2002;127(1):151-7. 
25. Xu H, Wipasa J, Yan H, Zeng M, Makobongo MO, Finkelman FD, et al. The mechanism and significance 
of deletion of parasite-specific CD4(+) T cells in malaria infection. The Journal of experimental medicine. 
2002;195(7):881-92. 
14 
 
26. Scholzen A, Minigo G, Plebanski M. Heroes or villains? T regulatory cells in malaria infection. Trends 
Parasitol. 2010;26(1):16-25. 
27. Weiss GE, Crompton PD, Li S, Walsh LA, Moir S, Traore B, et al. Atypical memory B cells are greatly 
expanded in individuals living in a malaria-endemic area. Journal of immunology. 2009;183(3):2176-82. 
28. Portugal S, Tipton CM, Sohn H, Kone Y, Wang J, Li S, et al. Malaria-associated atypical memory B cells 
exhibit markedly reduced B cell receptor signaling and effector function. Elife. 2015;4. 
29. Gomes PS, Bhardwaj J, Rivera-Correa J, Freire-De-Lima CG, Morrot A. Immune Escape Strategies of 
Malaria Parasites. Front Microbiol. 2016;7:1617. 
30. Stanisic DI, Barry AE, Good MF. Escaping the immune system: How the malaria parasite makes vaccine 
development a challenge. Trends Parasitol. 2013;29(12):612-22. 
31. Scholzen A, Sauerwein RW. Immune activation and induction of memory: lessons learned from 
controlled human malaria infection with Plasmodium falciparum. Parasitology. 2016;143(2):224-35. 
32. Sauerwein RW, Roestenberg M, Moorthy VS. Experimental human challenge infections can accelerate 
clinical malaria vaccine development. Nat Rev Immunol. 2011;11(1):57-64. 
33. Chulay JD, Schneider I, Cosgriff TM, Hoffman SL, Ballou WR, Quakyi IA, et al. Malaria transmitted to 
humans by mosquitoes infected from cultured Plasmodium falciparum. Am J Trop Med Hyg. 1986;35(1):66-8. 
34. Herrington DA, Clyde DF, Murphy JR, Baqar S, Levine MM, do Rosario V, et al. A model for Plasmodium 
falciparum sporozoite challenge and very early therapy of parasitaemia for efficacy studies of sporozoite 
vaccines. Trop Geogr Med. 1988;40(2):124-7. 
35. Verhage DF, Telgt DS, Bousema JT, Hermsen CC, van Gemert GJ, van der Meer JW, et al. Clinical 
outcome of experimental human malaria induced by Plasmodium falciparum-infected mosquitoes. Neth J 
Med. 2005;63(2):52-8. 
36. Epstein JE, Rao S, Williams F, Freilich D, Luke T, Sedegah M, et al. Safety and clinical outcome of 
experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update. J 
Infect Dis. 2007;196(1):145-54. 
37. Moorthy VS, Diggs C, Ferro S, Good MF, Herrera S, Hill AV, et al. Report of a consultation on the 
optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 
2009, Bethesda, MD, USA. Vaccine. 2009;27(42):5719-25. 
38. Talley AK, Healy SA, Finney OC, Murphy SC, Kublin J, Salas CJ, et al. Safety and comparability of 
controlled human Plasmodium falciparum infection by mosquito bite in malaria-naive subjects at a new facility 
for sporozoite challenge. PLoS One. 2014;9(11):e109654. 
39. Cheng Q, Lawrence G, Reed C, Stowers A, Ranford-Cartwright L, Creasey A, et al. Measurement of 
Plasmodium falciparum growth rates in vivo: a test of malaria vaccines. Am J Trop Med Hyg. 1997;57(4):495-
500. 
40. Sanderson F, Andrews L, Douglas AD, Hunt-Cooke A, Bejon P, Hill AV. Blood-stage challenge for 
malaria vaccine efficacy trials: a pilot study with discussion of safety and potential value. Am J Trop Med Hyg. 
2008;78(6):878-83. 
41. Bijker EM, Bastiaens GJ, Teirlinck AC, van Gemert GJ, Graumans W, van de Vegte-Bolmer M, et al. 
Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by 
preerythrocytic immunity. Proc Natl Acad Sci U S A. 2013;110(19):7862-7. 
42. Roestenberg M, Bijker EM, Sim BK, Billingsley PF, James ER, Bastiaens GJ, et al. Controlled human 
malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop 
Med Hyg. 2013;88(1):5-13. 
43. Sheehy SH, Spencer AJ, Douglas AD, Sim BK, Longley RJ, Edwards NJ, et al. Optimising Controlled 
Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and 
Syringe. PLoS One. 2013;8(6):e65960. 
44. Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, et al. Protection against malaria by 
intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013;341(6152):1359-65. 
45. Casares S, Brumeanu TD, Richie TL. The RTS,S malaria vaccine. Vaccine. 2010;28(31):4880-94. 
46. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, et al. A preliminary evaluation of a 
recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine 
Evaluation Group. N Engl J Med. 1997;336(2):86-91. 
47. Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, Jr., Hall T, et al. A phase I/IIa 
safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and 
lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naive adults. Vaccine. 
2007;25(29):5359-66. 
15 
 
48. Kester KE, Cummings JF, Ockenhouse CF, Nielsen R, Hall BT, Gordon DM, et al. Phase 2a trial of 0, 1, 
and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naive 
adults at the Walter Reed Army Institute of Research. Vaccine. 2008;26(18):2191-202. 
49. White MT, Bejon P, Olotu A, Griffin JT, Riley EM, Kester KE, et al. The relationship between RTS,S 
vaccine-induced antibodies, CD4(+) T cell responses and protection against Plasmodium falciparum infection. 
PLoS One. 2013;8(4):e61395. 
50. Stoute JA, Kester KE, Krzych U, Wellde BT, Hall T, White K, et al. Long-term efficacy and immune 
responses following immunization with the RTS,S malaria vaccine. J Infect Dis. 1998;178(4):1139-44. 
51. Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, et al. Randomized, 
double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive 
adults: safety, efficacy, and immunologic associates of protection. J Infect Dis. 2009;200(3):337-46. 
52. Sacarlal J, Aide P, Aponte JJ, Renom M, Leach A, Mandomando I, et al. Long-term safety and efficacy 
of the RTS,S/AS02A malaria vaccine in Mozambican children. J Infect Dis. 2009;200(3):329-36. 
53. Agnandji ST, Fendel R, Mestre M, Janssens M, Vekemans J, Held J, et al. Induction of Plasmodium 
falciparum-specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS,S/AS01(E) and 
RTS,S/AS02(D). PLoS One. 2011;6(4):e18559. 
54. Rts SCTP, Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, et al. A phase 3 trial of 
RTS,S/AS01 malaria vaccine in African infants. N Engl J Med. 2012;367(24):2284-95. 
55. Olotu A, Fegan G, Wambua J, Nyangweso G, Awuondo KO, Leach A, et al. Four-year efficacy of 
RTS,S/AS01E and its interaction with malaria exposure. N Engl J Med. 2013;368(12):1111-20. 
56. Rts SCTP. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants 
and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 
2015;386(9988):31-45. 
57. Walsh DS, Pichyangkul S, Gettayacamin M, Tongtawe P, Siegrist CA, Hansukjariya P, et al. Safety and 
immunogenicity of rts,s+trap malaria vaccine, formulated in the as02a adjuvant system, in infant rhesus 
monkeys. Am J Trop Med Hyg. 2004;70(5):499-509. 
58. Cummings JF, Spring MD, Schwenk RJ, Ockenhouse CF, Kester KE, Polhemus ME, et al. Recombinant 
Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-
gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection. Vaccine. 
2010;28(31):5135-44. 
59. Ward JF. DNA damage produced by ionizing radiation in mammalian cells: identities, mechanisms of 
formation, and reparability. Prog Nucleic Acid Res Mol Biol. 1988;35:95-125. 
60. Suhrbier A, Winger LA, Castellano E, Sinden RE. Survival and antigenic profile of irradiated malarial 
sporozoites in infected liver cells. Infect Immun. 1990;58(9):2834-9. 
61. Scheller LF, Azad AF. Maintenance of protective immunity against malaria by persistent hepatic 
parasites derived from irradiated sporozoites. Proc Natl Acad Sci U S A. 1995;92(9):4066-8. 
62. Nussenzweig RS, Vanderberg J, Most H, Orton C. Protective immunity produced by the injection of x-
irradiated sporozoites of plasmodium berghei. Nature. 1967;216(5111):160-2. 
63. Collins WE, Contacos PG. Immunization of monkeys against Plasmodium cynomolgi by X-irradiated 
sporozoites. Nat New Biol. 1972;236(67):176-7. 
64. Gwadz RW, Cochrane AH, Nussenzweig V, Nussenzweig RS. Preliminary studies on vaccination of 
rhesus monkeys with irradiated sporozoites of Plasmodium knowlesi and characterization of surface antigens 
of these parasites. Bull World Health Organ. 1979;57 Suppl 1:165-73. 
65. Clyde DF. Immunity to falciparum and vivax malaria induced by irradiated sporozoites: a review of the 
University of Maryland studies, 1971-75. Bull World Health Organ. 1990;68 Suppl:9-12. 
66. Rieckmann KH. Human immunization with attenuated sporozoites. Bull World Health Organ. 1990;68 
Suppl:13-6. 
67. Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL, et al. Protection of humans against 
malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis. 
2002;185(8):1155-64. 
68. Nardin EH, Herrington DA, Davis J, Levine M, Stuber D, Takacs B, et al. Conserved repetitive epitope 
recognized by CD4+ clones from a malaria-immunized volunteer. Science. 1989;246(4937):1603-6. 
69. Moreno A, Clavijo P, Edelman R, Davis J, Sztein M, Herrington D, et al. Cytotoxic CD4+ T cells from a 
sporozoite-immunized volunteer recognize the Plasmodium falciparum CS protein. Int Immunol. 
1991;3(10):997-1003. 
70. Malik A, Egan JE, Houghten RA, Sadoff JC, Hoffman SL. Human cytotoxic T lymphocytes against the 
Plasmodium falciparum circumsporozoite protein. Proc Natl Acad Sci U S A. 1991;88(8):3300-4. 
16 
 
71. Krzych U, Lyon JA, Jareed T, Schneider I, Hollingdale MR, Gordon DM, et al. T lymphocytes from 
volunteers immunized with irradiated Plasmodium falciparum sporozoites recognize liver and blood stage 
malaria antigens. Journal of immunology. 1995;155(8):4072-7. 
72. Wizel B, Houghten R, Church P, Tine JA, Lanar DE, Gordon DM, et al. HLA-A2-restricted cytotoxic T 
lymphocyte responses to multiple Plasmodium falciparum sporozoite surface protein 2 epitopes in sporozoite-
immunized volunteers. Journal of immunology. 1995;155(2):766-75. 
73. Doolan DL, Southwood S, Freilich DA, Sidney J, Graber NL, Shatney L, et al. Identification of 
Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proc Natl Acad Sci U S 
A. 2003;100(17):9952-7. 
74. Vaughan AM, Wang R, Kappe SH. Genetically engineered, attenuated whole-cell vaccine approaches 
for malaria. Hum Vaccin. 2010;6(1):107-13. 
75. van Dijk MR, Douradinha B, Franke-Fayard B, Heussler V, van Dooren MW, van Schaijk B, et al. 
Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of 
infected liver cells. Proc Natl Acad Sci U S A. 2005;102(34):12194-9. 
76. Labaied M, Harupa A, Dumpit RF, Coppens I, Mikolajczak SA, Kappe SH. Plasmodium yoelii sporozoites 
with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against 
infection. Infect Immun. 2007;75(8):3758-68. 
77. van Schaijk BC, Janse CJ, van Gemert GJ, van Dijk MR, Gego A, Franetich JF, et al. Gene disruption of 
Plasmodium falciparum p52 results in attenuation of malaria liver stage development in cultured primary 
human hepatocytes. PLoS One. 2008;3(10):e3549. 
78. Vaughan AM, O'Neill MT, Tarun AS, Camargo N, Phuong TM, Aly AS, et al. Type II fatty acid synthesis is 
essential only for malaria parasite late liver stage development. Cell Microbiol. 2009;11(3):506-20. 
79. VanBuskirk KM, O'Neill MT, De La Vega P, Maier AG, Krzych U, Williams J, et al. Preerythrocytic, live-
attenuated Plasmodium falciparum vaccine candidates by design. Proc Natl Acad Sci U S A. 
2009;106(31):13004-9. 
80. van Schaijk BC, Ploemen IH, Annoura T, Vos MW, Foquet L, van Gemert GJ, et al. A genetically 
attenuated malaria vaccine candidate based on P. falciparum b9/slarp gene-deficient sporozoites. Elife. 
2014;3. 
81. Mikolajczak SA, Lakshmanan V, Fishbaugher M, Camargo N, Harupa A, Kaushansky A, et al. A next-
generation genetically attenuated Plasmodium falciparum parasite created by triple gene deletion. Mol Ther. 
2014;22(9):1707-15. 
82. Douradinha B, van Dijk MR, Ataide R, van Gemert GJ, Thompson J, Franetich JF, et al. Genetically 
attenuated P36p-deficient Plasmodium berghei sporozoites confer long-lasting and partial cross-species 
protection. Int J Parasitol. 2007;37(13):1511-9. 
83. Spring M, Murphy J, Nielsen R, Dowler M, Bennett JW, Zarling S, et al. First-in-human evaluation of 
genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to 
adult volunteers. Vaccine. 2013;31(43):4975-83. 
84. Kublin JG, Mikolajczak SA, Sack BK, Fishbaugher ME, Seilie A, Shelton L, et al. Complete attenuation of 
genetically engineered Plasmodium falciparum sporozoites in human subjects. Sci Transl Med. 2017;9(371). 
85. Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, et al. Protection against a 
malaria challenge by sporozoite inoculation. N Engl J Med. 2009;361(5):468-77. 
86. Bijker EM, Teirlinck AC, Schats R, van Gemert GJ, van de Vegte-Bolmer M, van Lieshout L, et al. 
Cytotoxic markers associate with protection against malaria in human volunteers immunized with Plasmodium 
falciparum sporozoites. J Infect Dis. 2014;210(10):1605-15. 
87. Roestenberg M, Teirlinck AC, McCall MB, Teelen K, Makamdop KN, Wiersma J, et al. Long-term 
protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet. 
2011;377(9779):1770-6. 
88. Mordmuller B, Surat G, Lagler H, Chakravarty S, Ishizuka AS, Lalremruata A, et al. Sterile protection 
against human malaria by chemoattenuated PfSPZ vaccine. Nature. 2017;542(7642):445-9. 
89. Yayon A, Vande Waa JA, Yayon M, Geary TG, Jensen JB. Stage-dependent effects of chloroquine on 
Plasmodium falciparum in vitro. J Protozool. 1983;30(4):642-7. 
90. Teirlinck AC, McCall MB, Roestenberg M, Scholzen A, Woestenenk R, de Mast Q, et al. Longevity and 
composition of cellular immune responses following experimental Plasmodium falciparum malaria infection in 
humans. PLoS Pathog. 2011;7(12):e1002389. 
91. Bijker EM, Schats R, Visser LG, Sauerwein RW, Scholzen A. Ex vivo lymphocyte phenotyping during 
Plasmodium falciparum sporozoite immunization in humans. Parasite Immunol. 2015;37(11):590-8. 
17 
 
92. Felgner PL, Roestenberg M, Liang L, Hung C, Jain A, Pablo J, et al. Pre-erythrocytic antibody profiles 
induced by controlled human malaria infections in healthy volunteers under chloroquine prophylaxis. Sci Rep. 
2013;3:3549. 
93. Nahrendorf W, Scholzen A, Bijker EM, Teirlinck AC, Bastiaens GJ, Schats R, et al. Memory B-cell and 
antibody responses induced by Plasmodium falciparum sporozoite immunization. J Infect Dis. 
2014;210(12):1981-90. 
94. Carvalho LH, Sano G, Hafalla JC, Morrot A, Curotto de Lafaille MA, Zavala F. IL-4-secreting CD4+ T cells 
are crucial to the development of CD8+ T-cell responses against malaria liver stages. Nat Med. 2002;8(2):166-
70. 
95. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. 
Science. 2003;300(5617):337-9. 
96. Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. 
Science. 2003;300(5617):339-42. 
97. Tsuji M, Zavala F. T cells as mediators of protective immunity against liver stages of Plasmodium. 
Trends Parasitol. 2003;19(2):88-93. 
98. Fritsche G, Larcher C, Schennach H, Weiss G. Regulatory interactions between iron and nitric oxide 
metabolism for immune defense against Plasmodium falciparum infection. J Infect Dis. 2001;183(9):1388-94. 
99. Fell AH, Currier J, Good MF. Inhibition of Plasmodium falciparum growth in vitro by CD4+ and CD8+ T 
cells from non-exposed donors. Parasite Immunol. 1994;16(11):579-86. 
100. Brown J, Greenwood BM, Terry RJ. Cellular mechanisms involved in recovery from acute malaria in 
Gambian children. Parasite Immunol. 1986;8(6):551-64. 
101. Good MF, Xu H, Wykes M, Engwerda CR. Development and regulation of cell-mediated immune 
responses to the blood stages of malaria: implications for vaccine research. Annu Rev Immunol. 2005;23:69-99. 
102. Richards JS, Beeson JG. The future for blood-stage vaccines against malaria. Immunol Cell Biol. 
2009;87(5):377-90. 
103. Fowkes FJ, Richards JS, Simpson JA, Beeson JG. The relationship between anti-merozoite antibodies 
and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis. PLoS Med. 
2010;7(1):e1000218. 
104. Persson KE, Fowkes FJ, McCallum FJ, Gicheru N, Reiling L, Richards JS, et al. Erythrocyte-binding 
antigens of Plasmodium falciparum are targets of human inhibitory antibodies and function to evade naturally 
acquired immunity. Journal of immunology. 2013;191(2):785-94. 
105. Chiu CY, Hodder AN, Lin CS, Hill DL, Li Wai Suen CS, Schofield L, et al. Antibodies to the Plasmodium 
falciparum Proteins MSPDBL1 and MSPDBL2 Opsonize Merozoites, Inhibit Parasite Growth, and Predict 
Protection From Clinical Malaria. J Infect Dis. 2015;212(3):406-15. 
106. Srinivasan P, Ekanem E, Diouf A, Tonkin ML, Miura K, Boulanger MJ, et al. Immunization with a 
functional protein complex required for erythrocyte invasion protects against lethal malaria. Proc Natl Acad Sci 
U S A. 2014;111(28):10311-6. 
107. O'Donnell RA, de Koning-Ward TF, Burt RA, Bockarie M, Reeder JC, Cowman AF, et al. Antibodies 
against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in 
individuals immune to malaria. The Journal of experimental medicine. 2001;193(12):1403-12. 
108. Marsh K, Otoo L, Hayes RJ, Carson DC, Greenwood BM. Antibodies to blood stage antigens of 
Plasmodium falciparum in rural Gambians and their relation to protection against infection. Trans R Soc Trop 
Med Hyg. 1989;83(3):293-303. 
109. Stanisic DI, Richards JS, McCallum FJ, Michon P, King CL, Schoepflin S, et al. Immunoglobulin G 
subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of 
parasitemia and protection from symptomatic illness. Infect Immun. 2009;77(3):1165-74. 
110. Richards JS, Stanisic DI, Fowkes FJ, Tavul L, Dabod E, Thompson JK, et al. Association between 
naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from 
malaria and high-density parasitemia. Clin Infect Dis. 2010;51(8):e50-60. 
111. Roussilhon C, Oeuvray C, Muller-Graf C, Tall A, Rogier C, Trape JF, et al. Long-term clinical protection 
from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. PLoS Med. 
2007;4(11):e320. 
112. Teo A, Feng G, Brown GV, Beeson JG, Rogerson SJ. Functional Antibodies and Protection against 
Blood-stage Malaria. Trends Parasitol. 2016;32(11):887-98. 
113. Moorthy VS, Ballou WR. Immunological mechanisms underlying protection mediated by RTS,S: a 
review of the available data. Malar J. 2009;8:312. 
18 
 
114. McGregor IA, Carrington SP, Cohen S. Treatment of East African P. falciparum malaria with West 
African human gamma-globulin. Transactions of the Royal Society of Tropical Medicine and Hygiene. 
1963;57(3):170-5. 
115. Adalid-Peralta L, Fragoso G, Fleury A, Sciutto E. Mechanisms underlying the induction of regulatory T 
cells and its relevance in the adaptive immune response in parasitic infections. International journal of 
biological sciences. 2011;7(9):1412-26. 
116. Coggeshall LT, Kumm HW. Demonstration of passive immunity in experimental monkey malaria. The 
Journal of experimental medicine. 1937;66(2):177-90. 
117. Bruce-Chwatt LJ, Gibson FD. Transplacental passage of Plasmodium berghei and passive transfer of 
immunity in rats and mice. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1956;50(1):47-
53. 
118. Diggs CL, Osler AG. Humoral immunity in rodent malaria. II. Inhibition of parasitemia by serum 
antibody. Journal of immunology. 1969;102(2):298-305. 
119. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe malaria is associated with 
parasite binding to endothelial protein C receptor. Nature. 2013;498(7455):502-5. 
120. Nielsen MA, Pinto VV, Resende M, Dahlback M, Ditlev SB, Theander TG, et al. Induction of adhesion-
inhibitory antibodies against placental Plasmodium falciparum parasites by using single domains of VAR2CSA. 
Infect Immun. 2009;77(6):2482-7. 
121. Douglas AD, Williams AR, Knuepfer E, Illingworth JJ, Furze JM, Crosnier C, et al. Neutralization of 
Plasmodium falciparum merozoites by antibodies against PfRH5. Journal of immunology. 2014;192(1):245-58. 
122. Wright KE, Hjerrild KA, Bartlett J, Douglas AD, Jin J, Brown RE, et al. Structure of malaria invasion 
protein RH5 with erythrocyte basigin and blocking antibodies. Nature. 2014;515(7527):427-30. 
123. Blackman MJ, Heidrich HG, Donachie S, McBride JS, Holder AA. A single fragment of a malaria 
merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-
inhibiting antibodies. The Journal of experimental medicine. 1990;172(1):379-82. 
124. Egan AF, Burghaus P, Druilhe P, Holder AA, Riley EM. Human antibodies to the 19kDa C-terminal 
fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Parasite 
Immunol. 1999;21(3):133-9. 
125. Hodder AN, Crewther PE, Anders RF. Specificity of the protective antibody response to apical 
membrane antigen 1. Infect Immun. 2001;69(5):3286-94. 
126. Reiling L, Richards JS, Fowkes FJ, Wilson DW, Chokejindachai W, Barry AE, et al. The Plasmodium 
falciparum erythrocyte invasion ligand Pfrh4 as a target of functional and protective human antibodies against 
malaria. PLoS One. 2012;7(9):e45253. 
127. Badiane AS, Bei AK, Ahouidi AD, Patel SD, Salinas N, Ndiaye D, et al. Inhibitory humoral responses to 
the Plasmodium falciparum vaccine candidate EBA-175 are independent of the erythrocyte invasion pathway. 
Clin Vaccine Immunol. 2013;20(8):1238-45. 
128. Tran TM, Ongoiba A, Coursen J, Crosnier C, Diouf A, Huang CY, et al. Naturally acquired antibodies 
specific for Plasmodium falciparum reticulocyte-binding protein homologue 5 inhibit parasite growth and 
predict protection from malaria. J Infect Dis. 2014;209(5):789-98. 
129. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement System Part I - Molecular 
Mechanisms of Activation and Regulation. Front Immunol. 2015;6:262. 
130. Boyle MJ, Reiling L, Feng G, Langer C, Osier FH, Aspeling-Jones H, et al. Human antibodies fix 
complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection 
against malaria. Immunity. 2015;42(3):580-90. 
131. Peipp M, Beyer, T., Dechant, M., Valerius, T.  . Handbook of Therapeutic Antibodies. Chapter 8. 
Molecular Engineering III: Fc Engineering. 2008. 
132. Druilhe P, Khusmith S. Epidemiological correlation between levels of antibodies promoting merozoite 
phagocytosis of Plasmodium falciparum and malaria-immune status. Infect Immun. 1987;55(4):888-91. 
133. Groux H, Gysin J. Opsonization as an effector mechanism in human protection against asexual blood 
stages of Plasmodium falciparum: functional role of IgG subclasses. Res Immunol. 1990;141(6):529-42. 
134. Kumaratilake LM, Ferrante A. Opsonization and phagocytosis of Plasmodium falciparum merozoites 
measured by flow cytometry. Clin Diagn Lab Immunol. 2000;7(1):9-13. 
135. Hill DL, Eriksson EM, Li Wai Suen CS, Chiu CY, Ryg-Cornejo V, Robinson LJ, et al. Opsonising antibodies 
to P. falciparum merozoites associated with immunity to clinical malaria. PLoS One. 2013;8(9):e74627. 
136. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P. Mechanisms underlying the monocyte-mediated 
antibody-dependent killing of Plasmodium falciparum asexual blood stages. The Journal of experimental 
medicine. 1995;182(2):409-18. 
19 
 
137. Osier FH, Feng G, Boyle MJ, Langer C, Zhou J, Richards JS, et al. Opsonic phagocytosis of Plasmodium 
falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria. BMC 
Med. 2014;12:108. 
138. Joos C, Marrama L, Polson HE, Corre S, Diatta AM, Diouf B, et al. Clinical protection from falciparum 
malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum 
antibodies. PLoS One. 2010;5(3):e9871. 
139. Hill DL, Wilson DW, Sampaio NG, Eriksson EM, Ryg-Cornejo V, Harrison GL, et al. Merozoite Antigens 
of Plasmodium falciparum Elicit Strain-Transcending Opsonizing Immunity. Infect Immun. 2016;84(8):2175-84. 
140. Offeddu V, Thathy V, Marsh K, Matuschewski K. Naturally acquired immune responses against 
Plasmodium falciparum sporozoites and liver infection. Int J Parasitol. 2012;42(6):535-48. 
141. John CC, Moormann AM, Pregibon DC, Sumba PO, McHugh MM, Narum DL, et al. Correlation of high 
levels of antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection from 
infection. Am J Trop Med Hyg. 2005;73(1):222-8. 
142. Domarle O, Migot-Nabias F, Mvoukani JL, Lu CY, Nabias R, Mayombo J, et al. Factors influencing 
resistance to reinfection with Plasmodium falciparum. Am J Trop Med Hyg. 1999;61(6):926-31. 
143. John CC, Tande AJ, Moormann AM, Sumba PO, Lanar DE, Min XM, et al. Antibodies to pre-erythrocytic 
Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children. J Infect Dis. 2008;197(4):519-
26. 
144. Vanderberg JP. Studies on the motility of Plasmodium sporozoites. J Protozool. 1974;21(4):527-37. 
145. Stewart MJ, Nawrot RJ, Schulman S, Vanderberg JP. Plasmodium berghei sporozoite invasion is 
blocked in vitro by sporozoite-immobilizing antibodies. Infect Immun. 1986;51(3):859-64. 
146. Schwenk R, Asher LV, Chalom I, Lanar D, Sun P, White K, et al. Opsonization by antigen-specific 
antibodies as a mechanism of protective immunity induced by Plasmodium falciparum circumsporozoite 
protein-based vaccine. Parasite Immunol. 2003;25(1):17-25. 
147. Vanderberg JP, Frevert U. Intravital microscopy demonstrating antibody-mediated immobilisation of 
Plasmodium berghei sporozoites injected into skin by mosquitoes. Int J Parasitol. 2004;34(9):991-6. 
148. Hollingdale MR, Nardin EH, Tharavanij S, Schwartz AL, Nussenzweig RS. Inhibition of entry of 
Plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies. 
Journal of immunology. 1984;132(2):909-13. 
149. Hoffman SL, Wistar R, Jr., Ballou WR, Hollingdale MR, Wirtz RA, Schneider I, et al. Immunity to malaria 
and naturally acquired antibodies to the circumsporozoite protein of Plasmodium falciparum. N Engl J Med. 
1986;315(10):601-6. 
150. Mellouk S, Mazier D, Druilhe P, Berbiguier N, Danis M. In vitro and in vivo results suggesting that anti-
sporozoite antibodies do not totally block Plasmodium falciparum sporozoite infectivity. N Engl J Med. 
1986;315(10):648. 
 
  
20 
 
CHAPTER 2 
 
Adjusted flow cytometry-based hepatocyte traversal assay for 
screening of Plasmodium falciparum sporozoite inhibitory 
antibodies 
 
Marije C Behet1, Geert-Jan van Gemert1, Cornelus C. Hermsen1, Robert W Sauerwein1 and Anja 
Scholzen1, 2 
 
1 Radboud University Medical Center, Department of Medical Microbiology, Geert Grooteplein 28, 
Microbiology 268, Nijmegen, HB 6500, The Netherlands 
2 Current address: Innatoss Laboratories B.V., Kloosterstraat 9, RE3124, 5349 AB Oss, The Netherlands. 
 
 
 
  
21 
 
Abstract  
 
Background  
Immunization with whole sporozoites can induce sterile protection against subsequent Plasmodium falciparum 
sporozoite infection. Functional assays are considered as a promising approach to investigate the capacity of 
induced antibodies to interfere with sporozoite functionality. In the present study, different parameters were 
assessed to adjust the flow cytometry-based hepatocyte traversal assay for examining the inhibitory effect of 
antibodies on P. falciparum sporozoite traversal. 
 
Methods  
Cultured hepatocyte cell lines (HUH-7 and HC-04) were incubated with P. falciparum sporozoites in the 
presence of fluorescent labeled cell-impermanent dextran, and wounded cells were quantified by flow 
cytometry. Different culture media and conditions were tested for their influence on sporozoite traversal of 
hepatocytes. 
 
Results 
Consistently higher traversal rates were observed in HC-04 hepatocytes compared to HUH-7 hepatocytes when 
collected in either complete DMEM (medians 19.9% versus 8.6%; p=0.008) or Leibovitz medium (13.9% versus 
10.4%; p=0.009). Sporozoites stored for 24h in DMEM medium showed a strong reduction in traversal rates 
compared to freshly isolated sporozoites in side-by-side comparisons of media and storage of sporozoites 
(p=0.02). This reduction was less marked for sporozoites stored in Leibovitz medium (p=0.04). Traversal rates 
of sporozoites stored in complete DMEM strongly dropped after as little as 2h following salivary gland 
dissection (p<0.0001), while this was not the case for Leibovitz medium. Incubation of sporozoites with anti-
circumsporozoite (CSP) monoclonal antibody blocked hepatocyte traversal in a dose-dependent manner and 
consistently resulted in the same proportional traversal inhibition, independently of absolute traversal rates. 
 
Conclusion 
The present work demonstrates that the hepatocyte traversal assay can be improved for P. falciparum 
sporozoites by using HC-04 cells, which allow for higher traversal rates, and Leibovitz medium, which sustains 
sporozoite traversal capacity for longer. This adjusted version of the traversal assay is a highly reliable, simple 
and quick readout to study the functional activity of antibodies on P. falciparum sporozoites. 
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Background 
Plasmodia are characterized by a complex multi-stage life cycle in the human host. Sporozoites deposited in 
the skin of a mammalian host by P. falciparum-infected Anopheles mosquitoes travel to the liver via gliding 
motility and traversal of cell barriers by breaching host cell membranes [1]. Sporozoite traversal plays a critical 
role in progression of sporozoites from the skin to the liver, sporozoite survival in the liver sinusoids and their 
ability to eventually invade and infect hepatocytes [1-7]. Upon arrival in the liver, sporozoites traverse through 
and eventually invade hepatocytes after crossing the sinusoidal barrier [1,3]. After a maturation step in the 
liver, merozoites are released into the bloodstream, which then infect erythrocytes (asexual blood-stages) [8]. 
 
Sterilizing immunity against sporozoite/liver-stages in human volunteers against subsequent sporozoite 
challenge infection can be induced by different attenuated whole-parasite immunization approaches [9-12], 
and is most likely mediated by both humoral and cellular immune responses. Antibodies may interfere with 
sporozoites during their journey to the liver, and therefore reduce sporozoite invasion into hepatocytes to 
such an extent, that the residual infected hepatocytes can be eliminated by T-cell mediated responses. 
However, while whole-parasite vaccination approaches have been shown to induce malaria-specific antibodies 
as measured by enzyme-linked immunosorbent assay (ELISA) or indirect immunofluorescence assay (IFA) 
[10,12-16], these assays cannot distinguish antibody binding and functional activity [17,18]. Indeed, previous 
studies have demonstrated a divergence between data obtained from in vitro sporozoite 
neutralization/invasion assays and ELISAs [17,19]. Therefore, functional assays are considered a promising 
approach to study the capacity of immunization-induced antibodies to interfere with sporozoite function, such 
as sporozoite motility, traversal or invasion. 
 
While the readout of the gliding motility assay by microscopy is very laborious and somewhat subjective 
[18,20], hepatocyte invasion and development assays are mainly limited by the fact that P. falciparum 
sporozoites have high selectivity of the cells they can invade and mature in. Even the permissive HC-04 cell line 
supports only very low invasion and maturation rates [21], compared to primary human hepatocyte cultures 
[22], which are not easily available. Although the in vitro hepatocyte traversal assay can also only assess one 
facet of sporozoite functionality, the great benefit of the traversal assay in its flow cytometry based form is the 
fact that it can be conducted in a high-throughput manner and it can be easily applied to large numbers of 
samples. Traversal of hepatocytes can be assessed using an in vitro dextran incorporation assay [1,23]: only 
cells traversed and thus wounded by sporozoites incorporate a cell membrane-impermeant dextran, which is 
trapped inside the cell after resealing of the cell membrane. The flow cytometry based version of this assay to 
rapidly quantify dextran-positive cells has previously been described for P. berghei sporozoites [23]. This assay 
has since been used not only to assess traversal activity of murine malaria parasites [23-27], but also of P. 
falciparum sporozoites [20,25,28-30]. It should be ideally suited to screen and compare the ability of different 
sera or (monoclonal) antibodies to inhibit in vitro hepatocyte traversal of P. falciparum sporozoites. 
Prerequisites for this are well-above background dextran incorporation due to sufficiently high traversal 
activity of sporozoites, and reproducibility of the assay. While the in vitro hepatocyte traversal assay has 
previously been established for murine malaria parasites [1,23,24], so far, different hepatocyte cell lines and 
culture media have been used across laboratories for P. falciparum sporozoite experiments [1,25,28,30]. 
However, to date, it has not been examined whether different host cells and culture media could affect and/or 
enhance P. falciparum sporozoite traversal efficiency, and how reproducibly inhibition of traversal by 
antibodies can be assessed with this assay.  
 
Methods 
Cells and reagents 
The HC-04 cell line (Homo sapiens HC-04, MRA-975, deposited by Jetsumon Sattabongkot [21]) was obtained 
through the MR4 as part of the BEI Resources Repository (NIAID, NIH). The HUH-7 cell line was obtained 
through the Japanese Collection of Research Bioresources Cell Bank (JCRB0403). The following reagents were 
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obtained from Gibco, Invitrogen: Dulbecco’s Modified Eagle Medium (DMEM), F-12 Nutrient Mixture, Minimal 
Essential Medium (MEM), fetal bovine serum (FBS), penicillin/streptomycin, Glutamax and Trypsin-EDTA. 
Fluorescein isothiocyanate-dextran (FITC)-dextran (10,000 MW, D1820) and tetramethylrhodamine dextran 
(10,000 MW, D1816) were from Invitrogen. Leibovitz medium (L-15; L5520) was purchased from Sigma Aldrich. 
 
Cultivation of HUH-7 and HC-04 hepatocyte cell lines 
Human hepatoma cell lines HUH-7 and HC-04 were used for in vitro infection with sporozoites and cultured at 
37°C in an atmosphere of 5% CO2. HUH-7 hepatocytes were maintained in DMEM supplemented with 10% FBS, 
1% penicillin/streptomycin and 1% Glutamax. HUH-7 hepatocytes were seeded in 48 or 96 well plates at a cell 
density of 1x105 and 5x104 cells/well and 500 and 250 µl/well, respectively. HC-04 cells were maintained in HC-
04 cell culture medium, containing equal volumes of F-12 Nutrient Mixture and MEM supplemented with 10% 
FBS and 1% penicillin/streptomycin. HC-04 hepatocytes were seeded in 96 well plates at a cell density of 2.5 or 
5x104 cells/well (250 µl/well). 
 
Generation of P. falciparum parasites 
Plasmodium falciparum NF54 asexual and sexual blood stages were cultured in a semi-automated culture 
system [31-33]. Sporozoites were produced by feeding female Anopheles stephensi mosquitoes with cultured 
gametocytes by means of standard membrane feeding [34]. For in vitro traversal assays, salivary glands were 
hand dissected, collected in either DMEM or Leibovitz culture medium supplemented with 10% FBS and 1% 
penicillin/streptomycin, and homogenized in a homemade glass grinder. Sporozoites were counted in a Bürker-
Türk counting chamber using phase-contrast microscopy. When sporozoites were stored for up to 24h at 4°C, 
they were kept in 4ml amber glass bottles (548-0510, VWR International). 
 
Hepatocyte traversal assay 
Hepatocyte traversal assays were conducted as previously described [20]. P. falciparum sporozoites were 
added to flat-bottom 96-well plates containing monolayers of hepatoma cells in the presence of 0.5 mg/ml 
fixable dextran (Invitrogen). Each condition was set up in duplicate or triplicate at a final volume of 125 µl/well. 
Plates were centrifuged at 3,000 rpm (Eppendorf Centrifuge 5810 R) for 10 min at RT with low brake and 
incubated for 2 h at 37°C in 5% CO2. Cells were then gently washed three times with PBS to remove 
extracellular dextran, trypsinized with 75 μl 0.05% Trypsin-EDTA for 5 min at RT, taken up in 75 μl 10% FBS in 
PBS, and centrifuged for 5 min at RT either in Eppendorf tubes at 3,600 rpm (Eppendorf Centrifuge 5415 D) or 
in a V-bottom plate at 1,700 RPM (Eppendorf Centrifuge 5810 R). Cells were re-suspended in 300 μl 1% 
paraformaldehyde in PBS and stored no longer than 15h at 4°C in the dark until analysis on an ADP Cyan flow 
cytometer (Beckman Coulter). Each sample was run until 1.5x104 singlet cells were collected or the sample was 
depleted. Non-infected cells incubated with dextran served as a background control. Sporozoites pre-treated 
with 10 ug/ml of a monoclonal antibody (mAb) recognizing the circumsporozoite protein CSP (clone 3SP2; [35]) 
for 30 minutes on ice were included as a positive control. Sporozoite traversal was corrected for background 
dextran incorporation. The percent traversal inhibition by mAb CSP was calculated as follows: 1 – (average % 
dextran-positive cells in anti-CSP cultures/average % dextran-positive cells in sporozoite only cultures) x 100%. 
Initially, two different cell impermeant dextrans were compared and no difference found in traversal rates 
assessed using either FITC-dextran (D1820, Invitrogen; mean 6.7% ± SD 0.85%) or tetramethylrhodamine 
dextran (D1816, Invitrogen; mean 7.7% ± SD 0.99%; p=0.70, data not shown). Since the use of FITC-dextran 
precludes the potential use of P. falciparum sporozoites tagged with GFP, tetramethylrhodamine dextran was 
used in all follow-up experiments. 
 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism software version 5 (GraphPad Software Inc., 
California, USA). For analysis of data of traversal experiments, differences between the percentage of dextran-
positive cells in various conditions were tested using the paired, parametric Student’s t-test, or one-way 
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ANOVA with Bonferroni’s post hoc test. A p-value of <0.05 was considered significant. Correlation analysis was 
performed by Pearson correlation. 
 
Results  
Cell lines  
While the HUH-7 cell line, one of the most commonly used cell lines for experiments with different 
Plasmodium species, does not support P. falciparum invasion, in vitro growth and development in liver cells, 
the HC-04 cell line can be infected by P. falciparum sporozoites and sustain complete development of the 
parasite [21]. It was therefore assessed in direct comparison experiments whether these cells also differ in 
their ability to support sporozoite traversal. Flow cytometry dot plots of hepatocytes incubated with P. 
falciparum sporozoites in complete DMEM medium show a clearly defined group of traversed cells in the HC-
04 cell line, while the dextran-positive group is much more scattered in the HUH-7 cell line (Figure 1A). 
Moreover, the percentage of hepatocytes traversed by P. falciparum sporozoites was significantly higher for 
HC-04 hepatocytes (median 19.9% with interquartile range (IQR) 9.3%-21.7%) than for HUH-7 cells (median 
8.6%; IQR 4.5%-12.1%; Figure 1B, p=0.008). When P. falciparum sporozoites were collected in complete 
Leibovitz medium instead of DMEM medium, traversal was again significantly higher for HC-04 than in HUH-7 
cells (p=0.009, Figure 1C) with a median of 13.9% (IQR 9.3%-22.3%) and 10.4% (IQR 3.5%-12.5%), respectively. 
 
Collection and storage media 
Like DMEM medium, Leibovitz medium is a buffered medium, but the standard sodium bicarbonate/CO2 
buffering system used in DMEM medium has been replaced by free-base amino acids, higher levels of sodium 
pyruvate and galactose and a combination of phosphate buffers, resulting in a very stable pH. Additionally, the 
buffer conditions of Leibovitz medium more closely mimic the insect microenvironment. Absolute traversal 
rates of P. falciparum sporozoites differed depending on the medium used (Figures 1B and 1C), but overall 
there was no statistically significant difference between complete DMEM medium (median 15.32; IQR 8.4%-
20.3%) or Leibovitz medium (median 13.8%; IQR 9.5%-15.6%; p=0.38; Figure 2A). However, when sporozoites 
were stored for 24h in complete DMEM medium, traversal rates were significantly reduced compared to 
freshly isolated sporozoites (Figure 2B; p=0.02). While the traversal capacity of sporozoites stored in Leibovitz 
medium was also significantly reduced compared to freshly isolated sporozoites, this difference was less 
marked than for DMEM medium (Figure 2C and Supplementary Figure S1A; p=0.04). Seeing the profound 
effect of prolonged storage on sporozoite traversal, the effect of shorter storage times was subsequently 
investigated. Traversal rates of sporozoites stored in complete DMEM medium were already significantly 
reduced after just 2h (Figure 2D; p<0.0001). In contrast, the traversal capacity of sporozoites stored in 
Leibovitz medium remained initially comparable to fresh sporozoites. Traversal decreased more slowly and less 
marked than for DMEM medium after 6h and 24h (Figure 2E and Supplementary Figure S1B). Moreover, 
absolute traversal rates of sporozoites stored for up to 24h in DMEM medium were always significantly lower 
than for sporozoites stored in Leibovitz medium (Supplementary Figure S1B; p<0.0001 for up to 6h storage; 
p<0.05 for 24h). 
Therefore, while the medium used for collection of sporozoites does not exert a strong effect on sporozoite 
viability and traversal rates in fresh assays, the chosen medium for (short-term) storage of sporozoites is 
important. Given the fact that the traversal capacity of P. falciparum sporozoites appeared more stable in 
Leibovitz medium than in DMEM medium, Leibovitz medium was used in further traversal experiments. 
 
Dose titration of sporozoites and hepatocytes 
Titrations were performed to determine the most optimal numbers of sporozoites and hepatoma cells. In 2/3 
experiments conducted, the number of P. falciparum sporozoites added to HC-04 hepatocytes showed a near 
perfect linear correlation with the percentage of dextran-positive cells (Supplementray Figure S2A). This 
relationship was also observed when sporozoites were added to a two times lower number of HC-04 
hepatocytes in 1/2 experiments (Supplementray Figure S2B). No saturation was achieved during these 
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experiments, suggesting that a higher number of sporozoites might lead to higher traversal rates. However, 
this was not further tested, to reduce the number of mosquitoes to be dissected. Highest traversal rates were 
observed when 5x104 P. falciparum sporozoites were added to 2.5x104 cells/well. However, since the cells 
were looking healthier and more confluent when seeded at 5x104/well and this also allows more rapid flow 
cytometric acquisition, this seeding concentration was used in further experiments. 
 
 
Figure 1. Comparison of traversal rates in two different hepatoma cell lines. 
5x104 P. falciparum sporozoites and tetramethylrhodamine dextran were added to 96 well plates containing 5x104 
hepatoma cells/well. (A) Representative plots of HUH-7 and HC-04 cells traversed by fresh P. falciparum sporozoites, and 
background controls are shown. Traversal rates in HUH-7 and HC-04 hepatocytes were compared using either complete 
DMEM medium (B; five independent experiments) or Leibovitz medium (C; nine independent experiments). Differences 
between cell lines were tested using a paired, parametric Student’s t-test. 
 
Dose-dependent inhibition of traversal by an anti-CSP monoclonal antibody  
Inhibition of hepatocyte traversal by sporozoites was assessed by pre-treatment of sporozoites with increasing 
concentrations of anti-CSP mAb prior to addition to hepatocyte cultures (Figure 3A). Across three experiments, 
there was a dose-dependent inhibition of sporozoite traversal by anti-CSP (Figure 3B; Pearson R2=0.80, 
p=0.006). Subsequently, the reproducibility of the hepatocyte traversal assay was investigated by pre-
incubating sporozoites with a set dose of anti-CSP mAb and comparing traversal inhibition across twenty-four 
independent experiments. Pre-treatment of sporozoites with 10 µg/ml of mAb anti-CSP consistently resulted 
in strong reduction of absolute traversal rates (p<0.0001; Figure 3C). Traversal inhibition was remarkably 
reproducible (mean 83.6% with SEM 1.3%) and there was only a moderate correlation with absolute traversal 
rates in the individual experiments (Figure 3D and Supplementary Figure S3; Spearman r=0.4267; p=0.04). 
 
26 
 
 
Figure 2. Collection and storage media: DMEM versus Leibovitz medium 
(A) Side-by-side comparison of sporozoite traversal through HC-04 hepatocytes in either DMEM or Leibovitz (eight 
independent experiments). All data are shown as the mean of duplicate or triplicate measurements and presented as 
circles and squares for HUH-7 and HC-04 cells, respectively. Differences were tested using the paired Student’s t-test.  P. 
falciparum sporozoites were dissected from infected mosquito salivary glands and stored in complete DMEM (B) or 
Leibovitz (C) medium for 24h at 4 °C, or immediately subjected to traversal experiments. 5x104 sporozoites and 
tetramethylrhodamine dextran were added to monolayers of 5x104 HC-04 hepatocytes in 96 well plates in triplicates. Data 
from four independent experiments are shown. Additionally, isolated P. falciparum sporozoites were either immediately 
subjected to traversal experiments or stored for 2h, 6h or 24h at 4 °C in complete DMEM (D; one experiment) or Leibovitz 
(E; two independent experiments) medium. Data are shown as the mean of three (24h storage), five or six replicate wells 
(fresh, 2h and 6h storage) and presented in grey or black for sporozoites collected in complete DMEM or Leibovitz medium, 
respectively. Differences between fresh sporozoites (control) and sporozoites stored for 2h, 6h or 24h were tested using 
one-way ANOVA with Bonferroni’s post hoc test (* = p<0.05; ** = p<0.01; *** = p<0.001; **** = p<0.0001). 
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Figure 3. Dose-dependent inhibition of traversal by the anti-CSP mAb 
(A) Representative flow cytometry plots of P. falciparum sporozoites pre-treated with increasing concentrations of mAb 
anti-CSP. (B) 5x104 P. falciparum sporozoites in complete Leibovitz medium were pre-treated with increasing 
concentrations of mAb anti-CSP, ranging from 0.04 to 10 µg/ml, for 30 minutes on ice, prior to addition to monolayers of 
5x104 HC-04 hepatocytes in 96 well plates. Data from three independent experiments are shown as the mean of duplicate 
or triplicate measurements ± SD. Pearson correlation analysis was performed on these data sets. (C and D) The 
reproducibility of the hepatocyte traversal assay was investigated by comparing the percent traversal inhibition by 10 
µg/ml anti-CSP across twenty-four independent experiments. Data are presented as the mean of duplicate or triplicate 
measurements. Differences between sporozoites only and sporozoites treated with 10 ug/ml anti-CSP were tested using a 
paired, parametric Student's t-test. Note: Data from several independent experiments directly overlap each other in Figure 
4C; therefore, only data from sixteen independent experiments can appear to be seen. 
 
Discussion 
The present study shows that traversal rates in the flow cytometry-based hepatocyte traversal assay for P. 
falciparum sporozoites can be increased and the traversal capacity of sporozoites preserved for longer 
depends on the choice of hepatocyte cell line and culture medium.  
Traversal was shown to depend on the host hepatocyte cell line, with low traversal rates of P. falciparum 
sporozoites in HUH-7 hepatocytes, and higher traversal of HC-04 hepatocytes, one of the few hepatocyte cell 
lines permissive for functional development of P. falciparum sporozoites [21,36]. A possible explanation for 
this difference between the cell lines might be the origin of the cell lines. The HUH-7 cell line is a hepatocyte-
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derived cellular carcinoma cell line originating from a liver tumor [37], while the HC-04 cell line is derived from 
normal liver tissue [21]. This may, therefore, lead to differences in e.g. the production of major enzymes, such 
as the CYP450 enzyme family, which has previously been shown to be maintained in the HC-04 cell line [21,38], 
while CYP450 activity is low in the HUH-7 cell line [39]. Differences might also be due to differential expression 
of molecules important for sporozoite binding. One such example is the tetraspanin CD81, a receptor that has 
been shown to be crucial for sporozoite infectivity of human primary hepatocytes [40-43]. HUH-7 cells express 
the CD81 receptor prevalently at the plasma membrane [44], but the degree of expression differs among the 
clones [45]. On the other hand, HC-04 hepatocytes do not express surface CD81 (data not shown and [43]) and 
invasion of HC-04 cells has been shown to be independent of CD81 [43]. The absence of CD81 expression in 
HC-04 cells and the fact that absolute traversal rates of P. falciparum sporozoites were consistently higher for 
HC-04 cells than for HUH-7 cells, suggest that CD81 does also not play a critical role during in vitro traversal of 
HC-04 hepatocytes. However, other proteins or receptors might potentially explain the observed difference in 
sporozoite traversal between the cell lines. Taken together, this study shows that the HC-04 cell line can be 
used to enhance P. falciparum sporozoite traversal rates.  
Moreover, to our knowledge, this is the first study comparing the effect of two different media on in vitro 
sporozoite traversal, using both fresh sporozoites and sporozoites stored for up to 24h. Sporozoites stored in 
Leibovitz medium show superior traversal rates to sporozoites stored in DMEM medium. The effect of 
Leibovitz medium might be explained by the fact that Leibovitz medium lacks bicarbonate, resulting in an 
improved sporozoite survival [46]. Indeed, in a recent study, it was demonstrated in in vitro sporozoite gliding 
motility assays that P. vivax and P. falciparum sporozoites retain viability better over time when they were 
maintained in insect media rather than in standard dissection media [47]. The present data show that the time 
window for conducting traversal assays can be enhanced by the choice of medium, but that highest traversal 
rates are still obtained when using sporozoites freshly or stored for a maximum of 2h at 4 °C. 
With respect to the most optimal combination of cell and sporozoite numbers, previous studies also showed 
variation in the used doses. Some of them used an equal ratio of sporozoites and hepatocytes [20,24], while 
others used a higher ratio of either cells [1,2,26] or sporozoites [28,43]. Consistent with an increase of the 
likelihood of traversal in the latter scenario, the present study found higher traversal rates at a 2:1 ratio of 
sporozoites to cells. However, this setup requires a compromise for cell confluency when seeding fewer cells, 
or increasing the amount of sporozoites needed and thus, the number of mosquitoes to be dissected. 
Therefore, we considered an equal ratio of sporozoites (5x104) and hepatocytes (5x104) to be most optimal. 
During the collection of traversal data, it was observed that at an equal ratio of P. falciparum sporozoites and 
HC-04 cells, traversal rates varied greatly from 5 to 40% across experiments. This observed large variation in 
absolute traversal rates is consistent with previous observations of P. berghei, P. yoelii or P. falciparum 
sporozoites traversal rates through either mouse Hepa1-6 hepatocytes, HepG2, HepG2-CD81, THLE-2, THLE-3, 
HUH7 or HC-04 cells, which could be as low as ~5% or as high as ~40-50% [1,2,20,25,30,43]. Traversal values 
might further be underestimated, because cells that fail to re-seal their membrane after traversal will die, 
detach from the plate and therefore be lost during subsequent washing steps prior to flow cytometric analysis. 
Importantly, this study clearly shows that the degree of traversal inhibition at a given concentration of blocking 
antibody is largely independent of absolute traversal rates. This demonstrates the robustness of this assay and 
thus, its suitability to assess the functionality of immunization-induced or monoclonal antibodies. Of note, it 
has recently been demonstrated that the number of traversed hepatocytes does not correlate with the 
frequencies of infected hepatocytes, suggesting that the process of invasion and development is distinct from 
traversal in the cell lines tested [43]. As a functional assay, it may thus complement the more labor- and time-
intensive in vitro invasion assays or in vivo humanized mouse models to identify correlates of immunization-
induced or naturally acquired pre-erythrocytic immunity. 
 
Conclusions 
In conclusion, the present work demonstrates that the in vitro traversal assay can be improved by using HC-04 
cells, which allow for higher traversal rates, and Leibovitz medium, which sustains sporozoite traversal capacity 
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for longer. As proof of reproducibility, incubation of sporozoites with mAb anti-CSP consistently resulted in the 
same proportional traversal inhibition, which was largely independent of absolute traversal rates. This work 
highlights the in vitro traversal assay as a promising, reliable high-throughput functional assay to assess the 
inhibitory effect of immunization-induced or mAbs on hepatocyte traversal by P. falciparum sporozoites.  
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Supplementary Figures 
 
 
 
Supplementary Figure S1. Storage media: DMEM versus Leibovitz medium. 
(A) Percent HC-04 hepatocytes traversed by sporozoites stored for 24h as compared to fresh sporozoites. Traversal by 
fresh sporozoites is defined as 100%. Data are shown in grey or black for sporozoites collected in complete DMEM or 
Leibovitz medium, respectively. (B) Percent reduction in traversal in sporozoites stored for 2h, 6h or 24h is shown as 
compared to fresh sporozoites (defined as 100% and thus, 0% reduction in traversal). Data are presented in grey or black 
for sporozoites collected in complete DMEM or Leibovitz medium, respectively. Differences between sporozoites stored in 
either DMEM or Leibovitz medium for 2h, 6h or 24h were tested using one-way ANOVA with Bonferroni’s post hoc test (* = 
p<0.05; **** = p<0.0001). 
 
 
Supplementary Figure S2. Dose titration of sporozoites/cells. 
(A) 1x104 to 5x104 P. falciparum sporozoites and tetramethylrhodamine dextran in complete Leibovitz medium were added 
to a 96-well plate containing monolayers of 5x104 HC-04 cells/well (three independent experiments). (B) 1x104, 2.5x104 or 
5x104 sporozoites were added to 2.5x104 HC-04 cells/well (two independent experiments). Data are shown as the mean of 
triplicates ± SD. Pearson correlation analysis was performed on these data sets. 
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Supplementary Figure S3. Correlation between absolute traversal rates and traversal inhibition by anti-CSP antibody 
5x104 P. falciparum sporozoites and tetramethylrhodamine dextran in complete Leibovitz medium were added to a 96-well 
plate containing monolayers of 5x104 HC-04 cells/well (24 independent experiments). Sporozoites were pre-incubated with 
10 µg/ml anti-CSP, or with Leibovitz medium only as a control. Each dot in the correlation matrix represents the mean 
traversal inhibition by anti-CSP antibody of duplicate or triplicate measurements for each single experiment, in relation 
with absolute traversal rates in control wells in the same experiment. Pearson correlation analysis was performed on these 
data sets. 
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Abstract 
 
Background 
Long-lasting and sterile protective immunity against Plasmodium falciparum can be achieved by immunization 
of malaria-naïve human volunteers under chloroquine prophylaxis with sporozoites delivered by mosquito 
bites (CPS-immunization). Protection is mediated by sporozoite/liver-stage immunity. In this study, the 
capacity of CPS-induced antibodies to interfere with sporozoite functionality and development was explored. 
 
Methods 
IgG was purified from plasma samples obtained before and after CPS-immunization from two separate clinical 
trials. The functionality of these antibodies was assessed in vitro in gliding and human hepatocyte traversal 
assays, and in vivo in a human liver-chimeric mouse model. 
 
Results 
Whereas pre-treatment of sporozoites with 2 mg/ml IgG in the majority of the volunteers did not have an 
effect on in vitro sporozoite gliding motility, CPS-induced IgG showed a distinct inhibitory effect in the 
sporozoite in vitro traversal assay. Pre-treatment of P. falciparum sporozoites with post-immunization IgG 
significantly inhibited sporozoite traversal through hepatocytes in 9/9 samples when using 10 and 1 mg/ml 
IgG, and was dose-dependent, resulting in an average 16% and 37% reduction with 1 mg/ml IgG (p = 0.003) 
and 10 mg/ml IgG (p = 0.002), respectively. In vivo, CPS-induced IgG reduced liver-stage infection and/or 
development after a mosquito infection in the human liver-chimeric mouse model by 91.05% when comparing 
11 mice receiving post-immunization IgG to 11 mice receiving pre-immunization IgG (p = 0.0008). 
 
Conclusions 
It is demonstrated for the first time that CPS-immunization induces functional antibodies against P. falciparum 
sporozoites, which are able to reduce parasite-host cell interaction by inhibiting parasite traversal and liver-
stage infection. These data highlight the functional contribution of antibody responses to pre-erythrocytic 
immunity after whole-parasite immunization against P. falciparum malaria. 
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Background 
Malaria is caused by mosquito-transmitted protozoan Plasmodium falciparum parasites with a complex multi-
stage life cycle in the human host. When P. falciparum-infected Anopheles mosquitoes probe for blood, 
sporozoites are deposited in the skin, move by circular locomotion (gliding) [1], and traverse cell barriers by 
breaching host cell membranes [2]. When sporozoites have reached the liver via the blood circulation, they 
first cross the sinusoidal barrier, traverse through and eventually invade hepatocytes [2,3]. Previous studies 
have demonstrated the importance of P. falciparum sporozoite gliding motility for invasion of a hepatocyte 
[4,5]. Moreover, cell traversal has been shown to be important for the progression of sporozoites to the liver 
and thus, enhancement of successful infection [3,6-8]. Subsequent liver-stage development is completed by 
merozoite release into the bloodstream and invasion of erythrocytes (asexual blood-stages) [9]. 
 
Immunity against malaria can be naturally acquired in individuals living in malaria-endemic areas, however, 
only after continuous exposure to the parasite, and appears to wane in the absence of ongoing P. falciparum 
exposure [10]. Historic passive transfer studies have demonstrated a key role for antibodies in controlling 
blood-stage parasites during natural P. falciparum infection and reducing clinical symptoms of malaria [11-13], 
as confirmed in animal models of malaria [14-16]. Although antibodies are crucial in controlling blood-stages, 
naturally acquired immunity never results in complete parasite elimination. 
Generating long-lasting and sterilizing immunity against malaria with pre-erythrocytic subunit vaccines, has 
only had limited success. The RTS,S subunit vaccine, to date the only most advanced malaria vaccine candidate 
tested in Phase III clinical trials, is based on P. falciparum circumsporozoite protein (CSP), a major sporozoite 
surface protein [17]. The RTS,S vaccine has been shown to elicit strong CSP-specific antibodies and to induce 
protection in the majority of the volunteers in a CHMI model upon infectious mosquito bite challenge [18-21]. 
However, 4/5 and 5/9 protected volunteers developed delayed parasitaemia upon re-challenge with infectious 
mosquito bites ~ six or five months after the initial challenge, respectively [21,22]. Additionally, RTS,S 
vaccination only confers modest protection in the field [23-26]. Immunization with other subunit vaccines, for 
instance with the sporozoite surface protein 2 (a homolog for P. falciparum thrombospondin-related adhesion 
protein (TRAP)) which is expressed on both the surface of sporozoites [27,28] and within infected hepatocytes 
[28], induced only partial protection in mice, but complete protection when given together with CSP [29]. 
However, Phase I/IIa clinical trials in which humans were immunized with RTS,S/TRAP failed to provide 
protection in the majority of volunteers (unpublished data, as written by [30]). Moreover, immunization of 
humans with a recombinant liver-stage antigen-1 (LSA-1)-based vaccine elicited high antibody titers, but did 
also not protect against P. falciparum infection [31]. 
 
While the induction of sterile immunity with subunit vaccines has been shown to be difficult, sterile immunity 
against malaria can be achieved experimentally by whole-parasite immunization with attenuated sporozoites 
in animal models and human volunteers, targeting the sporozoite/liver-stage parasites (pre-erythrocytic 
stages). As early as the 1960s, it was shown that sterile protective immunity can be induced in animals and 
humans by immunization with Plasmodium sporozoites attenuated by gamma irradiation (RAS) and delivered 
by P. falciparum-infected mosquito bites [32-34]. Sera from RAS-immunized subjects were able to reduce 
sporozoite invasion into hepatocytes, as shown in both animal [35,36] and human models of malaria [37-39]. 
This immunization approach, however, requires a minimum of 1,000 bites from irradiated mosquitoes to 
induce sterilizing immunity in humans. Therefore, more studies to other potential immunization methods have 
been conducted. Very recently, it has been demonstrated that intravenous immunization of humans with a 
radiation-attenuated and cryopreserved P. falciparum sporozoite vaccine can also induce protection against P. 
falciparum malaria [40]. In vitro invasion experiments with hepatoma cells and sera from volunteers protected 
after 4–5 immunization doses revealed that immunization-induced antibodies were able to inhibit in vitro 
sporozoite invasion [40]. However, to circumvent the need for irradiation of parasites, another whole-parasite 
vaccination approach has been developed, to be specific the genetically engineered and attenuated parasites 
(GAP). Passive immunization of naive mice with pooled serum from mice immunized i.v. with Plasmodium 
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yoelii-GAP one day before mosquito bite challenge, reduced the liver parasite burden by 48 hours after 
infection [41]. Exposure of human volunteers to ~5 bites from mosquitoes infected with a first generation of P. 
falciparum GAP (PfGAP), followed by a high-dose exposure to ~200 PfGAP-infected mosquito bites, led to 
breakthrough infection in one out of six volunteers, consisting of breakthrough PfGAP-parasites [42]. While 
this Phase I study was not safe and therefore not successful, plasma from volunteers obtained three months 
after high-dose exposure could efficiently block in vitro hepatoma cell invasion by P. falciparum sporozoites 
[43]. 
 
Next to the RAS and GAP whole-parasite vaccination approaches, a highly efficient immunization regimen 
based on controlled human malaria infection (CHMI) that induces long-lasting sterile immunity in malaria-
naïve individuals has recently been established: volunteers are exposed to ~45 wild type P. falciparum-infected 
mosquito bites, while receiving a prophylactic regimen of chloroquine (ChemoProphylaxis and Sporozoites, 
CPS) [44,45]. CPS-immunization allows full liver-stage maturation and development of early asexual blood-
stage parasites, however, it induces protection specifically targeting pre-erythrocytic, but not blood-stages 
[46]. In previous CPS-immunization studies, cellular responses to both blood-stage parasites and sporozoites 
were found [45,47]. Antibodies targeting the cell-free sporozoites may interfere with migration and invasion of 
hepatocytes, and thus lower the initial liver parasite load and complement T-cell mediated protection. Analysis 
of antibody responses by P. falciparum protein-microarray identified two pre-erythrocytic antigens i.e. CSP and 
LSA-1 as the two proteins predominantly recognized after CPS-immunization [48]. Moreover, efficient 
induction of memory B-cells and antibodies was found to classical pre-erythrocytic antigens, to be specific CSP 
and LSA-1 (Nahrendorf and Scholzen et al., manuscript in preparation). While the induction of antibodies by 
CPS-immunization has been demonstrated, their functional activity against sporozoite/liver-stage parasites has 
not yet been established. This study, therefore, focused on the possible functional contribution of antibodies 
to pre-erythrocytic protective immunity after CPS-immunization. 
 
Methods 
Study design and plasma sample collection 
Citrated plasma samples were collected during two clinical CPS-immunization trials approved by the Central 
Committee for Research Involving Human Subjects of The Netherlands (Study 1 [44], ClinicalTrials.gov number 
NCT00442377; CCMO NL24193.091.09, and Study 2 [46], ClinicalTrials.gov number NCT01236612; CCMO 
NL34273.091.10). In both studies, healthy malaria-naïve Dutch volunteers were immunized three times at 
monthly intervals by exposure to 12–15 P. falciparum-infected mosquito bites, while receiving chloroquine 
prophylaxis. All subjects provided written informed consent before screening and the study team complied 
with the Declaration of Helsinki and Good Clinical Practice. The following plasma samples, collected before 
(pre) and after CPS-immunization (post), were selected for IgG purification based on availability: ten volunteers 
from Study 1 and three from Study 2 protected against sporozoite challenge infection and another three 
volunteers from Study 2 challenged with blood-stages. For the latter three, their protection status upon 
sporozoite challenge is therefore unknown. 
 
IgG purification from citrated plasma samples 
IgG purification from 3–8 ml plasma samples was performed using a 5 ml HiTrap Protein G HP column 
(Amersham Biosciences) according to manufacturer’s instructions and IgG was taken up in phosphate buffered 
saline (PBS, GIBCO). IgG concentrations were determined by a NanoDrop spectrophotometer (NanoDrop 
Technologies, NanoDrop program 1000 version 3.8.2.). For Study 1, due to limited plasma availability, IgG 
samples from two volunteers each were pooled, resulting in five pools of two volunteers. For Study 2, IgG 
samples from six individual CPS-immunized volunteers were available. 
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Generation of P. falciparum sporozoites 
Plasmodium falciparum NF54 asexual and sexual blood stages were cultured in a semi-automated culture 
system [49-51]. Sporozoites were produced by feeding female Anopheles stephensi mosquitoes using standard 
membrane feeding of cultured gametocytes [52]. For in vitro assays, salivary glands were hand dissected, 
collected in Leibovitz culture medium (Sigma Aldrich) supplemented with 10% foetal bovine serum (FBS, 
GIBCO), homogenized in a homemade glass grinder. Sporozoites were counted in a Bürker-Türk counting 
chamber using phase-contrast microscopy. 
 
Gliding assay 
Gliding assays were performed in eight-chamber glass Lab-Tek chamber slides (Nalgene, Nunc) pre-coated with 
25 μg/ml monoclonal anti-CSP (3SP2, [53]) to capture shed P. falciparum circumsporozoite protein. 
Sporozoites were pre-incubated in duplicate with 2 mg/ml pre- or post-immunization IgG (due to limited 
plasma/IgG availability) in the presence of 10% FBS for 30 min on ice and then sporozoite/IgG suspension 
(30,000 spz/well) was added to each well. After 90 min of incubation at 37 °C in 5% CO2, gliding trails were 
fixed with 4% paraformaldehyde (PFA) for 20 min at room temperature (RT). Each well was washed twice with 
PBS, blocked with 10% FBS in PBS for 20 min at RT and washed again. Gliding trails were visualized with 10 
μg/ml anti-CSP-FITC in 10% FBS in PBS, incubated for 60 min in the dark at RT, washed and mounted with 
Fluoromount-G (Southern Biotech) and 24x50 mm cover glasses (VWR International). The number of gliding 
trails was counted per 280 fields of view (per well) at an enlargement of 1,000x with oil immersion. 
 
Traversal assay 
The functional capacity of CPS-induced antibodies to inhibit sporozoite traversal through human hepatocytes 
in vitro was studied using an optimized flow cytometry based version (Behet et al., manuscript in preparation) 
of the dextran incorporation assay [2,54]. Only cells traversed by sporozoites and, therefore, wounded, 
incorporate dextran and the percent of dextran-positive cells can be quantified with flow cytometry. 
The HC-04 hepatocyte cell line (Homo sapiens HC-04, MRA-975, deposited by Jetsumon Sattabongkot [55]) was 
obtained through the MR4 as part of the BEI Resources Repository (NIAID, NIH). Cells were cultured in HC-04 
cell culture medium, containing equal volumes of F-12 Nutrient Mixture (GIBCO) and Minimal Essential 
Medium (GIBCO) supplemented with 10% FBS (GIBCO) and 1% penicillin/streptomycin (GIBCO), at 37 °C in an 
atmosphere of 5% CO2. 
 
Plasmodium falciparum sporozoites were pre-incubated with 10 mg/ml or 1 mg/ml IgG for 30 min on ice. Data 
from 2 pre-immunization IgG samples from Study 1 were lost for technical reasons. Sporozoites pre-treated 
with 1.25 μg/ml of the mycotoxin cytochalasin D [56] served as a positive control resulting in a mean traversal 
inhibition of 93.1% and non-infected cells incubated with dextran served as a background control. 
Sporozoites (5.104) were added to 96-well plates containing monolayers of 5.104 HC-04 hepatocytes in the 
presence of 0.5 mg/ml fixable tetramethylrhodamine dextran (10,000 MW, D1817, Invitrogen) in duplicates or 
triplicates, centrifuged at 3,000 RPM (Eppendorf Centrifuge 5810 R) for 10 min at RT with a low brake and 
incubated for 2 h at 37 °C in 5% CO2. After incubation, wells were gently washed three times with PBS to 
remove extracellular dextran, trypsinized with 0.05% Trypsin-EDTA (GIBCO) for 5 min at RT, taken up in 10% 
FBS in PBS, and centrifuged at 3600 RPM for 5 min at RT. Cells were re-suspended in 1% PFA in PBS and stored 
at 4 °C in the dark until flow cytometric analysis on an ADP Cyan flow cytometer (Beckman Coulter). Sporozoite 
traversal was corrected for background dextran incorporation and the percent inhibition of traversal was 
calculated as follows: 1 – (average% dextran-positive cells in post-immunization IgG cultures/average% 
dextran-positive cells in pre-immunization IgG cultures) x 100%. 
 
Passive immunization of human liver-chimeric mice and sporozoite challenge 
Human liver-chimeric mice over-expressing urokinase-type plasminogen activator on a severe combined 
immunodeficiency background (uPA+/+-SCID mice) were generated as previously described [57,58]. 
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Cryopreserved primary human hepatocytes (±1.106 cells/mouse, all from the same donor and purchased from 
BD Gentest (Erembodegem, Belgium) were injected in the spleens of uPA+/+-SCID mice within two weeks after 
birth [57]. Human albumin levels were measured at different time points after transplantation by using the 
Human Albumin ELISA Quantitation kit (Bethyl Laboratories Inc., Montgomery, TX). Mice with human albumin 
levels of >2 mg/ml were considered successfully engrafted and used for infection studies. All procedures were 
approved by the Animal Ethics Committee of the Faculty of Medicine and Health Sciences of the Ghent 
University (ECD 11/03). 
 
The day before P. falciparum infection by mosquito bites, human liver-chimeric mice were injected 
intraperitoneally with 10 mg of post-immunization IgG from five sets of two CPS-immunized volunteers per 
pool (Study 1) and six CPS-immunized volunteers (Study 2). Each mouse was injected with one IgG sample, and 
mice injected with pre-immunization IgG served as controls. Mice were challenged by exposure to P. 
falciparum-infected mosquito bites as previously described [58]. Briefly, the abdomen and chest of mice were 
shaved with electric clippers and subsequently, mice were positioned on a cardboard box containing 20 P. 
falciparum-infected mosquitoes (one mouse per box) and exposed for 20 minutes to infectious mosquito bites. 
Successful blood feeding (median: 16 mosquitoes) and sporozoite presence (100%) was confirmed by 
mosquito dissection after the challenge experiment [59,60]. 
Due to limited availability of liver-chimeric mice, each IgG sample was injected in one mouse. The relatively 
wide range in liver load in control mice receiving only infectious mosquito bites as described previously 
[58,61], was also reflected in the present study in the group of mice receiving pre-immunization IgG. This 
precludes paired analysis of mice receiving pre- and post-immunization IgG from the same donor, and only 
allows to compare the pre- and post-immunization groups at group level. 
 
Isolation of DNA and quantification of P. falciparum and human hepatocyte DNA 
Isolation of liver DNA and quantification of P. falciparum and human hepatocyte DNA was performed as 
previously described [58]. Briefly, five days after sporozoite challenge mice were maximally bled and sacrificed 
by cervical dislocation. The removed livers were cut into 12 standardized sections and stored in RNALater 
(Ambion) at 4 °C until analysis. For DNA extraction, 25 mg (±0.1 mg) liver tissue was taken from each section 
and P. falciparum, mouse and human hepatocyte DNA levels were quantified in a total of 300 mg of liver tissue 
(12 sections x 25 mg; ~25% of total liver) using a highly sensitive qPCR assay, targeting Pf18SRNA and mouse 
and human prostaglandin E receptor (PTGER2) genes, respectively [58,62]. The quantification of the relative 
amount of human and mouse hepatocytes in mixed liver tissues allowed us to assess the repopulation of 
chimeric mouse livers with human hepatocytes, and thus to express P. falciparum liver infection as a number 
of parasites per 106 human hepatocytes [58, 63]. DNA extracts from titrated samples of ring-stage P. 
falciparum-infected erythrocytes that were spiked with extracted DNA from a uninfected humanized liver, 
were used for preparation of P. falciparum standard curves. Standard curves were prepared by DNA extraction 
from a titration of defined numbers of human peripheral mononuclear cells (PBMCs) and mouse splenocytes. 
Percentage calculation was verified by making various ratios of mouse and human DNA extracts [58]. 
 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism software version 5 (GraphPad Software Inc., 
California, USA). For analysis of data of traversal experiments, differences between the percentage of dextran-
positive cells in pre- and post-immunization samples were tested using the paired Student’s t-test. Statistical 
analysis of humanized mouse data was performed using the non-paired, non-parametric Mann Whitney U-
test. A p-value of <0.05 was considered significant. 
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Results 
Sporozoite gliding motility is not consistently reduced by low IgG concentrations of CPS-induced antibodies 
To explore the capacity of CPS-induced antibodies to interfere with in vitro sporozoite gliding motility, 
sporozoite gliding trails produced by P. falciparum sporozoites pre-incubated with 2 mg/ml of either pre- or 
post-immunization IgG from five pools of two volunteers each (Study 1) or individual IgG samples from six CPS-
immunized volunteers (Study 2), were counted by microscopy. In vitro sporozoite gliding motility tested was 
highly variable, not only between volunteers, but also between replicates (Figure 1). In the presence of 2 
mg/ml post-immunization IgG, the number of gliding trails was reduced in 3 out of 11 samples (n = 1 from 
Study 1 (Pool 5), and n = 2 from Study 2 (Volunteers 1 and 3); Figure 1), but in the majority of the volunteers 
no effect could be observed. 
 
Figure 1 Effect of CPS-induced IgG on in vitro sporozoite gliding motility. The number of sporozoite gliding trails produced 
by sporozoites incubated with 2 mg/ml IgG was counted in 280 fields per well at an enlargement of 1,000x with oil 
immersion. Incubations were performed in duplicates and data are expressed as median with range. Pre- or post-
immunization IgG samples from five pools of two volunteers each (Study 1) or from six volunteers (Study 2), immunized by 
ChemoProphylaxis and Sporozoites immunization (CPS), were tested in 3 independent experiments in duplicate. Black 
squares and grey circles represent the number of gliding trails produced by sporozoites incubated with pre- or post-
immunization IgG, respectively. Filled symbols show volunteers protected against mosquito challenge. Open symbols 
represent volunteers with unknown protection status regarding mosquito challenge (blood-stage challenged). 
 
Sporozoite traversal is dose-dependently inhibited by CPS-induced antibodies 
Subsequently, the inhibitory activity of immunization-induced antibodies on in vitro hepatocyte traversal by 
sporozoites was investigated. The percentage cells traversed by sporozoites pre-incubated with two 
concentrations (1 or 10 mg/ml) of either pre- or post-immunization IgG from three pools of two CPS-
immunized volunteers each (Study 1) and six individual CPS-immunized volunteers (Study 2), was determined 
by flow cytometry (Figure 2A and Additional files 1A and B). Pre-treatment of sporozoites with 10 mg/ml post-
immunization IgG from both Study 1 and Study 2 lead to a statistically significant reduction in in vitro 
hepatocyte traversal for all volunteers, compared to pre-immunization IgG treatment (Figure 2B and C; Study 
1, p = 0.047; Study 2, p = 0.007). The mean percent traversal inhibition by 10 mg/ml IgG was 36.7% (p = 0.002; 
50.5% (range 31.4-70.5%) and 29.8% (range 9.7-54.6%) for Study 1 and 2, respectively). Traversal inhibition 
was concentration-dependent, and significantly higher for 10 mg/ml compared to 1 mg/ml IgG (p = 0.005; 
Figure 2D). Nevertheless, even as little as 1 mg/ml post-immunization IgG resulted in a significant inhibition of 
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sporozoite traversal (p = 0.003) of 16.2% (mean; range 1.6-45.5%; Figure 1D). Although the percentage of 
traversed cells varied between experiments with individual mosquito and sporozoite batches (Figure 2B and C), 
the variability between duplicate/triplicate measurements within each experiment for each IgG sample was 
very low (Additional files 1A and B; 1 mg/ml IgG and 10 mg/ml IgG, respectively). 
 
 
Figure 2 Effect of CPS-induced IgG on in vitro hepatocyte traversal. (A) The proportion of traversed (wounded) cells was 
determined by flow cytometric analysis, after gating out debris and doublets. Sporozoites with dextran only were used as a 
positive control and sporozoites pre-treated with cytochalasin D (cytoD) and dextran, as a negative control. Cells incubated 
with dextran only were used to correct for background. (B) Sporozoites were pre-incubated with 10 mg/ml pre- or post-
immunization IgG from three pools of two volunteers each (Study 1) or (C) from six individual volunteers (Study 2), all of 
which underwent ChemoProphylaxis and Sporozoites immunization (CPS). Samples were tested in 4 experiments with 3 
mosquito batches, in duplicate or triplicates. (D) The percentage inhibition of traversal was calculated for post- compared 
to pre-immunization IgG for each pool/volunteer at a concentration of either 1 or 10 mg/ml. Data are shown as the mean 
of duplicate or triplicate measurements, and presented as circles or squares for Study 1 and 2, respectively. Filled symbols 
show volunteers protected against mosquito challenge. Open symbols represent volunteers with unknown protection 
status regarding mosquito challenge (blood-stage challenged). Differences between pre- and post-immunization IgG, and 1 
and 10 mg/ml IgG was tested using the paired Student’s t-test. 
 
Functional CPS-induced antibodies inhibit in vivo sporozoite infection of the liver 
Finally, it was investigated whether in vitro inhibitory activity of CPS-induced IgG on sporozoite traversal would 
translate into inhibition of sporozoite infection of and/or development in the liver in vivo, using human liver-
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chimeric mice infected with P. falciparum sporozoites by mosquito bites. In two independent experiments, 
mice were passively immunized with 10 mg of either pre- or post-immunization IgG from five pools of two 
volunteers each (Study 1) and six individual CPS-immunized volunteers (Study 2) the day before challenge 
infection. qPCR analysis was performed on liver sections from all mice to determine the liver parasite burden 
after five days to allow full liver-stage development of P. falciparum parasites. The two groups of mice 
receiving pre- or post-immunization IgG had comparable levels of repopulation with human hepatocytes and 
body weight, and there was no statistically significant difference in the number of mosquitoes fed on both 
groups of mice (Table 1), nor between the two experiments conducted.  
Passive immunization of liver humanized uPA+/+-SCID mice with post-immunization IgG one day prior to 
mosquito bite challenge significantly reduced the number of infected hepatocytes by day 5 of infection (Table 
1). The median number of liver sections positive for P. falciparum infection (Pf+) was significantly higher for 
mice injected with pre- (median 5 Pf + liver sections, interquartile range (IQR) 4–10) than with post-
immunization IgG (median 3 Pf + liver sections, IQR 2–3; p = 0.003) and did not statistically differ between 
Study 1 and 2 samples. Additionally, the median number of P. falciparum parasites per million human 
hepatocytes in mice injected with either pre- or post-immunization IgG was 326.5 (IQR: 209.3- 354.5) and 29.2 
(IQR: 19.30-60.90), respectively and did not differ between Study 1 and 2 samples. The reduction of the 
median liver load by post-immunization IgG was 91.05%, comparing the two groups of mice (n = 11 each) 
receiving post-immunization or pre-immunization IgG (p = 0.0008). 
 
Discussion 
This study demonstrates for the first time that antibodies with inhibitory activity against pre-erythrocytic 
stages of P. falciparum are induced in human volunteers that have undergone CPS-immunization. 
The most striking result was that CPS-induced antibodies could strongly reduce the liver parasite load in 
human liver-chimeric mice, measured five days after infection by mosquito bite with P. falciparum sporozoites. 
This strong reduction in late stage liver infection (91.05%) might be explained by CPS-induced antibodies 
targeting sporozoites either in the skin, in the circulation, or during liver infection and/or development. In 
rodent malaria models, it has been demonstrated that mice immunized by gamma-irradiated Plasmodium 
berghei-infected mosquito bites exhibited high levels of anti-sporozoite antibodies that immobilize sporozoites 
in the skin by inhibiting their gliding motility and ability to invade dermal blood vessels [64-66]. Therefore, CPS-
induced antibodies might also limit the numbers of sporozoites injected into passively immunized mice and 
immobilizing the sporozoites in the mouse skin, thereby preventing their journey to the liver in the first place. 
However, the prolonged presence or trapping of sporozoites in the skin after mosquito bites has only been 
demonstrated in animal models of malaria and not in humans; this may be different for humans. To assess the 
effect of CPS-induced antibodies on sporozoite ejection during mosquito salivation and sporozoite motility in 
the skin, in vitro mosquito salivation assays [66] and in vivo intravital microscopy with Green-Fluorescent 
Protein-expressing P. falciparum parasites [64] can be used, respectively. 
The overall liver parasite burden of the control mice (receiving pre-immunization IgG) was lower compared to 
previous studies [58,61], likely due to mosquito and sporozoite batch variations. Another likely source of 
variation is the number of injected sporozoites between mice. Nevertheless, the obtained data were 
consistent across two independent experiments, and the data between two groups of mice receiving either 
pre- or post-immunization IgG were comparable. Finally, while mice injected with PBS could not be directly 
included in the IgG experiments due to limited availability of chimeric mouse numbers, PBS-injected mice used 
in other parallel experiments performed in the same time frame showed the same range in liver parasite 
burden as mice receiving pre-immunization IgG (Additional file 2). 
In vitro sporozoite gliding was inhibited by post-immunization IgG in only 3/11 volunteers. This low frequency 
may be due to the low concentration of IgG that had to be used because of limited supply (2 mg/ml, i.e. 2–5 
fold lower than the typical concentration in human plasma). The high intra- and inter-assay variability, despite 
the fact that always the same operator was carrying out the experiments, may also have contributed to this 
outcome, which is possibly due to variation between sporozoite batches or methodological factors (e.g. the 
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lack of a centrifugation step to settle sporozoites prior to gliding). Moreover, the manual readout by 
microscopy assessing shape or length of gliding trails remains somewhat subjective [67]. Overall, this assay 
appears more suitable for qualitative rather than quantitative analysis, e.g. for studying the phenotype of 
knock-out parasites [68,69]. 
 
The in vitro traversal assay, in contrast, is a high-throughput assay and the variation between replicate 
measurements is very tight (Additional files 1A and B). Although the percentage cells traversed varied between 
experiments (probably due to variation between sporozoite batches), incubation of sporozoites with 10 μg/ml 
of the anti-CSP monoclonal antibody (3SP2) consistently results in the same proportional traversal inhibition 
(median 86.4%; IQR 85.0-89.7%), independent of absolute traversal rates (Additional file 3). Moreover, the 
variability between duplicate/triplicate measurements for each IgG sample was very low. In contrast to the 
gliding assay, significant and consistent inhibition of traversal activity of sporozoites by CPS-induced antibodies 
was found, by as little as 1 mg/ml post-immunization IgG. For three of the volunteers whose IgG was assessed 
in this study, the protection status against mosquito-bite challenge remains unknown since they received a 
blood-stage challenge, but they did undergo the same immunization regimen as protected volunteers [46]. 
Consistent with this, their ability to reduce sporozoite traversal was comparable to that of volunteers known to 
be protected from mosquito challenge, and 2/3 blood-stage challenged volunteers also showed inhibition of 
gliding motility. 
 
A dose-dependency for the traversal inhibitory effect of CPS-induced IgG was observed, since traversal 
inhibition by 10 mg/ml IgG was about 2.2 fold higher than for 1 mg/ml. Traversal inhibition showed a broad 
range across all volunteers. Possible reasons for this may be the intra-individual differences in antibody 
specificity, affinity maturation and/or binding capacity to sporozoites. Of note, inhibition of sporozoite 
traversal in vitro did not reach 100 percent, when using an average plasma concentration of 10 mg/ml IgG, and 
was lower than the inhibition of liver-stage infection and/or development in vivo. This might be due to the fact 
that antibodies do not only interfere with sporozoite hepatocyte traversal, but also with other mechanisms of 
sporozoite functionality. Another targeted pathway might be hepatocyte invasion, as shown for plasma from 
RAS- or CPS-immunized mice [36], and for serum, IgG, or monoclonal antibodies derived from human 
volunteers immunized by RAS [37-39], an irradiated and cryopreserved sporozoite vaccine [40], GAP ([43], or 
subunit vaccines [61,70] - although it is not clear whether this process can be affected completely 
independently from traversal, which is a requirement for invasion [71]. Additionally, CPS-induced antibodies 
might also interfere with intrahepatic parasite development by inducing clearance of infected hepatocytes by 
means of antibody-dependent cell-mediated cytotoxicity, as shown in vitro in murine hepatic cells incubated 
with a monoclonal antibody recognizing Plasmodium heat shock protein 70 [72,73]. SCID mice, while devoid of 
adaptive lymphocytes, still have an innate immune system including natural killer (NK) cells and macrophages 
[74,75], both of which are capable of mediating antibody-dependent killing [76]. Whether such a mechanism 
may also play a role in the in vivo liver-chimeric uPA+/+-SCID model remains to be investigated. 
 
Determining the antigen targets of CPS-induced functional antibodies will help to shed further light on the 
developmental stage at which the sporozoite/liver-stage is targeted. CSP and LSA-1 antigens have previously 
been demonstrated to be predominantly recognized by CPS-induced antibodies, as shown by microarray 
analysis of 809 P. falciparum antigens [48] and enzyme-linked immunosorbent assay and ELISpot analysis 
(Nahrendorf and Scholzen et al., manuscript in preparation). RTS,S vaccination has been shown to elicit 
antibody titers against only CSP and the highest anti-CSP antibody titers were found in protected volunteers 
[18,20,21,25]. Other studies, however, found that antibody responses to both CSP and TRAP did not differ 
between protected and unprotected RAS-immunized volunteers, but protected volunteers were able to 
recognize novel P. falciparum antigens [77,78]. 
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 Mouse 
ID 
IgG 
sample 
ID 
Time 
point 
Human albumin 
levels (mg/ml) 
Proportion of HuHEPb in 
mouse liver (%) 
Weight 
mice (g) 
Number of fed 
mosquitoes (out of 20) 
Liver parasite burden (No. 
Pf/10^6 HuHEP) 
No. of Pf c positive liver 
sections (out of 12) 
Pre-CPSa IgG 
Study 1 B730R Pool 1 Pre 2,4 26,0 15,9 14 326,5 10 
 K1596RL Pool 2 Pre 2,6 37,2 11,5 19 209,3 5 
 B749RL Pool 3 Pre 3,0 39,7 12,1 17 77,2 5 
 K1589R Pool 4 Pre 4,0 33,0 12,5 14 280,1 11 
 K1576 Pool 5 Pre 3,1 35,0 12,2 20 373,0 10 
Median 3,0 35,0 12,2 17 280,1 10 
Study 2 K1630LR Vol.d 1 Pre 3,0 40,1 15,1 16 354,5 7 
 B934R Vol. 2 Pre 2,2 29,1 11,7 18 329,8 4 
 B934LR Vol. 3 Pre 2,6 37,7 12,8 17 37,6 3 
 B934L Vol. 4 Pre 1,7 28,5 9,6 12 463,1 4 
 K1575 Vol. 5 Pre 1,8 34,4 17,3 15 342,1 2 
 B881R Vol. 7 Pre 2,2 33,0 8,4 13 300,3 8 
Median 2,2 33,7 12,3 16 336,0 4 
Median Pre-CPS IgG Study 1 and 2: 2,6 34,4 12,2 16 326,5 5 
Post-CPS IgG 
Study 1 K1577L Pool 1 Post 1,9 29,2 15 16 90,5 1 
 K1540L Pool 2 Post 2,6 31,6 12,6 18 13,1 3 
 B733 Pool 3 Post 5,2 40,8 6,7 16 46,4 2 
 K1589 Pool 4 Post 4,5 35,9 13,1 15 20,8 3 
 B750L Pool 5 Post 2,5 33,4 12,2 16 302,6 6 
Median    2,6 33,4 12,6 16 46,4 3 
Study 2 K1666L Vol. 1 Post 4,6 41,0 15,7 14 37,1 3 
 B934 Vol. 2 Post 1,8 17,4 11,7 16 6,7 1 
 B905 Vol. 3 Post 4,2 41,2 12,7 18 28,3 2 
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 K1630L Vol. 4 Post 1,7 21,2 14,6 14 60,9 2 
 B865 Vol. 5 Post 2,3 36,5 17,3 14 29,2 3 
 K1683 Vol. 7 Post 2,3 31,3 9,7 15 19,3 3 
Median 2,3 33,9 13,7 15 28,8 3 
Median Post-CPS IgG Study 1 and 2: 2,5 33,4 12,7 16 29,2 3 
Significant difference Post- versus Pre-CPS 
IgGe 
ns ns ns ns p = 0.0008 p = 0.003 
aCPS ChemoProphylaxis and Sporozoites immunization. 
bHuHEP human hepatocytes. 
cPf P. falciparum. 
dVol. volunteer. 
eStatistics: significant difference between Post- and Pre-CPS IgG calculated using the non-parametric Mann–Whitney U-test. 
 
Table 1 Reduction of liver parasite burden by CPS-induced antibodies 
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Taken together, this suggests that reactivity of antibodies to pre-erythrocytic or cross-stage antigens other than 
CSP or TRAP may be associated with protective immunity and, therefore, analysis of plasma samples from 
(partially) protected CPS-immunized volunteers with a microarray containing ~3,000 P. falciparum genes is 
currently underway. This will be essential to identify novel pre-erythrocytic antigens that are associated with 
functional activity of CPS-induced antibodies and protective immunity. 
Importantly, liver-stage infection in liver-chimeric uPA+/+-SCID mice was not completely blocked when using 10 
mg/ml IgG (which is equivalent to the typical IgG concentration in human plasma). This indicates that in CPS-
immunized volunteers, other immune effector mechanisms may contribute to parasite elimination in concert 
with antibodies. CPS-induced antibodies may not fully prevent parasite infection, but may reduce the liver 
parasite load to such a extent, that T-cell mediated responses, for instance, might eliminate the residual 
infected hepatocytes and thus, prevent blood-stage infection, as observed in previous CPS-trials [45, 47]. 
 
Conclusions 
In conclusion, CPS-induced antibodies have functional inhibitory activity against pre-erythrocytic stages of P. 
falciparum by inhibiting sporozoite traversal in vitro and infection of hepatocytes in vivo. These findings 
highlight the importance of functional antibodies in pre-erythrocytic immunity against malaria and are essential 
to the current understanding of the mechanisms involved in pre-erythrocytic immunity. Open questions based 
on these findings that will be addressed in future studies, include the specificity of CPS-induced antibodies and 
whether their functional activity correlates with CPS-induced protection against malaria. 
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Additional files 
 
Additional file 1: Replicates from in vitro traversal experiments.  
Replicates from traversal experiments conducted with either 1 mg/ml (A) or 10 mg/ml (B) of pre- or post-immunization IgG 
from three pools of two volunteers (Study 1) or six individual volunteers (Study 2) are shown. Data are expressed as the 
mean percentage cells traversed ± SD. Black squares and grey circles represent the percentage cells traversed by 
sporozoites incubated with either pre-immunization or post-immunization IgG, respectively. Filled symbols show volunteers 
protected against mosquito challenge. Open symbols represent volunteers with unknown protection status regarding 
mosquito challenge (blood-stage challenged). 
 
 
Additional file 2: In vivo mosquito bite challenge experiments in human liver-chimeric mice.  
Data from human liver-chimeric mouse experiments conducted with 10 mg of pre- or post-immunization IgG are shown. 
Mice injected with PBS could not be directly included in the IgG experiments due to limited availability of chimeric mouse 
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numbers, however, PBS-injected mice used in other parallel experiments performed in the same time frame showed the 
same range in liver parasite burden as mice receiving pre-immunization IgG. Data are expressed as the median parasite load 
per million human hepatocytes ± interquartile range. 
 
 
Additional file 3: Sporozoites incubated with or without 10 µg/ml anti-CSP antibody.  
Data from 4 independent traversal experiments conducted with or without 10 μg/ml of monoclonal anti-CSP antibody are 
shown. (A) Data are expressed as the mean percentage cells traversed. Black circles and squares represent the percentage 
cells traversed by sporozoites incubated without or with 10 μg/ml anti-CSP antibody, respectively. (B) The percentage 
inhibition of traversal was calculated for sporozoites only compared to sporozoites incubated with 10 μg/ml anti-CSP 
antibody. Data are expressed as the median percentage traversal inhibition ± interquartile range.   
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Abstract 
 
Background 
A highly efficacious vaccine is needed for malaria control and eradication. Immunization with Plasmodium 
falciparum NF54 parasites under chemoprophylaxis (chemoprophylaxis and sporozoite (CPS)-immunization) 
induces the most efficient long-lasting protection against a homologous parasite. However, parasite genetic 
diversity is a major hurdle for protection against heterologous strains. 
 
Methods 
We conducted a double-blind, randomized controlled trial in 39 healthy participants of NF54-CPS immunization 
by bites of 45 NF54-infected (n = 24 volunteers) or uninfected mosquitoes (placebo; n = 15 volunteers) against 
a controlled human malaria infection with the homologous NF54 or the genetically distinct NF135.C10 and 
NF166.C8 clones. Cellular and humoral immune assays were performed as well as genetic characterization of 
the parasite clones. 
 
Results 
 NF54-CPS immunization induced complete protection in 5/5 volunteers against NF54 challenge infection at 14 
weeks post-immunization, but sterilely protected only 2/10 and 1/9 volunteers against NF135.C10 and 
NF166.C8 challenge infection, respectively. Post-immunization plasma showed a significantly lower capacity to 
block heterologous parasite development in primary human hepatocytes compared to NF54. Whole genome 
sequencing showed that NF135.C10 and NF166.C8 have amino acid changes in multiple antigens targeted by 
CPS-induced antibodies. Volunteers protected against heterologous challenge were among the stronger 
immune responders to in vitro parasite stimulation. 
 
Conclusions 
Although highly protective against homologous parasites, NF54-CPS-induced immunity is less effective against 
heterologous parasite clones both in vivo and in vitro. Our data indicate that whole sporozoite-based vaccine 
approaches require more potent immune responses for heterologous protection. 
 
Trial registration 
This trial is registered in clinicaltrials.gov, under identifier NCT02098590. 
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Background 
Malaria has a significant impact on human health and economic welfare worldwide. In 2015, it caused over 200 
million cases of disease and nearly half a million deaths [1]. Despite a significant decrease in malaria deaths 
having been observed in the last 15 years [1], the emergence of insecticide-resistant mosquitoes [2] and drug-
resistant parasites [3] are threatening malaria control efforts, highlighting the need for a highly effective 
vaccine.  
While naturally acquired immunity likely never results in sterile protection against the parasite [4], generation 
of long-lasting and sterilizing immunity against malaria is the goal of pre-erythrocytic vaccine approaches. So 
far, only one sub-unit vaccine, RTS,S (Mosquirix, GlaxoSmith Kline), has been recommended for defined clinical 
application [5]. This vaccine is based on a major sporozoite surface protein, the circumsporozoite protein (CSP), 
and has been shown to induce a short-term, 30–50% efficacy in reducing the incidence of clinical malaria in 
endemic areas, as well as in the controlled human malaria infection (CHMI) model [6–8]. Sterilizing immunity 
can be induced by attenuated whole sporozoite approaches. Immunization with radiation-attenuated 
sporozoites requires bites of at least 1000 infected mosquitoes to induce sterile protection in 50% of 
volunteers [9], or a total dose of 675 k cryopreserved sporozoites injected intravenously for full homologous 
protection [10]. In contrast, bites by only 30–45 malaria-infected mosquitoes [11, 12] or 150 k intravenously 
injected cryopreserved sporozoites [13] in the chemoprophylaxis and sporozoite (CPS) regimen induces 
complete sterile protection against the homologous parasite. CPS-induced protection can last for at least 2.5 
years, showing unprecedented efficiency and sustainability of the protective immune response [14]. 
Specifically, strong effector memory T cell responses are induced [11, 12], as well as memory B cell and 
antibody responses targeting preerythrocytic stage antigens with functional activity against homologous 
sporozoites, inhibiting parasite development in liver cells in vitro and in vivo in human liver-chimeric mice [15–
17]. 
Despite these advances, a major hurdle for the induction of protection against heterologous strains is the well-
known genetic diversity of Plasmodium falciparum, allowing parasite evasion and reducing the protective 
efficacy. More recently, immunization with radiation attenuated sporozoites provided 53% protection against 
a heterologous challenge [18]. There is also incidental evidence for CPS-induced heterologous protection in the 
CHMI model [19], but this has not been systematically addressed. Here, we describe the first double-blind, 
placebo-controlled CHMI trial of NF54-CPS immunization by a total of 45 P. falciparum NF54-infected 
mosquitoes followed by a challenge infection with either P. falciparum NF135.C10 clone from Cambodia or 
NF166.C8 clone from Guinea. Parasites were characterized by whole genome sequencing and CPS-induced 
cellular and humoral responses were analyzed. 
 
Methods 
Study design and participants 
This single center, double-blind, randomized, placebo-controlled trial was conducted at the Radboud university 
medical center (Nijmegen, The Netherlands) between February and November 2015. Study participants were 
healthy male and female volunteers (18–35 years old) with no history of malaria and screened for eligibility, 
including a complete medical and family history, physical examination, blood hematological and biochemical 
parameters, and serology for HIV, hepatitis B and C, and the asexual stages of P. falciparum as previously 
described [20]. All candidate participants provided written informed consent at the screening visit. 
 
Study approval 
The study was approved by the Central Committee for Research Involving Human Subjects of The Netherlands 
(CCMO NL48732.091.14) and conducted according to the principles outlined in the Declaration of Helsinki and 
Good Clinical Practice standards. This trial is registered at ClinicalTrials.gov, identifier NCT02098590. 
 
  
57 
 
Procedures 
All included study subjects (n = 41, Fig. 1) received chloroquine in a prophylactic dose (i.e., a loading dose of 
300 mg of chloroquine on each of the first 2 days, followed by 300 mg once a week), for a total duration of 13 
weeks. While under chloroquine prophylaxis, study groups 1, 2 and 3 received three immunizations with bites 
of 15 P. falciparum NF54-infected Anopheles stephensi mosquitoes. Groups 4, 5 and 6 received three mock 
immunizations with bites of 15 uninfected mosquitoes. Volunteers were followed on an outpatient basis from 
days 6 to 10 after each immunization. Blood was examined daily, including hemocytometry, white-blood cell 
counts, lactic acid dehydrogenase, and highly sensitive troponin-T. From day 7 to 9, blood was also checked for 
malaria parasites by thick blood smear microscopy and quantitative real-time PCR (qPCR) was performed 
retrospectively (after study de-blinding), as described previously [21, 22]. 
At 14 weeks after discontinuation of chloroquine prophylaxis, all participants were exposed to bites of five P. 
falciparum-infected A. stephensi mosquitoes (Table 1). Subjects of groups 1 and 4 were challenged with the 
heterologous NF135.C10 clone, groups 2 and 5 with the heterologous NF166.C8 clone, and groups 3 and 6 with 
the homologous NF54 strain. Mosquitoes were examined to verify that a blood meal was taken and the 
presence of sporozoites in mosquito salivary glands was confirmed by dissection. If insufficient infected 
mosquitoes had taken a blood meal, subjects were exposed to additional mosquitoes.  
After challenge infection, subjects visited the clinical trial site twice daily from day 6 to day 15 and once daily 
from day 16 until day 21. Blood was drawn for parasitological assessments at every visit and safety laboratory 
measurements were performed once daily as described above. Malaria symptoms, including fever, headache, 
malaise, fatigue, myalgia, arthralgia, nausea, vomiting, chills, diarrhea, and abdominal pain, were solicited. All 
signs and symptoms (solicited and unsolicited) were recorded and graded by the attending physician as mild 
(easily tolerated), moderate (interferes with normal activity), or severe (prevents normal activity) or, in case of 
fever, as grade 1 (>37.5 °C to 38.0 °C), grade 2 (38.1 °C to 39.0 °C), or grade 3 (> 39.0 °C).  
Subjects were treated with a curative regimen of 1000 mg atovaquone and 400 mg proguanil once daily for 3 
days when parasitemia above the treatment threshold (100 parasites per milliliter of blood) was detected by 
qPCR [22]. Subjects that remained qPCR negative were presumptively treated with the same regimen 28 days 
after challenge infection. Complete cure was confirmed by two consecutive negative qPCR measurements after 
treatment. 
 
Randomization and masking 
All study subjects, in two time-separated cohorts, were randomly allocated to one of the six study groups using 
a computer-generated list of random numbers (Microsoft Excel 2007, Redmond, WA, USA), with study groups 
stratified equally over each cohort. Randomization was prepared by two independent investigators and was 
stored ecurely, in sealed opaque envelopes with restricted access. Subjects, investigators and primary outcome 
assessors were masked to group assignment. During the study, the homologous (NF54) challenge strain 
infection of the second cohort was delayed as there was no sufficiently infected batch of mosquitoes available 
(> 40% infected; according to our standard operating procedures). Challenge strain blinding had to be lifted for 
this group (six subjects), allowing them to be challenged 2 weeks later. The investigators remained blinded to 
immunization allocation of all participants and to the challenge strain allocation of the NF135.C10 and 
NF166.C8 groups until the end of the study. All study subjects and immunology assessors remained blinded 
during the entire study. The partial de-blinding procedure was documented and reported to the Central 
Committee for Research Involving Human Subjects of The Netherlands. 
 
Primary study outcome 
The primary outcome was the pre-patent period, namely time to parasitemia (a single qPCR measurement with 
a parasite density greater than 100 parasites per milliliter of blood) in subjects after challenge infection. Study 
sample size was determined in order to be able to detect a difference in pre-patent period of 3 days between 
the immunization and control groups (with α = 0.05, power = 0.90). 
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Figure 1: Clinical trial profile.  
CVD = cardiovascular disease; BMI = body mass index; ECG = electrocardiogram   
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Parasites 
NF54 is a longstanding and well-characterized strain isolated several decades ago from a person with airport 
malaria near Schiphol Airport (Amsterdam, The Netherlands) and likely originating from West Africa [23]. The 
NF135.C10 clone originated from a clinical isolate in Cambodia [24]. The NF166.C8 clone originated from a 
patient after a recent visit to Guinea (West Africa) [25]. 
 
Parasite culture and generation of infected mosquitoes 
P. falciparum NF54, NF135.C10, and NF166.C8 asexual and sexual blood stages were cultured in a 
semiautomated culture system [26–29]. A. stephensi mosquitoes for immunizations and challenge infections 
were reared in the Radboud university medical center insectary (Nijmegen, The Netherlands) according to 
standard operating procedures. Infected mosquitoes were obtained by standard membrane feeding on 
gametocyte cultures of the different strains as described previously [29]. For in vitro sporozoite infectivity 
assays, salivary glands from infected A. stephensi mosquitoes were hand dissected and collected in complete 
William’s B culture medium without serum. Salivary glands were homogenized in a homemade glass grinder 
and the number of P. falciparum sporozoites was counted in a Bürker-Türk counting chamber using phase 
contrast microscopy [15]. 
 
Plasma samples 
Citrated plasma samples were collected from 24 CPS-immunized volunteers at different time points using 
citrated vacutainer cell preparation tubes (CPT vacutainers; Becton Dickinson). Samples collected 11–14 days 
before the first CPS immunization (pre-immunization) and 1 day before challenge infection (18 weeks after the 
last immunization; post-immunization) were used for analysis of malaria antigen-specific antibody levels and 
assessment of functional activity in vitro. Plasma samples were stored in aliquots at – 20 °C and re-thawed no 
more than three times. Prior to use for in vitro sporozoite infectivity assays in primary human hepatocytes, 
citrated plasma aliquots were heat-inactivated for 30 minutes at 56 °C and spun down at 13,000 rpm for 5 
minutes at room temperature. 
 
Peripheral blood mononuclear cell (PBMC) isolations and cryopreservation 
Venous whole blood was collected in CPT vacutainers at different time points. PBMCs were isolated from  
peripheral blood samples, cryopreserved and stored as described previously [11]. Briefly, PBMCs were isolated 
by centrifugation, washed in ice-cold phosphate buffered saline, and counted in 0.1% Trypan blue with 5% Zap-
o-Globin II Lytic Reagent (Beckman Coulter) to assess cell viability. Cells were cryopreserved at a concentration 
of 107 PBMCs per milliliter in ice-cold fetal bovine serum (Gibco) containing 10% dimethylsulfoxide (Merck, 
Germany) using Mr. Frosty freezing containers (Nalgene). Subsequently, PBMC samples were stored in vapor-
phase nitrogen. PBMC samples collected 11–14 days before the first CPS immunization (pre-immunization) and 
1 day before challenge infection (18 weeks after the last immunization; postimmunization) were used for in 
vitro PBMC restimulation experiments and flow cytometric analysis. 
 
Humoral immunological assays 
Malaria antigen-specific antibody levels  
Specific antibodies to P. falciparum CSP (full-length protein, obtained from Genova Biotechniques Pvt. Ltd. in 
Hyderabad, India [30]) in citrated anti-coagulated plasma samples were determined by a standardized enzyme-
linked immunosorbent assay (ELISA) at indicated time points as previously described. Antibody levels were 
expressed as arbitrary units (AU) in relation to a pool of 100 sera from adults living in an area in Tanzania where 
malaria is highly endemic, with this positive control set at 100 AU [12, 17] (see also Additional file 1: S1 for 
detailed information). ELISA data analysis was performed with Auditable Data Analysis and Management 
System for ELISA (ADAMSEL, version 1.1) as previously described [17]. Post-immunization plasma samples were 
corrected for baseline responses for CSP.  
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In vitro sporozoite infectivity assay of primary human hepatocytes  
To test CPS-induced functional antibody activity against sporozoite development, fresh primary human 
hepatocytes were isolated and cultured from patients undergoing partial hepatectomy as described in 
Additional file 1: S2. Briefly, viable hepatocytes (5 × 104 hepatocytes/well) in complete William’s B medium 
were seeded into 96-well flat-bottom plates (Falcon, 353219) coated with 0.056 mg/mL rat tail collagen I per 
well (Roche Applied Science, 11179179-001), and cultured at 37 °C in an atmosphere of 5% CO2. Two to three 
days after seeding of hepatocytes, batches of fresh P. falciparum NF54, NF135.C10, or NF166.C8 sporozoites in 
Williams B medium were pre-incubated with heat-inactivated naive human control serum (10% final 
concentration) and heat-inactivated pre- or post-CPS immunization plasma at a final concentration of 10% for 
30 minutes on ice (final concentration of serum/plasma in each sample: 20%). Sporozoites pre-incubated with 
an anti-CSP monoclonal antibody (mAb 2A10, 10 μg/mL final concentration, MR4; MRA-183A) served as a 
positive control. Sporozoites in the presence of 20% heat-inactivated naive human control serum served as 
standard control; 5 × 104 of pre-incubated sporozoites were added to 96-well plates containing monolayers of 
primary human hepatocytes in triplicate. Five to six days post-infection, the number of P. falciparum-infected 
hepatocytes was assessed by staining for P. falciparum Heat shock protein-70 and indirect immuno-
fluorescence analysis using a Leica DMI6000B inverted microscope as described in Additional file 1: S3 and S4. 
 
Cellular immunological assays 
For the assessment of P. falciparum-specific cellular immune responses, pre- and post-immunization PBMCs  
from CPS-immunized volunteers who received NF135.C10- and NF166.C8-challenge infection were re-
stimulated in vitro with cryopreserved P. falciparum NF54-infected erythrocytes (PfRBCs), as described 
previously [11, 14] and in detail in Additional file 1: S5. Briefly, after thawing, PBMCs in complete culture 
medium (final concentration of 10 × 106 cells/mL) were stimulated in vitro in duplicate with either 106 
cryopreserved NF54 PfRBCs or 106 uninfected erythrocytes (negative control) for 24 h at 37 °C with 5% CO2. 
Fluorochrome-labeled monoclonal antibody to CD107a was added for the duration of the stimulation. During 
the last 4 h, 10 μg/mL Brefeldin A and 2 μM monensin were added to the test wells, and 10 ng/mL PMA (Sigma-
Aldrich) and 1 μg/mL ionomycin were added to positive control wells. After 24 h of stimulation in total, cells 
were stained with a Live/Dead fixable dead cell stain dye and fluorochrome-labeled antibodies against the 
surface markers CD3, CD4, CD8, gamma delta T cell receptor, and CD56, and against the intracellular cytotoxic 
marker granzyme B and the cytokine interferon (IFN)-γ. Samples were kept cold and in the dark in 1% 
paraformaldehyde in phosphate buffered saline until measured by flow cytometry on the same day. Both time 
points for each volunteer were thawed, stimulated and stained within the same experimental round. Samples 
were acquired using a 10-colour Gallios flow cytometer (Beckman Coulter), and single stained cells were run 
every round for compensation. Data analysis was performed using FlowJo software (Version 10.0.8, Tree Star). 
Uninfected erythrocyte responses were subtracted from PfRBC-specific responses for every volunteer for each 
time point, and post-immunization responses were corrected for pre-immunization responses. 
 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism software (version 5, GraphPad Software Inc., 
California, USA). Differences in pre-patent period by qPCR between groups were determined by Log-Rank test. 
Differences in antibody levels across the immunization groups were analyzed with one-way ANOVA with 
Bonferroni’s multiple comparison post-hoc correction. For analysis of in vitro sporozoite infectivity data, 
differences were tested using the paired Student’s t-test, except when comparing between immunization 
groups, when a oneway ANOVA with Bonferroni’s multiple comparison post-hoc correction was used. A P value 
of < 0.05 was considered significant. 
 
Genetic analysis of parasites 
Genomic DNA was obtained from the three study strains and 2.3 μg of each were submitted for Illumina 
sequencing. The resulting fastq reads (150 bp) were aligned to the P. falciparum 3D7 reference genome (v.3, 
plasmoDB) using bowtie2 software (bowtie-bio.sourceforge.net). Single nucleotide polymorphisms (SNPs) were 
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called with samtools and bcf/vcftools software (samtools.sourceforge.net). An alignment of all SNPs (with 
bcftools quality score > 100) was used to compare the study strains to others from Ghana, Guinea, Kenya, 
Cambodia, Thailand, and Vietnam in a combined analysis of genetic variation, as described by Campino et al. 
[31]. Furthermore, genes that were identified to elicit a humoral immune response in CPS immunization were 
examined [16]. This panel of 11 pre-erythrocytic genes including CSP and LSA-1, complemented by MAEBL, was 
checked for amino acid changes in the translated protein. 
 
Results 
Protective efficacy of CPS immunization against heterologous challenge 
A total of 41 volunteers were included into the study, of whom 24 immunization and 15 placebo-control  
volunteers completed the clinical trial and were included in the per protocol analysis. One volunteer withdrew 
after being unable to attend the study visits and one was excluded due to a concomitant condition (Fig. 1). The 
baseline characteristics of the study population are shown in Table 1. 
As previously observed, NF54-CPS immunization induced sterile protection against a homologous NF54 
challenge in 5 out of 5 volunteers (Fig. 2a) [11, 12, 32]. In contrast, 2 out of 10 volunteers were sterilely 
protected after challenge with NF135.C10, with 6 out of 10 volunteers showing a prolonged pre-patent period 
compared to mock-immunized controls (more than twofold the standard deviation of controls) (Fig. 2b). After 
NF166.C8 challenge, 1 out of 9 NF54-immunized volunteers was fully protected, while 8 out of 9 volunteers 
showed no delay to patency (Fig. 2c). There was also no difference in mean day 7 parasitemia (representing the 
liver parasite burden) between immunized volunteers and controls challenged with NF166.C8 (Additional file 2: 
Figure S1). In line with a previous study [25], NF135.C10 and NF166.C8 showed higher infectivity than NF54.  
Overall, NF54-CPS immunization induced only modest protection against heterologous clones. As a marker for 
the induction of immune responses, antibody levels to the major sporozoite vaccine-target antigen CSP [7, 8] 
were measured. All volunteers showed a post-immunization CSP antibody titer as determined by ELISAs and 
corrected for baseline (median 3.7 AU; interquartile range (IQR) 2.9–4.5), which did not significantly differ 
between groups (group 1: 24.7 (IQR 10.4–45.2), group 2: 24.7 (IQR 17.0–37.1), and group 3: 74.1 (IQR 20.9–
187.0)). 
 
Table 1: Baseline characteristics of subjects included in the analysis. 
 
  
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 
Number of participants 
(n=39) 10 9 5 5 5 5 
Sex        
 Male 3 (30%) 2 (22%) 2 (40%) 3 (60%) 2 (40%) 5 (100%) 
 Female 7 (70%) 7 (78%) 3 (60%) 2 (40%) 3 (60%) 0 (0%) 
Age (years) 21.5 (1.8) 21.1 (2.6) 22.4 (1.6) 20.1 (1.3) 20.4 (2.5) 22.6 (3.1) 
BMI (kg/m2) 21.8 (2.3) 21.4 (1.7) 22.0 (3.1) 20.6 (2.0) 24.8 (3.3) 23.2 (1.7) 
        
P. falciparum strain       
 Immunization NF54 NF54 NF54 uninfected uninfected uninfected 
 Challenge NF135.C10 NF166.C8 NF54 NF135.C10 NF166.C8 NF54 
Data are n (%), mean (SD). BMI=body-mass index 
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Figure 2: Parasitemia following homologous and heterologous challenge infection. 
The percentage of volunteers remaining qPCR negative (Kaplan-Meier survival proportions) after challenge infection with a 
homologous NF54 (n=5 immunized; n=5 controls) (A) or heterologous NF135.C10 (n=10 immunization; n=5 controls) (B) or 
NF166.C8 (n=9 immunized; n=5 controls) (C) strain is shown. Solid lines represent CPS-immunized volunteers and dotted 
lines represent placebo-control immunized volunteers. ** p<0.01 as determined by Log-rank (Mantel Cox) Test. 
 
In vitro inhibition of intra-hepatic sporozoite development by CPS-induced antibodies 
Next, functional antibody activity to inhibit sporozoite development in primary human hepatocytes in vitro was 
tested. Post-immunization plasma from all 24 NF54-CPS-immunized volunteers significantly reduced 
homologous intra-hepatic sporozoite development (P < 0.0001; Fig. 3a). However, inhibition of intra-hepatic 
NF135.C10 and NF166.C8 development was significantly lower (P < 0.01), with a median percentage inhibition 
of 40.7% (IQR 29.6–59.1), 26.9% (IQR 15.6–35.0), and 31.0% (IQR 22.6–43.2) for NF54, NF135.C10, and 
NF166.C8 sporozoites, respectively (Fig. 3b). Intra-hepatic development of both heterologous clones was 
equally inhibited by NF54-CPS immunization induced antibodies (Fig. 3b). While these in vitro data reflect the 
clinical outcome in vivo at group level, individual inhibition in vitro did not correlate with in vivo pre-patent 
periods and/or parasitemia (data not shown). 
 
Genetic diversity of NF54, NF135.C10, and N166.C8 challenge strains 
The genetic diversity among P. falciparum mutants has been shown to be a strong factor in parasite evasion of 
protective immune responses. Whole genomes of the parasite clones used in this study were sequenced. High 
quality SNPs were called with about equal numbers for NF135.C10 and NF166.C8 (Additional file 2: Table S1; 
Figure S3). All polymorphisms were used to infer a phylogeny including isolates from Southeast Asia and East 
and West Africa [31]. As expected, NF54 and NF166.C8 were very similar to West African isolates, while 
NF135.C10 showed more resemblance to other Southeast Asian strains (Fig. 4). We next compared amino acid 
changes of 12 genes encoding target antigens for CPS-induced antibodies as previously described [16]. With the 
exception of EIF3A, all examined proteins showed amino acid changes in either NF135.C10 or NF166.C8 with 
respect to NF54 (Table 2). Remarkably, in contrast to their relative geographical distances, 11 out of 12 proteins 
in NF166.C8 and 8 out of 12 in NF135.C10 were different compared to NF54. 
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Figure 3: Neutralizing effect of CPS-induced antibodies on in vitro sporozoite functionality of homologous and 
heterologous P. falciparum strains. 
A. The number of primary human hepatocytes infected by homologous NF54 sporozoites in the presence of Pre- or Post-
immunization plasma in all n=24 CPS-immunized volunteers was determined by microscopy. B. P. falciparum NF54, 
NF135.C10 or NF166.C8 sporozoites were pre-incubated with Pre- or Post-immunization plasma from CPS-immunized 
volunteers and the percent inhibition of intra-hepatic development of NF54, NF135.C10 or NF166.C8 was calculated for 
Post- compared to Pre-immunization plasma for each individual volunteer and presented as squares (NF135.C10), triangles 
(NF166.C8) or circles (NF54). Data are shown as the mean of triplicate measurements for each individual volunteer (Figure 
3A) or the median of all data points with an interquartile range (Figure 3B). Differences in the percent inhibition of intra-
hepatic development between parasite strains were tested using One-way ANOVA with Bonferroni's multiple comparison 
correction. 
 
 
Figure 4: Whole-genome sequencing shows genetic variations between study strains. 
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Phylogenetic positions of the three P. falciparum strains (NF54, NF135.C10 and NF166.C8) used in the study relative to 
other known P. falciparum strains. Whole-genome sequencing was used to infer relatedness to P. falciparum strains from 
different areas [30] . Asian strains, THA, Thailand (dark red). VIE, Vietnam (light red). CAM, Cambodia (orange). East Africa 
represented by KEN, Kenya. West African strains, GUI, Guinea (light green) and GHA, Ghana (dark green). NF strains and 
7G8 (blue). 
 
Table 2: Amino acid changes in genes involved in the humoral immune response after CPS immunization. 
Alterations in gene and protein sequences, based on whole genome sequencing, for 12 genes from NF135.C10 and 
NF166.C8 were compared to NF54. Single nucleotide polymorphisms and small insertions/deletions are shown together as 
sequence changes with expected changes in the in silico translated protein sequence (counting altered amino acids). 
Changes in CSP protein sequence are indicated with single-letter amino acid code. 
 
  PfNF135.C10  PfNF166.C8  
Gene Sequence changes Protein changes Sequence changes Protein changes 
PF3D7_1036400 
LSA-1 
6 4 14 9 
PF3D7_0108300 Conserved 
unknown 
21 12 15 8 
PF3D7_1033100 
AdoMetDC/ODC 
10 9 9 8 
PF3D7_0108300 
MSP2 
13 7 8 7 
PF3D7_0304600 
CSP 
6 
6 
A98G 
S301N 
K317E 
E318Q 
N321K 
A361E 
 
7 
7 
S301N 
K314Q 
K317E 
E318K 
N321K 
K322T 
E357Q 
PF3D7_0509400 
RNApol 
6 4 9 6 
PF3D7_0630600 
Conserved unknown 
7 2 8 3 
PF3D7_0502400 
MSP8 
2 1 4 3 
PF3D7_1147800 
MAEBL 
2 0 3 1 
PF3D7_0703700 
Conserved unknown 
0 0 1 1 
PF3D7_0829000 
Conserved unknown 
0 0 1 1 
PF3D7_1212700 
EIF3A 
1 0 1 0 
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Humoral and cellular markers of protection 
Next, we tested a number of previously established markers associated with exposure and homologous 
protection after CPS immunization [11, 33]. Figure 5 shows the distribution of antibody-mediated inhibition of 
intrahepatic sporozoite development as well as the cellular markers IFN-γ and granzyme B in CD4+ and CD8+ 
cells in all immunized volunteers undergoing heterologous challenge. Remarkably, CD107a expression, 
particularly in CD4+ T cells, was not increased as previously found (data not shown) [11]; 2 out of 3 
heterologous protected volunteers were among the highest antibody-mediated inhibitors of in vitro 
heterologous intra-hepatic development (Fig. 5, orange square: NF135.C10-challenged; green triangle: 
NF166.C8-challenged), with the highest numbers of IFN-γ-producing CD8+ T cells against PfRBC. The third 
protected volunteer showed only average neutralizing antibody responses and IFN-γ-producing CD4+ and CD8+ 
T cells, but had a high number of granzyme B+ CD8+ T cells (orange upside down triangle: NF135.C10-
challenged). The group of NF135.C10 volunteers with a prolonged pre-patent period did not distinguish 
themselves from the unprotected volunteers. 
 
 
Figure 5: Analysis of in vitro intra-hepatic sporozoite development inhibition by CPS-induced antibodies, cellular 
responses and protection status in vivo.   
CPS-induced antibody-mediated inhibition of in vitro challenge strain intra-hepatic development and cytotoxic and 
cytokine-producing T cell responses to NF54 infected RBCs are shown. The 10th and 90th percentile of each response in all 
(n=19) CPS-immunized volunteers that received a heterologous challenge infection are shown as grey box-and-whisker 
plots. The green triangle represents one out of nine CPS-immunized volunteers sterilely protected against NF166.C8 
challenge infection, while the orange square and upside down triangle represent the two out of ten CPS-immunized 
volunteers with sterile protection against NF135.C10 challenge infection. 
 
Discussion 
This randomized, controlled clinical trial shows that CPS immunization with P. falciparum NF54 sporozoites 
induces modest sterile protection against challenge infection with genetically distinct P. falciparum parasites. In 
line with these clinical observations, antibodies induced by NF54-CPS immunization inhibit intra-hepatic 
development of both homologous and heterologous sporozoites in vitro, but less efficiently inhibit 
heterologous clones. P. falciparum-specific IFN-γ and granzyme B T cell responses are also induced, 
corroborating previous studies [11, 12], though unlike these studies, there was no clear induction of CD107a  
responses. We have previously shown that PBMCs from NF54-exposed volunteers have equivalent responses to 
homologous and heterologous PfRBC stimulation [24]. Here, volunteers protected against heterologous 
challenge showed relatively high cellular and/or antibody responses. However, none of these individual 
markers predicts protection.  
In this study, heterologous protection was assessed against a primary challenge infection in a double-blind 
manner, strongly reducing any potential for bias. However, this study lacks the power to discriminate the low 
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protective efficacy seen in the NF166.C8 group with statistical significance. Furthermore, although we chose to 
test two geographically diverse heterologous strains, we do not know how representative these are for the 
total genetic diversity for P. falciparum in the field.  
P. falciparum parasite strain diversity is a major impediment to the development of effective, sterilizing 
immunity [34]. Indeed, previous studies with single-protein vaccines show that antigen polymorphisms 
decrease vaccine efficacy [35–37]. However, genetic diversity may be less challenging for whole sporozoite 
vaccines representing a broader antigen repertoire that could increase the chances for generating functional, 
cross-strain immunity. In fact, immunization with radiation-attenuated sporozoites by 1000 mosquitoes [38] or 
with a total of 1.35 × 106 sporozoites administered intravenously [39] has been shown to induce 80%  
protection against challenge with the heterologous challenge strain 7G8 (IMTM-22 isolate from Brazil) at 3 
weeks post-immunization, rapidly waning to only 10% protection at 24 weeks [38, 39]. Doubling the dose of 
intravenous sporozoite immunization to a total of 2.7 × 106 showed an adjusted 53% efficacy against 7G8 at 33  
weeks [18]. These data indicate that induction of heterologous protection requires substantial high 
immunization dosages, which puts constraints on vaccine manufacturing and costs. In contrast, the CPS 
regimen shows a 10- to 20-fold higher efficiency for homologous protection, likely because volunteers are 
exposed to the full pre-erythrocytic cycle and the initial phase of the blood stage [40]. Previously, 2 out of 13 
NF54-CPS-immunized volunteers receiving a suboptimal immunization dose were protected against a 
rechallenge infection with NF135.C10 at 14 months after the last immunization [19]. Both studies with 
radiation-attenuated and CPS immunization showed higher homologous than heterologous protective efficacy. 
However, none of these studies used an immunization regimen sufficient for more than 90% homologous 
protective efficacy. The current study is the first randomized, controlled trial with a whole sporozoite 
immunization regimen sufficient for complete homologous protection, testing primary heterologous challenge 
infection 18 weeks after the last immunization [11]. 
Despite 100% protection against homologous challenge, we obtained only a modest 10–20% protection against 
heterologous strains. The observed difference in protection against homologous and heterologous infections 
may be explained by various factors. (1) Unequal distribution of induced immune responses between study 
groups; however, anti-CSP antibody titers show a clear consistency and similarity between study groups. (2) 
Differences in numbers of inoculation sporozoites or stringency of the challenge infection. The former is 
unlikely as mosquito salivary gland infections were similar between the generated strain batches (Additional 
file 2: Table S2). As NF135.C10 and NF166.C8 show higher sporozoite infectivity compared to NF54 [25], it may 
be more difficult to protect against the NF135.C10 and NF166.C8 clones. However, intra-hepatic sporozoite 
development of NF135.C10 and NF166.C8 was equipotently inhibited by a functional anti-CSP mAb, 2A10 
(Additional file 2: Figure S2; IC50 concentrations of 2.5 μg/mL (95% CI 0.58–11 μg/mL), 3.5 μg/mL (95% CI 1.1–
11 μg/mL), and 0.88 μg/mL (95% CI 0.26–2.9 μg/mL)), which makes this explanation less likely. (3) Genetic 
variation between the challenge parasites, shown to be considerable with amino acid changes in either 
NF135.C10 or NF166.C8 in 11 out of 12 target proteins for CPS-induced antibodies [16]. We consider decreased 
immune efficacy against genetically diverse parasite strains as the most likely explanation for the modest 
protection against heterologous parasites. 
Since 3 out of 19 volunteers with sterile protection against heterologous challenge tended to show more 
potent responses to previously identified immune markers [11, 15, 33], decreased efficacy against 
heterologous parasites may be overcome by stronger immune responses. Improvement of the strength of 
cellular and antibody responses may be achieved by altering immunization regimens. For instance, this may be 
achieved by increasing the immunization liver-stage antigen load by raising the NF54 sporozoite immunization 
dose, as has been done with radiation-attenuated sporozoites [18, 41]. Alternatively, increased liver-stage 
infectivity with a parasite such as NF135.C10 likely increases the antigen load without the need to increase the 
number of sporozoites administered. A mixture of parasite strains or sequential immunizations with different 
strains are alternative options, but will complicate the product manufacturing or its practical application. The 
latter approach might be more efficient, as heterologous sporozoites would evade strain-specific neutralizing 
immunity, thereby increasing the liver parasite burden at second and third immunizations. These studies 
should aim to find the optimal balance between the desired induction of cross-stage immunity and the related  
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adverse events that may occur. Taken together, our findings highlight the need to further explore the 
immunological basis of cross-strain protection against P. falciparum in order to improve existing whole-
sporozoite immunization strategies. 
 
Conclusions 
These data demonstrate that, despite providing complete protection against homologous challenge infection, 
CPS immunization with the NF54 strain provides only modest sterile protection against the genetically distinct 
NF135.C10 and NF166.C8 clones. Our immunological and parasite sequencing data suggest that genetic 
variation between the strains reduces the efficiency of antibodies to block heterologous parasites. Since 
protected volunteers tended to be higher immune responders, this study underscores the need for whole 
sporozoite vaccination regimens to increase the height or breadth of immune responses to achieve 
heterologous protection. 
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Supplementary Figures 
 
 
 
Supplementary Figure 1: First-wave parasitemia after challenge. 
Parasitemia on day 7 post challenge in immunized (open circles) and control (closed circles) volunteers. The line and error 
bars show the geometric mean and 95% CI interval.  
 
 
 
 
Supplementary Figure 2: Inhibition of in vitro homologous and heterologous intra-hepatic sporozoite development in 
primary human hepatocytes by mAb 2A10. 
P. falciparum NF54 (blue), NF135.C10 (orange) and NF166.C8 (green) sporozoites in the presence of 10% heat-inactivated 
naive human control serum were pre-incubated with 3-fold serial dilutions of the 2A10 monoclonal antibody (0.027-20 
µg/ml), targeting the repeat region of the circumsporozoite protein (CSP), and added to primary human hepatocyte 
cultures. Six days post-infection, the number of P. falciparum infected hepatocytes was assessed as described in 
Supplementary information S4 and S5.  
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Supplementary Figure 3: Amino acid changes in CSP. 
 
Supplementary Tables 
 
Supplementary Table 1: Whole-genome sequencing statistics. 
 
Strain 
Mio read 
pairs 
Median coverage (excl. apicoplast 
and mitochondrial DNA) 
% genome with 
min. 5x coverage SNPs Indels 
NF54 3.5 20 94.7 — — 
NF135.C10 4.8 25 95.0 13,352 3863 
NF166.C8 5.6 30 95.6 12,418 3566 
 
Supplementary Table 2: Mosquito salivary gland infectivity and sporozoite load of the three clones. 
Mean mosquito salivary gland infectivity and sporozoite load determined one day prior to challenge infection by dissecting 
a sample of 10 mosquitoes per strain. 
 
  
No. 
volunteers 
Sporozoite 
load 
Percent 
infectivity 
Cohort 1       
NF54 4 26,500 90 
NF135.C10 8 18,000 100 
NF166.C8 6 59,500 100 
Cohort 2       
NF54 6 44,300 100 
NF135.C10 7 23,500 80 
NF166.C8 8 17,000 90 
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Abstract  
Long-lasting and sterile homologous protection against malaria can be achieved by exposure of malaria-naive 
volunteers under chemoprophylaxis to Plasmodium falciparum-infected mosquitoes (CPS-immunization). While 
CPS-induced antibodies neutralize sporozoite infectivity in vitro and in vivo, antibody-mediated effector 
mechanisms are still poorly understood. Here, it was investigated whether complement contributes to CPS-
induced pre-erythrocytic immunity.  
 
Sera collected before and after CPS-immunization in the presence of active or inactive complement were 
assessed for recognition of homologous NF54 and heterologous NF135.C10 sporozoites, complement fixation, 
sporozoite lysis, and possible subsequent effects on in vitro sporozoite infectivity in human hepatocytes. CPS-
immunization induced sporozoite-specific IgM (p<0.0001) and IgG (p=0.001) antibodies with complement-fixing 
capacity (p<0.0001). Sporozoite lysis (p=0.017), traversal (p<0.0001) and hepatocyte invasion inhibition 
(p<0.0001) by CPS-induced antibodies were strongly enhanced in the presence of active complement. 
Complement-mediated invasion inhibition in the presence of CPS-induced antibodies negatively correlated with 
cumulative parasitaemia during CPS-immunizations (p=0.013). While IgG antibodies similarly recognized 
homologous and heterologous sporozoites, IgM binding to heterologous sporozoites was reduced (p=0.023). 
Although CPS-induced antibodies did not differ in their ability to fix complement, lyse sporozoites or inhibit 
traversal of homologous and heterologous sporozoites, heterologous sporozoite invasion was more strongly 
inhibited in the presence of active complement (p=0.008).  
 
These findings demonstrate that CPS-induced antibodies have complement-fixing activity, thereby significantly 
further enhancing functional inhibition of homologous and heterologous sporozoite infectivity in vitro. The 
combined data highlight the importance of complement as an additional immune effector mechanism in pre-
erythrocytic immunity after whole-parasite immunization against Plasmodium falciparum malaria.  
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Introduction 
Malaria is one of the world's chief causes of morbidity and mortality by infectious diseases and has a significant 
impact on public and economic health worldwide. Nearly half of the world’s population is at risk of malaria and 
in 2015, there were roughly 200 million clinical cases and nearly half a million deaths attributed to malaria (1). 
Malaria is caused by the protozoan parasite Plasmodium and characterized by a complex multi-stage life cycle 
in the human host. Sporozoites deposited into the skin by a female Plasmodium falciparum-infected Anopheles 
mosquito first travel to the liver by gliding motility (2) and crossing cell barriers by breaching host cell 
membranes (3). After an invasion and maturation step in the liver, merozoites progress to invade erythrocytes 
leading to the clinical symptoms of malaria (4). Although a significant decrease in malaria mortality rates has 
been observed in the last 15 years (1), malaria control efforts are threatened by the emergence of drug-
resistant parasites (5) and insecticide-resistant mosquitoes (6), stressing the need for a highly effective vaccine.  
While achieving sterile immunity by subunit vaccination has proven to be difficult (7-9), long-lasting and sterile 
protection against a homologous P. falciparum malaria infection can be accomplished experimentally by whole-
parasite immunization with live attenuated sporozoites. For instance, this can be achieved in healthy human 
volunteers by intravenous injection of 150K cryopreserved sporozoites (PfSPZ-CVac; (10)) or by exposure to 
bites of 30-45 P. falciparum-infected mosquitoes under chloroquine chemoprophylaxis (ChemoProphylaxis and 
Sporozoites; CPS) (11, 12). This immunity is long-lasting, involving effector memory T-cell responses, as well as 
memory B-cell and antibody responses recognizing pre-erythrocytic stage antigens (12-17). CPS-induced 
antibodies show neutralizing activity against sporozoite and liver-stage parasites, and are capable of reducing 
liver-stage infection in hepatocytes in vitro and in vivo in a human liver-chimeric mouse model (18). CPS-
induced antibodies show a much stronger effect on reducing liver-stage infection in vivo than in vitro, 
suggesting that additional effector mechanisms besides the direct neutralization of sporozoites by antibodies 
may be involved. 
One possible mechanism is activation of complement representing a system of heat-sensitive, soluble and cell-
surface associated proteins that are involved in pathogen opsonization, recruitment of phagocytes, and 
pathogen lysis via downstream C3 complement protein deposition (19). The complement pathway plays a key 
role in antibody-mediated inhibition of P. falciparum merozoite invasion, thereby reducing P. falciparum blood-
stage replication and preventing clinical disease (20). Additionally, P. falciparum sporozoites are susceptible to 
complement activation by human antibodies that are naturally acquired after exposure to multiple infections in 
malaria-endemic areas. Naturally acquired antibodies are able to promote complement deposition and 
activation, resulting in enhanced antibody-mediated traversal inhibition in vitro (21). Here, we studied whether 
antibody-dependent complement activation contributes to pre-erythrocytic antibody-mediated protective 
immunity against P. falciparum malaria sporozoites induced by CPS-immunization. To this end, CPS-induced 
antibodies were assessed for their functional capacity to fix complement proteins on sporozoites, induce 
sporozoite lysis, and further impact in vitro hepatocyte traversal and invasion by sporozoites in the presence of 
active complement, tested for both the homologous NF54 and the genetically and geographically distinct 
NF135.C10 parasite clone. 
 
Results  
CPS-immunization induces sporozoite-specific IgG and IgM antibodies 
Sporozoite-specific IgG antibodies were specifically induced in 15 out of 16 volunteers after completed CPS-
immunization using NF54-infected mosquitoes, with a median fold increase of 1.6 and an interquartile range 
(IQR) of 1.2-3.1 (Figure 1A, p<0.0001; Figures S1A and C, p=0.004) as compared to baseline. CPS-immunization 
also strongly induced sporozoite-specific IgM antibodies in 15 out of 16 volunteers with a median fold increase 
of 2.3 (IQR 1.8-2.9; Figure 1B, p<0.0001; Figures S1B and D, p<0.0001). There was no correlation between IgG 
and IgM antibodies (Figure S2A, p=0.192). Specific IgG and IgM antibodies were induced against the dominant 
circumsporozoite protein (CSP) (Figures S1C and D, p=0.0026 and p=0.0012) and were positively correlated 
(Figure S2B, p=0.0194). While whole sporozoite-specific IgG antibodies did not correlate with anti-CSP-IgG 
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antibody levels (Figure S2C, p=0.269), sporozoite-specific IgM antibodies correlated with anti-CSP-IgM antibody 
levels (Figure S2D, p=0.003).  
 
IgG1 and IgM isotype antibodies to CSP are most prevalent in CPS-immunized volunteers  
Antibody isotype is a major factor in subsequent activation of the classical complement pathway. Both anti-
CSP-specific IgM (Figure 1D, p=0.0012) and  IgG1 (Figure 1E, p=0.0123) antibodies were significantly increased, 
while IgG2, IgG3 and IgG4 antibodies against CSP remained undetectable after CPS-immunization (data not 
shown). Anti-CSP-IgG1 levels strongly correlated with total CSP-specific IgG, confirming that CSP-IgG1 
antibodies are primarily induced in CPS-immunized volunteers (Figure 1E, p=0.0001). The combined data 
demonstrate that CPS-immunization predominantly induces IgG1 and IgM antibodies, both of which are known 
to be potent activators of the complement pathway (22).  
 
CPS-induced antibodies fix complement and lyse homologous P. falciparum NF54 sporozoites 
C3 complement protein deposition on sporozoites and sporozoite membrane permeability were strongly 
enhanced in the presence of post-immunization antibodies and active complement (Figures 2A and B, p<0.0001 
and p=0.016). As expected, there was a strong correlation between C3 deposition and sporozoite membrane 
permeability, suggesting that antibody-dependent C3 deposition on sporozoites results in functional sporozoite 
lysis (Figure 2C, p=0.0067).  
Activation of the complement pathway can also occur via antibody-independent pathways. Indeed, C3 
deposition and sporozoite lysis also occurred in the presence of pre-immunization serum with median fold 
increases of 12.2 (IQR 10.2-13.7) and 1.30 (IQR 1.1-1.6), respectively (Figures S3A and B, p<0.0001 and 
p=0.0009). However, this effect was much weaker than in the presence of CPS-induced antibodies (Figures S3C 
and D, p<0.0001 and p=0.002) with median fold increases of 16.2 (IQR 14.5-20.0) and 1.8 (IQR 1.4-2.2). Thus, 
complement activation against sporozoites via the antibody-dependent classical pathway is more potent than 
via antibody-independent pathways. 
It was next investigated to which degree complement activation is mediated by anti-CSP-specific IgG 
antibodies. C3 deposition on sporozoites and sporozoite lysis was enhanced in the presence of post- rather 
than pre-immunization IgG (Figures 2D and E, p<0.05 and p<0.01). Sporozoite lysis in the presence of anti-CSP-
depleted post-immunization IgG was also significantly lower than for post-immunization IgG (Figure 2E, 
p<0.05). The combined data suggest that anti-CSP IgG antibodies contribute to the functional CPS-induced 
complement-mediated antibody response, but also shows that antibodies to other sporozoite surface-
expressed proteins may be involved as well. 
 
Complement-dependent inhibition of homologous P. falciparum NF54 sporozoite infectivity  
Antibody-mediated inhibition of sporozoite traversal was enhanced in the presence of active complement, with 
median traversal inhibition percentages of 31.2 (IQR 16.2-40.4) and 60.8 (IQR 48.3-64.6) for inactive and active 
complement, respectively (Figure 3A, p<0.0001). Similarly, sporozoite invasion was more efficiently reduced in 
the presence of active complement, with median invasion inhibition percentages of 87.2 (IQR 77.2-90.1) and 
70.1 (IQR 59.4-78.4) for active and inactive complement, respectively (Figure 3B, p<0.0001). Cumulative 
parasitaemia during CPS-immunizations negatively correlated with NF54 invasion inhibition in vitro by CPS-
induced antibodies in the presence of active complement (Figure 3C, p=0.013), but not inactive complement 
(Figure S4A, p=0.2518).  
 
Complement-dependent inhibition of heterologous P. falciparum NF135.C10 sporozoite infectivity  
It has previously been shown that CPS-induced antibodies can inhibit in vitro hepatocyte invasion by 
sporozoites of both the homologous NF54 strain, but also the genetically and geographically distinct NF135.C10 
clone (23, 24). Therefore, we next examined whether the effects of complement on NF54 sporozoites also 
extend to heterologous NF135.C10 sporozoites. Both CPS-induced IgG and IgM antibodies recognized 
NF135.C10 sporozoites (Figures 4A and B, p<0.0001). Complement fixation and lysis of heterologous 
sporozoites was also enhanced by post-immunization antibodies in the presence of active complement (Figures 
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4C and D, p=0.012 and p=0.029). Similar to NF54 sporozoites, heterologous traversal and invasion was more 
efficiently inhibited by post-immunization antibodies in the presence of active complement (Figures 4E and F, 
p<0.0001). Median traversal inhibition percentages were 71.6% (IQR 59.0-78.2) and 28.2% (IQR 17.7-34.3) and 
median invasion inhibition percentages were 91.8% (IQR 90.5-94.5) and 53.0% (IQR 38.4-62.2) for active and 
inactive complement, respectively. There was no correlation between complement-dependent NF135.C10 
invasion inhibition by CPS-induced antibodies in vitro and pre-patent period following NF135.C10 challenge 
infection, although only a limited number of volunteers could be tested (Figure S4B, p=0.083; n=4 volunteers). 
These combined data suggest that broadly neutralizing and complement-fixing antibodies are also potent 
against heterologous parasites. 
 
 
 
Figure 1: Recognition of P. falciparum homologous NF54 sporozoites by CPS-induced antibodies 
Homologous NF54 sporozoites were pre-incubated with 10% inactive complement and 10% heat-inactivated pre- or post-
immunization serum from CPS-immunized volunteers (n=16). The amount of CPS-induced (A) IgG and (B) IgM antibodies 
recognizing sporozoites were determined by flow cytometry and shown as the geometric mean fluorescence intensity 
(MFI). IgG (C) and IgM (D) antibody levels to CSP before (Pre) and after completed CPS-immunization (Post) were 
determined in CPS-immunized volunteers (n=24) by ELISAs and shown as arbitrary units (AU), as defined by serial dilutions 
of a reference standard serum pool with high antibody concentrations. (E) CSP-specific IgG1 antibodies in pre- and post-
immunization samples from CPS-immunized volunteers (n=15) were determined by CSP-specific IgG1 subclass ELISAs and 
shown as arbitrary units. Differences between pre- and post-immunization samples were determined by paired Student's t-
test and a p-value of <0.05 was considered statistically significant. 
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Figure 2: Complement activation and lysis of P. falciparum homologous NF54 sporozoites by CPS-induced antibodies 
Homologous NF54 sporozoites were pre-incubated with 10% inactive or active complement, and 10% heat-inactivated pre- 
or post-immunization serum from CPS-immunized volunteers. (A) C3 complement protein deposition on NF54 sporozoites 
by 10% post-immunization serum (n=12 volunteers) in the presence of inactive or active of complement was assessed and 
shown as MFI. C3 deposition by post-immunization serum was corrected for baseline responses by subtracting C3 
deposition by pre-immunization serum. (B) Sporozoite damage by CPS-induced antibodies (n=12 volunteers) in the 
presence of 10% inactive or active complement is shown as the percent of sporozoite damage, and corrected by subtracting 
the percent sporozoite damage in the presence of pre-immunization antibodies. (C) Scatter plots showing C3 complement 
protein deposition and the percent damaged sporozoites per donor were corrected for pre-immunization values and 
analysed by Spearman correlation analysis (n=12 CPS-immunized volunteers). Samples in the presence or absence of active 
complement are shown in grey circles and black squares, respectively. (D) NF54 sporozoites were pre-incubated with 10 
mg/ml of purified pre-, post-immunization and post-immunization IgGs depleted from CSP-specific antibodies (n=5 
volunteers) in the presence of 10% active complement. C3 complement protein deposition and (E) sporozoite damage by 
purified IgGs are shown as C3 deposition (MFI) and percent of sporozoite damage, respectively. Comparisons between 
multiple groups were tested with one-way ANOVA with Bonferroni multiple comparison post hoc test. Data are shown as 
the mean of duplicate measurements and presented as black squares or grey circles for samples tested in the presence of 
inactive or active complement, respectively. Asterisks represent p-values of: p<0.05 (*) and p<0.01 (**). 
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Figure 3: In vitro traversal and invasion inhibition of P. falciparum homologous NF54 sporozoites by CPS-induced 
antibodies in the presence or absence of complement 
The percentage inhibition of traversal (A; 14 volunteers) and invasion (B; 17 volunteers) was calculated for 10% post- 
compared to pre-immunization serum for each volunteer in the presence of 10% inactive or active complement. (C) 
Spearman correlation analysis between cumulative parasitaemia (P. falciparum parasites per milliliter) during three CPS-
immunizations and invasion inhibition by CPS-induced antibodies in the presence of active complement (uncorrected for 
HIS; n=17 volunteers). Data are shown as the mean of duplicate measurements and presented as black squares or grey 
circles for samples tested in the presence of inactive or active complement, respectively.  
 
Comparison of complement-mediated effects on P. falciparum NF54 and NF135.C10 sporozoite infectivity  
There were no significant differences in the binding of specific IgG antibodies to NF54 or NF135.C10 
sporozoites (Figure 5A, p=0.494). In contrast, NF135.C10 sporozoites were less opsonized by specific IgM 
antibodies in comparison to NF54 (Figure 5B, p=0.023). Nevertheless, this did not translate into differences in 
C3 deposition and lysis (Figures 5C and D, p=0.53 and p=0.69). Traversal inhibition was not significantly 
different between the two strains (Figure 5E, p=0.18), with median enhanced traversal inhibition of 29.4% (IQR 
23.4-41.1) and 48.4% (IQR 27.3-57.7) for NF54 and NF135.C10 sporozoites, respectively. NF54 sporozoite 
invasion was more strongly neutralized by CPS-induced antibodies in the absence of active complement with a 
median invasion inhibition of 70.1% (IQR 59.4-78.4) and 53.0% (IQR 38.4-62.2) for NF54 and NF135.C10 
sporozoites, respectively (p=0.019). Invasion inhibition of NF54 and NF135.C10 sporozoites in the presence of 
active complement was not significantly different (median 87.2%, IQR 77.2-90.2 and 91.8%; IQR 90.5-94.5 for 
NF54 and NF135.C10  respectively). However, invasion of heterologous sporozoites was more strongly inhibited 
in the presence of active complement than for NF54 sporozoites (Figure 5F, p=0.008) with median enhanced 
invasion inhibition of 22.5% (IQR -2.7-25.5) and 42.3% (IQR 36.4-46.4) for NF54 and NF135.C10 sporozoites, 
respectively. 
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Figure 4: Complement activation and inhibition of heterologous P. falciparum NF135.C10 sporozoites 
Heterologous P. falciparum NF135.C10 sporozoites were pre-incubated with 10% heat-inactivated pre- or post-
immunization serum (n=24 volunteers) and 10% inactive complement. The amount of CPS-induced (A) IgG and (B) IgM 
antibodies recognizing sporozoites were determined by flow cytometry and shown as MFI. (C) C3 complement deposition 
on NF135.C10 sporozoites in the presence of 10% inactive (black) or active complement (grey) by 10% pre- or post-
immunization CPS serum (n=15 volunteers) is shown as the MFI. C3 complement protein deposition in the presence of post-
immunization serum was corrected for C3 deposition in the presence of pre-immunization serum. (D) Sporozoite damage 
by pre- or post-immunization antibodies (n=14 volunteers) in the presence of 10% active or inactive complement is shown 
as the percent sporozoite damage, and corrected for the percent sporozoite damage in the presence of pre-immunization 
antibodies. The percentage inhibition of heterologous sporozoite traversal (E; 13 volunteers) and invasion (F; n=8 
volunteers) was calculated for 10% post- compared to pre-immunization serum for each volunteer in the presence of 10% 
inactive or active complement. Data are shown as the mean of duplicate measurements and presented as black squares or 
grey circles for samples tested in the presence of inactive or active complement, respectively. Differences between pre- and 
post-immunization samples or inactive and  active complement were determined by paired Student's t-test and a p-value of 
<0.05 was considered statistically significant. 
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Figure 5: Comparison of complement activation and inhibition between NF54 and NF135.C10 sporozoites  
Recognition of homologous NF54 and heterologous NF135.C10 sporozoites by post-immunization IgG (A) and IgM (B) 
antibodies are shown as fold increase over baseline (pre-immunization) antibodies (n=16 CPS-immunized volunteers). (C) 
Enhanced C3 complement protein deposition on homologous and heterologous sporozoites are shown as the MFI and is 
corrected for complement fixation by pre-immunization antibodies and inactive complement (n=12 volunteers). (D) 
Enhanced sporozoite damage of homologous and heterologous sporozoites are shown as the percent sporozoite damage 
and is corrected for damage in the presence of pre-immunization antibodies and inactive complement (n=11 volunteers). 
The percentage enhanced inhibition of both homologous and heterologous sporozoite traversal (E; n=9 volunteers) and 
invasion (F; n=7 volunteers) in the presence of active complement was calculated for 10% post- compared to pre-
immunization serum for each volunteer in the presence of 10% inactive or active complement. To calculate the percent 
enhanced inhibition by active complement and post-immunization antibodies, inhibition in the presence of complement 
was corrected for inhibition in the presence of inactive complement. Data are shown as the mean of duplicate 
measurements. Differences between parasite strains were determined by paired Student's t-test and a p-value of <0.05 was 
considered statistically significant. 
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Discussion 
The present study shows that CPS-immunization with P. falciparum NF54 sporozoites induces complement-
fixing antibodies that are capable of activating the classical complement pathway, resulting in membrane-
compromised sporozoites and further reduction of homologous and heterologous sporozoite infectivity in vitro. 
This is supported by previous findings from in vitro assays with Plasmodium gallinaceum, revealing the 
importance of the classical complement pathway in inducing sporozoite death (25). 
Sporozoite-specific IgM responses contribute to CPS-induced immunity with the potential benefit of higher 
avidity to P. falciparum target antigens and efficient complement fixation (26). Some volunteers tend to have a 
stronger induction of sporozoite-specific IgM than IgG antibodies, while sporozoite-specific IgG antibodies are 
more strongly induced in other volunteers. As shown in the present study, CSP- and sporozoite-specific IgM 
antibodies are still present at 18 weeks after the last CPS-immunization, corroborating previous observations 
(27). This suggests that an initial IgM response is developed, whereby not all epitope-specific responses might 
be followed by class-switching to IgG over the next two to three weeks (28). The functional relevance and 
importance of IgM antibodies has been previously shown in the Plasmodium chabaudi model, where 
Plasmodium-specific IgM-producing memory B-cells are readily induced in response to repeated parasite 
exposure (29). Interestingly, the magnitude and breadth of P. falciparum-specific IgM antibody responses are 
also higher in African adults with naturally acquired anti-malarial immunity whom are resistant to malaria, 
when compared to adults susceptible to malaria (30). Additionally, it was very recently shown that 
immunization of Tanzanian individuals with radiation attenuated cryopreserved P. falciparum sporozoites 
(PfSPZ) induces functional anti-sporozoite IgM antibodies with human hepatocyte invasion inhibitory and 
complement-fixing activity (31). 
Humoral reactivity to CSP is induced following CPS-immunization (16, 17) but induction of sporozoite-specific 
IgG does not correlate with anti-CSP-IgG levels. In fact, even virtually complete depletion of anti-CSP-specific 
IgG (median percent CSP depletion 91.7%, IQR 79.8-96.4%; S2 Table) still leaves complement-fixing activity 
against sporozoites intact. This may suggest that only a fraction of anti-CSP-specific antibodies may still be 
sufficient for complement activation. It is more likely, however, that CPS-induced IgG antibodies with different 
antigenic specificities than CSP (17, 27) might show functional activity. 
Showing some variation between volunteers, it is clear that CPS-induced antibodies can efficiently enhance C3 
fixation with subsequent enhanced homologous and heterologous sporozoite lysis. Complement fixation 
efficacy depends on antibody-intrinsic features, such as epitope specificity of antibodies, antibody affinity as 
well as antibody isotype, or Fc-receptor glycosylation. High affinity antibodies can activate complement more 
efficiently, since antibodies may switch classes in a particular order dependent on the degree of affinity 
maturation (32-35). As for antibody isotype, it is very likely that some individuals with low IgG concentrations 
may have high IgM levels, while other individuals might rely more on IgGs for complement-fixing activity. While 
CPS-immunization predominantly induces anti-CSP-specific IgG1 and IgM antibodies, RTS,S (CSP) subunit 
vaccination primarily induces IgG1 antibodies against CSP repeats (36). On the other hand, CSP-specific 
naturally acquired antibodies are mainly IgG1, IgG3 and IgM (21), showing that the induction of anti-CSP 
antibody isotypes differs between these immunizations. A possible explanation for the absence of IgG2, IgG3 
and IgG4 responses following CPS-immunization might be that IgG subclass responses following whole 
sporozoite immunization may be polarized towards IgG1, the most abundant immunoglobulin and induced 
upon exposure to soluble protein antigens and membrane proteins (22). IgG2 and IgG4 antibody responses are 
only produced following exposure to bacterial polysaccharide antigens, in response to helminth infections or 
following repeated or long-term exposure to non-infectious antigens (allergens; (37)), respectively.  
Alternatively, the observed variation in classical complement activation might be due to variation in the density 
of fragment crystallizable (Fc) regions, since a minimum threshold concentration of Fc regions is required for 
stronger classical pathway activation (34). Moreover, Fc-receptor glycolysation can affect antigen-binding 
characteristics and thus, also antibody activity (22, 38). 
As a next step, we studied the functional consequences of enhanced complement fixation on sporozoite 
infectivity in vitro. NF54 human hepatocyte invasion is more strongly inhibited by CPS-induced antibodies than 
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NF135.C10 invasion in the absence of active complement, as recently reported by us (26). Despite lower IgM 
binding to NF135.C10 sporozoites which is most likely due to genetic diversity in the CSP protein sequence (24), 
there were no differences in complement protein deposition and sporozoite lysis. This can be explained by the 
fact that IgM antibodies generally have a lower threshold for complement fixation as compared to IgG 
antibodies and are therefore still very efficient in complement activation, despite the fact that they bind less 
efficient to heterologous NF135.C10 sporozoites. Interestingly, NF135.C10 invasion inhibition is twice as high as 
NF54 in the presence of active complement. These data suggest that opsonization for complement might also 
occur independently of strain-specific epitopes and that complement has more added value when antibodies 
alone are less efficient in binding and neutralization, e.g. due to parasite genetic diversity. Antibody-mediated 
complement activation may also have additional indirect effects on sporozoite clearance, including modulation 
of the inflammatory response, induction of antibody-dependent cellular cytotoxicity (ADCC) or phagocytosis 
(39). 
Unexpectedly, some C3 deposition and sporozoite death also takes place before immunization, suggesting that 
some C3 complement proteins may directly bind to sporozoites via the alternative pathway. Some sporozoite 
proteins may contain carbohydrates that might activate the antibody-independent mannose-binding lectin 
(MBL) pathway (40-45). While MBL-deficient mice show no altered resistance to liver-stage infection, MBL 
binding may take place and modulate host defense (46). More likely, malaria-naive volunteers may have cross-
reactive antibodies that recognize sporozoites or mosquito salivary gland material and thus, are able to interact 
with complement proteins. Although possibly contributing, our data clearly show that complement activation is 
primarily activated and functional in the presence of malaria-specific antibodies. Additionally, it has recently 
been shown that C3 deposition on CSP by naturally acquired antibodies strongly correlates with C1q fixation to 
CSP (21). Here, we show that NF54 invasion inhibition by CPS-induced antibodies and active complement is 
negatively associated with cumulative parasitaemia during CPS-immunizations. Previous studies in human and 
animal models of malaria support a role for complement activation during malaria infection with increased 
membrane attack complexes (47) or reduced serum complement protein levels (48-53). It was previously 
observed in a humanized liver-chimeric mouse model that CPS-induced antibodies had a much stronger 
inhibitory effect on P. falciparum liver-stage infection in vivo than in vitro (18). A possible explanation for this 
observation might be that CPS-induced IgGs could potentially interact with human complement, which has 
previously shown to be produced by human hepatocytes in human-liver chimeric mice (54), resulting in a more 
pronounced effect on liver-stage inhibition in vivo. Additionally, resistance to natural infection with 
Plasmodium malaria parasites has been associated with IgG1 and IgG3 antibody isotypes, both of which are 
very potent in fixing complement and activating the complement system (20, 55-57). This is further supported 
by the fact that children living in a P. falciparum holoendemic area in Papua-New Guinea with high levels of 
complement-fixing antibodies to CSP have a reduced risk of clinical malaria as compared to children with 
undetectable functional antibodies (21). Taken together, these studies suggest that the complement system 
plays a role in anti-malarial immunity and protection from malaria infection in vivo. 
In summary, these findings demonstrate for the first time that CPS-induced antibodies can interact with the 
complement system, further reducing homologous and heterologous sporozoite infectivity in vitro. Together, 
these data highlight the importance of the complement pathway and provide new knowledge on antibody-
mediated immune mechanisms involved in pre-erythrocytic immunity to homologous and heterologous 
sporozoites after whole-parasite immunization against P. falciparum malaria.  
 
Materials and methods 
Study design experimental controlled human malaria infection  
Citrated plasma and serum samples were used from a double-blind, randomized, placebo-controlled CPS-
immunization trial conducted at the Radboud university medical center in 2015 (Nijmegen, The Netherlands; 
ClinicalTrials.gov identifier: NCT02098590; (24)). Due to limited plasma sample availability, citrated plasma 
samples from a second open-labeled, randomized CPS-immunization study conducted in 2014-2015 
(NCT02080026) were used. All study subjects provided written informed consent and both studies were 
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approved by the Central Committee for Research Involving Human Subjects of The Netherlands (CCMO 
NL48732.091.14 and NL48301.091.14).  
In both CPS trials (NCT02098590 and NCT02080026), volunteers were subjected to NF54 CPS-immunization. 
While receiving chloroquine in a prophylactic dose, subjects were immunized three times (NCT02098590) or 
four times (NCT02080026) at monthly intervals by exposure to bites from 15 P. falciparum NF54-infected 
Anopheles stephensi mosquitoes. Fourteen weeks after discontinuation of chloroquine prophylaxis, subjects 
underwent a primary challenge infection by exposure to bites of 5 mosquitoes infected with the homologous P. 
falciparum NF54 strain (58), or the genetically distinct NF135.C10 (23) and NF166.C8 (59) clones. Of note, study 
subjects from the second, open-labeled and randomized CPS-immunization study were only exposed to NF54-
infected mosquito bites (NCT02080026). All subjects were followed up closely from day 6 to 10 after each CPS-
immunization and from day 6 to 21 after mosquito bite challenge infection for symptoms and signs of malaria. 
When the treatment threshold (100 parasites per milliliter of blood) by quantitative PCR between day 7 and 9 
was reached (60, 61), blood-stage parasitaemia was treated with a curative regimen of atovaquone and 
proguanil once daily for three days. Cumulative blood-stage parasitaemia during all three CPS-immunizations 
(NCT02098590) was calculated by summing up the number of parasites per milliliter of blood as determined by 
qPCR from day 6 to 10 after each CPS-immunization. NF54 CPS-immunization induced sterile protection in 5/5, 
2/10 and 1/9 subjects against NF54, NF135.C10 or NF166.C8 mosquito bite challenge infection, respectively. 
6/10 NF135.C10-challenged subjects showed a prolonged pre-patent period (trial NCT02098590). With respect 
to the second CPS-immunization study (NCT02080026), 5/9 study subjects were completely protected from 
homologous NF54 mosquito bite challenge. 
 
Parasite strains 
P. falciparum NF54 and NF135.C10 sporozoites were used for in vitro sporozoite assays. Plasmodium 
falciparum NF54 has been isolated from an individual near Schiphol Airport (The Netherlands) and most likely 
originates from West Africa (58, 62). The genetically and geographically distinct P. falciparum NF135.C10 clone 
originates from a clinical isolate in Cambodia (23). 
 
Parasite culture and generation of P. falciparum-infected mosquitoes 
P. falciparum NF54 and NF135.C10 asexual and sexual blood-stages were cultured in a semi-automated culture 
system as previously described (63-65). Anopheles stephensi mosquitoes were reared in the insectary of 
Radboud university medical center and female mosquitoes were infected by standard membrane feeding on 
NF54 or NF135.C10 gametocyte cultures (66). For in vitro sporozoite assays, salivary glands from infected 
mosquitoes were hand dissected 14-28 days after mosquito infection, collected in Leibovitz culture medium 
without serum, and homogenized in a homemade glass grinder. The number of P. falciparum NF54 or 
NF135.C10 sporozoites was determined using a Bürker-Türk counting chamber using phase contrast 
microscopy (18). 
 
Human hepatoma HC-04 cell line 
The HC-04 human hepatocyte cell line (Homo sapiens HC-04, MRA-965), deposited by Jetsumon Sattabongkot 
(67), was acquired through the MR4 as part of the Biodefense and Emerging Infections Research Resources 
Repository (BEI Resources). Cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM)/Ham’s F-12 
nutrient mixture medium (GIBCO) supplemented with heat-inactivated 10% fetal bovine serum (FBS, GIBCO), 
1% glutamine (GIBCO) and 1% penicillin/streptomycin (GIBCO) at 37 ˚C in an atmosphere of 5% CO2. 
 
Citrated plasma, serum samples and complement source 
Citrated plasma samples and serum samples from 24 CPS-immunized volunteers were collected 11-14 days 
before the first CPS-immunization (pre-immunization) and one day before challenge infection (18 weeks after 
the last immunization; post-immunization) (Clinical Trials.gov identifier: NCT02098590) using citrated 
vacutainer cell preparation tubes (CPT vacutainers, Becton Dickinson) or serum vacutainer tubes (Becton 
Dickinson). Samples were used for determination of immunoglobulin (Ig) subclasses, antibody opsonization 
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assays (citrated plasma samples) or in vitro sporozoite assays (serum). Samples were stored in aliquots at -20 
°C. Prior to use in in vitro sporozoite assays, serum aliquots were heat-inactivated for 30 minutes at 56 °C, 
centrifuged at 13,000 rpm for 5 minutes at room temperature and kept at 4 ˚C. 
Due to limited plasma availability, additional citrated plasma samples were collected one week before the first 
CPS-immunization (pre-immunization) and one day before challenge infection (15 weeks after the last 
immunization; post-immunization) from 5 sterilely protected CPS-immunized volunteers (ClinicalTrials.gov 
identifier: NCT02080026) and used for IgG purifications and depletion from CSP-specific antibodies. Purified 
IgGs were assessed for their ability to activate complement and induce sporozoite lysis in the presence or 
absence of CSP-specific antibodies. 
An external source of human complement was used in all in vitro sporozoite assays to determine the 
complement-fixing activity of CPS-induced antibodies (either heat-inactivated CPS serum or purified IgGs) 
independently of possible differences in complement activity present in each CPS-immunized volunteer. This 
specific batch was consistently used for all experiments and samples, and added either fresh (normal human 
serum; active complement) or heat-inactivated (heat-inactivated serum; inactive complement). Heat-
inactivation has been previously validated. This complement source consisted of pooled sera from 5 malaria-
naive Australian donors and has been validated for the absence of circumsporozoite protein (CSP)-specific 
antibodies by a standardized enzyme-linked immunosorbent assay (ELISA) as previously described (21). 
 
IgG purifications from citrated plasma samples 
IgG purifications from citrated pre- and post-immunization plasma samples from CPS-immunized volunteers 
(n=5) were performed using a 5 ml HiTrap Protein G HP affinity column (Amersham Biosciences) according to 
the manufacturer's instructions. A fraction of purified post-immunization IgGs was depleted from 
circumsporozoite protein (CSP)-specific antibodies by running IgGs three times over a CSP affinity column that 
was constructed by coupling CSP (Gennova Biotechniques Pvt. Ltd., India) to a 1ml HiTrap NHS activated HP 
affinity column (GE Healthcare, 17-0717-01). IgGs were purified and depleted from CSP-specific antibodies 
using an ÄKTA prime machine and Unicorn software (GE Healthcare, version 1.0). Purified IgGs were taken up 
in phosphate buffered saline (PBS). IgG concentrations and CSP depletion efficacy (Tables S1 and S2) were 
determined by a standardized total IgG and CSP-IgG ELISA prior to use in an in vitro complement deposition and 
sporozoite damage assay. 
 
Total IgG, CSP-IgG, CSP-IgM and CSP-specific Ig subclass ELISAs 
Total IgG concentrations and CSP-specific IgG antibodies in purified pre-immunization IgGs, post-immunization 
IgGs, CSP-depleted post-immunization IgGs, and CSP-specific IgM antibody levels in pre- and post-immunization 
plasma samples were determined by total IgG, CSP-IgG and CSP-IgM ELISAs. CPS-induced immunoglobulin 
isotypes to CSP were determined by CSP-specific Ig subclass ELISAs. All these ELISAs are described in detail in 
Supplementary Materials and Methods. 
 
IgG and IgM antibody opsonization of whole sporozoites 
Recognition of whole sporozoites by immunization-induced IgG and IgM antibodies was determined by an in 
vitro flow-cytometry-based antibody opsonization assay as described in detail in Supplementary Materials and 
Methods. Briefly, 5x104 P. falciparum NF54 or NF135.C10 sporozoites/well in a v-bottom 96 well plate were 
incubated with 10% heat-inactivated pre- or post-immunization serum and 10% heat-inactivated normal 
human serum (inactive complement) for 30 minutes at 37 ˚C. Following incubation, samples were washed with 
PBS and centrifuged at 3,220 g for 5 minutes at room temperature, and stained with fluorescently labeled 
antibodies targeting sporozoite circumsporozoite protein (CSP), IgG and IgM antibodies for 30 minutes in the 
dark at 4 ˚C. Unstained sporozoites and single compensation controls were taken along. Following incubation, 
samples were fixed with 1% paraformaldehyde (PFA) for 20 minutes in the dark at 4 ˚C and taken up in PBS. 
Samples were kept at 4 °C in the dark until flow cytometric analysis. Flow cytometric analysis was performed 
with a LSRII flow cytometer (BD BioSciences) and data analysis was performed with FlowJo software (version 
10.0.8, Tree Star). 
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In vitro complement deposition and sporozoite damage assay 
C3 complement protein deposition on whole sporozoites and sporozoite damage due to complement activation 
in the presence or absence of immunization-induced antibodies were assessed with an in vitro flow-cytometry-
based assay as described in detail in Supplementary Materials and Methods. Briefly, 5x104 P. falciparum NF54 
or NF135.C10 sporozoites/well in a v-bottom 96 well plate were incubated with 10% heat-inactivated pre- of 
post-immunization serum and 10% fresh normal human serum (active complement) or 10% inactive 
complement for 30 minutes at 37 ˚C. In case of purified IgGs, sporozoites were incubated with 10 mg/ml pre-
immunization IgGs, post-immunization IgGs or post-immunization IgGs depleted from CSP in the presence of 
10% active complement. Following incubation, PBS/20 mM EDTA was added to all samples and plates were put 
at 4 ˚C for 5 minutes to inactivate complement. Subsequently, sporozoites were stained with fluorescently 
labeled antibodies targeting sporozoite CSP, C3 complement protein deposition and a fixable viability dye for 
30 minutes in the dark at 4 ˚C. Unstained sporozoites and single compensation controls were taken along. After 
incubation, samples were processed and analysed as described in the previous section. The geometric mean 
fluorescent intensity (MFI) and percent membrane-compromised sporozoites of post-immunization samples 
were corrected for that of pre-immunization responses by subtracting the MFI and percent membrane-
compromised sporozoites of pre-immunization responses from that of post-immunization responses. 
 
In vitro sporozoite hepatocyte traversal inhibition assay 
The antibody-dependent complement-mediated effect of CPS-induced antibodies to further augment inhibition 
of in vitro human hepatocyte traversal by P. falciparum sporozoites in the presence of active complement was 
assessed as previously described with small adaptations (18). Briefly, freshly dissected NF54 and NF135.C10 
sporozoites were pre-incubated with 10% heat-inactivated pre- or post-immunization CPS serum for 30 
minutes at 4 ˚C. Subsequently, 5x104 sporozoites/well were added in duplicate to flat-bottom 96-well plates 
containing monolayers of 5x104 HC-04 cells in the presence of 10% active or inactive complement, and 0.5 
mg/ml fixable tetramethylrhodamine dextran (ThermoFischer Scientific). HC-04 cells alone in the presence of 
dextran served as a background control. After 2 hours of incubation at 37 °C in 5% CO2, cells were gently 
washed and processed for flow cytometric analysis. Flow cytometric analysis was performed with a Cyan ADP 
(Beckman Coulter) flow cytometer and data were analysed with FlowJo software (version 9.6.7, Tree Star). The 
percentage of dextran-positive cells was first corrected for background reactivity by subtracting the 
background, and the percent traversal inhibition was calculated as follows: 1 - (average % dextran-positive cells 
in post-immunization cultures / average % dextran-positive cells in pre-immunization cultures) * 100%. 
 
In vitro sporozoite infectivity assay of a human hepatoma cell line 
Neutralization of P. falciparum sporozoite hepatocyte invasion in vitro by CPS-induced antibodies was assessed 
in a flow-cytometry based in vitro invasion assay as described in detail in Supplementary Materials and 
Methods. Briefly, P. falciparum NF54 or NF135.C10 were pre-incubated with 10% heat-inactivated pre- or post-
immunization CPS serum for 30 minutes at 4 ˚C. Subsequently, 5x104 sporozoites/well were added to flat-
bottom 96-well plates containing monolayers of 5x104 HC-04 cells in the presence of 10% active or inactive 
complement. After 3 hours of incubation at 37 °C in 5% CO2, intracellular and invaded parasites were stained 
with a fluorescently labeled antibody targeting CSP and cells were processed for flow cytometric analysis. Flow 
cytometric analysis was performed with a Gallios (Beckman Coulter) flow cytometer and data were analysed 
with FlowJo software (version 10.0.8, Tree Star). The percentage of CSP-positive sporozoites was first corrected 
for background reactivity by subtracting the background (uninfected HC-04 cells in the presence of 3SP2-Alexa 
Fluor-488 antibody). The percent invasion inhibition was calculated as follows: 1 - (average % CSP-positive cells 
in post-immunization cultures / average % CSP-positive cells in pre-immunization cultures) * 100%. 
 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism software (version 5, GraphPad Software Inc., 
California, USA). For analysis of in vitro sporozoite data, antibody binding, C3 complement deposition on 
sporozoites and sporozoite lysis, differences between pre- and post-immunization samples, HIS and NHS or 
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parasite strains were tested using the two-tailed paired Student's t-test. Comparisons of two non-matching 
groups (controls versus CPS-immunized volunteers) or comparisons between multiple groups (pre- and post-
immunization IgG, and CSP-depleted post-immunization IgGs) were tested with the unpaired Student's t-test 
and one-way ANOVA with Bonferroni multiple comparison post hoc test, respectively. Correlation analyses 
were conducted with Spearman correlation analysis.  A p-value of <0.05 was considered significant. Asterisks 
represent p-values of p<0.05 (*) and p<0.01 (**). 
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Supplemental Information  
 
 
 
Figure S1: Induction of IgG and IgM sporozoite-specific antibodies in control versus CPS-immunized volunteers  
Homologous NF54 sporozoites were pre-incubated with 10% heat-inactivated pre- or post-immunization serum from 
control volunteers and 10% inactive complement. Recognition of homologous NF54 sporozoites by IgG (A) and IgM (B) 
antibodies from control volunteers (n=10) all of which were under chloroquine prophylaxis while exposed to uninfected 
mosquito bites instead of infected mosquito bites. Differences in IgG (C) and IgM (D) antibody recognition of NF54 
sporozoites by control volunteers (n=10) and CPS-immunized volunteers (n=16) are shown. Data are shown as the mean of 
duplicate measurements in MFI. Differences between pre- and post-immunization serum were tested using the paired 
Student's t-test, while differences between controls and CPS-immunized volunteers were tested using the unpaired 
Student's t-test. Data were considered statistically significant at p<0.05.  
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Figure S2: Antibody specificity of CPS-induced sporozoite-specific IgG and IgM antibodies  
(A) Scatter plot of sporozoite-specific IgG and IgM antibodies targeting homologous NF54 sporozoites is shown (n=16 CPS-
immunized volunteers). (B) Scatter plot of CSP-IgG and CSP-IgM antibodies is shown (n=16 CPS-immunized volunteers). (C) 
Correlation analysis for NF54 sporozoite-specific and CSP-specific IgG antibodies as previously determined by ELISAs (23) is 
shown for n=16 volunteers. (D) Correlation analysis for NF54 sporozoite-specific and CSP-specific IgM antibodies is shown 
(n=16 CPS-immunized volunteers). Data are shown as the mean of duplicate measurements. Correlation analyses were 
conducted using Spearman correlation analysis. Data were considered statistically significant at p<0.05.  
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Figure S3: Importance of antibody-independent pathways for complement activation and sporozoite lysis  
Activation of the complement pathway via antibody-independent pathways was characterized by looking at C3 complement 
protein deposition on homologous NF54 sporozoites (A) or NF54 sporozoite lysis (B) in the presence of malaria-naive (pre-
immunization) antibodies (n=12 volunteers) in the presence of active (NHS) or inactive (HIS) complement. To show that 
homologous complement activation was more strongly induced by post-immunization antibodies, C3 deposition (C) and 
sporozoite lysis (D) by CPS-induced antibodies in the presence of active complement, compared to pre-immunization 
antibodies, are shown. Antibody-independent complement activation of heterologous NF135.C10 sporozoites was shown as 
C3 deposition. Data are shown as the mean of duplicate measurements. Differences between parasite strains (matched 
volunteers) were tested using the paired Student's t-test. Data were considered statistically significant at p<0.05.  
 
 
 
 
Figure S4: Correlation analyses of invasion inhibition and cumulative parasitaemia or prepatent period 
(A) Spearman correlation analysis between cumulative parasitaemia (P. falciparum NF54 parasites per milliliter) during 
three CPS-immunizations and NF54 invasion inhibition by CPS-induced antibodies in the presence of inactive complement 
(uncorrected for HIS; n=17 volunteers). (B) Spearman correlation analysis between NF135.C10 pre-patent period (days after 
challenge) and NF135.C10 invasion inhibition by CPS-induced antibodies in the presence of active complement (n=4 
volunteers). Data were considered statistically significant at p<0.05. 
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Table S1: Total IgG concentrations  
 
Volunteer ID Pre-immunization IgG  
(mg/ml) 
Post-immunization IgG 
(mg/ml) 
CSP-depleted post-immunization IgG 
(mg/ml) 
1 44.4 15.5 27.7 
2 15.1 101.3 36.7 
3 39.2 29.9 9.7 
4 16.4 16.7 13.1 
5 15.7 42.9 14.8 
 
 
 
Table S2: CSP depletion efficacy 
Volunteer ID Post-immunization IgG  
(HIT=100 AU) 
CSP-depleted post-immunization 
IgG 
(HIT=100 AU) 
Percent CSP depleted from 
post-immunization IgG (%) 
1 200.7 39.4 80.4 
2 1316.0 45.5 96.5 
3 175.5 14.5 91.7 
4 25.9 5.4 79.2 
5 1339.4 50.7 96.2 
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Abstract 
 
Background 
There is a strong interest in pre-erythrocytic subunit vaccines against malaria based on antigens other than 
circumsporozoite protein (CSP). Human volunteers immunized under ChemoProphylaxis and Sporozoites (CPS) 
develop long-lasting and sterile protection against P. falciparum. CPS-induced antibodies primarily recognize 
pre-erythrocytic antigens and strongly neutralize liver-stage infection in vitro and in vivo. Here, the CPS model 
is used to investigate whether non-CSP-specific antibodies can prevent P. falciparum liver-stage infection and 
identify potential non-CSP antibody target antigens for clinical vaccine development.  
 
Methods 
IgGs from protected CPS-immunized volunteers (n=5) were purified from plasma samples obtained before and 
after CPS-immunization. Immunization-induced antibodies were depleted from CSP-specific antibodies using a 
CSP specific-affinity column. IgGs were assessed for their capability to neutralize liver-stage infection in 
hepatoma cells in vitro and in liver-chimeric FRG mice in vivo. 
 
Results 
Post-immunization (4/5) and CSP-depleted post-immunization IgGs (2/5) inhibited sporozoite infectivity in vitro 
by ≥30% in HCO4 hepatoma cells . Post-immunization IgGs (5/5) reduced in vivo liver-stage infection of FRG 
mice by 82%. Interestingly, CSP-depleted IgGs (2/5) maintained the ability to inhibit in vivo liver-stage burden in 
these mice by 88.0% and preferentially recognized the periphery of liver-stage parasites, suggesting that 
antibodies targeting proteins other than CSP can inhibit parasite infection in vivo.  
 
Conclusion 
These data demonstrate that non-CSP-specific antibodies can effectively inhibit liver-stage infection in vitro and 
in vivo, and argue for the investigation of novel sporozoite and liver stage proteins as potential vaccine 
candidate antigens. 
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Introduction 
Malaria remains one of the most common and severe infectious diseases worldwide with an estimated 214 
million clinical cases and 438,000 deaths annually (1). The disease is caused by Plasmodium parasites with 
Plasmodium falciparum being the deadliest species. When Plasmodium falciparum (P. falciparum) sporozoites 
are transmitted to humans by infected female Anopheles mosquitoes, sporozoites migrate from the dermis into 
the blood circulation and subsequently to the liver where they invade hepatocytes. After maturation and 
replication over seven days, tens of thousands of merozoites are released in the blood circulation. These invade 
and multiply asexually inside erythrocytes, causing the clinical symptoms of malaria (2). Although a significant 
decrease in malaria mortality rates has been observed in the last decades, the emergence of insecticide-
resistant mosquitoes and drug-resistant parasites are hampering malaria control efforts, stressing the need for 
a highly effective vaccine to further accelerate malaria eradication efforts (1, 3-5).  
The most advanced subunit vaccine candidate to date is the RTS,S subunit vaccine (Mosquirix, 
GlaxoSmithKline), which is based on a major P. falciparum sporozoite surface protein, the circumsporozoite 
protein (CSP), which is fused to hepatitis B virus surface antigen virus-like particles (6). RTS,S vaccination has 
been shown to elicit strong CSP-specific humoral and CD4+ T-cell responses that were associated with RTS,S-
induced protection (7-10). However, phase III clinical trials with the RTS,S subunit vaccine have only provided 
partial, rapidly waning protection against clinical disease in infants, children and adults living in highly malaria-
endemic areas (11-14). Given the modest efficacy and lack of sterile protection induced by the RTS,S subunit 
vaccine, more effective pre-erythrocytic vaccines are urgently needed to meet the World Health Organization 
target of greater than 75% protection lasting for at least 4 years by 2025 (1).  
One way to develop a more effective subunit vaccine is the identification of immunological antigenic targets 
other than CSP that are capable of preventing liver-stage infection and confer sterile protection against 
malaria. While RTS,S subunit vaccination does not result in sterile protection, long-lasting and sterile protection 
against homologous P. falciparum strains can be achieved by exposure of healthy human volunteers to P. 
falciparum-infected mosquito bites under the cover of ChemoProphylaxis (CPS) (15, 16). CPS-induced 
antibodies recognize a broad array of pre-erythrocytic antigens (17, 18) and are capable of effectively 
preventing liver-stage infection in vitro and in passively immunized humanized mice in vivo (19, 20). Although 
humoral reactivity to CSP is induced following CPS-immunization, CSP antibody titers do not predict protection, 
but rather reflect parasite exposure during CPS-immunization (21). This suggests that antigens other than CSP 
might play a role in CPS-induced immunity. Therefore, the CPS immunization regimen might be a very valuable 
tool to identify novel, non-CSP antibody target antigens for the development of more effective pre-erythrocytic 
subunit vaccines. In the present study, the CPS model was used to investigate for the first time whether non-
CSP-specific antibodies can potentially prevent liver-stage infection.  
 
Results  
Non-CSP-specific antibodies inhibit in vivo liver-stage infection in passively immunized liver-chimeric mice 
Post-immunization IgGs from 5 volunteers immunized by the CPS immunization regimen were depleted of CSP-
specific antibodies (Table S1 and S2). Following passive transfer of IgG and subsequent infectious P. falciparum 
mosquito bite challenge of FRG huHep mice, liver infection of P. falciparum GFP-luciferase-expressing parasites 
was monitored from days 4-6 post infection. As two mice injected with pre-immunization IgG deceased during 
the experiment, the average pre-immunization liver burden was used as reference for liver-stage inhibition. It 
was previously shown that pre-immunization IgG from malaria-naive volunteers has no effect on liver infection 
(20).  
At the peak of parasite liver burden on day 6, prior administration of CSP-containing post-immunization IgG 
from four out of five volunteers strongly reduced parasite liver burden with inhibition (86.5% median 
inhibition; interquartile range (IQR): 69.4-90.9%) compared to mice injected with pre-immunization IgG 
(Figures 1A-D, p=0.0015). The fifth volunteer showed a more modest reduction of only 1.7-fold (median 
percent invasion inhibition 41.9%; Figure 1E). Reduction of in vivo liver-stage burden by post-immunization IgG 
did not correlate with CSP antibody titers as previously determined by ELISAs (22) (Supplementary Figure 2; 
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p=0.6833), suggesting that in addition to CSP, a range of other antigens might play a role in preventing liver-
stage infection in vivo. 
Interestingly, CSP-depleted IgGs from volunteers 2 and 5 retained the ability to strongly reduce liver-stage 
infection (median invasion inhibition percentage of 88.0%). Moreover, these IgGs were able to prevent the 
substantial liver schizont growth between day 5-6 post-infection as observed in mice passively immunized with 
pre-immunization IgG (Supplementary Figure 1). In contrast, post-immunization IgG from two other volunteers 
completely lost their neutralizing activity after depletion of CSP-specific antibodies (Supplementary Figure 1D 
and E), while CSP-depleted IgG from one volunteer was still able to slightly reduce in vivo liver-stage burden by 
54.6% (Supplementary Figure 1C). As a positive control, liver-stage infection of mice injected with 150ug of 
anti-CSP mAb was strongly inhibitory and reduced liver burden by 93.9% at day 6 post-infection 
(Supplementary Figure 1F).  
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Figure 1: Both CSP-containing and CSP-depleted IgG from CPS-immunized volunteers inhibit in vivo infection of 
humanized liver-chimeric FRG mice after P. falciparum mosquito bite challenge 
Humanized liver-chimeric FRG mice were injected with 16 mg of polyclonal IgG from n=5 CPS-immunized and protected 
volunteers. IgG was taken before the first CPS-immunization (pre-immunization; Pre-IgG), after completed CPS-
immunization shortly before challenge infection (post-immunization; Post-IgG) and a fraction of post-IgG was depleted from 
antibodies recognizing full length P. falciparum CSP (CSP-depleted Post-IgG). Following passive transfer (n=1 mouse per 
volunteer and IgG sample), mice were challenged by bites of 50 mosquitoes infected with P. falciparum GFP luciferase-
expressing parasites. Mice injected with 150 ug of the 2A10 mAb, a monoclonal antibody targeting CSP, served as a positive 
control. Liver-stage burden was normalized to mice injected with pre-immunization IgG and the percent reduction of liver-
stage burden was calculated as follows: 1- (average photons/flux in mice injected with (CSP-depleted) post-immunization 
IgGs / pooled average photons/flux in mice injected with pre-immunization IgGs) * 100%. Black and grey bars represent 
single mice injected with post-immunization IgGs or CSP-depleted post-immunization IgGs, respectively. 
 
Non-CSP-specific antibodies neutralize in vitro hepatocyte traversal and invasion by sporozoites  
Next, we determined whether these antibodies were capable of inhibiting early infection processes such as 
hepatocyte invasion and traversal. Therefore, each IgG sample was also tested in a short-term (90 minute) in 
vitro inhibition of sporozoite traversal and invasion (ISTI) assay (23, 24). CSP-containing IgGs were able to 
inhibit both invasion and traversal by >30% in all cases but less efficient following CSP-depletion (Figure 3). Of 
the two CSP-depleted IgGs with maintained in vitro function, only one (volunteer 2) retained functional activity 
in vivo.  
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Figure 2: Both CSP-containing and CSP-depleted IgG from CPS-immunized volunteers inhibit invasion and traversal of 
hepatocytes in vitro. In vitro inhibition of sporozoite hepatocyte invasion (A) and traversal (B) by P. falciparum sporozoites 
was determined and is shown for each volunteer. Invasion or traversal rates were normalized to P. falciparum sporozoites 
incubated with pre-immunization IgG. Dotted line indicates 30% inhibition, the limit of sensitivity for this assay. Each data 
point represents a technical replicate with bars indicating mean ± SD. 
 
Inhibitory non-CSP-specific antibodies recognize the sporozoite as well as intra-hepatic parasites  
Immunofluorescent analysis (IFA) showed that CSP-containing post-immunization IgGs from all volunteers 
recognized P. falciparum salivary gland sporozoites and day 5 liver-stages isolated from FRG HuHep mice, 
consistent with CSP expression at these stages as previously shown (25) (Figure 3 and Supplementary Fig. S2). 
Inhibitory CSP-depleted IgG of volunteer 1 maintained staining of the sporozoite stage yet failed to recognize 
liver stages (Figure 3). Interestingly, staining of day 5 P. falciparum liver stages with in vivo-inhibitory CSP-
depleted post-immunization IgGs from volunteers 2 and 5 revealed that these preferentially recognized the 
periphery of intra-hepatic parasites (Figures 3B and E). Moreover, CSP-depleted post-immunization IgGs from 
one of these two volunteers failed to stain sporozoites (volunteer  5, Figure 3E). These combined data suggest 
that non-sporozoite-specific antibodies can target multiple stages of the parasite and may be acting directly 
against both the sporozoite and liver stages. 
 
Discussion 
This study shows for the first time that CPS-immunization with P. falciparum NF54 sporozoites induces 
antibodies that are still capable of strongly reducing P. falciparum liver-stage burden in vitro and in vivo in the 
absence of CSP-specific antibodies. Although only a limited number of CPS-immunized volunteers were tested 
in the present study, we clearly observe significant individual differences between these volunteers. Moreover, 
inhibitory non-CSP-specific antibodies from one volunteer only recognized the periphery of the intra-hepatic 
parasite, illustrating that non-sporozoite antibodies can limit P. falciparum liver stage infection in vivo.  
Although we have previously shown the function of CPS-induced antibodies in humanized liver-chimeric mice, 
this relied on measuring parasite liver burden at a single time point at the peak of liver burden (19, 20). One 
novel aspect of this study is the use of non-lethal bioluminescent imaging to assess the parasite liver burden 
from a single infection event over multiple days in individual mice, allowing us to observe antibody-mediated 
inhibition of exponential in vivo liver-stage growth from days 4-6. Indeed, we observed a profound effect of 
antibodies on liver-stage development at days 5-6, suggesting that these antibodies were acting after infection 
of the liver. This corroborates a previous report using antibodies against the P. yoelii parasitophorous vacuole 
membrane (PVM) protein Hep17 (30), but to date, this phenomenon has not been confirmed for other proteins 
nor has there been evidence in the context of infection with human malaria parasites. Interestingly, we 
observed only minimal or no antibody-mediated inhibition of traversal or invasion with CSP-depleted IgG in our 
short-term 90-minute in vitro hepatocyte invasion assay. This discrepancy could be explained by antibodies 
acting on the parasite liver stages, which do not develop in the in vitro assay, and could help explain previous 
reports identifying differences between the in vitro and in vivo performance of antibodies (20, 23).   
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Figure 3: Immunofluorescence staining of P. falciparum sporozoites and intra-hepatic parasites by purified IgGs  
Purified IgGs were assessed for their ability to recognize salivary gland sporozoites or day 5 P. falciparum intracellular 
parasites from infected liver-chimeric FRG mice. P. falciparum liver-stages were stained for human IgG antibodies in red and 
counter-stained with anti-binding immunoglobulin protein (BiP) polyclonal IgG in green. Salivary gland sporozoites were 
stained with a monoclonal antibody against P. falciparum CSP in green. DNA was stained with DAPI in blue. 
 
A number of possible antigenic targets of CPS-induced antibodies other than CSP may be considered, including 
thrombospondin-related adhesion protein (TRAP) and liver-stage antigen-1 (LSA-1) (18, 31). TRAP, also known 
as sporozoite surface protein 2 (SSP2), is expressed on sporozoites and intra-hepatic parasites (32, 33). Mice 
immunized with a combination of SSP2 and CSP were completely protected (34), but failed to induce protection 
in ten out of eleven humans (35). LSA-1 is a liver stage-specific protein in the PVM until rupture of infected 
hepatocytes and an unlikely target protein (36); immunization of healthy humans with recombinant liver-stage 
antigen-1 (LSA-1) elicited high antibody titers and cellular responses, but no protection against P. falciparum 
infection (36). Another potential target from earlier serological studies with CPS sera is merozoite apical 
erythrocyte-binding ligand (MAEBL) (31), which is localized on salivary gland sporozoites and essential for 
sporozoite invasion of hepatocytes (37-39). Antibodies to P. yoelii MAEBL can partially reduce sporozoite 
invasion and development in primary mouse hepatocytes (40). Indeed, MAEBL-deficient P. falciparum 
sporozoites are severely attenuated for liver infection in vitro and in vivo, while antibodies against P. falciparum 
MAEBL strongly reduced liver-stage development in vitro and in vivo (31, 39). For the CSP-depleted IgG which 
only bound the surface of the developing schizont rather than the sporozoite, the inhibitory antibodies are 
likely directed against the PVM, but the exact nature of the antigen targets bound by non-CSP antibodies 
remains to be determined.   
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This study presents a powerful approach to P. falciparum vaccine antigen discovery. Classic approaches rely on 
identifying individual candidate antigens and subsequently testing the function of antibodies against these 
individual targets to prevent infection. Here, we begin with the in vivo function of antigenically complex, 
polyclonal antibodies without any a priori knowledge of specificity and work backwards to identify antibody 
characteristics. The ability to infect humanized liver-chimeric mice with wild type P. falciparum sporozoites is 
critical for such an approach. While the creation of transgenic rodent parasites carrying the P. falciparum 
homolog of vaccine candidates have been used to test the in vivo function of antibodies against P. falciparum 
antigens (41, 42), this approach requires knowledge of the antigen up front and is not suitable for testing 
multiple or unknown antigen candidates at once. Thus, in addition to providing evidence for non-CSP-based 
antibody function, this work lays the framework for antigen discovery efforts in future clinical trials with 
similarly complex immunogens, such as late-arresting genetically attenuated parasites(43). This can pave the 
way for subunit vaccines which include multiple antigenic targets which may be required to achieve high levels 
of sterile immunity (44). 
 
Methods 
Study design experimental controlled human malaria infection  
Citrated plasma samples were used from a double-blind, randomized, placebo-controlled trial conducted at the 
Radboud university medical center (Nijmegen, The Netherlands) ClinicalTrials.gov identifier: NCT02098590; 
(22)). All study subjects provided written informed consent and the study was approved by the Central 
Committee for Research Involving Human Subjects of The Netherlands (CCMO NL48732.091.14). 
 
Plasma samples 
Citrated plasma samples were collected from n=5 NF54 CPS-immunized volunteers 11-14 days before the first 
CPS-immunization (pre-immunization) and one day before challenge infection (18 weeks after the last 
immunization; post-immunization) using citrated vacutainer cell preparation tubes (CPT vacutainers; Becton 
Dickinson). These volunteers were sterilely protected against a homologous challenge infection with NF54-
infected mosquito bites. 
 
IgG purifications from citrated plasma samples 
IgG purifications from citrated pre- and post-immunization plasma samples were performed using a 5 ml HiTrap 
Protein G HP affinity column (Amersham Biosciences) according to manufacturer's instructions. A fraction of 
purified post-immunization IgGs was depleted from circumsporozoite protein (CSP)-specific antibodies using a 
CSP affinity column. Purified IgGs were taken up in phosphate buffered saline (PBS), concentrated to a 
concentration between 20-200 mg/ml and filter-sterilized. IgG concentrations and CSP depletion efficacy were 
determined by a standardized total IgG or CSP-IgG enzyme-linked immunosorbent assay (ELISA) prior to use in 
invasion and traversal assays in vitro, and humanized mice in vivo. Total IgG ELISA and CSP-depletion efficacy 
data are shown in Supplementary Tables 1 and 2. 
 
Total IgG ELISA 
Total IgG concentrations in purified IgGs were determined by total IgG-ELISAs, following the same protocol as 
CSP-IgG ELISA (as described below) with small adaptations. Briefly, polystyrene flat-bottom 96-well plates were 
coated overnight with 1 ug/ml goat anti-human IgG (ImmunoPure, ThermoFischer Scientific). Purified IgGs 
were diluted 1:2,000 in PBS containing 0.05% Tween20 and 1% milk (PBST/1% milk) and a seven-point 1:3 
dilution series was carried out for each IgG sample. All samples from each volunteer were measured on the 
same plate. As a standard and positive control, purified IgGs with a fixed concentration (10 mg/ml) was diluted 
1:2,000 in PBST/1% milk and included on every plate in a seven-point 1:3 dilution series in duplicate. IgG 
concentrations of purified samples were calculated in relation to the positive control. Spectrophotometrical 
absorbance at 450 nm was measured using the iMark Microplate Absorbance Reader (Bio-Rad). ELISA data 
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analysis was performed with Auditable Data Analysis and Management System for ELISA (ADAMSEL, version 
1.1) as previously described (21).  
 
CSP-IgG ELISA 
Levels of P. falciparum circumsporozoite protein (CSP)-specific antibodies in purified IgGs were determined by 
ELISAs as previously described with small adaptations (22). Briefly, polystyrene flat-bottom 96-well plates were 
coated overnight with 1 ug/ml CSP in PBS (Genova Biotechniques Pvt. Ltd., India). Purified IgG samples were 
diluted 1:50 in PBS containing 0.05% Tween20 and 1% milk (PBST/1% milk) and a seven-point 1:2 dilution series 
was carried out for each IgG sample. All samples from each volunteer were measured on the same plate. As a 
standard and positive control, a plasma pool from 100 Tanzanian hyper-immune adults living in a highly 
malaria-endemic area (HIT) was diluted 1:200 in PBST/1% milk and included on every plate in a seven-point 1:2 
dilution series in duplicate. Antibody levels were expressed as arbitrary units (AU) in relation to the positive 
control, set at 100 AU (15). Spectrophotometrical absorbance at 450 nm was measured using the iMark 
Microplate Absorbance Reader (Bio-Rad). ELISA data analysis was performed with Auditable Data Analysis and 
Management System for ELISA (ADAMSEL, version 1.1) as previously described (21).  
 
Parasite strain, culture and generation of P. falciparum -GFP-luciferase-infected mosquitoes 
Plasmodium falciparum GFP-luciferase expressing blood-stage parasites were cultured in a semi-automated 
culture system as previously described (45-47). Anopheles stephensi mosquitoes were reared in the insectary of 
Center for Infectious Disease Research. Female mosquitoes were infected by standard membrane feeding on 
gametocyte cultures as previously published (48). Prevalence and magnitude of P. falciparum infection in 
mosquitoes was assessed on days 7-10 after gametocyte feeds by midgut dissection and examination of GFP-
positive midguts by live fluorescence microscopy. Mosquito cages with a prevalence of >50% and average 
oocyst number of >10 oocysts/midgut were pooled and used for infection of FRG huHep mice. 
 
Passive immunization of human liver-chimeric FRG mice and in vivo challenge infection 
Passive immunizations of human liver-chimeric FRG mice and challenge infections were conducted as 
previously described(20). Briefly, human hepatocyte donor-matched human liver-chimeric FRG mice (FRG 
huHep mice) were purchased from Yecuris Corporation (USA) and only animals with serum albumin levels of 
more than 3 mg/ml were used for experiments. For passive immunizations, mice were intravenously or 
intraperitoneally injected with 150 ug of the 2A10 monoclonal antibody (mAb) targeting P. falciparum CSP as a 
positive control (obtained from MR4) or 16 mg of purified IgGs from CPS-immunized volunteers 16-24 hours 
before mosquito bite challenge infection. Mosquito bite challenge infections were carried out by exposing mice 
to bites of about 50 Anopheles mosquitoes infected with P. falciparum expressing GFP-luciferase parasites for 
10 minutes with lifting to encourage probing and injection of sporozoites rather than uptake of blood meal. On 
days 4-6 after mosquito bite challenge, liver-stage burden of mice was characterized using bioluminescence 
and an in vivo imaging system (IVIS) and determined as total flux in pixels/second (p/s).  
 
Ethics statement animals 
All animal procedures were conducted in accordance with the regulations of the Seattle Biomedical 
Institutional Animal Care and Use Committee (IACUC), adhering to the NIH Office of Laboratory Animal Welfare 
standards (OLAW welfare assurance #A3640-01). 
 
Human hepatoma HC-04 cell line 
The HC-04 human hepatocyte cell line (Homo sapiens HC-04, MRA-965) was deposited by Jetsumon 
Sattabongkot (51) (MR4; BEI Resources). Cells were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM)/Ham’s F-12 nutrient medium (GIBCO) supplemented with 10% fetal bovine serum (FBS, GIBCO) and 
1% penicillin/streptomycin (GIBCO) at 37 ˚C in an atmosphere of 5% CO2. 
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In vitro inhibition of sporozoite invasion and traversal (ISTI) 
Purified IgGs were tested at 2 mg/ml in ISTI assays as described previously(23). Briefly, freshly dissected P. 
falciparum sporozoites were incubated with 2 mg/ml IgGs for 15 minutes at 37 °C. 3.3x104 sporozoites/well  
were subsequently added to HC-04 cells (seeded 105 cells per well in flat bottom 96-well plate day before ISTIs) 
in triplicate in the presence of FITC-dextran. Plates were then centrifuged at 500xg for 3 minutes at room 
temperature, and incubated for 90 minutes at 37 °C and an atmosphere of 5% CO2. Cells were then washed, 
trypsinized, fixed and permeabilized, and subsequently stained with an anti-CSP mAb conjugated to AlexaFluor-
647. Samples were analysed with a LSRII flow cytometer (BD Biosciences) and FlowJo software (version 10.3). 
HC-04 cells were considered invaded and traversed if they were CSP-AlexaFluor-647 positive and FITC-dextran 
positive, respectively. Sporozoites incubated with 10 ug/ml of the 2A10 monoclonal antibody served as a 
positive control for traversal and/or invasion inhibition. Post-immunization IgG samples were normalized to 
their respective pre-immunization IgG controls and 2A10 monoclonal control was normalized to sporozoites 
incubated with 10 ug/mL of non-specific mouse IgG. 
 
Immunofluorescence staining of P. falciparum salivary gland sporozoites and day 5 liver-stage parasites 
Immunofluorescence assay (IFA) of salivary gland sporozoites and liver-stages was performed as previously 
published (23). Briefly, freshly-dissected P. falciparum sporozoites were fixed with 10% formalin and allowed to 
air dry on glass microscope slides. Sporozoites were subsequently stained with polyclonal IgG at 0.5mg/mL. 
Binding of human IgG was visually with a goat anti-human IgG secondary antibody conjugated to AlexaFluor-
594 (Life Technologies) at a 1:2,000 dilution. Sporozoites were then counterstained with a mAb 2A10 
conjugated to AlexaFluor-488 and DNA was visualized by DAPI staining.  
For day 5 liver-stages, livers were isolated from P. falciparum-infected FRG huHep mice 5 days after sporozoite 
infection. Liver sections were stained with IgG at 0.5 mg/mL and a 1:1,000 dilution of rabbit polyclonal anti-Bip 
as a parasite marker. Human IgG was visualized using goat anti-human IgG conjugated to AlexaFluor-594 (Life 
Technologies) at 1:2000 dilutions and Bip was visualized using goat anti-rabbit IgG conjugated to  AlexaFluor-
488 (Life Technologies) at 1:500 dilution. All images were acquired using Olympus 1 x 70 Delta Vision 
deconvolution microscopy at 100x magnification for sporozoites and 60x magnification for liver-stages with 
identical exposure settings and post-acquisition contrast/brightness adjustments. 
 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism software (version 6, GraphPad Software Inc., 
California, USA). A p-value of <0.05 was considered significant.  
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Figure S1: In vivo P. falciparum liver-stage burden of liver-chimeric FRG mice that were passively immunized with purified 
IgGs  
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Liver-chimeric FRG mice were injected with 16 mg of polyclonal IgG from n=5 CPS-immunized and protected volunteers IgG 
was taken before the first CPS-immunization (pre-immunization; Pre-IgG), after completed CPS-immunization shortly before 
challenge infection (post-immunization; Post-IgG) and a fraction of post-IgG was depleted from antibodies recognizing full 
length P. falciparum CSP (CSP-depleted Post-IgG). Following passive transfer (n=1 mouse per volunteer and IgG sample), 
mice were challenged by bites of 50 mosquitoes infected with P. falciparum GFP luciferase-expressing parasites and liver 
burden was monitored from day 3-6 after mosquito bite challenge infection and shown for each individual volunteer as 
total flux in photons per second (A-E). Mice injected with 150 ug of the 2A10 mAb, a monoclonal antibody targeting CSP, 
served as a positive control (F). Liver-stage burden was normalized to mice injected with pre-immunization IgG. Mice 
injected with pre-immunization IgG from volunteer 4 and 5 passed away during the experiment and therefore, the median 
liver-stage burden of the remaining three mice receiving malaria-naive IgG was plotted. 
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Figure S2: Correlation analysis CSP-IgG antibody titers and reduction in vivo liver-stage burden by post-immunization IgGs 
To determine whether the neutralizing activity of CPS-induced IgGs on liver-stage infection in vivo correlates with the 
presence of CSP-specific IgG antibodies, Spearman correlation analysis was conducted. A p-value of <0.05 was considered 
significant.   
108 
 
 
 
Figure S3: Immunofluorescence assay of liver stages and sporozoites using pre-challenge and pre-immunization IgG. 
Antibody binding to day 5 P. falciparum-infected livers and P. falciparum salivary gland sporozoites was determined using 
immunofluorescence as in Figure 3 on IgG isolated from one day prior to challenge (C-1) and one day prior to the first 
immunization (I-1).  For some volunteers, IgG was unavailable in sufficient quantity for testing and hence, were not 
determined as indicated.   
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Supplementary Tables 
 
Supplementary Table 1: Total IgG concentrations 
 
Volunteer ID Pre-immunization IgG  
(mg/ml) 
Post-immunization IgG (mg/ml) CSP-depleted post-immunization IgG 
(mg/ml) 
1 198.1 45.1 45.2 
2 24.8 35.9 78.0 
3 57.1 45.3 33.0 
4 188.5 56.8 38.1 
5 42.9 47.9 29.0 
 
 
Supplementary Table 2: CSP depletion efficacy 
 
Volunteer ID Post-immunization IgG  
(HIT=100 AU) 
CSP-depleted post-immunization IgG 
(HIT=100 AU) 
Percent CSP depleted from post-
immunization IgG (%) 
1 761.2 undetectable 100.0 
2 323.5 undetectable 100.0 
3 727.4 undetectable 100.0 
4 282.4 undetectable 100.0 
5 48,712.5 53.1 99.9 
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Abstract  
 
Background 
Individuals in malaria-endemic areas slowly acquire immunity against clinical malaria upon repeated exposure 
to Plasmodium parasites. Whether humoral immunity against pre-erythrocytic stages also play a role in 
naturally acquired resistance is less clear. The aim of the present study is to determine whether naturally 
occurring pre-erythrocytic immunity explains the variation in time to infection with Plasmodium falciparum 
malaria. 
 
Methods 
In this longitudinal study, malaria-exposed children from Burkina Faso received dihydroartemisinin-piperaquine 
at baseline, to clear parasites before the start of active surveillance for Plasmodium infection. Plasma samples 
were collected at enrolment and antibody levels to the pre-erythrocytic antigens circumsporozoite protein 
(CSP) and liver-stage antigen-1 (LSA-1), as well as the presence of sporozoite-specific IgG and IgM antibodies, 
and their neutralizing activity on in vitro sporozoite gliding motility and invasion in human hepatoma cells, were 
determined. 
 
Results 
Despite low pre-erythrocytic antibody titers, in vitro sporozoite gliding motility and hepatocyte invasion was 
reduced in most assays using sporozoite specific-antibodies from naturally exposed children (median inhibition 
percentages of 59.6% [IQR 27.8-77.0%] and 19.4% [IQR 15.2-40.9%], respectively). Gliding inhibition correlated 
with CSP antibody levels (P<0.0001), sporozoite-specific IgG (P<0.0001) and IgM antibodies (P=0.01).  Children 
with high anti-CSP antibody levels and gliding inhibitory activity showed delayed incidence of P. falciparum 
infection compared to children with lower anti-CSP levels and functional activity (P=0.04 and P=0.008 for CSP 
antibody levels and sporozoite gliding inhibition, respectively).  
 
Conclusion 
By combining results of in vitro assays that recapitulate hypothesized mechanisms of protection with 
longitudinal epidemiological data, this study provides evidence that the variation in risk of malaria infection is 
at least associated with and possibly, as suggested by our functional assays, partially explained by naturally 
occurring pre-erythrocytic antibody-mediated immunity targeting sporozoites.  
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Introduction 
Nearly half of the world population is at risk of malaria, and infections with the Plasmodium species responsible 
for most morbidity and mortality, P. falciparum,  were estimated to have caused ~200 million clinical cases and 
roughly 0.5 million deaths in 2015 (1). Although widespread use of artemisinin-based combination treatment 
and increasing availability of insecticide-treated bed nets have resulted in a significant decrease in malaria 
transmission in the past decade (2), the emergence of drug-resistant parasites (3) and insecticide-resistant 
mosquitoes (4) underscore the need for a highly effective vaccine. Induction of sterile immunity against pre-
erythrocytic sporozoites and liver-stage parasites would prevent clinical disease as well as onward human-to-
mosquito transmission, directly benefiting individuals receiving the vaccine and indirectly, their community. 
The RTS,S subunit vaccine (Mosquirix, GlaxoSmithKline), the most advanced subunit vaccine candidate to date, 
is based on a major P. falciparum sporozoite surface protein, the circumsporozoite protein (CSP; (5)) and is 
thought to confer protection against P. falciparum malaria by neutralizing sporozoite invasion of hepatocytes 
and thereby reducing exposure to disease-causing blood-stage parasites (6). However, Phase III field trials 
showed that this vaccine conferred only modest, rapidly waning protection against infection and clinical 
disease in infants, children and adults living in highly malaria-endemic areas (7-11). On the other hand, sterile 
protection against Plasmodium pre-erythrocytic stages can be induced experimentally by immunization of 
malaria-naive individuals by means of chemoprophylaxis and sporozoites (CPS) (12, 13), radiation-attenuated 
sporozoites (RAS) (14) or genetically attenuated sporozoites (15, 16). These whole sporozoite (CPS, RAS or 
genetically attenuated) vaccination studies have shown that humoral immune responses in vaccinated 
individuals interfere with P. falciparum sporozoite infectivity in vitro and in vivo (17-22), providing insights into 
possible mechanisms of acquired resistance to infection.  
 
The observations from these vaccine trials and studies involving sporozoite inoculation contrast with the 
limited epidemiological evidence of naturally acquired functional humoral immunity to Plasmodium pre-
erythrocytic stages. Individuals living in malaria-endemic areas routinely experience multiple malaria infections 
and slowly acquire immunity against malaria, although this immunity appears to wane in the absence of 
ongoing falciparum exposure (23). Naturally occurring anti-parasite immunity is mainly directed against blood-
stage parasites, limits parasitaemia and protects, after several years of exposure, from clinical disease (24). 
Historic passive IgG transfer studies have demonstrated a key role for antibodies in controlling blood-stage 
parasites during natural P. falciparum infections and reducing clinical symptoms of malaria (25-27), as 
confirmed in animal models (28-30). Whether pre-erythrocytic humoral immunity also plays a role in naturally 
acquired resistance is less clear. Field studies suggest that antibody responses to CSP increase with age and 
more likely reflects parasite exposure than protection (31). On the other hand, combined antibody titers to 
CSP, liver-stage antigen-1 (LSA-1) and thrombospondin-related adhesive protein (TRAP) have been associated 
with a reduced incidence of clinical malaria in Kenyan children (32), and antibody responses to LSA-1 alone 
have been associated with a delayed time to re-infection following parasite clearance (33) and a reduced risk of 
clinical malaria (34). Additionally, antibodies from naturally exposed individuals have been shown to reduce 
sporozoite invasion of hepatocytes in vitro (18, 35, 36), which suggests that some of naturally occurring 
antibody responses targeted to sporozoite antigens might have a direct protective effect against infection, 
rather than being only markers of exposure or correlated with the causal mediators of immunity. 
 
In this treatment re-infection study undertaken in an area of high malaria transmission in Burkina Faso, 
schoolchildren aged 5 to 10 years had their P. falciparum parasites cleared using dihydroartemisinin-
piperaquine (DHA-PPQ) prior to the start of an intensive follow-up to actively detect new infections using 
sensitive molecular methods. The aim of the present analysis was to determine whether naturally acquired 
(functional) pre-erythrocytic immunity could influence time to re-infection with falciparum malaria parasites.   
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Results  
Study population and follow-up  
Of the 58 school-aged children who were recruited and received treatment at enrolment, six were PCR-positive 
three weeks after DHA-PPQ administration and were not eligible to continue follow-up. One child who was only 
followed for one routine visit, when no infection was detected, and who withdrew from the study did not have 
immune responses quantified and was not included in this analysis. 
 
Overall, parasitological and immunological data from 51 intensively followed children were analysed (Table 1). 
Every week, these study participants had finger prick blood samples collected and tested for malaria infection 
by nested PCR (see Methods section). After parasites were detected by field PCR, samples were collected every 
day for seven days, then weekly until day 35 after infection detection. These children were clinically monitored 
and if symptoms developed, they received first-line malaria treatment on the same day. All samples collected 
during the follow-up were tested by 18S qPCR. All but one study participant had P. falciparum parasites 
detected by 18S qPCR in samples collected during weekly routine visits or during the intensive sampling period. 
Malaria infection caused clinical disease in 43/50 children. One child developed symptomatology suggestive of 
malaria but no parasites were detected in samples collected before and during the clinical episode; data from 
this child were censored after the onset of symptoms. The median time from confirmation of parasite 
clearance (i.e. three weeks after anti-malarial treatment) to infection detection by field PCR or onset of 
symptoms was 27 days; the child who did not have parasites detected by field PCR and remained asymptomatic 
throughout the follow-up is not included in this calculation. Similarly, the median time to parasite detection by 
18S qPCR was 30 days. In Figure 1, both the times of first 18S qPCR positive result and, if applicable, of 
development of clinical disease are presented for all study participants.  
 
 
 
Figure 1. Effects of immune responses against liver- and blood-stage antigens on malaria infection risk.  
Time-to-infection data from all study participants (n=51) are shown. The black line represents the percentage of the study 
population that remained uninfected at different time-points. Circles indicate when individuals with first parasite detection 
at the start of the corresponding dashed line developed clinical symptoms.  
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Table 1. Baseline characteristics 
       
Number of individuals  
   
  
  Treated  
   
58   
  Infected on day 21 (post-treatment) 6   
  Withdraw 
  
1   
  Followed 
   
51   
  
     
  
Age of participants included in the analysis (in years)   
  
     
  
  Median [IQR] 
  
7.1 [5.7 - 8.1]   
  
     
  
  
    
% (N)   
Gender 
     
  
  Female 
   
37.2 (19)   
  
     
  
Reported bed net use 
  
51.0 (26)   
  
     
  
Hemoglobin types 
    
  
  AA 
   
70.6 (36)   
  AC 
   
21.6 (11)   
  AS 
   
5.9 (3)   
  SS 
   
2.0 (1)   
  
     
  
Total number of weekly surveillance visits 222   
Median (IQR) number of weekly visits/participant 4 [2 - 6]   
              
 
Sporozoite-specific IgG and IgM antibodies are acquired in malaria-exposed children 
Antibody titers to the CSP pre-erythrocytic antigen were low in naturally exposed children and not different 
from malaria-naive adults (Figure 2A, P=0.11; non-parametric tests were used for all comparisons presented in 
this article), while LSA-1 antibody levels were significantly higher in malaria-exposed children than for malaria-
naive donors (Figure 2B, P=0.006). Additionally, as expected, asexual antibody titers in naturally exposed 
children were significantly higher than for malaria-naive donors (Figure 2C,  P<0.0001).  
 
Additionally, IgG and IgM antibodies from naturally exposed schoolchildren recognizing Plasmodium 
sporozoites were quantified by fluorescently labelled anti-IgG and anti-IgM antibodies and flow cytometric 
analysis. Whole sporozoite-specific IgG and IgM antibody levels in naturally exposed children were significantly 
higher than in malaria-naive adults (Figures 2D and 2E, P=0.02 and P=0.004 for IgG and IgM, respectively). 
Additionally, there were strong correlations between sporozoite-specific IgG and IgM antibodies (Figure S1A, 
P=0.0005, Spearman’s rank correlation coefficient 0.75), and between CSP-IgG antibody levels and whole 
sporozoite-specific IgG antibodies (Figure S1B, Spearman’s rank correlation coefficient 0.83, P<0.0001).  
 
Naturally acquired antibodies in children neutralize in vitro sporozoite gliding motility 
Although antibody titers to pre-erythrocytic antigens were low, their possible neutralizing activity was screened 
in an in vitro sporozoite motility assay. Sporozoites pre-treated with PBS showed an average gliding trail surface 
of 7,392 (95% confidence interval (CI), 4,151-9,388) pixels. To characterize the effect of human plasma on 
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sporozoite gliding motility that is independent of naturally acquired immunity, sporozoites were incubated in 
the presence of plasma from malaria-naive individuals (n=5) and showed an average gliding trail surface of 
1,427 (95% CI, 646.6-2,207) pixels, which is considerably larger than the gliding trail surface of sporozoites 
incubated with 30 μg/mL of a monoclonal anti-CSP antibody, our positive and internal control, 141 (95% CI, 
71.9-225.4) pixels.  
 
Plasma of the majority of schoolchildren reduced in vitro sporozoite gliding motility with a median gliding 
inhibition of 59.6% (IQR 27.8-77.0%), and incubation of sporozoites with plasma from three study children even 
resulted in lower gliding trail surfaces than the positive control. We defined two populations: one with poor 
gliding inhibition (individuals whose plasma inhibited less than 20% of sporozoite gliding motility, n=8) and the 
other with strong gliding inhibition (more than 80% gliding inhibition, n=8). The former group had similar 
gliding trail surface (median 1,353; IQR 1,311.7 -1,639.2) compared to malaria-naive donors (median 1605.7; 
IQR 824.3 - 1,652) (Figure 2F) whilst strong gliding inhibitors had a median trail surface of 186,2 (IQR 9.,4 - 
208.6), which was significantly lower compared to malaria-naive donors (Figure 2F, P<0.01). In vitro gliding 
inhibition did not correlate with LSA-1 IgG antibody levels (Figure S2A, P=0.11, Spearman’s rank correlation 
coefficient 0.23), but correlated with CSP-specific IgG antibodies (Figure S2B, P<0.0001, Spearman’s rank 
correlation coefficient 0.76), whole sporozoite-specific IgG (Figure S2C, P<0.0001, Spearman’s rank correlation 
coefficient 0.81) and IgM antibodies (Figure S2D, P=0.01, Spearman’s rank correlation coefficient 0.61). While 
sporozoite-specific IgG and IgM antibody levels of poor gliding inhibitors did not significantly differ from 
malaria-naive adults, sporozoite-specific antibody levels of strong gliding inhibitors were significantly higher 
compared to poor gliding inhibitors (Figure S2E; (P<0.0001 and P0.004 for IgG and IgM antibodies, respectively) 
and malaria-naive adults (Figure S2E and F, P<0.0001 and P=0.0006 for IgG and IgM antibodies, respectively). 
This suggests that, i.e. quantitative differences in measured immune responses might explain variation in these 
protective phenotypes. 
 
Antibodies in malaria-exposed children neutralize in vitro sporozoite infectivity of hepatocytes 
The inhibitory effect of naturally acquired antibodies on in vitro sporozoite invasion of hepatocytes was also 
assessed in a number of selected samples previously shown to inhibit gliding motility strongly or poorly (n=16 
subjects; n=8 subjects in each group). In vitro invasion was inhibited by naturally acquired antibodies (median 
invasion inhibition, 19.4% [IQR 15.2-40.9%]), and plasma from individuals categorized as strong gliding 
inhibitors (see section above) also prevented hepatocyte invasion more effectively compared to poor gliding 
inhibitors and malaria-naive donors (Figure 2G, P=0.005 and P=0.0002, respectively). Indeed, there was a 
positive correlation between gliding and invasion inhibition (Figure S3A, P=0.02, Spearman’s rank correlation 
coefficient 0.60), suggesting that gliding inhibition in vitro by naturally acquired antibodies might serve as a 
good surrogate for hepatocyte invasion inhibition in vitro. As with gliding inhibition, sporozoite invasion 
inhibition in vitro correlated with sporozoite-specific IgG (Figure S3B, p=0.004, Spearman’s rank correlation 
coefficient 0.71) and CSP-specific IgG antibodies (Figure S3D, P=0.002, Spearman's rank correlation coefficient 
0.76), but not with LSA-1-specific IgG antibodies (p=0.08, Spearman’s rank correlation coefficient 0.48). In 
contrast, sporozoite-specific IgM antibody levels did not correlate with invasion inhibition (Figure S3C, P=0.14, 
Spearman’s rank correlation coefficient 0.42).  
 
Evidence of natural risk-modifying pre-erythrocytic immunity 
For each immunity-related phenotype, children were categorized in two groups: participants with high 
antibody responses (or high sporozoite gliding inhibition activity) were those with assay values higher than the 
study population median (Figure 3A); children considered to have low antibody responses had values lower 
than the median. Study subjects with high CSP responses and those whose plasma inhibited sporozoite gliding 
movement more efficiently developed P. falciparum infection, defined as qPCR-based parasitaemia of at least 
0.1 parasites per μL, later compared to children with lower responses (Figure 3B; P=0.04 and P=0.008 for CSP 
responses and sporozoite gliding inhibition, respectively). High anti-LSA-1 antibody levels, on the other hand, 
did not influence time to infection (P=0.30). Blood stage immunity, i.e. high response in the asexual stage lysate 
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assay, was also associated with longer time to infection (Figure 3C, P=0.005). We repeated these analyses 
excluding children with haemoglobin S and haemoglobin C mutations, as these conditions might influence both 
immunity (37) and parasite carriage (38). Despite the lower number of individuals included in this analysis 
(n=36), similar results were obtained (P=0.01 for both CSP and asexual stage lysate assays and P=0.05 for the 
sporozoite gliding inhibition assay). 
 
 
Figure 2. Naturally acquired pre-erythrocytic antibody levels and their functionality against sporozoite infectivity in vitro. 
Malaria antigen-specific antibody levels in children from Burkina Faso (n=51) and Dutch malaria-naive adults (n=9) to pre-
erythrocytic antigens (A) circumsporozoite protein (CSP), (B) liver-stage antigen-1 (LSA-1), and (C) asexual lysate as an 
internal control were determined by ELISAs and expressed as arbitrary units (AU). The amount of (D) IgG and (E) IgM 
antibodies recognizing sporozoites was determined by flow cytometry and shown as the geometric mean fluorescence 
intensity (MFI). To this end, P. falciparum NF54 sporozoites were pre-treated with 10% heat-inactivated plasma from 
children from Burkina Faso (n=17) and malaria-naive adults (n=8) and stained with fluorescently labelled antibodies against 
IgG and IgM antibodies. (F) The gliding motility of P. falciparum NF54 sporozoites, pre-treated with plasma from children 
from Burkina Faso (n=50) and malaria-naive adults (n=5), was determined by in vitro gliding motility assays. Gliding trail 
length of sporozoites incubated with plasma from malaria-naive donors (n=5) or naturally exposed children whom are poor 
(n=8) or strong (n=8) inhibitors of gliding motility are shown. (G) The percent hepatocytes invaded by P. falciparum NF54 
sporozoites pre-treated with plasma from children from Burkina Faso (n=16 whom have previously shown to be either poor 
(n=8) or strong (n=8) gliding inhibitors) and malaria-naive adults (n=9), was determined by in vitro invasion assays in human 
hepatoma cells. Comparisons between multiple groups were tested with Kruskal-Wallis test with Dunn's multiple 
comparison post hoc test. Data were considered statistically significant at p<0.05.  
 
Since children with high CSP responses were more likely to have high antibody responses to asexual stage 
parasite lysate compared to low CSP responders (60% versus 40%, respectively; P=0.12), multivariate Cox 
models were fit to assess the mutually adjusted effects of these phenotypes on time to infection detection 
(Table 2). While the relationship between anti-CSP responses and time to malaria infection was not statistically 
significant in a model that also included results of the asexual stage lysate assay, higher inhibition of in vitro 
sporozoite gliding motility remained associated with protection against falciparum infection after adjustment 
for blood-stage immunity (Hazard ratio 0.54 95% CI [0.29 – 1.01]).  
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Figure 3. Effects of immune responses against liver- and blood-stage antigens on malaria infection risk.  
To assess the effect of different immune responses on infection risk, individuals were classified based on whether the 
results of their assays were higher or lower than the study population median (see Results): in (A), vertically aligned cells 
represent the same individual, and orange cells indicate that assay results are higher than the median. In (B), Kaplan-Meier 
curves for individuals with high and low CSP responses and gliding inhibition (GI) phenotypes are presented; in (C), curves 
for individuals categorized based on their responses to asexual stage antigens (AL) are shown. 
 
Table 2. Multivariate Cox models for time-to-infection outcome. 
 Model I Hazard ratio   95% confidence interval   P-value 
  
    
  
High CSP response 0.63 
 
0.34 - 1.16 
 
0.14 
High response to asexual stage lysate  0.50 
 
0.28 - 0.91 
 
0.02 
  
    
  
Model II  Hazard ratio 
 
95% confidence interval 
 
P-value 
  
    
  
High gliding inhibition activity 0.54 
 
0.29 - 1.01 
 
0.05 
High response to asexual stage lysate  0.53 
 
0.29 - 0.97 
 
0.04 
            
 
Discussion 
The identification of individuals living in endemic areas who are at least partially protected against malaria 
infection through their anti-pre-erythrocytic stages immune responses would be informative for malaria 
vaccine development. In this longitudinal study that only included schoolchildren aged between 5 and 10 years, 
we show that time to P. falciparum infection is longer in children with antibodies that more efficiently reduce 
in vitro sporozoite gliding motility. We also observed that immune responses targeted to blood-stage parasites 
were associated with anti-pre-erythrocytic stage antibody levels; in statistical models including these two types 
of immunity, they are both associated with delayed Plasmodium infection. These epidemiological data together 
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with the in vitro data showing functional activity against sporozoites, suggest that pre-erythrocytic immunity is 
likely to be one of the determinants of infection risk in endemic areas, even though it is non-sterilizing. 
 
Studies using plasma from individuals vaccinated with RTS,S subunit vaccine or who underwent whole-
sporozoite vaccination show that vaccine efficacy measured by controlled human malaria challenge infection 
parallels the outcome of vaccine-induced antibodies in in vitro sporozoite infectivity assays (17, 19, 21). In this 
study, we showed that malaria-exposed schoolchildren, who often have higher prevalences of falciparum 
parasites compared to other age groups (39-42), carried antibodies that can effectively prevent sporozoite 
gliding motility and invasion of hepatocytes measured in vitro. Functional pre-erythrocytic antibody-mediated 
immunity has previously been shown in malaria-exposed adults and antibodies have shown to reduce in vitro 
sporozoite invasion into human hepatoma cells (18, 35, 36). Nevertheless, this is to, our knowledge, the first 
time we show that functional pre-erythrocytic antibodies are present in this specific age group. While reduction 
in sporozoite gliding movement was associated with both whole-sporozoite-specific IgG and IgM levels, 
hepatocyte invasion was only linked to sporozoite-specific IgG. The effect of IgM on sporozoite migration and 
motility might be important as, due to their large pentameric structures, antibodies of this type are mainly 
found in the blood and the lymph nodes (47), which might increase their likelihood of targeting parasites 
inoculated in the skin. Of note, we show for the first time that in vitro inhibition of sporozoite gliding motility is 
correlated with in vitro inhibition of hepatocyte invasion by naturally acquired antibodies. This suggests that in 
vitro gliding assays can be used to screen a large group of malaria-exposed individuals for the presence of 
functionally active antibodies. In support of this, previous studies have suggested that gliding motility and 
invasion might have a common molecular basis (43-45). Of note, we observed that naturally acquired 
antibodies from malaria-exposed children of Burkina Faso are about 1.7-fold less efficient than CPS-
immunization induced antibodies in inhibiting P. falciparum sporozoite invasion of hepatocytes in vitro (46). A 
possible explanation for this difference in functional activity could be that frequent and ongoing blood-stage 
Plasmodium infection may impact the induction and efficiency of malaria-specific immune responses towards 
pre-erythrocytic stages by amongst other inhibiting CSP-specific germinal center B-cell differentiation (47) and 
inducing apoptosis of long-lived antibody-producing plasma cells and memory B-cells (48).  
 
We also observed that pre-erythrocytic antibody titers to CSP and LSA-1, two antigens that have been linked to 
protection in field studies including children and adults (32-34), were low, relative to asexual antibody titers, in 
malaria-exposed schoolchildren living in our study area. However, despite low pre-erythrocytic antibody titers, 
naturally acquired antibodies are capable of reducing sporozoite infectivity in vitro. Analogously, in a recent 3-
year longitudinal study of Kenyan children in an area of declining malaria transmission, it was observed that 
antibody titers targeted at merozoite antigens decrease over time, while antibody complement-fixing activity 
remains stable over a long period of time (49). This suggests that effector mechanisms of antibody-mediated 
immunity may be better maintained than simply antibody levels, which could perhaps be explained by a 
(relatively) low threshold for a given antibody concentration that is required to exert its functional activity. In 
support of this, it has recently been shown that naturally acquired antibodies from Papua New Guinean 
children can fix complement on P. falciparum sporozoites and further reduce sporozoite infectivity in vitro, and 
although the prevalence of naturally acquired functional anti-CSP antibodies was low, high levels of 
complement-fixing antibodies were associated with a reduced risk of clinical malaria (50). Taken together, it is 
very likely that antibodies targeting pre-erythrocytic antigens other than CSP are responsible for the observed 
effects on in vitro sporozoite infectivity. Indeed, previous studies have shown that vaccine-induced or naturally 
acquired antibodies recognize schizont egress antigen-1 (SEA1), thrombospondin-related adhesive protein 
(TRAP), merozoite apical erythrocyte-binding ligand (MAEBL), apical membrane antigen-1 (AMA-1), sporozoite-
threonine-asparagine-rich protein (STARP), MB2, LSA-1 or other falciparum antigens that have not yet been 
characterized (51-55). In support of this hypothesis, antibodies targeting MB2, MAEBL or STARP proteins have 
shown to inhibit in vitro sporozoite invasion in human hepatocytes (53, 55, 56). 
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In our analysis, we used immunological data and results of in vitro sporozoite assays to assess the potential 
influence of pre-erythrocytic immunity on malaria infection risk. Unambiguous quantification of protection 
against Plasmodium malaria infection due solely to pre-erythrocytic immunity, i.e. independent of existing 
asexual blood-stage immunity, is complicated by the fact that there is currently no marker of sporozoite 
inoculation. Studies with intensive follow-up using sensitive molecular diagnostic tests, which would allow 
detection of parasites in the blood few days after inoculation and before significant blood-stage immunity is 
mounted, are thus required to detect protection linked to pre-erythrocytic immune responses that are not 
influenced by immunity against blood-stage infections. In the present study, we observed that higher 
functional antibody responses against sporozoites were associated with longer time to Plasmodium re-
infection. These findings are consistents with previous field epidemiological data that found protective 
associations between pre-erythrocytic antigen specific antibodies and protection against malaria disease and 
infection (32-34). To assess whether our estimates were dependent on our definition of infection, we also 
performed sensitivity analyses that used different parasitaemia thresholds (see Supplementary Appendix). In 
comparisons that used included lower parasite levels as primary outcome, similar results were observed. 
Noteworthy, in the present cohort, we observed that pre-erythrocytic immune responses correlated with 
blood-stage immune responses. Although the phenotype of effective inhibition of sporozoite gliding was still 
associated with delayed infection incidence in a multivariate model that also included asexual blood-stage 
immunity as explanatory variable, it is possible that we might not have fully eliminated confounding between 
these variables. Alternative study designs might help determine whether anti-sporozoite immunity is only a 
marker of exposure (and consequently of blood-stage immunity) or is causally linked to protection: for 
example, as has been hypothesized, children receiving seasonal chemoprophylaxis might have reduced blood-
stage immunity but not necessarily reduced liver-stage immunity, which could facilitate the detection of pre-
erythrocytic-specific protection (57).  
  
One limitation of our study is the fact that only children between 5 and 10 years old were recruited. Indeed, in 
addition to immuno-epidemiological studies that measure antibody responses against specific antigens, studies 
comparing incidences of Plasmodium infection in different age groups are also informative to understand the 
total effect of P. falciparum-targeted immunity, rather than antigen-specific. Although the risk of clinical 
malaria decreased with increasing age, there was no significant difference in the incidence of malaria infection 
detected by PCR in adults versus children In a detailed longitudinal study in Mali (58). However, this apparent 
lack of age-related protection against infection, which suggests limited natural pre-erythrocytic immunity, 
needs to be considered in light of the recent evidence that the frequency of exposure to malaria vectors is 
associated with age. The rate of sampling by mosquitoes is arguably a major non-immunological determinant 
of an individual’s risk of becoming infected with falciparum parasites and data from Burkina Faso indicate that 
on average adults are more likely to be bitten by mosquitoes compared to schoolchildren and toddlers (59). A 
positive association between age and mosquito exposure means that in some settings the number of parasite 
inoculations in older individuals might be considerably higher than the number of parasite inoculations in 
children. If imperfect, non-sterilizing, pre-erythrocytic immunity is assumed to reduce the probability of 
Plasmodium infection development after individual parasite inoculations, the measured, cumulative protection 
over a given period of time is thus likely to depend on the rate of exposure to Anopheles mosquitoes. One 
approach to avoid that substantial differences in inoculation risk influence effect estimates would be to 
simultaneously quantify mosquito exposure or to only study individuals of similar age, provided there is 
sufficient variation in the rate of immunity acquisition against liver-stage parasites. Although our study did not 
recruit adults, who presumably are more likely to have developed pre-erythrocytic immunity over the years of 
cumulative exposure, the narrow age range of our study participants might have limited age-related 
differences in mosquito exposure. 
 
In conclusion, this study shows for the first time that functional anti-sporozoite antibody responses are 
acquired in malaria-exposed schoolchildren and functional pre-erythrocytic immunity most likely also 
influences infection risk in malaria-endemic areas. Knowledge on functional effector mechanisms of naturally 
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acquired pre-erythrocytic antibodies will contribute to an improved understanding of how pre-erythrocytic 
immunity to Plasmodium (re-)infection is acquired and maintained in malaria-endemic areas. This knowledge 
will be important for future malaria vaccine development. 
 
Methods 
Study design  
This study was performed in the village of Balonghin, located in the health district of Saponé, Burkina Faso. 
Malaria transmission in this village is high and seasonal (60), and mostly due to P. falciparum. Children aged 
between 5 and 10 years with haemoglobin levels above 8 g/dL and no parasites, asexual stage or gametocytes, 
detected by microscopy were eligible. At enrolment, dihydroartemisinin-piperaquine was used to clear 
submicroscopic infections. Twenty-one days after treatment administration, finger prick blood samples were 
collected and tested for parasite clearance using nested PCR (61). Subsequently, participants were examined 
during weekly visits, when finger prick samples were collected for infection detection. Filter paper samples 
collected during these routine visits were tested on the day of collection or one day later. After parasite 
detection, finger prick blood samples were collected every day for one week, and every week afterwards, up to 
35 days after parasite detection. Study participants were closely monitored for the development of malaria 
symptoms. Artemether-lumefantrine anti-malarial treatment was given upon the detection of symptoms or 35 
days after initial detection of infection by field PCR, whichever came first. 
 
Citrated plasma 
Citrated plasma samples were collected from all study subjects at enrolment using citrated vacutainer cell 
preparation tubes (CPT vacutainers, Becton Dickinson). Samples were stored at -80 °C and used for malaria-
antigen-specific IgG ELISAs and in vitro sporozoite assays. Prior to use for in vitro sporozoite assays, plasma 
aliquots were heat-inactivated for 30 minutes at 56 °C, centrifuged at 13,000 rpm for 5 minutes at room 
temperature and kept at 4 ˚C. 
 
Parasite strain, culture and generation of P. falciparum-infected mosquitoes 
Plasmodium falciparum NF54 is an well-established and well-characterized strain, most likely originating from 
West Africa (62). P. falciparum NF54 asexual and sexual blood-stages were cultured in a semi-automated 
culture system as described previously (63-65). Anopheles stephensi mosquitoes were reared in the insectary of 
Radboud university medical center according to standard operating procedures. Female mosquitoes were 
infected by standard membrane feeding on NF54 gametocyte cultures (66). For in vitro sporozoite assays, 
salivary glands from infected mosquitoes were hand dissected, collected in Leibovitz culture medium without 
serum (with supplements for in vitro gliding motility assay), and homogenized in a homemade glass grinder. 
The number of P. falciparum NF54 sporozoites was counted in a Bürker-Türk counting chamber using phase 
contrast microscopy (17). 
 
Human hepatoma HC-04 cell line 
The HC-04 human hepatocyte cell line (Homo sapiens HC-04, MRA-965, deposited by Jetsumon Sattabongkot 
(67)), was acquired through the MR4 as part of the Biodefense and Emerging Infections Research Resources 
Repository (BEI Resources). Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM)/Ham’s F-12 
nutrient mixture medium (GIBCO) supplemented with 10% heat-inactivated fetal bovine serum (FBS, GIBCO), 
1% glutamine and 1% penicillin/streptomycin (GIBCO) at 37 ˚C in an atmosphere of 5% CO2. 
 
Malaria antigen-specific IgG ELISAs 
Levels of malaria antigen-specific antibodies to pre-erythrocytic antigens circumsporozoite protein (CSP), liver-
stage antigen-1 (LSA-1) and asexual lysate in plasma samples were determined by standardized enzyme-linked 
immunosorbent assays (ELISAs) as previously described (68). Briefly, polystyrene flat-bottom 96-well plates 
were coated overnight at 4° with 0.5 µg/mL CSP in PBS (Genova Biotechniques Pvt. Ltd., India). Plates were 
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washed with PBS and blocked with 5% milk in PBS for 30 minutes at room temperature. Citrated plasma 
samples were diluted 1:50 in PBS containing 0.05% Tween20 and 1% milk (PBST/1% milk) and a three-point 1:3 
dilution series was carried out for each sample in duplicate. As a standard and positive control, a pool of 100 
sera from Tanzanian hyper-immune adults living in a highly malaria-endemic area (HIT; (12)) was diluted 1:200 
in PBST/1% milk and included on every plate in a seven-point 1:2 dilution series in duplicate. Following a 3 hour 
incubation period at room temperature, plates were washed and bound CSP-specific IgG antibodies were 
detected with a horseradish peroxidase (HRP)-conjugated detection antibody, followed by development with a 
HRP substrate (tetra-methyl-benzidine). The reaction was stopped after 20 minutes with 0.2M H2SO4. 
Spectrophotometrical absorbance at 450 nm was measured using the iMark Microplate Absorbance Reader 
(Bio-Rad). ELISA data analysis was performed with Auditable Data Analysis and Management System for ELISA 
(ADAMSEL, version 1.1) as previously described (69). Antibody levels were calculated in relation to the positive 
control (HIT plasma pool), which was set at 100 arbitrary units (AU). 
 
IgG and IgM antibody opsonization of whole sporozoites 
Recognition of whole sporozoites by naturally acquired IgG and IgM antibodies was determined by an in vitro 
flow-cytometry-based antibody opsonization assay as previously described with small adaptations (46). Briefly, 
P. falciparum NF54 sporozoites were added to v-bottom 96-well plates at a concentration of 5x104 
sporozoites/well, washed with PBS and incubated with 10% heat-inactivated plasma samples for 30 minutes at 
37 ˚C in duplicate. After incubation, samples were washed with PBS and sporozoites were stained with 
fluorescent detection antibodies targeting sporozoite CSP (3SP2-Alexa Fluor-488), IgG antibodies (IgG-PerCP) 
and IgM antibodies (IgM-Alexa Fluor-647) diluted in PBS/2% bovine serum albumin (BSA), for 30 minutes in the 
dark at 4 ˚C. Unstained sporozoites were taken up in PBS/2% BSA and single compensation controls were taken 
along (sporozoites stained with only one single antibody; 3SP2-Alexa Fluor-488, IgG-PerCP or IgM-Alexa Fluor-
647). After incubation, samples were washed with PBS, fixed with 1% paraformaldehyde (PFA), again washed 
with PBS, taken up in PBS, and kept at 4 °C in the dark until flow cytometric analysis. Flow cytometric analysis 
was performed with a LSRII flow cytometer (BD BioSciences) and data analysis was performed with FlowJo 
software (version 10.0.8, Tree Star). 
 
In vitro sporozoite gliding motility assay  
Flat-bottom optical-bottom 96-well plates with cover glass base were coated with 5 ug/ml of a monoclonal 
antibody 3SP2 (targeting P. falciparum CSP) diluted in PBS, incubated overnight at 4 °C. Following incubation, 
wells were washed twice with 150 µL/well PBS, blocked for 20 minutes at room temperature with 100 ul/well 
Leibovitz (Lonza) supplemented with 1% penicillin-streptomycin (GIBCO), 1% L-glutamine (GIBCO) and 10% 
heat-inactivated FBS (GIBCO). P. falciparum NF54 sporozoites were collected in Leibovitz medium 
supplemented with 1% penicillin-streptomycin and 1% L-glutamine and kept on ice until use. Sporozoites (100 
µL) were pre-incubated with citrated samples (70 µL; 40% final concentration) for 30 minutes at room 
temperature and added to each well in triplicate (50 μL/well) at a concentration of 10,000 sporozoites/well. 
Sporozoites were allowed to glide for 90 minutes at 37 °C, 98% humidity, 93% N2, 4% CO2 and 3% O2. Wells 
were washed thrice with 100 μL/well PBS and gliding trails were fixed for 15 minutes at room temperature with 
4% paraformaldehyde (Affymetrix). Following fixation, wells were washed thrice with 100 μL/well PBS and 
blocked with 150 μL/well 10% FBS/PBS for 20 minutes at room temperature. Subsequently, gliding trails were 
stained for 1 hour at room temperature with 50 μL/well of biotinylated anti-CSP monoclonal antibody, followed 
by a wash step (thrice with PBS) and a 1 hour incubation at room temperature with streptavidin-Alexa Fluor-
594 (Life Technologies) diluted in 10% FBS in PBS.  Subsequently, wells were washed thrice with 100 μL/well 
PBS and stored in 150 μL/well PBS at 4 °C in the dark until analysis. Gliding trails were imaged automatically 
with the Biotek Cytation (25 images per well at 200x magnification) and images were analyzed automatically by 
FIJI software analysis with Otsu as a threshold. Results were plotted in Graphpad Prism version 5.03. The 
number of pixels present on a stitched image made from 25 individual pictures taken per well is a measure for 
the amount of shed CSP in that particular well and therefore, differences in the number of pixels can be 
interpreted as differences in sporozoite gliding trail motility. 
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In vitro sporozoite infectivity assay of a human hepatoma cell line 
Neutralization of P. falciparum sporozoite hepatocyte invasion in vitro by CPS-induced antibodies was assessed 
in a flow-cytometry based in vitro invasion assay as previously described with small adaptations (46). Freshly 
dissected P. falciparum NF54 sporozoites were pre-incubated with 10% heat-inactivated field plasma samples 
for 30 minutes at 4 ˚C. Following pre-incubation, 5x104 sporozoites/well were added in duplicate to flat-bottom 
96-well plates containing monolayers of 5x104 HC-04 cells. After a 3 hour pre-incubation period, cells were 
washed with PBS, trypsinized and trypsin activity was neutralized by adding 10% FBS in PBS. Following fixation 
and permeabilization of HC-04 cells, intracellular sporozoites were stained with an anti-CSP monoclonal 
detection antibody fluorescently labeled with Alexa Fluor 488 (3SP2-Alexa Fluor-488). Samples were taken up 
in 1% PFA and put at 4 °C in the dark until flow cytometric analysis on the same day. Flow cytometric analysis 
was performed with a Gallios (Beckman Coulter) flow cytometer and data were analysed with FlowJo software 
(version 10.0.8, Tree Star). The percentage of CSP-positive sporozoites was first corrected for background 
reactivity by subtracting the background (uninfected HC-04 cells in the presence of 3SP2-Alexa Fluor-488 
antibody). The percent invasion inhibition was calculated as follows: 1 - (average % CSP-positive cells in post-
immunization cultures / average % CSP-positive cells in pre-immunization cultures) * 100%. 
 
Statistical analysis 
For analysis of in vitro sporozoite data, comparisons of two non-matching groups (controls versus field 
samples) or comparisons between multiple groups were performed using Mann-Whitney U test and Kruskal-
Wallis test followed by Mann-Whitney U test between two groups, respectively. The associations between 
immune responses and malaria infection risk were analysed using survival analysis methods. Log-rank test was 
used to compare times to infection incidence for individuals with different values of immune phenotypes. Cox 
survival models were fit to assess the effect of pre-erythrocytic immunity after adjustment for blood-stage 
immunity; the proportional hazards assumption was tested using Schoenfeld residuals. In these analyses, study 
participants were considered to have high or low responses (binary explanatory variables) based on the study 
population median (see Figure S4). The first scheduled weekly visit or intensive follow-up visit after field PCR 
positivity when parasitaemia of at least 0.1 parasites per μL was detected by 18S qPCR was considered the time 
of infection incidence. This threshold parasitaemia was chosen to minimise false-positive results. In the 
Supplementary Appendix, sensitivity analyses were included that used different cut-offs of 18S qPCR-based 
density to determine infection positivity. Stata 14 (StataCorp LP, Texas, USA) and GraphPad Prism software 
(version 5, GraphPad Software Inc., California, USA) were used for statistical analysis. A p-value of <0.05 was 
considered statistically significant. 
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Supplementary Appendix 
 
Methods 
 
Sensitivity analyses 
In our analysis, we used the threshold density of 0.1 parasites per μL to determine infection detection because 
lower densities are more likely to be linked to false-positive results. As a less conservative definition, we 
considered parasite densities as low 0.01 parasites per μL as evidence of infection as long as another sample 
collected within seven days was also positive by qPCR. In analyses that used this definition, children with higher 
anti-CSP antibody levels had a non-significant delay in infection establishment compared to children with lower 
anti-CSP responses (P=0.07). Immune responses that reduce sporozoite gliding were also associated with 
delayed infection incidence (P=0.02; Logrank test), as were responses against asexual lysate (P=0.003).  
 
Using another definition of infection, i.e. parasitaemia threshold of 1 parasite per μL, immunity that reduces 
sporozoite gliding, but not antibodies targeting CSP was significantly associated with protection against 
infection (P=0.01 and P=0.09, respectively). Responses against asexual stage parasite lysate were also 
protective (P=0.002). 
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 Figure S1. Correlation analyses of naturally acquired sporozoite-specific IgG and IgM antibodies 
(A) Scatter plot of sporozoite-specific IgG and IgM antibodies targeting P. falciparum NF54 sporozoites is shown (n=17 
children). (B) Correlation analysis for P. falciparum NF54 sporozoite-specific and CSP-specific IgG antibodies as determined 
by ELISAs is shown. Correlation analyses were conducted with Spearman correlation analysis. A p-value of <0.05 was 
considered statistically significant. 
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Figure S2. Antibody specificity and in vitro gliding inhibition by naturally acquired antibodies 
(A) Scatter plot of in vitro gliding inhibition and LSA-1-specific IgG antibodies as determined by ELISAs is shown (n=51 
children). (B) Scatter plot of in vitro gliding inhibition and CSP-specific IgG antibodies as determined by ELISAs is shown 
(n=51 children). Samples selected for future experiments had either poor (orange; n=8 subjects) or strong (green; n=8 
subjects) gliding inhibitory activity. Correlation analysis for sporozoite-specific (C) IgG or (D) IgM antibodies and in vitro 
gliding inhibition by naturally acquired antibodies was conducted with samples from 17 children. Recognition of P. 
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falciparum NF54 sporozoites by sporozoite-specific (E) IgG and (F) IgM antibodies from naturally exposed children (n= 17) or 
malaria-naive adults (n=8) was shown as the geometric mean fluorescent intensity (MFI) and divided in subgroups: malaria-
naive adults (black), poor (orange) versus strong gliding inhibitors (green). Correlation analyses were conducted with 
Spearman correlation analysis. Comparisons between multiple groups were tested with Kruskal-Wallis test followed by 
Mann-Whitney U test between two groups. Data were considered statistically significant at p<0.05.  
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Figure S3. Inhibition of in vitro sporozoite invasion by antibodies from children in Burkina Faso 
Gliding motility and invasion of P. falciparum NF54 sporozoites pre-treated with plasma from children from Burkina Faso 
and malaria-naive adults was determined by in vitro gliding motility and invasion assays in human hepatoma cells. (A) 
Scatter plot of in vitro gliding and invasion inhibition by naturally acquired antibodies is shown. Additionally, correlation 
analyses of the percent invasion inhibition with whole sporozoite-specific (B) IgG, (C) IgM antibodies or (D) CSP-specific IgG 
antibodies is shown. Children whom had poor or strong neutralizing effect on sporozoite infectivity are shown in orange 
and green circles, respectively. Correlation analyses were conducted with Spearman correlation analysis. Data were 
considered statistically significant at p<0.05.  
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Figure S4. Distribution of immune phenotypes.  
The distribution of log10-transformed antibody responses (x-axes) against CSP, LSA-1 and asexual lysate (AL) are presented 
in panels (A), (B) and (C). The y-axes in these panels represent the percentages of study population with various levels of 
responses. In (A) and (B), one and seven individuals had undetectable responses and, to be included in this figure, were 
assigned response values equivalent to half of the lowest limit of detection. In (D), the results of gliding assays are 
presented: the left plot presents the distribution of log10-transformed sporozoite gliding trail; the right plot shows gliding 
inhibition (y-axis) for each study participant (different bars; x-axis). The median gliding inhibition (59.6%) was used to define 
high and low inhibition. 
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CHAPTER 8 
 
Human antibodies activate complement against Plasmodium 
falciparum sporozoites, and are associated with protection against 
malaria in children 
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Abstract 
 
Background 
Antibodies targeting Plasmodium falciparum sporozoites play a key role in human immunity to malaria. 
However, antibody mechanisms that neutralize sporozoites are poorly understood. This has been a major 
constraint in developing highly efficacious vaccines, as we lack strong correlates of protective immunity.  
 
Methods 
We quantified the ability of human antibodies from malaria-exposed populations to interact with human 
complement, examined the functional effects of complement activity against P. falciparum sporozoites in vitro, 
and identified targets of functional antibodies. In children and adults from malaria-endemic regions, we 
determined the acquisition of complement-fixing antibodies to sporozoites and their relationship with antibody 
isotypes and subclasses. We also investigated associations with protective immunity in a longitudinal cohort of 
children (n=206) residing in a malaria-endemic region. 
 
Results 
We found that antibodies to the major sporozoite surface antigen, circumsporozoite protein (CSP), were 
predominately IgG1, IgG3 and IgM, and could interact with complement through recruitment of C1q and 
activation of the classical pathway. The central repeat region of CSP, included in leading vaccines, was a key 
target of complement-fixing antibodies.  We show that antibodies activate human complement on P. 
falciparum sporozoites, which consequently inhibited hepatocyte cell traversal that is essential for establishing 
liver-stage infection, and lead to sporozoite death in vitro. The natural acquisition of complement-fixing 
antibodies in malaria-exposed populations was age-dependent, and was acquired more slowly to sporozoite 
antigens than to merozoite antigens. In a longitudinal cohort of children, high levels of complement-fixing 
antibodies were significantly associated with protection against clinical malaria.  
 
Conclusion 
These novel findings point to complement activation as an important mechanism of anti-sporozoite human 
immunity, thereby enabling new strategies for developing highly efficacious malaria vaccines. We also present 
evidence that complement-fixing antibodies may be a valuable correlate of protective immunity in humans. 
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Background 
Malaria is a substantial cause of global morbidity and mortality, and the effectiveness of current interventions 
is under threat due to increasing reports of drug and insecticide resistance. To achieve malaria control and 
elimination there is a pressing need to develop and license highly efficacious malaria vaccines. This is a global 
priority, and the World Health Organization have set the ambitious goal to license a malaria vaccine that is at 
least 75% efficacious against clinical malaria by 2030 [1]. Currently, there is no licensed vaccine against 
Plasmodium falciparum, the main cause of malaria morbidity and mortality [2]. Vaccine development is 
significantly challenged by the lack of knowledge on the targets and mechanisms of functional immunity that 
confer protection against malaria, and a lack of correlates of protections. Defining mechanisms is crucial to 
identify strong correlates of protection, which will aid vaccine evaluation and enhance current vaccine 
candidates by inducing potent functional immune responses [3]. 
 
Plasmodium sporozoites are transmitted to humans when an infected female Anopheles mosquito probes the 
skin in search of a blood vessel [4]. Sporozoites are passively carried in the blood circulation to the liver, where 
they develop within hepatic cells generating thousands of merozoites [5] that initiate blood-stage replication 
and subsequently cause symptomatic and severe malaria. Vaccines targeting sporozoites are attractive because 
less than 100 sporozoites are transmitted to humans [6] and blocking sporozoites will prevent infection and 
subsequent disease. Even partial immunity to sporozoites could reduce the number of successful hepatocyte 
infections and subsequent blood stage parasitaemia, which may confer protection against clinical malaria or 
reduce disease severity.  
The predominant sporozoite surface antigen is circumsporozoite protein (CSP). Antibodies to CSP have been 
directly shown to confer protection against infection in animal malaria models [7, 8], have had some 
association with protection in human vaccine trials [9], and can be acquired through natural exposure to 
malaria [10, 11]. However, an enduring question that remains unanswered is how antibodies to sporozoites 
and CSP function to protect against infection. The most advanced malaria vaccine candidate, RTS,S/AS01 
(RTS,S), is based on the central-repeat and C-terminal regions of CSP [12], and induces antibody and CD4+ T cell 
responses [13]. RTS,S was only partially efficacious against clinical malaria in Phase III clinical trials (vaccine 
efficacy 29-36% in children aged 5-17 months after 48 months of follow up) [14], and the functional 
mechanisms of vaccine-induced immunity remain unknown. These knowledge gaps severely impair our ability 
to enhance current vaccine and design new vaccines that induce potent functional immunity for greater 
efficacy.   
Sporozoites can take several hours to reach the liver [4], leaving them highly susceptible to immune attack at 
the inoculation site in the skin and in the circulation. The success of invasion and development in the liver is 
dependent on sporozoite motility including: i) gliding to migrate out of the skin [15], ii) traversal to pass 
through cells and iii) hepatocyte invasion and maturation [16]. Anti-CSP antibodies can neutralize motility in 
vitro, although the relationship between function and protective immunity has not been demonstrated [17-19], 
and direct inhibitory activity of antibodies generally requires relatively high antibody concentrations [18, 20]. 
Furthermore, there are little data on whether IgG subclass influences antibody function, and what epitopes are 
primarily targeted.   
 
We hypothesized that antibodies of the right type and specificity may fix and activate complement to 
neutralize P. falciparum sporozoites. Harnessing complement activity by antibodies is an attractive mechanism 
of functional immunity because complement could act early following inoculation to combat sporozoites 
(Additional file 1: Figure S1). Complement activation can occur via the classical pathway whereby C1q interacts 
with immune complexes, referred to as C1q-fixation [21]. This leads to sequential activation of downstream 
complement proteins such as C3, and formation of the membrane attack complex (MAC) that mediates cell 
death. Activation can also occur via the alternative pathway involving direct C3 activation against pathogens 
[21]. Currently, it is unknown if P. falciparum sporozoites are susceptible to complement deposition and attack, 
and whether antibodies function to promote complement activation and consequently neutralize sporozoite 
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function or lead to sporozoite death. We investigated the ability of antibodies to CSP and P. falciparum 
sporozoites to recruit human complement proteins, and demonstrated the functional effects of complement 
activation against sporozoites in vitro. We also explored the natural acquisition of complement-fixing 
antibodies, and then assessed whether functional antibodies were associated with protection in a prospective 
longitudinal cohort of children.   
 
Methods  
Aims and study participants  
There were several aims to this study: 
 i) determine whether human antibodies fix complement, ii) explore the relationship between 
functional antibodies and isotype/subclass/specificity, iii) examine the natural acquisition of functional 
antibodies in young children, and iv) assess the association between functional antibodies and protection 
against malaria in children. To meet these aims we tested antibody samples from previously described cohort 
studies as summarized below. Note that all three study sites were considered to be malaria holo- or hyper-
endemic, and bed nets of any type were not in place at this time.   
 i) To maximize the likelihood of detecting functional anti-CSP antibodies, we tested two cohorts of 
malaria-exposed adults from distinct areas, as anti-CSP antibodies have been previously reported to be 
acquired with age as a result of repeated malaria exposure. Sera from adults living in the Madang Distract 
(Papua New Guinea, PNG, N=116) were collected in 2001-2002 [22], and plasma from adults living in the 
Kanyawegi sub district, Kisumu county (Kenya, N=104) were collected in August 2007 [23].  
 ii) We then preferentially selected 30 samples from each adult cohort (PNG and Kenyan) to further 
characterize the antibody response, based on IgG/C1q-fixation reactivity to CSP, and sample availability.   
 iii) The majority of malaria morbidity occurs in children under 5 years, and so we tested a cohort of 
young children (0.3-5.9 years) to examine the acquisition of functional antibodies, and compared this to adults 
from the same area. Plasma from children/adults living in the Chulaimbo sub district, Kisumu county (Kenya, 
N=75) were collected in February-March 2007 [24]. Samples were categorized into groups based on the median 
ages of 0.5, 1, 2, 5 and 35 years (ages ranged between 0.3-0.7, 1-1.5, 1.8-3.0, 4.7-5.9, 19.6-69.2; n=11, n=14, 
n=18, n=16 and n=16, respectively).  
 iv) To assess the relationship between functional antibodies and protection against malaria, we tested 
samples from a longitudinal prospective treatment-to-reinfection study. Plasma samples from children living in 
the Madang Province (PNG, N=206) aged 5-14 years (median=9.3 years) were collected at enrolment in 2004-
2005 [25]. Children were treated to clear parasitemia present at baseline, and then actively followed every 2 
weeks for symptomatic illness and parasitemia, and by passive case detection over a period of 6 months. A 
clinical episode of P. falciparum malaria was defined as fever and P. falciparum parasitemia >5000 parasites/µl 
 
We also generated two pools of Kenyan donors with high C1q-fixation reactivity from the adult Kenyan cohort. 
Pool 1 (n=10) was used in IgG-purification experiments, using the Melon gel purification kit as described by the 
manufacturer (Thermo Fischer Scientific, Waltham, USA). Pool 2 (n=19) was used in the in vitro hepatocyte 
traversal experiments. To minimize potential background reactivity from residual complement that may remain 
after heat-inactivation, antibodies from pool 2 (and control pool from residence of Melbourne, Australia) were 
purified by ammonium sulfate precipitation [26]. Sterile saturated ammonium sulfate was slowly added with 
continuous agitation to plasma (diluted 1/5 in sterile saline) to a final concentration of 50%. Following 30 
minutes incubation on ice, the precipitate was pelleted (20,000 RCF x 10 minutes), then washed in 50% sterile 
saturated ammonium sulfate. The precipitate was repeatedly washed in excess PBS using centrifugation 
concentration devises as described by the manufacturer (100 kDa cut-off, Millipore, Burlington, USA), and re-
suspended to the same starting volume of plasma.  
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Parasites  
Aseptic, purified, non-attenuated cryopreserved P. falciparum 3D7 sporozoites (Sanaria, Rockville, USA) were 
provided by PATH’s Malaria Vaccine Initiative or purchased from Sanaria. Freshly dissected P. falciparum NF54 
and NF166.C8 sporozoites were generated at Radboud University Medical Center (Radboudumc, Nijmegen, The 
Netherlands) as described [20, 27].   
 
Antigens and antibodies  
Recombinant P. falciparum CSP was expressed in Pichia pastoris and purified using high performance liquid 
chromatography (HPLC) (Sanaria) [28]; the protein was based on the 3D7 sequence beginning at amino acid 
residue 50 and contained 22 NANP repeats and 4 NVDP repeats. Peptide representative of the P. falciparum 
CSP central repeat B-cell epitope (NANP)15 was synthesized and purified using HPLC (Life Tein, Hillsborough, 
USA). Full length, recombinant merozoite surface protein 2 (MSP2) was expressed in Escherichia coli as 
previously described [29].  
 
Rabbits were immunized with three doses of 200 μg CSP four weeks apart (the first immunization was 
administered in complete Freud’s adjuvant and the last two in incomplete Freud’s adjuvant). The terminal 
bleed was obtained 12 days after the final immunization, and anti-CSP IgG was purified at Walter and Eliza Hall 
Institute. Pre-immune IgG was purified in-house using the Melon gel purification kit as described by the 
manufacture (Thermo Fischer Scientific). Animal immunizations were approved by the Animal Ethics 
Committee of the Walter and Eliza Hall Institute. We were provided with subclass switched mouse anti-NANP 
monoclonal antibodies (MAbs) 2H8-IgG1/IgG2a and 3C1-IgG1/IgG3 (LakePharma, Belmont, USA) by PATH’s MVI 
[30].  
 
Antibody isotypes and subclasses by enzyme-linked immunosorbent assay (ELISA)  
Ninety-six well flat bottom MaxiSorp plates (Thermo Fischer Scientific) were coated with 0.5 μg/ml antigen in 
PBS overnight at 4°C. Plates were washed thrice in PBS-Tween20 0.05% (v/v), blocked using 1% (w/v) casein in 
PBS for 2 hours at 37°C, and then washed again. Human antibody samples were applied in duplicate at 1/2000 
(IgG/M) or 1/500 (IgG subclasses) dilutions in 0.1% (w/v) casein in PBS (diluting buffer) for 2 hours at room 
temperature (RT), and then washed. Antibody isotypes were detected using goat anti-human IgG/IgM horse 
radish peroxidase (HRP) conjugated antibodies (Millipore) at 1/2500 dilution for 1 hour at RT, followed by 
washing and incubation with 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) substrate (Sigma-
Aldrich, St. Louis, USA) for 1 hour at RT in the dark. The reaction was stopped using 1% (w/v) sodium dodecyl 
sulfate in PBS (OD measured at 405 nm). IgG subclasses were detected using mouse anti-human 
IgG1/IgG2/IgG3/IgG4 antibodies (Invitrogen) at 1/1000 dilution for 1 hour at RT, followed by washing and 
incubation with goat anti-mouse IgG HRP conjugated antibodies (Millipore) at 1/1000 dilution for 1 hour at RT. 
Plates were washed and incubated with tetramethylbenzidine (TMB) substrate (Sigma-Aldrich) for 1 hour at RT 
in the dark, and the reaction was stopped using 1M sulfuric acid (OD measured at 450 nm).  Rabbit and murine 
antibodies were detected using goat anti-rabbit/mouse HRP conjugated antibodies (Millipore, Abcam) at 
1/2000 and ABTS substrate. 
 
Complement-fixation by ELISA and Western blot  
Ninety-six well flat bottom MaxiSorp plates were coated with antigen, blocked and washed as described above. 
Human antibody samples were applied in duplicate at 1/100-1/250 dilution for 2 hours at RT, and then washed. 
Plates were incubated with  10 μg/ml human C1q, C1q-depleted serum (Millipore), C5-depleted serum (for 
C2/C3/C4-fixation, Millipore) or fresh pooled non-immune serum (for C5b-C9-fixation) at 1/10 dilution for 30 
minutes at RT, washed, and detected using anti-C1q/C2/C3/C4/C5b-C9 antibodies at 1/1000-1/2000 dilution 
(Dako, Santa Clara, USA; Abcam, Cambridge, UK; Millipore) for 1 hour at RT. Plates were washed and incubated 
with the appropriate HRP conjugated antibodies (Abcam, Sigma-Aldrich, Millipore) at 1/2000 dilution for 1 hour 
at RT followed by washing. Complement-fixation was detected using TMB substrate as described above (MSP2 
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experiments utilized ABTS). Complement-fixation using murine and rabbit antibodies were conducted using the 
same methods.  
 
Complement-fixation to 3D7 P. falciparum sporozoites by ELISA was conducted using the same method as 
above (coating 10,000 cells per well); however, all incubation times did not exceed 1 hour, were conducted at 
RT, and the washing buffer contained PBS only. To measure complement-fixation by Western blot, 10,000 
sporozoites were incubated with human antibody samples at 1/10 dilution and fresh normal human serum at 
25% in PBS for 15 minutes at 37°C with agitation. Sporozoites were washed twice in cold protease inhibitor 
(1600 x RCF, 4 minutes), processed for SDS-PAGE and then blotted into nitrocellulose membrane (under 
reducing conditions). The membrane was blocked in 10% (w/v) skim milk in PBS-Tween20 0.5% (v/v) and 
probed using anti-C1q/iC3b antibodies (Serotec, Kidlington, UK) followed by HRP conjugated antibodies, with 
membrane stripping (Sigma-Aldrich), washing and blocking in between. Protein bands were detected using 
chemiluminescent substrate and autoradiography film (GE life sciences, Chicago, USA). Membranes were also 
probed with anti-CSP antibodies as a loading control.   
 
Experimental controls and standardization   
Human antibody samples (serum/plasma) tested by ELISA were excluded if duplicates varied by greater than 
25% (unless duplicates differed by optical density (OD) <0.1). OD values were corrected by subtracting 
background reactivity of control wells containing no serum/plasma. Cohort experiments that spread across 
multiple ELISA plates were standardized for plate-to-plate variation using positive control wells containing 
highly reactive samples from malaria-exposed individuals. Malaria-naïve sera from Melbourne donors were 
tested as negative controls.  Test samples giving ODs greater than the mean + 3 standard deviations of malaria 
naïve controls were considered positive. This positive cut-off value was used to convert OD into arbitrary units 
(AU) as follows: AU = sample corrected OD / positive cut-off OD, so that samples with AU>1 were considered 
positive. All plasma/serum samples were heat-inactivated at 56°C for 45 minutes prior to use.    
 
Sporozoite cell traversal  
Traversal was conducted as previously described [20] using freshly dissected P. falciparum NF54 and NF166.C8 
sporozoites. Briefly, sporozoites were pre-incubated with pooled human antibody samples (malaria-exposed 
Kenyan and malaria-naïve Melbourne pools purified by ammonium sulfate precipitation) at 1/10 dilution, or 
vaccine-induced rabbit anti-CSP IgG and pre-immune IgG at 1 and 10 μg/ml, for 30 minutes on ice. 
Sporozoite/antibody samples were added to HC-04 cells seeded on 96-well plates, along with 10% normal 
human serum (NHS; active complement) or heat-inactivated serum (HIS; inactive complement), and 
tetramethylrhodamine (Rh) labelled dextran (50,000 sporozoites and 50,000 HC-04 cells per well). Sporozoites 
were allowed to traverse HC-04 cells under these conditions (in the presence of immune/non-immune 
antibodies and active/inactive complement) for 2 hours at 37°C in 5% CO2, and were then washed in PBS. HC-
04 cells were then trypsinised, washed in 10% FBS in PBS, and re-suspended in 1% paraformaldehyde. 
Traversed HC-04 cells were measured as Rh-positive, and quantified by flow cytometry using the Cyan 
(Beckman Coulter) and FlowJo software (gating strategy shown in Additional fila 1: Figure S2A). The percentage 
of Rh-positive cells was corrected for background reactivity using HC-04 cells treated with dextran only.  
Traversal inhibition by immune antibodies (Kenyan pool and rabbit anti-CSP IgG) compared to non-immune 
antibodies (Melbourne pool and rabbit pre-immune IgG) in the presence of NHS and HIS was calculated as 
follows: (1-[% traversed cells in the presence of immune antibodies / % traversed cells in the presence of non-
immune antibodies]) × 100. Sporozoites were also pre-incubated with anti-CSP MAb 3SP2 as a positive control.  
 
Sporozoite cell death by flow cytometry  
50,000 3D7 P. falciparum sporozoites were incubated with rabbit anti-CSP antibodies at 1/10 dilution and 20% 
human serum (normal or C5-depleted) for 10 minutes at 37°C. Sporozoites were placed on ice and dead cells 
were stained using the DNA-binding dye, propidium iodide (PI). PI-positive cells were quantified by flow 
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cytometry using FACSVerse (BD Biosciences) and FlowJo software (gating strategy shown in Additional file 1: 
Figure S2B).  
 
Statistical analysis 
Data were analyzed using GraphPad Prism version 6.05 and Stata 13.1. The following two-tailed non-parametric 
tests were performed where appropriate: Spearman’s correlation coefficient (Rho), Wilcoxon matched-pairs 
signed rank test, Man Whitney U test, and Kruskal-Wallis test. To investigate the association between anti-CSP 
IgG and IgM with C1q-fixation in PNG adults we performed a multiple linear regression with robust standard 
errors. To evaluate associations between antibodies and malaria risk in the longitudinal study, Kaplan-Meier 
survival curves were plotted to show the cumulative proportion of children who had experienced an episode of 
malaria during follow-up, stratified by antibody response group. Hazard ratios (HR) of the risk of malaria during 
follow-up were calculated using the Cox proportional hazards model (using first episodes of malaria only), and 
adjusted HRs were calculated by including age, location of residence, and parasitemia status at enrolment [25]. 
 
Results  
Naturally-acquired anti-CSP antibodies are predominately IgG1, IgG3 and IgM 
Antibody isotype and subclass influence the ability to fix C1q and activate the classical pathway. Therefore, we 
characterized naturally-acquired antibodies to the most abundant sporozoite surface protein, CSP, for possible 
interaction with complement. We measured antibody levels by ELISA and converted OD into AU. Among a 
selection of malaria-exposed adults from Papua New Guinea and Kenya (n=30 in each group), 40% and 75% 
were positive for anti-CSP IgM, respectively (Figures 1A and 1B). IgM antibodies are potent complement 
activators whereas IgG complement activity is mediated primarily by IgG1 and IgG3 subclasses, whereby IgG3 
generally has greater activity [31]. The predominant subclasses in PNG and Kenyan adults were the 
complement-fixing subclasses IgG1 (seropositivity 67% and 100%, respectively) and IgG3 (seropositivity 76% 
and 97%, respectively). In contrast, the seroprevalence of IgG2 and IgG4 antibodies were lower (PNG 
seropositivity 15% and 7%; Kenyan seropositivity 48% and 16%, respectively). 
 
Naturally-acquired human antibodies and vaccine-induced antibodies promote complement-fixation to 
recombinant CSP 
We next investigated whether naturally-acquired antibodies in humans and vaccine-induced antibodies in 
animals were capable of promoting complement activation. Since the classical pathway is initiated by antibody-
C1q interactions [31, 32] we tested whether antibodies to CSP could fix C1q using ELISA-based methods. 
Among a selection of PNG adults (n=30), 77% of individuals were positive for this activity. Furthermore human 
anti-CSP antibodies also fixed other complement components downstream of C1q, including C4, C2, C3 and 
C5b-C9 (reflecting MAC-formation) [21], all of which strongly positively correlated with C1q-fixation 
(Spearman’s correlation coefficient (Rho) 0.794, 95% confidence interval (CI) 0.591 to 0.903; Rho=0.763, 95% CI 
0.548 to 0.884; Rho=0.784, 95% CI 0.584 to 0.895 and Rho=0.836, 95% CI 0.674 to 0.921; p<0.001 for all tests, 
respectively) (Figures 1C and 1D). We confirmed that C3-fixation was mediated by anti-CSP antibodies and the 
classical pathway and not by the alternative pathway using C1q-depleted serum as a source of complement, 
which significantly reduced reactivity by 61-88% (p=0.031) (Figure 1E). We next addressed whether 
complement-fixing antibodies could be elicited by CSP immunization of rabbits, as rabbit IgG is known to 
engage [33] and activate human complement [34]. Vaccine-induced IgG demonstrated strong reactivity to 
recombinant CSP and to the central repeat region of CSP represented by synthetic (NANP)15 peptide, and 
promoted C1q and C3-fixation to CSP (Figure 2). Collectively these data demonstrated that antibodies can fix 
C1q and activate the classical pathway against CSP.    
 
Anti-CSP antibody isotype and subclass are associated with complement-fixation  
We examined the relationship between IgG and C1q-fixation to CSP in two different cohorts of malaria-exposed 
adults from PNG (N=116) and Kenya (N=104). Although there was a consistent positive trend between IgG and 
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C1q-fixation in both populations, we observed marked differences in the ability to C1q among individuals with 
similar levels of anti-CSP IgG (Figure 3). This suggests that additional factors and/or antibody properties 
influenced function. 
 
Figure 1. Naturally-acquired human anti-CSP antibodies are predominately IgG1, IgG3 and IgM, and can promote 
complement-fixation to CSP. Antibodies from malaria-exposed adults (n=30 in each group) living in PNG (A, C-E) and 
Kenyan (B) were tested for IgG/IgM and complement-fixation to CSP by ELISA. Results were standardized to arbitrary units 
(AU) based on malaria-naïve negative controls from Melbourne (seropositivity defined as AU>1, shown as dotted line), and 
mean and range of duplicates were graphed (mean only for scatter plots). (A-B) IgG subclasses and IgM reactivity to CSP; 
median, interquartile range and percentage of positive samples are shown. (C) Correlations between C1q-fixation and 
C4/C3/C3/C5b-C9-fixation to CSP (Spearman’s correlation coefficient, Rho). (D) Examples of C1q and C3-fixation to CSP by 
individual serum samples (V15, V32, V33, V45, V46; from PNG donors, n=5). (E) C3-fixation to CSP by individual samples (V6, 
V7, V32, V37, V43; from PNG donors, n=5) in the presence of normal human serum (NHS) and serum depleted of C1q (C1q 
dep.) (Wilcoxon matched-pairs signed rank test). Non-standardized data is shown as only one Melbourne control (Melb.) 
was tested. 
 
To confirm that IgG alone is capable of promoting C1q-fixation, we compared purified IgG and whole plasma 
from a pool of Kenyan adults with high levels of C1q-fixing antibodies (n=10). Purified IgG could fix C1q, but less 
effectively than plasma, possibly due to the loss of IgM that is known to potently activate complement 
(Additional file: Figure S3A). To explore the relative contributions of IgG and IgM in promoting C1q-fixation in 
more detail, we performed a linear regression with data from PNG adults (N=116).  For every unit increase in 
anti-CSP IgG there was an increase in C1q-fixation of 0.785 AU (95% CI 0.585 to 0.985; p<0.001), and this value 
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was lower after adjusting for anti-CSP IgM (0.579, 95% CI 0.342 to 0.851; p<0.001) (Additional file: Table S1). 
Inclusion of IgM only slightly improved the fit of the model (IgG R-squared=0.67 and IgG/IgM R-squared=0.71), 
suggesting that most variation in C1q-fixation responses could be explained by anti-CSP IgG for these samples. 
 
Figure 2. Vaccine-induced rabbit anti-CSP IgG can fix human complement proteins to CSP. Purified IgG from rabbit serum 
before (pre-imm.) and after (a-CSP) CSP-immunization were tested for IgG and complement-fixation to CSP by ELISA. 
Results were corrected for background reactivity using no-IgG controls, and mean and range of duplicates were graphed. 
(A), IgG reactivity to CSP and (NANP)15 peptide (pre-immune IgG shown in the open symbol was tested at 10 μg/ml); results 
from two independent experiments are shown. (B), C1q and C3-fixation to CSP tested in the presence (+) and absence (-) of 
complement to confirm specificity for complement-fixation.    
 
Of the IgG subclasses, IgG1 and IgG3 are the most potent at activating the classical complement pathway. As 
expected, anti-CSP IgG1 and IgG3 both strongly correlated with C1q-fixation to CSP among a selection of PNG 
adults (n=30, Rho=0.829, 95% CI 0.662 to 0.917 and Rho=0.792, 95% CI 0.592 to 0.900; p<0.001 for both tests). 
These antibodies also strongly correlated with C4, C2, C3 and C5b-C9-fixation (Table 1), which further 
supported that complement activation was via the antibody-dependent classical pathway. To identify which 
subclass was prevalent in samples with high levels of C1q-fixing antibodies (above median AU=2.2, n=14), we 
compared the ratio of anti-CSP IgG1-to-IgG3 (Additional file: Figure S3B). There tended to be an increased IgG3 
response, whereas the ratio of anti-CSP IgG-to-IgM was highly variable indicating that IgM may be important in 
selected individuals (Additional file: Figure S3C). Overall, characterizing the antibody response is an important 
consideration when assessing functional antibody responses. 
 
P. falciparum sporozoites are susceptible to complement-fixation by human antibodies 
Initially we tested antibodies from a highly reactive PNG adult for the ability to promote complement-fixation 
on sporozoites by ELISA (Figure 4A; reactivity to CSP shown in Additional file 1: Figure S4A). Consistent with 
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complement-fixation to CSP, we observed greater C1q and C3-fixation in the presence of antibodies from the 
PNG individual than the malaria-naïve individual. It is noteworthy that some C3-fixation was observed in the 
presence of malaria-naïve antibodies, suggesting that C3 may bind directly to the sporozoite surface to some 
extent, although this was substantially lower than C3-fixation in the presence of malaria-exposed antibodies. 
To confirm these findings, we tested antibodies from a highly reactive Kenyan adult for complement-fixation on 
sporozoites by Western blot (Figure 4A; reactivity to CSP shown in Additional file 1: Figure S4A). C1q and 
enhanced C3-fixation occurred in the presence of malaria-exposed antibodies, and some direct C3-fixation was 
also observed in the presence of malaria-naïve antibodies (repeat Western blots with reduced exposure time to 
observe the C3b band more clearly shown in Additional file: Figure S4B). These data show that naturally-
acquired antibodies from malaria-exposed individuals promote complement-fixation on sporozoites via the 
antibody-dependent classical pathway. 
 
Table 1. Correlations between antibodies and complement-fixation to CSP among malaria-exposed PNG adults (n=30).    
Antibody Rho C1q a Rho C4 a Rho C2 a Rho C3 a Rho C5b-C9 a 
IgG 0.831  
(0.666 to 0.919) 
0.813 
(0.625 to 0.912) 
0.797  
(0.606 to 0.901) 
0.831 
(0.666 to 0.919) 
0.803 
(0.616 to 0.904) 
IgG1 0.829  
(0.662 to 0.917) 
0.839 
(0.672 to 0.925) 
0.830 
(0.664 to 0.918) 
0.895 
(0.784 to 0.950) 
0.745 
(0.518 to 0.874) 
IgG2 0.607  
(0.276 to 0.809) 
0.443 
(0.046 to 0.720) 
0.404 
(0.008 to 0.691) 
0.552 
(0.198 to 0.779) 
0.485 
(0.108 to 0.740) 
IgG3 0.792 
(0.592 to 0.900) 
0.795 
(0.586 to 0.904) 
0.788 
(0.585 to 0.898) 
0.801  
(0.608 to 0.905) 
0.754 
(0.527 to 0.880) 
IgG4 0.416 
(0.039 to 0.689) 
- - - - 
IgM 0.826 
(0.656 to 0.916) 
0.655 
(0.363 to 0.830) 
0.620 
(0.325 to 0.805) 
0.738 
(0.506 to 0.870) 
0.791 
(0.596 to 0.898) 
a Spearman’s correlation coefficient (Rho) and 95% CI between anti-CSP antibodies and complement-fixation to CSP. Only 
significant values (p<0.05) are shown. Rho values between 0.6-0.69, 0.7-0.79, and >0.8 are shaded in light, medium and 
dark blue, respectively. 
 
Sporozoite traversal inhibition by human and vaccine-induced rabbit antibodies is enhanced by complement 
We examined whether antibodies inhibited sporozoite traversal, and whether this was enhanced in the 
presence of active complement. Sporozoites rely on their traversal form of motility to pass through the 
sinusoidal cell layer and several hepatic cells before encountering a terminal hepatocyte for cellular invasion 
and development [16]. We tested rabbit anti-CSP IgG previously shown to fix human complement to evaluate 
whether the functional effect of antibodies to CSP were enhanced by complement. Rabbit anti-CSP IgG 
inhibited sporozoite traversal of HC-04 cells (compared to rabbit pre-immune IgG), and inhibitory activity was 
substantially enhanced in the presence of normal human serum (NHS) compared to heat-inactivated human 
serum (HIS), whereby complement proteins were active and inactive, respectively (Figure 4B). To establish 
whether complement also enhanced function of human antibodies, which contain antibodies to CSP and other 
malaria antigens, we tested purified antibodies (including IgG and IgM) from a pool of malaria-exposed Kenyan 
adults (n=19 samples, Additional file 1: Figure S5) and malaria-naïve Melbourne donors, and quantified P. 
falciparum sporozoite transversal (Figure 4C). Kenyan antibodies inhibited NF54 sporozoite traversal 
(compared to Melbourne antibodies) 2-fold higher in the presence of active complement compared to inactive 
complement (mean and range of two independent experiments: 46%, 45.7 to 46.2% and 18.2%, 11.8 to 24.6%, 
respectively). We confirmed this effect using sporozoites from a second P. falciparum strain, NF166.C8, 
whereby antibody-mediated traversal inhibition was only observed in the presence of active complement and 
was not detected when tested antibodies with inactivated complement (30.7%, [27.1 to 34.2%] and -4.7%, [-
14.6 to 5.2%], respectively). Therefore the ability of antibodies to inhibit sporozoite traversal was enhanced in 
the presence of active human complement.  
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Figure 3. Naturally-acquired human anti-CSP IgG correlates with the ability to promote C1q-fixation to CSP, despite 
individual differences in reactivity. Antibodies from malaria-exposed adults living in PNG (A; N=116; top panel) and Kenya 
(B; N=104; bottom panel) were tested for IgG and C1q-fixation to CSP by ELISA. Results were standardized to arbitrary units 
(AU) based on malaria-naïve negative controls from Melbourne (seropositivity defined as AU>1, shown as dotted line) and 
mean and range of duplicates were graphed (mean only for scatter plots).  The left panels show correlations between IgG 
and C1q-fixation to CSP (Spearman’s correlation coefficient, Rho). The right panels show selected examples of IgG and C1q-
fixation to CSP by individual samples (right; serum samples from PNG donors: V7, V49, V51, V52, V53 and Kenyan donors: 
AR18, AR22, AR28, AR36, AR47). 
 
Antibody-mediated complement-fixation leads to sporozoite death 
We examined whether sporozoites were susceptible to complement-mediated death since formation of the 
MAC can lead to membrane damage and possible lysis of target cells. Cell death caused by complement might 
be a contributing mechanism in inhibition of cell traversal. P. falciparum sporozoites were incubated with 
rabbit anti-CSP IgG and NHS containing active complement, or C5-depleted serum as a negative control as 
MAC-formation is C5-dependent (Figure 4D). We observed a 2-fold increase in the percentage of dead cells (PI-
positive) [35] when sporozoites were incubated with complement and anti-CSP IgG compared to pre-immune 
IgG (mean and range of two independent experiments: 32.8%, 28.1 to 37.4% and 16.1%, 13.6 to 18.6%, 
respectively). Few PI-positive cells were detected following treatment with anti-CSP IgG and C5-depleted serum 
(4.4%, 4.1 to 4.7%). These data show that anti-CSP IgG and complement interact to enhance complement-
mediated sporozoite death.  
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Figure 4. Antibodies promote complement-fixation on P. falciparum sporozoites, which enhances antibody-mediated 
traversal inhibition and can lead to sporozoite death. (A) Antibody samples from malaria-exposed (PNG and Kenyan) and 
malaria-naïve (Melbourne) individuals were tested for the ability to fix human C1q and C3 to 3D7 P. falciparum sporozoites 
by ELISA and Western blot. ELISA (top panel): samples were tested in duplicate and mean and range were graphed (C1q-
fixation data is from two independent experiments). Western blot (bottom panel): sporozoites were incubated with human 
antibody samples and normal human serum (active complement), and then washed and processed for Western blotting 
under reduced conditions. Any complement proteins that had deposited on the sporozoite surface were detected using C1q 
and C3-specific antibodies, and the sporozoite surface antigen, CSP, was used as a loading control. (B-C) In vitro traversal 
inhibition of freshly dissected sporozoites incubated with HC-04 cells, in the presence of normal and heat-inactive human 
serum (NHS and HIS, respectively). Each condition was tested in duplicate, and mean and range were graphed. (B) Traversal 
inhibition of NF54 sporozoites treated with rabbit anti-CSP IgG (compared to rabbit pre-immune IgG). (C) Traversal 
inhibition of NF54 and NF166.C8 sporozoites treated with malaria-exposed Kenyan pool (compared to malaria-naïve 
Melbourne pool); results from two independent experiments are shown. (D) Percentage of dead 3D7 sporozoites (PI+ cells) 
treated with rabbit anti-CSP IgG and pre-immune IgG, in the presence of NHS or C5-depleted serum (C5dep.); mean and 
range of two independent experiments were graphed. 
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The NANP-repeat epitope is a target of C1q-fixing antibodies  
The NANP-repeat sequence is a major B-cell epitope of P. falciparum CSP and a key target of antibodies 
generated by the RTS,S vaccine [36]. Among PNG adults (n=30), 55% were positive for C1q-fixation to (NANP)15 
peptide and 77% were positive for C1q-fixation to CSP. These variables were strongly correlated (Rho=0.841, 
95% CI 0.679 to 0.925; p<0.001), suggesting that NANP was a significant target of C1q-fixation to CSP (Figure 
5A) Among Kenyan adults (n=30), a lower proportion of individuals were positive for C1q-fixation to (NANP)15 
and CSP (36% and 44%, respectively), and these variables only moderately correlated (Rho=0.489, 95% CI 0.094 
to 0.751; p=0.015) (Figure 5B). 
 
IgG and IgM isotype reactivity of PNG samples to (NANP)15 positively correlated with C1q-fixation to CSP 
(Rho=0.525, 95% CI 0.185 to 0.752; p=0.004 and Rho=0.812, 95% CI 0.622 to 0.911; p<0.001, respectively) 
(Figure 5A). To further understand the role of antibody isotype, we categorized samples into four groups based 
on low/high reactivity for NANP-specific IgG and IgM (defined by median AU) and compared C1q-fixation 
reactivity to CSP. Most samples were defined as either low or high for both antibody isotypes. Those with high 
NANP-IgG/IgM antibodies had significantly higher C1q-fixation levels to CSP (by AU=4.9) than individuals with 
low NANP-IgG/IgM antibodies (p<0.001) (Additional file 1: Figure S6A). Interestingly, two samples with high 
complement activity were classified as NANP-IgM high and NANP-IgG low, suggesting the importance of IgM 
for complement-fixation in these individuals. IgG and IgM isotype reactivity of Kenyan samples to (NANP)15 
moderately correlated with C1q-fixation to CSP (Rho=0.425, 95% CI 0.024 to 0.709 ; p=0.034 and Rho=0.613, 
95% CI 0.276 to 0.816; p=0.001, respectively) (Figure 5B) Furthermore, individuals with high NANP-IgG/IgM 
antibodies only had a minor increase in C1q-fixation to CSP (by AU=1.86) than individuals with low NANP-
IgG/IgM (p=0.043) (Additional file: Figure S6B). Collectively, these data show that NANP-specific antibodies 
were variably associated with C1q-fixation to CSP among individuals, and between the two malaria-endemic 
populations. To further establish that NANP-specific antibodies mediate C1q-fixation to CSP, we tested mouse 
anti-NANP MAbs (2H8 and 3C1) that had been subclass-switched so that there were 2H8-IgG1/IgG2a and 3C1-
IgG1/IgG3 antibody pairs. All four MAbs demonstrated similar IgG-reactivity against CSP and (NANP)15, but only 
2H8-IgG2a and 3C1-IgG3 effectively fixed C1q compared to their IgG1 subclass counterparts, which is known to 
not fix human complement (Figure 5C) [31].  
 
Age associated acquisition of naturally-acquired complement-fixing antibodies to CSP 
The bulk of malaria morbidity and mortality occurs in endemic areas where transmission is stable and relatively 
intense, particularly in children aged less than 5 years. We therefore investigated the acquisition of C1q-fixing 
antibodies to CSP among young children (n=59) compared to adults (n=16) living in a P. falciparum 
holoendemic area in western Kenya when transmission was high. We also compared complement-fixation 
responses to a major merozoite surface protein, merozoite surface protein 2 (MSP2), which is an established 
target of complement-fixing antibodies in blood-stage immunity [37]. In this setting, young children are known 
to be acquiring immunity to blood-stage infection and are susceptible to severe malaria, whereas adults have 
more established immunity due to extensive exposure to infections. Study participants were categorized into 
groups based on their median ages of 0.5, 1, 2, 5 and 35 years (ages ranged 0.3-0.7, 1-1.5, 1.8-3.0, 4.7-5.9 and 
19.6-69.2 years, respectively). Reactivity for C1q-fixation and IgG to CSP was relatively low among all children 
age groups and was significantly higher among adults (p<0.001 for both tests) (Figure 6A). In contrast, we 
observed higher reactivity for C1q-fixation to MSP2, a known target of naturally-acquired immunity [29]. 
Interestingly, children in the 5 year age group had C1q-fixing antibody levels similar to adults (p=0.275), which 
were higher than observed in younger children (p<0.001). Taken together, these results suggest that 
complement-fixing antibodies to CSP are poorly acquired during early childhood compared to the merozoite 
antigen MSP2, and that C1q-fixing antibodies to CSP are overall acquired more slowly than those to blood stage 
antigens.   
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Figure 5. Antibodies that target the NANP epitope of CSP can promote C1q-fixation. Antibodies from malaria-exposed 
adults living in PNG (n=30) (A) and Kenya (n=30) (B) were tested for IgG, IgM and C1q-fixation to (NANP)15 peptide by ELISA, 
and correlated with C1q-fixation to CSP (Spearman’s correlation coefficient, Rho). Results were standardized to arbitrary 
units based on malaria-naïve negative controls from Melbourne (seropositivity defined as AU>1, shown as dotted line) and 
mean of duplicates were graphed. (C) Mouse anti-CSP MAbs 2H8-IgG1/IgG2a and 3C1-IgG1/IgG3 were tested for CSP-IgG, 
NANP-IgG and C1q-fixation to CSP by ELISA. Results were corrected for background reactivity using no-IgG controls, and 
mean and range of duplicates were graphed.  
 
High levels of C1q-fixing antibodies are associated with protection against clinical malaria in children 
From a longitudinal cohort study of children (N=206, 5-14 years) who were resident in a malaria endemic 
region of PNG [25], only a minority had antibodies that promoted C1q-fixation to CSP (positivity 40%), weakly 
correlating with anti-CSP IgG (Rho=0.280, 95% CI 0.140 to 0.409; p<0.001). When stratified into four age groups 
(≤8, 8.1-9, 9.1-10 and ≥10 years), there was no significant association between age and C1q-fixing antibodies 
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(p=0.211) (Figure 7A). However, children with concurrent parasitemia at the time of enrolment as determined 
by PCR showed significantly higher C1q-fixation activity than uninfected children (positivity 45% and 31%, 
respectively; p<0.001) (Figure 7A), reflecting their recent exposure to sporozoites. 
 
Figure 6. Acquisition of C1q-fixing antibodies and total IgG to CSP and MSP-2 antigens in malaria-exposed Kenyan 
children and adults. Kenyan children and adults (N=75) were categorized into groups based on the median ages 0.5, 1, 2, 5 
and 35 years (n=11, n=14, n=18, n=16 and n=16, respectively).  Samples were tested for C1q-fixation and total IgG to CSP 
(A) and MSP-2 (B) by ELISA. Results were standardized to arbitrary units based on malaria-naive negative controls from 
Melbourne (seropositivity defined as AU>1, shown as dotted line), and mean of duplicates were graphed along with group 
median, interquartile range and percentage of positive samples. Reactivity between two groups and more than two groups 
were compared using the Mann-Whitney U test and Kruskal-Wallis test, respectively. 
 
To obtain epidemiologic evidence supporting the importance of antibody-mediated complement-fixation to 
CSP in acquired immunity to malaria, we investigated whether the minority of PNG children with high levels of 
functional antibodies had a reduced risk of clinical malaria. Children were treated for malaria and then actively 
monitored for the duration of the study, enabling us to establish any association between C1q-fixing antibody 
levels at enrolment and the subsequent risk of developing clinical malaria. Children were divided into three 
response groups based on C1q-fixation reactivity: i) negative (AU<1), ii) low-positive (bottom 50% positive 
samples, 1<AU≤1.525), and iii) high-positive (top 50% of positive samples, AU>1.525) (Additional file 1: Figure 
S7). In Kaplan-Meier survival analysis, children with high levels of C1q-fixation had a lower rate of malaria 
during follow-up (Figure 7B). Importantly, we found that children with high levels of C1q-fixing antibodies at 
enrolment had a significantly reduced risk of clinical malaria compared to children who were negative for C1q-
fixing antibodies (Cox Proportional Hazards model; HR=0.39 [0.18-0.87], p=0.020), which remained significant 
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after adjusting for potential confounders of age, location of residence, and parasitemia at baseline (adjusted 
HR=0.42 [0.19-0.94], p=0.034). A significant association was not observed for children with low C1q-antibodies 
compared to those who were negative (HR=0.70 [0.38-1.38], p=ns and adjusted HR=0.69 [0.35-1.37], p=0.2). 
Furthermore, there was no significant association between IgG to CSP and risk of malaria (adjusted HR 0.50 
[0.19-1.32] comparing children with high IgG responses compared to IgG negative individuals). Although the 
prevalence of naturally-acquired functional anti-CSP antibodies was generally low, these data suggest that high 
levels of C1q-fixing antibodies are associated with naturally-acquired anti-malarial immunity and protection 
against disease.  
 
 
Figure 7. High levels of C1q-fixing antibodies to CSP are associated with protection against clinical malaria in children. 
PNG children (N=206) were tested for C1q-fixation to CSP by ELISA. Results were standardized to arbitrary units based on 
malaria-naïve negative controls from Melbourne (seropositivity defined as AU>1, shown as dotted line). (A) C1q-fixation to 
CSP was categorized by age (≤8, 8.1-9, 9.1-10 and ≥10, n=47, n=39, n=38 and n=71, respectively), and parasitemic status at 
enrolment by PCR. Each sample was tested in duplicate, and mean value was used to generate box-plots whereby; top, 
center and bottom horizontal lines represent the 75th percentile, median and 25th percentile (respectively), upper and 
lower whiskers represent the highest and lowest values within 1.5x-inerquartile range (respectively), and values that 
exceed this range are presented as symbols. Reactivity between two groups and more than two groups were compared 
using the Mann-Whitney U test and Kruskal-Wallis test, respectively. (B) Kaplan-Meier survival curve showing the 
cumulative proportion of children who had experienced an episode of malaria during follow-up (time in days), stratified into 
three groups based on C1q-fixation reactivity: negative (AU<1), low-positive (bottom 50% of positive samples, 1<AU≤1.525) 
and high-positive (top 50% of positive samples, AU>1.525) as shown in blue, red and green, respectively (n=116, n=39 and 
n=39, respectively; p=0.0438, Wilcoxon Breslow test, unadjusted for confounders). 
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Discussion  
Developing highly efficacious vaccines requires knowledge of the functional mechanisms that contribute to 
protection against malaria, and the identification of correlates of protective immunity. Here we show that 
naturally-acquired human anti-CSP antibodies can function by fixing C1q and activating complement, and this 
activity significantly correlated with IgG1, IgG3 and IgM antibodies. C1q-fixing antibodies were also shown to 
target the central NANP-repeat region of CSP. Importantly, we provide the first direct evidence that P. 
falciparum sporozoites are susceptible to human complement via the antibody-dependent classical pathway, 
resulting in enhanced traversal inhibition and sporozoite death in vitro. Furthermore, we found the natural 
acquisition of C1q-fixing antibodies to CSP in children occurs more slowly than observed for blood-stage 
antigens. Although poorly acquired in general, the minority of children who acquired high levels of C1q-fixing 
antibodies to CSP had a significantly reduced risk of developing clinical malaria, which identified the first 
functional correlate of immunity to sporozoites in human studies. Together, these findings reveal that 
antibodies to CSP and P. falciparum sporozoites can function by activating human complement, and provide 
initial epidemiological evidence linking antibody function and protective immunity.  
To detect functional anti-CSP antibodies we measured their ability to fix C1q, which is unique to the antibody-
dependent classical complement pathway, as well as downstream complement proteins. There were strong 
correlations between C1q-fixation and C4/C2/C3/C5b-C9-fixation demonstrating that C1q-fixation alone was a 
sufficient measure of complement activity that we used in subsequent cohort experiments. 
We demonstrated that immune antibodies promote deposition and activation of human complement against 
whole P. falciparum sporozoites and had functional effects. While anti-CSP antibodies can directly inhibit 
sporozoite traversal and invasion in vitro [17-19], high antibody concentrations have generally been required 
and the relationship between function and protection has not been established. Furthermore, the presence of 
anti-CSP IgG alone is an insufficient correlate of protection in humans. We found that naturally-acquired 
human antibodies had only weak activity in direct inhibition of P. falciparum sporozoite traversal, but activity 
was substantially enhanced by active human complement; when using sporozoites from the NF54 line there 
was a >2-fold increase in inhibitory activity when antibodies were tested in the presence of active complement 
(compared to inactivated complement), whereas substantial traversal inhibition of NF166.C8 sporozoites was 
only seen when antibodies were tested with complement present. Inhibiting sporozoite traversal may be 
important as it is essential for establishing liver-stage infection in animals [16, 38].  Mouse studies of the rodent 
species, P. berghei, reported that glycan-specific antibodies activated mouse complement and inhibited 
traversal and invasion of sporozoites  [39]. Interestingly, this was not mediated by murine IgG2a, which we 
have shown is capable of fixing C1q, possibly due to differences in epitope-specificity. There are important 
differences between human malaria immunity and murine models. Murine models typically use the rodent 
malaria P. berghei, which has substantial biological and functional differences from P. falciparum, including in 
the major target antigen CSP as P. berghei does not have the major NANP epitope of P. falciparum. 
Furthermore, complement activity in laboratory mice is much lower than human complement, which plays an 
important role in immunity [40]. Murine immune responses to Plasmodium infection are typically dominated 
by murine-IgG1 which does not fix complement, whereas human IgG1 and IgG3 dominate human responses 
and both subclasses potently activate complement. The future development of new animal models of malaria 
that better represent antibody-complement interactions may be valuable for vaccine development. Future 
research to further define the antibody titres, types, and specificity required for optimal complement fixation 
and functional effects would be valuable to help inform vaccine development. 
Antibodies alone cannot kill target cells, but our findings suggest that they can mediate this effect by 
recruitment and activation of complement. We directly showed that incubation with antibodies and 
complement can lead to sporozoite death. It has been previously been proposed that murine antibody-
complement interactions lead to morphological changes and bleb formation of P. falciparum sporozoites [41]. 
However in these studies, complement fixation and activation was not directly shown and the potential effect 
of complement was not quantified (only qualitative data were presented), and antibodies were predominantly 
murine IgG1, which cannot interact with complement as we have also shown [31]. Interestingly we found that 
148 
 
sporozoites were partially susceptible to direct complement attack as indicated by some direct C3 deposition 
and cell death. However, complement susceptibility was enhanced by 2-fold in the presence of immune 
antibodies.  
The NANP-repeat sequence is a known B-cell epitope of CSP, and an important target of RTS,S-induced 
antibodies [36]. We found this epitope to also be a target C1q-fixation using synthetic NANP peptide and 
NANP-specific MAbs. This supports future investigation of whether RTS,S-induced antibodies mediate 
complement-fixation, as they are known to predominately target this epitope. NANP-specific antibodies can 
neutralize sporozoite function in vitro [42], and can reduce liver-stage burden in humanized mice that are 
susceptible to P. falciparum [8] or mice challenged with transgenic P. falciparum/P. berghei sporozoites [43], 
although high antibody concentrations appear to be required for function. Our data suggest that complement 
may substantially enhance the function of these antibodies, reducing the critical concentrations needed to 
mediate functional effects. There were significant correlations between C1q-fixation to NANP and CSP, and 
between NANP-specific IgG/IgM and C1q-fixation to CSP, but the strength of correlations varied between the 
PNG and Kenyan populations. It is possible that antibodies to other regions of CSP mediate complement-
fixation, such as epitopes in the C-terminal and N-terminal regions, which warrants further investigation. 
 
We identified a subset of individuals from PNG and Kenya with high anti-CSP IgG reactivity that demonstrated a 
weak ability to fix C1q. This highlights the notion that total IgG reactivity is not wholly reflective of functional 
activity, and may explain why measuring anti-CSP IgG alone is a poor correlate of protective immunity. Anti-CSP 
IgG can directly fix C1q, and IgM is also likely to play some role as we observed high levels of anti-CSP IgM in 
selected individuals that strongly fixed C1q. Anti-CSP IgG was predominately the IgG1 and IgG3 subclasses, 
which are known to active complement. However, IgG2 and IgG4 were also detected in some individuals, which 
may negatively impact C1q-fixation by out-competing the complement-fixing subclasses; therefore, the overall 
isotype and subclass profile is important for functional activity. Other antibody factors such as epitope 
specificity, affinity, and glycosylation are also important in determining function. 
A striking new finding is that children with high levels of C1q-fixing antibodies to CSP had a significantly reduced 
risk of clinical malaria compared to children that had undetectable functional antibodies. Previously, there has 
been no association between anti-CSP antibodies and protection in malaria-exposed populations [44, 45]. 
Whereas we show important initial epidemiologic evidence of the potential role of anti-CSP antibodies that fix 
complement in malaria immunity, supported by findings on the functional outcomes of antibody-complement 
interactions. This is the first identification of a functional antibody response to sporozoite antigens that is 
associated with protective immunity in malaria-exposed children suggesting this as a significant new correlate 
of immunity. Our findings suggest that although the natural development of strong complement-fixing 
antibodies occurs only in a minority of children, when such antibodies do develop they contribute to protective 
immunity. These findings support future investigation of whether C1q-fixing antibodies are induced by vaccines 
such as RTS,S, and whether functional antibodies are associated with vaccine efficacy and could be used a 
correlate of protection. 
The cell-free high-throughput assay to detect and quantify functional, complement-fixing antibodies to CSP we 
developed in this study could be applied in large-scale clinical trials for vaccine evaluation Although this may 
not wholly represent all interactions that occur on the sporozoite surface, CSP is a well validated antigen that is 
known to be the major target of naturally-acquired immunity to sporozoites [11, 46, 47] and is the basis of 
leading vaccine candidate, RTS,S [12]. Future studies should investigate other potentially important sporozoite 
antigens as targets of complement-fixing antibodies and the importance of non-repeat CSP epitopes, which 
may have important implications in vaccine development, and whether complement activation leads to 
additional effects or outcomes.    
 
Conclusions 
In summary, this study demonstrates for the first time that immune antibodies fix and activate human 
complement against CSP and P. falciparum sporozoites, which inhibited sporozoite traversal and lead to 
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sporozoite death. These data provide key knowledge on antibody functional mechanisms against sporozoites, 
and help us identify which antibody types and epitopes are important in mediating anti-malarial immunity.  We 
also obtained promising evidence that a strong level of C1q-fixing antibodies to CSP is associated with 
protection against clinical malaria, and may be a valuable correlate of protective immunity. This is the first 
evidence of a functional antibody response to sporozoites associated with protection against malaria in 
children.  The future application of these approaches to quantify functional immunity in vaccine trials may 
greatly aid our understanding of how vaccines work and why efficacy has been sub-optimal in trials to date. 
The antibody C1q-fixation assay may be a suitable correlate of protective immunity in vaccine development 
and trial evaluation, and studies of acquired human immunity. Defining the functional mechanisms that confer 
protective immunity against malaria is essential to develop and evaluate much-needed highly efficacious 
malaria vaccines.  These findings have strong translational significance by revealing a mechanism of anti-
sporozoite immunity, and thereby enabling the development of strategies to maximize this effector mechanism 
in the development of highly efficacious malaria vaccines 
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Supplementary Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1. Timeline of Plasmodium sporozoites from inoculation in the skin to establishing infection in the liver, and 
opportunities for immune attack. Estimation of how long sporozoites spend in the skin and circulation before establishing 
liver-stage infection, where they are highly susceptible to antibody binding and complement attack. After inoculation, 
sporozoites spend the first 60 minutes (shown in blue) migrating in the skin using their gliding form of motility. Once 
sporozoites encounter a blood vessel to invade, they enter the circulatory system and are passively carried around the body 
(shown in purple). By 90 minutes, sporozoites are likely to arrest at the liver, where they must pass through the sinusoidal 
cell layer and Kupffer cells using their traversal form of motility (shown in green). Once this barrier has been breached, 
sporozoites are then accessible to hepatocytes to facilitate cellular invasion and development. Therefore, sporozoites are 
vulnerable to immune recognition for an estimated 100 minutes after inoculation, proving ample time to mount an immune 
response and inhibit parasite development in the liver.    
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Figure S2. Gating strategy for P. falciparum sporozoite traversal and sporozoite death experiments. (A) Sporozoite 
traversal was measuring by quantifying the percentage of wounded HC-04 cells. The HC-04 cell population was gated, 
doublets were excluded, and wounded cells were Rhodamine-positive. Top panel: HC-04 cells incubated with dextran only 
(in the absence of sporozoites, antibodies and complement) were used to correct for background reactivity. Bottom panel: 
HC-04 cells incubated with sporozoites and dextran only (in the absence of antibodies and complement) as a positive 
control, showing a high proportion of Rhodamine-positive cells (i.e. wounded by sporozoite traversal). (B) Sporozoite death 
was measured by quantifying the percentage of PI-positive cells. Percentage of maximum PI-positive sporozoites treated 
with normal human serum and rabbit anti-CSP IgG (red line) or rabbit pre-immune IgG (blue line). 
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Figure S3. The effects of antibody isotype/subclass on C1q-fixation to CSP. (A) Plasma from Kenyan individuals (n=10) with 
high C1q-fixation reactivity were pooled, and IgG was purified (and re-constituted to the original plasma volume). The 
pooled plasma and purified IgG were tested for IgG, IgM and C1q-fixation reactivity to CSP, and the mean and range of 
duplicates were graphed. (B-C) Antibodies from malaria-exposed PNG adults (n=30) were tested for C1q-fixation to CSP by 
ELISA, and the top 50% of samples (above median AU=2.2, n=14) were examined for isotype/subclass reactivity. Samples 
are listed in ascending order for C1q-fixation, and the ratio of anti-CSP IgG1-to-IgG3 and anti-CSP IgG-to-IgM are shown. The 
group median (n=30) was also used to calculate each ratio and confirm that variability was not due to differences in assay 
sensitivity (open bars).  
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Table S1. Linear regression to examine the relationship between antibody isotype and C1q-fixation to CSP in PNG adults 
(N=116).  
Isotype  Coefficient Robust SE 95% CI p-value R-squared 
IgG 0.785 0.101 0.585 to 0.985 <0.001 0.67 
IgG and IgMa 0.597 0.128 0.342 to 0.851 <0.001 0.71 
IgM  1.036 0.185 0.670 to 1.402 <0.001 0.50 
a IgG after adjusting for IgM (variables were deemed to not be collinear , VIF=1.62). Analysis was performed in 114 
individuals after the exclusion of two outliers (defines as having standardised residuals that excluded the range <-3 to >+3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S4. Malaria-exposed individuals tested for complement-fixation to P. falciparum sporozoites are highly reactive to 
CSP, and can mediate C3b-fixation on whole sporozoites. (A) IgG and C1q-fixation reactivity to CSP by malaria-exposed 
PNG and Kenyan individuals who were tested for complement-fixation to sporozoites (ELISA and Western blot). The results 
were standardized to arbitrary units based on malaria-naïve negative controls from Melbourne (seropositivity defined as 
AU>1), and the mean and range of duplicates were graphed. (B) Malaria-exposed and malaria-naïve samples from Kenya 
and Melbourne (respectively) were re-tested for C1q and C3-fixation to sporozoites by western blot. The predominant 
sporozoite surface antigen, CSP, was used as a loading control. To distinguish the alpha chain of C3 and C3b the exposure 
time was reduced. 
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Figure S5. Malaria-exposed Kenyan pool tested for P. falciparum sporozoite traversal demonstrates high reactivity for 
IgG, IgM and C1q-fixation to CSP. Plasma from Kenyan individuals (n=19) with high C1q-fixation reactivity were pooled, and 
antibodies (including IgG and IgM) were purified by ammonium sulfate precipitation (ASP, and re-constituted to the original 
plasma volume). The pooled plasma and ASP-purified sample were tested for IgG and IgM-reactivity to CSP, to confirm that 
antibodies were not lost during the purification process. The ASP-purified sample was also tested for C1q-fixation to CSP 
(note that the pooled plasma was not tested), and the mean and range of duplicates were graphed.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S6. NANP-specific antibodies are involved in mediating C1q-fixation to CSP. Antibodies from malaria-exposed 
adults from PNG (n=30, A) and Kenya (n=30, B) were tested for IgG/IgM-reactivity to (NANP)15 and C1q-fixation to CSP. 
Samples were categorized as having high (hi) or low (lo) reactivity for anti-NANP IgG and IgM defined as above or below the 
median AU value (PNG: IgG=0.73 and IgM=2.18; Kenyan: IgG=1,73 and IgM=1.58). The mean of duplicates are shown, and 
the group median and inner-quartile range were graphed. C1q-fixation reactivity between IgG/IgM high and IgG/IgM low 
groups was compared using the Mann-Whitney U test.  
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Figure S7. C1q-fixation, age, and anti-CSP IgG among PNG children stratified by negative, low-positive and high-positive 
groups for C1q-fixation to CSP. PNG children (N=206) were tested for C1q-fixation to CSP by ELISA, and categorized into 
three groups based on C1q-fixation reactivity; negative (-, AU<1), low-positive (lo+, 1<AU≤1.525) and high-positive (hi+, 
AU>1.525). C1q-fixation to CSP, age and anti-CSP IgG were categorized by C1q-fixation group. The group median, 
interquartile range and percentage of positive samples are also shown. Reactivity between two groups and more than two 
groups were compared using the Mann-Whitney U test and Kruskal-Wallis test, respectively. 
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General discussion 
In this thesis we explore the role of functional antibodies in pre-erythrocytic immunity induced by 
immunizations with Plasmodium falciparum sporozoites under chemoprophylaxis or natural exposure to 
Plasmodium falciparum sporozoites. Data are obtained using samples from malaria-naive adults undergoing 
the ChemoProphylaxis and Sporozoites (CPS) immunization regimen and from children living in a malaria-
endemic area of Burkina Faso. For CPS-immunization, volunteers were exposed to Plasmodium falciparum-
infected mosquito bites and subsequently challenged with infected mosquito bites. CPS-immunized volunteers 
were protected from challenge infection with homologous sporozoites delivered by mosquito bites (1). 
 
Fundamental questions that we address in this thesis for better understanding pre-erythrocytic anti-malarial 
humoral immune responses are: 
• Do antibodies induced following immunization with Plasmodium falciparum sporozoites under 
chemoprophylaxis or natural Plasmodium malaria exposure have neutralizing activity against 
Plasmodium falciparum pre-erythrocytic stages? 
• What is the importance of the complement system in pre-erythrocytic anti-malarial immunity? 
• Do functional antibodies have strain-transcending activity and can they interfere with heterologous 
sporozoite infectivity in vitro? 
• What is the antigen-specificity of functional antibodies targeting Plasmodium falciparum pre-
erythrocytic stages? 
 
Our findings show that CPS immunization-induced antibodies significantly reduce homologous Plasmodium 
falciparum sporozoite infectivity in vitro and have a much more pronounced effect on liver-stage infection in 
vivo in passively immunized liver-chimeric mice (Chapter 3). These antibodies are still able to inhibit liver-stage 
infection in vivo in the absence of antibodies targeting CSP, suggesting that other antigens than CSP might play 
a role (Chapter 6). Additionally, CPS-induced antibodies inhibit both homologous and heterologous sporozoite 
infectivity in vitro (Chapter 4) and interact with the complement system to further reduce homologous and 
heterologous sporozoite infectivity in vitro (Chapter 5). Although CPS-induced antibodies alone are less 
efficient in inhibiting heterologous sporozoite infectivity (Chapter 4), heterologous sporozoite infectivity in vitro 
is similary reduced by CPS-induced antibodies in the presence of active complement (Chapter 5). With respect 
to naturally acquired pre-erythrocytic anti-malarial immunity, we found that naturally acquired antibodies 
significantly reduce sporozoite gliding motility and invasion in human hepatocytes in vitro, despite low antibody 
titers to pre-erythrocytic antigens relative to asexual lysate (Chapter 7). Of note, naturally acquired antibodies 
are less efficient than CPS immunization-induced antibodies in inhibiting Plasmodium falciparum sporozoite 
invasion of hepatocytes. We further observed that naturally acquired antibodies have complement-fixing 
activity and enhance in vitro hepatocyte traversal inhibition and sporozoite death in the presence of active 
complement. Lastly, we found that high levels of complement-fixing antibodies are associated with a reduced 
risk of clinical malaria (Chapter 8). These findings will now be discussed in detail and in context.  
 
Induction of sporozoite-neutralizing antibodies by CPS-immunization or natural malaria exposure 
Correlates of protective anti-malarial immunity are currently absent, but highly needed for vaccine 
development and population monitoring in malaria-endemic areas (2). Naturally acquired long-term anti-
malarial protection requires the persistence of merozoite-specific antibodies above protective thresholds (3). 
Plasmodium parasite-specific antibody titers do not per se predict protection (4), suggesting that functional 
antibody effector mechanisms might give more relevant information on anti-malarial immunity rather than the 
presence of specific antibodies, since antibody levels do not give information about the quality of such 
antibodies. Antibodies targeting Plasmodium blood-stage parasites have shown to interact with the 
complement system and can interfere with e.g. merozoite invasion into erythrocytes, P. falciparum blood-stage 
replication and opsonic phagocytosis of merozoites, thereby reducing clinical disease (5). In contrast to blood-
stage immunity, the functional importance of antibodies in parasite pre-erythrocytic immunity is less well 
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established. How can malaria-specific antibodies potentially affect the pre-erythrocytic and liver-stage of 
Plasmodium parasites? Antibodies might interfere with the sporozoite journey from the skin to the liver. During 
their journey to the liver, Plasmodium sporozoites move by gliding motility, characterized by redistribution of 
its main sporozoite surface protein, the circumsporozoite protein (6-8). Additionally, the ability for sporozoites 
to traverse through different host cell types is important for preventing sporozoite clearance and successful 
parasite development in the human host (9-12). Following migration through cells, Plasmodium sporozoites will 
invade a final hepatocyte and undergo full maturation, followed by merozoite release in the blood stream, 
initiating the blood-stage cycle (13). 
 
Currently, there is a lack of functional immunological assays to examine humoral immune effector mechanisms 
on Plasmodium falciparum sporozoite infectivity and development. The sporozoite gliding motility assay by 
microscopy has been established for various Plasmodium species. We observed that sporozoite gliding motility 
is only inhibited by a low number of CPS-immunized volunteers most likely due to low antibody concentrations 
used (Chapter 3). We only used 2 mg/ml of purified IgGs due to limited sample availability, which is 2-5 fold 
lower than physiological IgG levels in humans. Nevertheless, the gliding assay is laborious, has a high intra-and 
inter-assay variability and a subjective manual readout (14). We found this assay highly subjective and more 
suitable for qualitative rather than quantitative analysis. To fix the high-througput of this assay and allow more 
objective, quantitative microscopic analysis, the gliding assay and its readout has been further optimized by 
TropIQ Health Sciences. We applied this optimized gliding assay to screen a large number of samples from 
children of Burkina Faso, demonstrating that naturally acquired antibodies are capable of interfering with 
sporozoite gliding motility in vitro (Chapter 7). 
 
Next to the gliding motility assay, we have further optimized and validated a flow-cytometry-based functional 
assay with human hepatoma cells, allowing us to examine the effect of antibodies on Plasmodium falciparum 
sporozoite traversal through hepatocytes (Chapter 2). This flow-cytometry-based approach has been further 
explored with plasma samples from a CPS trial where CPS-induced protection has previously shown to be dose-
dependent. While only 5/10 subjects were protected after exposure to three times five Plasmodium 
falciparum-infected mosquito bites, 4/5 and 8/9 volunteers were protected following immunizations with three 
times fifteen or ten infected mosquito bites, respectively (15). We examined whether the efficiency and 
presence of functional antibodies in these volunteers might depend on the immunization dose. To this end, the 
efficiency of neutralizing antibody responses (tested at 10 mg/ml IgG) on sporozoite traversal in vitro was 
explored. No differences in traversal inhibition were observed between the three immunization groups (Behet 
et al, unpublished data), indicating that in vitro traversal inhibition by CPS-induced antibodies does not explain 
why immunization dose influences protection. Functional antibodies may exert a different mode of action or 
target other antigens when neutralizing sporozoite migration through hepatocytes or hepatocyte infection. 
While hepatocyte traversal and subsequent hepatocyte infection are the most important processes in 
sporozoite liver-stage infection, it is very likely that the molecular basis of hepatocyte traversal is different from 
that of hepatocyte infection. Indeed, this is supported by previous studies showing for instance that knock-
down of traversal-associated genes does not per se affect in vitro sporozoite gliding motility and hepatocyte 
infection by Plasmodium falciparum sporozoites. However, host cell traversal is crucial for Plasmodium 
falciparum sporozoites to establish liver-stage infection in vivo: knockdown of traversal-related genes in 
sporozoites results in completely abrogated in vivo liver-stage infection in a humanized mouse model (10, 16-
18).  
 
Given the fact that human hepatocyte invasion is the final step in liver-stage development and the gold 
standard to look at the effect of immunization-induced or naturally acquired antibodies on inhibition of 
Plasmodium falciparum sporozoite infectivity, efficient in vitro systems that support invasion and maturation of 
Plasmodium falciparum sporozoites are highly needed. Hepatocyte invasion and development assays are 
limited by the fact that Plasmodium falciparum sporozoites have strong preferences for host cells they can 
invade and develop in. Primary human hepatocytes are superior over human hepatoma cell lines regarding 
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Plasmodium infection rates and completion of liver-stage development (19). Access to primary human 
hepatocytes allows us to further advance the readout of Plasmodium falciparum sporozoite infectivity in vitro 
and mimic a more natural situation with respect to e.g. proliferative capacity, gene expression and drug 
metabolism activity (20-23). We therefore have set up, optimized and established protocols for primary human 
hepatocyte isolations from liver pieces derived from patients undergoing hepatectomy and hepatocyte 
infection assays with Plasmodium falciparum sporozoites (24). These isolated primary human hepatocytes have 
been used for in vitro sporozoite infectivity assays in the presence or absence of CPS-induced anti-malarial 
antibodies (Chapter 4). The number of infected human hepatocytes was first determined by a laborious and 
manual microscopy readout, which has been further optimized to allow a quicker and objective readout. To 
this end, multiple images from each condition are automatically acquired under fluorescence illumination at 
high resolution and subsequently stitched by Fiji (ImageJ) software to merge these microscopy images into one 
single overview picture, hereby retaining microscopic resolution. These single overview pictures are then 
analysed by executing a macro, a simple program that automates a series of ImageJ commands, that 
automatically counts the number of liver-stage parasites in each condition (as described in Chapter 4). 
 
Although complete Plasmodium falciparum liver-stage development is achieved in primary human hepatocytes, 
disadvantages of primary human hepatocytes are that they require being isolated from human livers, which is a 
very laborious process and completely depends on the availability of human livers, and do not grow 
continuously in cell culture (21). While murine Plasmodium berghei and Plasmodium vivax sporozoites can 
efficiently invade and mature in hepatoma cell lines (25-29), only one human hepatoma cell line, the HC-04 cell 
line, is known to support exo-erythrocytic development of Plasmodium falciparum malaria parasites (30), 
providing an in vitro model allowing to study the effect of antibodies on liver-stage infection in vitro. To 
overcome the challenges with primary human hepatocyte isolation and culture, we have set up and optimized 
a flow-cytometry-based in vitro invasion assay with Plasmodium falciparum sporozoites, HC-04 human 
hepatoma cells and fluorescently labeled monoclonal CSP-targeting antibodies as described in Chapters 5 and 
7. Advantages of this hepatoma-based invasion assay are that it is a quick and reliable assay without the need 
for primary human hepatocytes and the more laborious microscopy readout. However, it is important to take 
into account that this assay only measures the initial three-hour invasion process and not the full liver-stage 
development stage as in primary human hepatocytes. To ensure we measure truly invaded sporozoites and not 
traversed sporozoites, invasion and traversal assays were conducted side by side with the same human 
hepatoma cells, Plasmodium sporozoite batch and antibodies from CPS-immunized volunteers. Whereas only 
1-2% of hepatoma cells was invaded by sporozoites, roughly 40% of cells was wounded by sporozoite traversal 
as determined by intracellular staining with a fluorescently labelled anti-CSP monoclonal antibody and dextran 
staining, respectively. This direct comparison shows that this optimized flow-cytometry-based hepatoma 
invasion assay can distinguish invaded sporozoites from traversing sporozoites. Using this assay, we show that 
naturally acquired antibodies are capable of reducing sporozoite invasion in vitro. Functional antibody-
mediated immunity towards Plasmodium pre-erythrocytic stages may play an important role in anti-malarial 
immunity induced by natural exposure to Plasmodium parasites as well (Chapter 7). However, of note, 
functional antibody efficacy of naturally exposed individuals was lower compared to that of CPS-immunized 
individuals as observed in Chapter 5, with median invasion inhibition percentages of 40.4% (IQR 17.6-58.9%) 
and 70.1% (IQR 59.4-78.4%), respectively. A possible explanation for this discrepancy could be that naturally 
acquired antibodies are more skewed towards blood-stage immunity due to consistent exposure to blood-
stage parasites. This is supported by a longitudinal cohort study in Mali, where they show that sterile immunity 
to Plasmodium falciparum pre-erythrocytic stages is not acquired despite years of repeated malaria exposure, 
while clinical anti-blood-stage immunity is acquired (31). Possible reasons for the induction of less efficient 
naturally acquired pre-erythrocytic immunity in this population could be e.g. extensive parasite genetic 
diversity or immune dysregulation. 
 
While CPS-induced and naturally acquired antibodies have shown to affect sporozoite gliding, migration 
through hepatocytes and/or hepatocyte infection (Chapters 3-5 and 7), their effect on liver-stage development 
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has not yet been investigated. There is some evidence that antibodies can block at the level of liver-stage 
development in vitro: antibodies from mice immunized with irradiated sporozoites could inhibit 
exoerythrocytic form development in hepatoma cells, suggesting that the antigenic content of liver-stage 
parasites may serve as immunogens (32), but the exact mechanism remains unclear. Possible theories are that 
antibodies may interfere with intra-hepatic parasite replication and development following hepatocyte 
invasion by binding to sporozoites and thereby affecting subsequent liver-stage development, or to antigens of 
intra-hepatic parasites that are presented on the hepatocyte surface membrane and thus, mark these infected 
cells for destruction by fragment crystallizable (Fc)-receptor-bearing immune effector cells. This may promote 
antibody-dependent cellular cytotoxicity (ADCC) and/or complement-mediated lysis of the infected hepatocyte 
(33, 34). One way to address this question would be to infect primary human hepatocytes with Plasmodium 
falciparum malaria sporozoites and subsequently incubate these infected human hepatocytes with CPS-
induced or naturally acquired anti-malarial antibodies in the presence of active complement. With respect to 
microscopy readout, it would be very helpful to develop another macro with FIJI (ImageJ) software that is able 
to distinguish differences in parasite sizes or circularity, hereby allowing us to determine whether antibodies 
may have any effects on intra-hepatic parasite development. 
 
Although the effect of antibodies on sporozoite infectivity has been and can be explored in different in vitro 
assays, these assays do not reproduce natural Plasmodium sporozoite infection by mosquito bite and the 
complete sporozoite journey from the skin to the liver. Immunodeficient human liver-chimeric mice engrafted 
with human hepatocytes have become increasingly important as small pre-clinical animal models for the study 
of malaria parasite liver-stage infection and possible effects of antibodies on liver-stage infection in vivo (35, 
36). (CPS-induced) antibodies could for instance immobilize sporozoites in the skin or target gliding motility 
and/or migration through human host cells, thereby limiting the number of sporozoites that are reaching the 
liver. Indeed, we show that CPS-induced antibodies had a much stronger inhibitory effect on Plasmodium 
falciparum pre-erythrocytic infection in vivo in liver-chimeric mice than in vitro (Chapter 3). Another possible 
explanation might be that CPS-induced IgGs could potentially interact with human complement proteins, which 
have previously shown to be produced by human hepatocytes in human-liver chimeric mice as determined by 
mass spectometric analysis of chimeric mouse plasma (37), resulting in a more pronounced effect on liver-stage 
inhibition in vivo. Of importance, in vitro sporozoite infectivity assays have been conducted in the absence of 
complement. For further exploration of the importance of the complement system for pre-erythrocytic 
antibody-mediated immunity, it is important to investigate this in in vitro assays, allowing us to characterize the 
precise contribution of the complement system to anti-sporozoite antibody-mediated immunity.  
 
Taken together, we show that whole parasite immunization (CPS)-induced and naturally acquired antibodies 
are capable of neutralizing Plasmodium pre-erythrocytic stages. Remaining questions are how these 
neutralizing antibodies are acquired by whole parasite immunizations or during natural infection(s) with 
Plasmodium parasites. Is one single exposure or immunization sufficient enough or are multiple exposures or 
immunizations required to induce functional antibodies? Previous CPS trials have shown that antibody titers 
and memory B-cell numbers targeting pre-erythrocytic and cross-stage antigens increase stepwise after each 
immunization (38). It is most likely that multiple immunizations or exposures are required to achieve a 
threshold for functional antibody activity. To follow up on this, with respect to merozoite-specific antibodies, 
antibody titers against merozoite antigens drop over time, while functional antibody activity is better 
maintained over a long period of time as observed in a 3 year longitudinal cohort of Kenyan children (39). This 
could perhaps be explained by a (relatively) low threshold for a given antibody concentration that is required to 
exert its functional activity. Likewise, it is known that CPS-induced antibody titers drop over time in the 
absence of parasite exposure, while memory B-cells remain stable (38). Do functional CPS-induced or naturally 
acquired pre-erythrocytic antibodies also remain stable over time with respect to anti-sporozoite inhibitory 
activity? Of note, pre-erythrocytic or merozoite antigens against which titers are determined may simply not be 
related to antigens relevant for antibody functionality. The stability of these functional antibodies could be 
assessed by testing plasma samples from CPS-immunized volunteers or naturally exposed individuals, collected 
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over different time points, in in vitro sporozoite infectivity assays to test whether the functional activity of 
immunization-induced or naturally acquired pre-erythrocytic antibodies changes over time. 
 
Importance of the complement system in protection against Plasmodium falciparum pre-erythrocytic stages 
Next to opsonization and direct neutralization of pathogens, activation of the complement system by 
antibodies is another important immune effector mechanism of humoral immunity (40). Previous studies in 
human and animal models of malaria have demonstrated complement activation during malaria infection, with 
reduced serum complement protein levels during acute Plasmodium infection (41-45) or increased membrane 
attack complexes as compared to controls or patients with less severe disease (46, 47). Complement activation 
depends on Fc-receptor antigen-antibody binding for immune effector functions and not per se on recognition 
of antigenic targets via the variable region of antibodies (40). Various antibody factors are determining the 
efficiency of antibody functions, such as antibody isotype, epitope specificity, antibody allotype, antibody 
affinity and glycosylation.  
 
Antibody isotypes and anti-malarial complement-mediated immunity 
IgG antibodies are central mediators of host defense and effective in inducing various immune effector 
mechanisms, such as opsonization, complement activation or phagocytosis (48). Important functions of IgG 
antibodies in anti-malarial immunity are e.g. direct neutralization of sporozoites in the skin or blood (49, 50), 
preventing hepatocyte invasion (51, 52), or facilitating sporozoite uptake and destruction by phagocytes (53, 
54). On the other hand, IgM antibodies are superior to bivalent antibody isotypes at triggering specific immune 
effector mechanisms, such as opsonization for phagocytosis (55, 56). Moreover, one single IgM antibody can 
trigger the complement system 1,000 times more efficiently than IgG antibodies due to its pentameric 
structure (57, 58). Antibody isotype and IgG subclass impacts activation of the classical complement pathway, 
with IgG1, IgG3 and IgM antibodies being the most efficient in triggering the classical complement pathway 
(59). In contrast, IgG2 and IgG4 subclass antibodies are less efficient in activating complement (60, 61). The 
latter two isotypes are more relevant in antibody responses to bacterial capsular polysaccharide antigens or 
allergens and helminth infections, respectively (59). In malaria-endemic areas, antibodies targeting merozoites 
have been shown to be predominantly cytophylic subclasses IgG1 and IgG3 (62-67): they fix and activate the 
complement system to inhibit merozoite invasion and lysis, and are associated with resistance to malaria (66-
69). Women carrying a specific mutation for IgG3 show increased transplacental transfer of malaria-specific 
IgG3 during pregnancy, and infants from these women have extended persistence of malaria-specific IgG3 
antibodies and a reduced risk of clinical malaria during infancy (70). 
 
With respect to subunit vaccination or whole parasite immunization approaches, RTS,S vaccination of malaria-
naive individuals has previously shown to induce mainly IgG1 and IgG2 anti-CSP repeat antibodies, with IgG1 
being the dominant antibody isotype (71, 72). These anti-CSP repeat antibodies may contribute to RTS,S-
induced protective immunity for instance by opsonization of sporozoites (54) or Fc-receptor-mediated 
phagocytosis of sporozoites by phagocytes (73). Additionally, RTS,S vaccination has shown to induce functional 
IgG1 and IgG3 antibodies in malaria-exposed children in an African pediatric Phase 3 trial. These antibodies are 
capable of interacting with the complement system and Fc-receptors in opsonic phagocytosis, and appear to be 
associated with a reduced risk of malaria (Dobaño, presented at the ASTMH conference in 2017, unpublished). 
In Chapter 5, we show that antibodies induced by CPS-immunization targeting the dominant sporozoite surface 
protein CSP, are predominantly IgG1 and IgM isotypes. This is similar to malaria-exposed individuals from 
Papua New Guinea, where CSP-recognizing naturally acquired antibodies are mainly IgG1, IgG3 and IgM 
(Chapter 8), all of which are very potent in activating the classical complement pathway (59). The induction of 
IgG1 and IgG3 antibody isotypes following whole parasite immunization or natural Plasmodium malaria 
infection is not surprising. The isotypic restriction of specific IgG subclasses depends e.g. on the biochemical 
nature of antigens: most antibodies targeting proteins are of IgG1 and IgG3 isotypes, such as Plasmodium 
parasites, while antibodies recognizing carbohydrates are mainly of IgG2 isotype. Moreover, cytokine 
environment and B-cell activators also influence the expression of specific IgG subclasses with e.g. IFN-ƴ, 
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interleukin (IL)-10, IL-21 and CD40 ligand interactions resulting in class-switching to IgG1 and/or IgG3 antibody 
isotypes (74-76). Importantly, we found that these complement-fixing antibodies are associated with a reduced 
risk of clinical malaria (Chapter 8). Complement fixation of merozoites by human antibodies is similarly 
mediated by activation of the classical pathway (69). While the induction of certain antibody isotypes against 
Plasmodium pre-erythrocytic stages has not previously been investigated, we show here that as expected, 
whole parasite immunization or natural Plasmodium malaria infection induces IgG1 and IgG3-biased immune 
responses towards sporozoites and that complement activation of pre-erythrocytic stages is similarly mediated 
to that of blood-stage parasites. 
 
Although antibody-mediated protection against Plasmodium falciparum blood-stages has mostly been 
associated with IgG antibodies, a very few studies have evaluated the role of P. falciparum-specific IgM 
antibody responses against blood-stage parasites, for instance IgM antibodies have shown to mediate lysis of 
Plasmodium-infected erythrocytes in the presence of complement (69). Research examining the possible 
contribution of IgM antibodies to pre-erythrocytic immunity is even scarcer, urging the need for further 
exploration of the importance of IgM antibodies in pre-erythrocytic immunity. IgM memory B-cells and 
antibodies play a more important role in long-term humoral protection than was thought: IgM memory B-cells 
can be recalled upon future pathogen encounters. In the specific case of malaria, Plasmodium-specific IgM 
antibodies have shown to limit parasite replication in murine models of malaria (77, 78). Additionally, a murine 
model of malaria showed that MSP-1 specific IgM memory B-cells act as first responders upon re-infection with 
Plasmodium chabaudi malaria and generate both T-cell dependent short-lived plasmablasts and T-cell 
independent long-lived plasma cells (79, 80). This could be similar for humans. In an area hyperendemic for 
malaria in Burkina Faso, a negative association is found between malaria-specific IgM antibody levels and 
parasite densities in the blood (81), and interestingly, naturally acquired IgM antibody responses from malaria-
resistant individuals have shown to recognize a greater proportion of Plasmodium falciparum antigens as 
compared to malaria-susceptible individuals (82). Induction of malaria-specific IgM antibodies in CPS-
immunized volunteers has previously been reported and IgM in fact predominated over IgG antibody responses 
in CPS-induced P. falciparum antigen recognition (83). Taken together, this indicates a possible role for IgM 
antibodies after whole parasite immunization or natural Plasmodium malaria exposure. In Chapter 5, we show 
individual differences in antibody isotypes induced by CPS-immunization; some volunteers tend to have higher 
sporozoite-specific IgG antibody levels, while other volunteers seem to rely more on IgM antibodies. This is 
supported by previous findings, showing that antibody isotypes induced by CPS-immunization vary widely 
between the volunteers, also for various regions of the same antigen (83). Thus, CPS-induced humoral immune 
responses and individual antibody isotypes are diverse and broad. 
 
To get a better overview of the individual contributions of IgG and IgM isotype antibodies, we could look at the 
individual contributions of purified IgG or IgM antibodies compared to total serum to inhibiting sporozoite 
infectivity in vitro in the presence or absence of complement. While IgM antibodies are exceptional in 
activating the complement system, they might have some direct neutralizing effect on sporozoites. CPS-
induced IgM antibodies are able to recognize whole sporozoites and CSP as described in Chapter 5. In a pilot 
study, we explored which other pre-erythrocytic antigens are recognized by CPS-induced IgM antibodies. To 
this end, ten CPS-immunized volunteers with the top 5 highest and bottom 5 lowest CSP-IgM antibody levels 
were selected for screening for recognition of LSA-1 and MSP-1 antigens. Although we do not find a significant 
induction of IgM antibodies against these liver- and cross-stage antigens (Behet and Haukes et al, unpublished), 
this observation is supported by a previous study where LSA-1 and MSP-1-specific IgM antibodies were also not 
reported in CPS-immunized volunteers (83). As a result of their large pentameric structures, IgM antibodies are 
mainly found in the blood and the lymph nodes (84). IgM antibodies might possibly be important in targeting 
sporozoites in the skin and blood stream. Additionally, CPS-induced IgM antibodies have previously shown to 
recognize liver-stage antigens (83), implying that IgM antibodies may also target liver-stage parasites due to the 
highly vascularized liver. While the neutralizing efficacy of CPS-induced IgM antibodies on Plasmodium 
sporozoite infectivity remains to be determined, it was recently shown that immunization of Tanzanian 
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individuals with radiation attenuated cryopreserved P. falciparum sporozoites induces functional anti-
sporozoite IgM antibodies with human hepatocyte invasion inhibitory and complement-fixing activity (85). This 
implies that malaria-specific IgM antibodies can indeed directly neutralize sporozoites. 
 
Importance of antibody affinity for Plasmodium-specific pre-erythrocytic humoral immune responses 
Inter-individual differences in the efficiency of antibodies to neutralize Plasmodium sporozoite infectivity in 
vitro are prominent as described in Chapters 3, 4 and 5. Some CPS-immunized volunteers have antibodies that 
are more efficient in neutralization or complement fixation than others, the so-called high versus low functional 
antibody responders. It is likely that these high funtional antibody responders may have higher affinity 
antibodies or more antibodies recognizing specific malaria antigen targets. Currently, it is still unknown how 
these antibodies bind to sporozoites and which binding affinity is required for neutralization and/or any other 
functional antibody immune effector mechanisms. A possible reason for the discrepancy in antibody 
functionality between the high and low functional antibody responders might be, next to antigenic targets of 
antibodies, differences in the affinities of antibodies. When the human immune system is initially exposed to 
Plasmodium sporozoites or a particular malaria-specific antigen, low and high affinity antibody-producing B-cell 
clones will be produced. Antibody affinity refers to the strength of the interaction between an antibody 
antigen-binding site and an epitope. High affinity antibodies bind rapidly to the specific antigen and maintain 
this interaction better under complex conditions. On the other hand, low affinity antibodies bind weakly to the 
antigen. Antibodies that are produced initially in response to antigens are high molecular weight IgM 
antibodies with low affinity but high avidity, while continuous exposure to the same antigen will provoke the 
selection of antibodies that are of lower molecular weight classes (e.g. IgG antibodies) with higher affinity for 
that specific antigen (86). B-cell clones recognizing the antigen with high affinity will survive in time, while B-
cells producing low affinity antibodies will undergo apoptosis, a process known as affinity maturation. Affinity 
maturation is a process of affinity-selected differentiation of B-cells and achieved by somatic hypermutation 
and clonal selection (87). Somatic hypermutation results in a broad spectrum of antibodies with different 
affinities by alterations of the variable regions of immunoglobulins (88-90). Clonal selection then favours 
survival of high affinity antibody-producing B-cell clones, ensuring that the immune system will react 
increasingly effectively to a subsequent encounter with the same antigen (91). Although antibody affinity does 
not per se correlate with functional activity, it is most likely that sufficient high affinity antibodies are required 
to promote complement fixation and phagocytosis. Therefore, it will be important to take the vaccination 
protocols into account. Standard prime-boost or multiple-dose vaccination will increase the magnitude of anti-
malarial immune responses, allowing B-cell affinity maturation and thus, resulting in higher affinity malaria 
antigen-specific B-cell clones and hence, the secretion of high affinity and broadly neutralizing antibodies (92). 
 
Importance of glycosylation for Plasmodium-specific pre-erythrocytic humoral immune responses 
Glycosylation involves the post-translational attachment of carbohydrates to proteins following post-
translation, further modifying proteins. Glycolysation significantly alters recognition of epitopes and can 
enhance the antigenicity of proteins. Recently, it was shown for the first time that Plasmodium surface proteins 
CSP and TRAP are  glycolysated in sporozoites, a finding that could impact the selection of vaccine antigens and 
possible vaccine efficacy (93), since this might affect antibody binding to antigens or immunization of 
individuals.  
 
IgG antibodies are heavily glycosylated, but only little is known about how glycolysation of antibodies is 
regulated. Fc-receptor glycolysation can affect antigen-binding characteristics and thus, also antibody activity 
(59, 94). Small glycan changes may already have profound effects on immune Fc-effector cell functionality (95). 
Glycosylation changes following influenza vaccination are comparable in both African and European subjects 
and independent of age and vaccination type (96). This independence of baseline geographical regions in 
antibody glycosylation is confirmed by another study, where vaccine-induced glycosylation changes are 
restricted to induced antigen-specific antibody responses. Interestingly, different antigen-specific IgG 
glycosylation profiles can be induced by distinct vaccine regimens, indicating that antibody glycosylation can 
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possibly be directly altered by vaccination (95). Depending on the time of vaccination, the infectious pathogen 
will encounter IgGs with different glycosylation profiles, which affects human Fc receptor (FcR) binding (97) and 
thus, may impact downstream antibody effector mechanisms that are relevant in immunity (96). To further 
explore the importance of IgG glycosylation for anti-malarial pre-erythrocytic antibody-mediated immune 
effector mechanisms, glycosylation profiles of given antigen-specific antibodies could be assessed and linked to 
anti-malarial protection in addition to antibody titers and functional assays. Knowledge on protein or antibody 
glycosylation may impact future clinical anti-malarial vaccine development. 
 
In summary, the presence of specific antibody isotypes is important for the functional component of pre-
erythrocytic stage immunity towards Plasmodium parasites and should be taken into account for clinical 
vaccine development. In non-malaria related diseases, specific induction of IgG2, IgG4 or IgA antibodies can be 
found following vaccination against e.g. influenza virus (98), Streptococcus pneumoniae infection (99), pollen 
allergens (100) or pertussis (101). Vaccines that induce specific antibody isotypes to Plasmodium pre-
erythrocytic stages, such as IgG1, IgG3 and IgM, might further enhance malaria vaccine efficacy by improving 
the quality of antibody responses. Additionally, more knowledge is required on the induction and acquisition of 
sporozoite-specific complement-fixing antibodies over time, since this might give us relevant information on 
the relevance and maintenance of this functional immune effector mechanism over a longer period of time. For 
instance, antibody-mediated complement fixation of merozoites has shown to be better maintained than 
antibody titers to merozoite antigens in a 3-year longitudinal cohort of Kenyan children, and has previously 
shown to strongly correlate with antibody-mediated complement-dependent inhibition of merozoite invasion 
(69) This indicates that some effector mechanisms of antibody-mediated immunity may be better maintained 
than simply antibody levels (39). It remains to be questioned whether the same is true for naturally acquired 
and immunization-induced pre-erythrocytic antibody-mediated immunity. 
 
Further exploration of other immune effector mechanisms that might be involved in CPS-induced or naturally 
acquired pre-erythrocytic immunity is needed, such as phagocytosis of sporozoites by phagocytes or antibody-
dependent cell cytotoxicity (ADCC). Phagocytic activity of antibodies can be explored by determining 
phagocytosis of Plasmodium sporozoites by FcR-positive monocytic cells derived from the THP-1 cell line (102-
104). Opsonic phagocytosis assays for Plasmodium-infected erythrocytes, merozoites and sporozoites are 
currently being employed (104-106), and could be further tailored and optimized for the use of Plasmodium 
sporozoites. In a murine model of malaria, opsonization of P. berghei sporozoites by CSP-specific antibodies 
increase phagocytosis and elimination by Kupffer cells in vitro (53). Additionally, naturally acquired opsonic 
phagocytosis antibodies from African children are strongly associated with protection against malaria (106), 
and RTS,S-induced opsonizing CSP-specific antibodies may contribute to RTS,S-induced protection (54). Taken 
together, this suggests that antibodies capable of opsonic phagocytosis could possibly serve as a correlate of 
protection in malaria. In addition, binding of antibody Fc regions to FcRs on natural killer (NK) cells or other 
myeloid cells will induce cytokine production and release of cytotoxic granules, resulting in ADCC. This process 
depends amongst other on antibody allotype, the density of antigen and antibody isotype, where IgG1 and 
IgG3 are the most efficient in inducing ADCC. For blood-stage immunity, naturally acquired antibodies 
protective from Plasmodium falciparum blood-stages inhibit parasite growth and invasion in vitro in interaction 
with monocytes (107) and are predominantly IgG1 and IgG3 (108). Additionally, plasma from malaria-resistant 
individuals has shown to induce NK-cell-mediated ADCC of infected erythrocytes and inhibit Plasmodium 
growth in vitro (109). In support of this, ADCC is associated with a reduced risk against febrile malaria in a 
longitudinal cohort of Ghanaian children (110). Since CSP-specific antibodies induced by CPS-immunization are 
predominantly of the IgG1 isotype, ADCC might play a role in CPS-induced immunity as well and should thus be 
further examined. Many setups for blood-stage ADCC are currently available. Antibodies can recognize parasite 
antigens on the membrane of the infected hepatocyte and mediate ADCC (111), especially by NK-cells. To set 
up a liver-stage based-ADCC assay, immunization- or naturally acquired antibodies could be added to infected 
human hepatocytes, allowing the recognition of parasite antigen targets expressed on the surface of infected 
hepatocytes by these antibodies, followed by a wash step to remove unbound antibodies. Subsequently, NK 
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cells could be added to these antigen-antibodies complexes on the hepatocyte surface and ADCC efficacy could 
be determined by means of e.g. fluorescently labelled dyes. Of note, the development and validation of a 
robust, successful ADCC assay depend on several factors, such as optimization of the target to effector cell ratio 
for multiple donors, since individuals will most likely have different Fc-receptor densities and affinities for 
antibodies. Moreover, peripheral blood mononuclear cells (PBMCs) require to be isolated from blood to serve 
as a source of effector cells (NK-cells) and are preferably used within 48 hours following isolation for optimal 
activity. Last, but not least, importantly, the ADCC readout cannot discriminate between antibody-dependent 
cell-mediated killed cells versus apoptosis or necrosis, that occurs independently of the presence of antibodies. 
 
Last but not least, cellular receptors (Fc-receptor; FcR) are crucial for different immunoglobulin isotypes 
interactions in pre-erythrocytic immunity to Plasmodium falciparum malaria. FcRs are widely expressed on 
immune cells and provide a link between effector mechanisms of innate immune cells and antigen-specific 
adaptive immune responses (112). Individual FcRs have different affinities for different IgG antibody subclasses 
(113, 114); immune complexes binding to FcRs of innate immune effector cells will induce both activating and 
inhibitory signaling pathways, leading to amongst other regulating humoral responses, cell degranulation, 
phagocytosis, ADCC and antigen presentation. In conclusion, functional assays may be more difficult, time-
consuming, less well-established and amendable to high-throughput than simple measurements of antibody 
titers for well-defined antigens, but are needed and justified since specific functional properties of naturally 
acquired and immunization-induced antibodies may be better correlates of anti-malarial protection. 
 
Induction of strain-transcending functional antibodies following CPS-immunization  
Previous CPS trials have demonstrated the induction of sterile and long-lasting protection against homologous 
Plasmodium falciparum infection in volunteers immunized by exposure to Plasmodium falciparum NF54 
sporozoites under chemoprophylaxis (1, 115, 116). Given the large genetic diversity of Plasmodium falciparum 
parasites, it is essential to investigate whether CPS-immunization can also induce protection against 
heterologous parasite strains. In an open label follow-up study, CPS-immunized volunteers that were previously 
protected from a homologous Plasmodium falciparum NF54 sporozoite challenge infection were re-challenged 
with the genetically and geographically distinct parasite clone Plasmodium falciparum NF135.C10, fourteen 
months after the last CPS-immunization with Plasmodium falciparum NF54 sporozoites. Two out of thirteen 
volunteers were fully protected from NF135.C10 challenge infection, while eleven out of thirteen showed 
delayed parasitaemia, suggesting at least some degree of anti-parasitic immunity (117). CPS-induced antibodies 
from these re-challenged CPS-immunized volunteers (117) are less efficient in neutralizing heterologous 
NF135.C10 and NF166.C8 sporozoite traversal in vitro when compared to homologous NF54 sporozoite 
traversal (Behet et al, unpublished).  
 
In Chapter 4, we explored in a dedicated clinical trial with a greater number of volunteers whether the NF54 
CPS immunization regimen could induce protection against a primary challenge infection with the homologous 
Plasmodium falciparum NF54 or the genetically distinct Plasmodium falciparum NF135.C10 and NF166.C8 
clones. In line with previous CPS trials, NF54 CPS-immunization induces sterile protection in volunteers whom 
are challenged with the homologous NF54 strain, but only protects two out of ten and one out of nine 
volunteers against Plasmodium falciparum NF135.C10 and NF166.C8 challenge infection, respectively. We next 
examined the importance of CPS-induced antibodies in interfering with both homologous and heterologous 
sporozoite invasion in primary human hepatocytes in vitro. Likewise for reducing hepatocyte traversal in vitro 
(Behet et al, unpublished), CPS-induced antibodies are also less efficient in neutralizing heterologous 
sporozoite development in primary human hepatocytes when compared to NF54 sporozoites (Chapter 4). On 
the other hand, interestingly, complement-fixing antibodies seem to be more relevant for interfering with 
heterologous sporozoite infectivity in vitro, despite the fact that less IgM antibodies bind to heterologous than 
homologous sporozoites (Chapter 5). A possible reason for this could be that IgM antibodies generally have a 
lower threshold for complement fixation and are therefore still very efficient in complement activation. Of 
note, CPS-induced antibodies are less efficient in neutralizing heterologous sporozoite infectivity in in vitro 
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invasion and development assays, however, does this occur in vivo as well? As a next step, this should be 
explored in a human liver-chimeric mouse model, providing us with more knowledge on the importance of 
antibody-mediated immunity in heterologous liver-stage infection in vivo.  
 
Antigen-specificity of functional antibodies targeting Plasmodium pre-erythrocytic stages 
Development of subunit vaccines may be a logistically attractive alternative to whole parasite immunization. 
Identification of antibody antigenic targets will be crucial for further dissection of protective anti-malarial 
immune responses as well as the development of more effective pre-erythrocytic subunit vaccines than e.g. the 
CSP-based RTS,S subunit vaccine that only offers modest and rapidly waning protection from malaria in 
individuals living in highly malaria-endemic areas (118-122). One of the most studied malaria proteins is the 
sporozoite antigen CSP, which forms a dense coat on the sporozoite surface and continues to be transcribed 
during the liver-stage (123). CSP is involved in sporozoite motility and hepatocyte invasion (6, 124). CSP is a 
glycosylphosphatidylinositol (GPI)-anchored glycolipid protein, consisting of a conserved domain structure with 
N- and C-terminal domains that are separated by a NANP repeat region (125, 126). The CSP protein has shown 
to bind hepatocyte heparin sulfate proteoglycans, which is thought to be important in parasite migration to the 
liver and hepatocyte invasion (127-130). Cleavage of the N-terminal domain is required for attachment to and 
efficient hepatocyte infection by sporozoites (130-132). Protease inhibitors affecting N-terminal cleavage 
inhibit in vitro hepatocyte invasion and in vivo liver-stage infection in a rodent model of malaria (132). With 
respect to protective immunity, the role of the NANP repeat region of Plasmodium falciparum CSP is still 
unknown and research into antibody responses to functional N- and C-terminal domains from the CSP protein 
is limited. Immunization of rodents with Plasmodium falciparum N-terminal CSP induced antibodies that 
neutralize sporozoite invasion into hepatocytes in vitro (133). Additionally, immunization of rodents with 
combined formulations of N- and C-terminal regions of CSP induced antibodies that could more efficiently 
neutralize hepatocyte invasion in vitro than antibodies targeting only one of these domains (134). 
 
Antigen-specificity of naturally acquired antibodies and memory B-cells 
Long-term natural exposure to Plasmodium falciparum parasites induces only weak CSP-specific germinal 
center memory B-cell responses (135, 136) and low antibody titers to CSP (137), that mainly target the NANP 
repeat region, but also recognize also non-repeat sequences (138). With respect to naturally acquired 
antibodies to Plasmodium pre-erythrocytic stages, antibody responses to liver-stage antigen-1 (LSA-1) have 
been associated with a reduced risk of clinical malaria in Kenyan children (139), suggesting that not only 
sporozoite, but also liver-stage antigens should be investigated as targets of anti-malarial humoral immune 
responses. Identification of proteins that are expressed at the sporozoite and liver-stage is essential for the 
selection of new potential vaccine candidates beyond the well-studied antigens such as CSP and LSA-1. Such 
novel antigen identification is being pursued by e.g. analysis of the Plasmodium falciparum sporozoite surface 
proteome (140), sporozoite transcriptome (141), or liver-stage transcriptome in FRG human liver-chimeric mice 
during Plasmodium liver-stage infection in vivo and in vitro at various days. Next to LSA-1 antibody responses, 
monoclonal antibodies cloned from the B-cell receptors of rare affinity-matured CSP NANP repeat-recognizing 
memory B-cells from naturally exposed individuals can inhibit parasite transmission and development in vivo 
(142). In Chapter 8, it has been shown that CSP is an important epitope of complement-fixing antibodies from 
Kenyan and Papua New Guinean adults. Taken together, these data suggest that antibody-mediated immune 
effector mechanisms may also play an important role in anti-sporozoite immunity in naturally exposed 
individuals. More knowledge on humoral immune effector mechanisms and antigens relevant for naturally 
acquired antibodies would further improve our understanding on the age-specificity, acquisition and 
persistence of naturally acquired humoral immunity towards Plasmodium pre-erythrocytic stages, and how to 
use this knowledge to develop vaccines that might boost naturally acquired antibody-mediated immune 
responses.  
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Antigen-specificity of immunization-induced antibodies and memory B-cells 
While the induction of CSP-specific antibodies and memory B-cell responses is low and inefficient in individuals 
that are naturally exposed to Plasmodium infection, CSP is a target of antibody-mediated immune responses 
induced by RAS-immunization and the CSP-based RTS,S subunit vaccine (71, 119, 143-145). With respect to 
CSP-specific antibody responses induced by RAS-immunization, protected RAS-immunized individuals have 
higher anti-CSP antibody titers compared to unprotected individuals (144), and neutralization of in vitro 
hepatocyte invasion by sporozoites most closely paralelled non-repeat CSP flanking region antibody levels 
(146). However, even more strongly than reactivity to any individual antigen, a panel of nineteen pre-
erythrocytic antigens including CSP, is associated with RAS-induced sterile protection of human volunteers 
from challenge infection (147). 
 
The RTS,S vaccine is composed of the C-terminal domain and the repeat region of Plasmodium falciparum CSP 
(148). Previous studies suggest that RTS,S-induced protection is most likely mediated by high titers of anti-
repeat antibodies in combination with CSP-specific CD4+ T-cell responses (145, 149-152). Interestingly, RTS,S-
induced full length CSP and C-terminal-specific antibodies, but not anti-CSP NANP repeat antibodies, have been 
associated with antibody-mediated phagocytic activity (73). In a cohort of RTS,S vaccinated Mozambican 
children, the magnitude and breadth of antibody responses to liver-stage and blood-stage antigens is lower 
than in controls, suggesting that RTS,S vaccination confers protection by neutralizing hepatocyte invasion by 
sporozoites and thus, results in reduced exposure and hence induction of antibodies to liver- and blood-stage 
parasites (153). The magnitude of humoral antibody responses likewise reflects parasite exposure during CPS-
immunization, with unprotected volunteers having significantly higher antibody responses than protected 
volunteers (38). While it is known that CPS-immunization induces antibodies recognizing CSP, it is currently yet 
unknown which CSP domains are targeted by CPS-induced antibodies. Curiously, only 2 out of 215 monoclonal 
antibodies derived from memory B-cells from malaria-naive volunteers undergoing CPS-immunization, 
recognize the C-terminal of Plasmodium falciparum CSP, highlighting the rarity of P. falciparum CSP C-terminal 
reactive B-cells. These C-terminal reactive monoclonal antibodies have shown to poorly recognize sporozoites 
and weakly inhibit sporozoite infectivity in vitro and in vivo (154). Of note, these volunteers received 
intravenous injection of non-irradiated, cryopreserved sporozoites while taking chloroquine prophylaxis and 
hence, the outcome might be different from CPS immunization trials with live sporozoites delivered by 
mosquito bites. Nevertheless, CPS-immunization induces malaria-specific antibodies that mediate strong 
neutralization of liver-stage infection in vitro and in vivo (52). In Chapters 5 and 6, we investigated for the first 
time the functional importance of CSP-specific antibodies in CPS-induced antibody-mediated immunity. It was 
shown that CSP-depleted antibodies are still capable of complement activation in vitro and inhibiting 
homologous liver-stage infection in an FRG humanized mouse model in vivo. These data suggest that in 
addition to CSP, a range of other antigens might play a role in complement activation and preventing 
homologous liver-stage infection. Additionally, CSP-depleted antibodies preferentially recognize the periphery 
of intra-hepatic parasites in day 5 FRG-infected liver sections, as shown by immunofluorescence staining, 
implying that antigens expressed on infected hepatocytes or the parasite parasitophorous vacuole membrane 
(PVM) are immunogenic and may be important as well. Moreover, it was discovered that components of the 
sporozoite inner membrane complex appear to be exposed on the sporozoite surface and accessible to 
antibodies, suggesting that these proteins may also be considered for vaccine candidate antigen selection for 
clinical vaccine development (93). The importance of liver-stage parasites for the induction of CPS-induced 
protective immunity is supported by previous data where primaquine treatment concurrent with 
sporozoite/chloroquine immunization abrogated protection in a rodent model of malaria (155).  
 
Taken together, these data suggest that CPS-induced pre-erythrocytic antibody responses are not solely 
mediated by CSP and most likely rely on recognition of a range of pre-erythrocytic antigens (156). Indeed, 
previous studies confirm that protected CPS-immunized volunteers exhibited a broad and diverse antibody 
response to a relatively large repertoire of P. falciparum antigens, such as schizont egress antigen-1 (SEA-1), 
thrombospondin-related adhesive protein (TRAP), merozoite apical erythrocyte-binding ligand (MAEBL) and 
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LSA-1 (83, 157). As expected, malaria antigen-specific antibody titers decline in the absence of parasite 
exposure between the last CPS-immunization and challenge infection (38). Of note, high titers of the total pool 
of antibodies directed against a specific antigen may not be per se required for protection or functionally 
relevant. It could be that only high affinity antibodies are functionally active. Indeed, previous data showed 
that the magnitude of individual or combined humoral responses to CSP, LSA-1, apical membrane antigen-1 
(AMA-1) and merozoite surface protein-1 (MSP-1) does not predict protection from mosquito bite challenge 
infection, but rather reflects parasite exposure during CPS-immunizations (38). Recently, plasma samples from 
38 CPS-immunized volunteers were probed on a P. falciparum proteome microarray containing 7455 full-length 
or segmented protein features, representing 4805 P. falciparum genes and covering about 91% of the total P. 
falciparum proteome. Protein microarray analysis identified 548 reactive antigens representing 483 unique 
proteins (Obiero et al, unpublished). Differences in antibody profiles between protected and unprotected CPS-
immunized volunteers identified antigens associated with susceptibility to infection and CPS-induced protective 
immunity. Likewise for RAS-induced sterile protection, a panel of six novel P. falciparum antigens rather than 
one single antigen is associated with CPS-induced protection (Obiero et al, unpublished). Of note, while the 
well-known classical antigens CSP and LSA-1 are highly seroprevalent in CPS-immunized volunteers, they were 
neither individually nor in combination associated with protection or susceptibility to infection (Obiero et al, 
unpublished), supporting previous findings that individual or combined humoral responses to CSP and LSA-1 do 
not predict protection from malaria infection (38). While CPS-induced antibodies recognize various P. 
falciparum antigens, however, it is currently unknown which other antigenic targets are relevant for functional 
antibody activity.  
 
One way is to investigate the importance of already known antigens other than CSP for functional CPS-induced 
antibody-mediated activity by depleting antibodies to predefined antigenic targets. CPS-immunized individuals 
have shown to generate antibodies against several P. falciparum antigens (157) (Obiero et al, unpublished). 
Plasmodium falciparum MAEBL, TRAP and SEA-1 antigens are recognized by most protected CPS-immunized 
volunteers (83). Total plasma from CPS-immunized volunteers could be depleted from antibodies specific for 
e.g. MAEBL, TRAP or SEA-1 using affinity columns and the functional inhibitory activity of depleted antibodies 
on liver-stage infection in vitro and in vivo can be characterized. A major disadvantage of this approach is that 
the specificity of antibodies needs to be known beforehand, while their functional relevance is not yet known. 
Moreover, antigen-specific affinity columns require to be set up, optimized and validated for each individual 
protein to be investigated by this approach. Additionally, correct folding and post-translational modification of 
the recombinant proteins has to be ensured to be able to truly deplete all relevant antibodies with this 
specificity. Depletion efficacy can determined by e.g. enzyme-linked immunosorbent assays. 
 
Another approach is to investigate the memory B-cell pool instead of circulating antibodies. Following each 
immunization or infection, antibodies in the circulation are produced by short-lived plasmablasts: only a few of 
these plasmablasts become long-lived, mature plasma cells that may survive for decades in survival niches in 
the bone marrow and secrete low-level specific antibodies for extended periods of time (158, 159). In contrast 
to these individual, mature plasma cells in the bone marrow, memory B-cells can be easily isolated from blood. 
They are known to persist for a lifetime and are important for generating an antibody response by proliferating 
and differentiating into antibody-secreting cells upon re-exposure to a target antigen (160, 161). By isolating 
individual clones of memory B-cells with their own unique B-cell receptors (BCRs) based on their recognition of 
a given malaria antigen, one can test a unique antibody clone for their specificity and subsequently screen 
them for any functional activity against malaria sporozoites. However, another more attractive approach would 
be to first screen antibodies produced by memory B-cells for anti-sporozoite functionality and subsequently 
characterize the antibody specificities of these functional antibodies. While laborious isolation of all memory B-
cells, including non-malaria-specific ones, is required for this approach, an advantage of this approach is that 
the antigenic targets of antibodies are not required to be known upfront. Of note, since total serum contains so 
many different CPS-induced antibody specificities and cannot be controlled for the amount of different 
antibodies, it is not possible to use serum. One memory B-cell can produce one specific antibody (162). Ideally, 
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only one memory B-cell would be stimulated and cultured in each well, allowing to directly link functional anti-
sporozoite inhibitory activity to antigen recognition. However, in this specific case, about 5,000-15,000 memory 
B-cells per volunteer should be stimulated, cultured and tested for functional activity, which is impractical. 
Nevertheless, it is necessary to have a low number of CPS-induced antibody specificities per sample for this 
approach. A specified number of memory B-cells could be stimulated in culture, allowing us to look at patterns 
of functional antibody data and antigens recognized by these antibodies. Taking into account that antigens with 
a common specificity have a frequency of 1:1,000 up to 1:10,000 IgG-positive memory B-cells (38), the number 
of B-cells per condition should be lower than that. In a pilot series of experiments to trial the latter approach, 
we have set up and optimized short-term (14-day) B-cell stimulation protocols with varying concentrations of 
purified IgG-positive memory B-cells from CPS-immunized volunteers in the presence or absence of feeder cells 
or different cytokine stimuli. Previous experiments using a monoclonal anti-CSP antibody have shown that an 
IgG concentration for a given antigen in the range of 0.5-1.0 ug/ml is sufficient enough to inhibit in vitro 
hepatocyte traversal by sporozoites (Behet et al, unpublished). Therefore, various attempts were made to 
enhance IgG production of B-cells, such as duration of culture, addition of fresh cytokines and time point of 
harvesting supernatants. IgG concentrations and CSP-specific antibody titers in the generated supernatants 
were determined by ELISAs. CSP-specific antibodies were included as a positive control for inhibition of 
sporozoite traversal in vitro and protein microarray analysis. Antibodies capable of inhibiting sporozoite 
traversal in vitro were subsequently subjected to microarray analysis to determine the antigen-specificity of 
these functionally active antibodies. Integrated analysis of traversal inhibition and protein microarray data 
suggest that certain antigens are associated with inhibition of in vitro sporozoite infectivity (Behet, Obiero and 
Borgers et al, unpublished)y. However, these preliminary, unpublished data definitely need further validation 
before final conclusions can be drawn, since supernatants containing CSP-specific antibodies that served as our 
positive control did not always inhibit in vitro hepatocyte traversal by sporozoites or were not always 
recognized by protein microarray analysis. This is most likely due to the fact that the IgG concentrations in our 
supernatants were well below the relevant concentration as established for a known inhibitory monoclonal 
antibody and for protein microarray analysis (Behet and Borgers et al, unpublished). This problem could be 
solved by extensive expansion of the individual B-cell clones and thus, resulting in extended antibody 
production, allowing us to achieve sufficient high IgG concentrations for selection of malaria antigen-specific B-
cell clones on basis of the functional activities of secreted antibodies, e.g. by screening for neutralization of in 
vitro sporozoite infectivity. To gain larger concentrations of the individual antibodies, memory B-cells may be 
immortalized by a variety of approaches, such as Epstein-Barr virus (EBV) transformation (163) or CD40 ligand 
stimulation of the CD40 receptor in the presence of cytokines (164, 165). Limitations of these approaches are 
the low frequency of efficient immortalization and limited proliferative activity of CD40L-stimulated B-cells, 
most likely due to the transition of memory B-cells to terminally differentiated plasmablasts. However, memory 
B-cells can also be immortalized by means of genetic modification by forced expression of Bcl-6 and Bcl-xL into 
B-cells. Transduction of Bcl-6 and Bcl-xL into memory B-cells has shown to result in the generation of highly 
stable immortalized human B-cell lines (166). Advantages of immortalized human B-cell receptor-positive and 
antibody-secreting B-cell lines are rapid proliferation, expression of surface immunoglobulin, prolonged 
survival and antibody production (166, 167). Antibodies secreted by immortalized memory B-cells could then 
be screened for neutralization of hepatocyte invasion and subsequently subjected to protein microarray 
analysis to determine the antigen-specificity of neutralizing CPS-induced antibodies. 
  
Of note, clonal selection has recently shown to be important for protective memory B-cell responses in 
Plasmodium malaria infection (168). Next to the identification of functional antibody antigenic targets, high-
throughput and full-length sequencing of heavy and light chains expressed by individual malaria antigen-
specific memory B-cells could be pursued, allowing comprehensive characterization of functional antibody 
repertoires and antigen-specific B-cell receptor sequences (169). Antibody repertoire diversity and plasticity is 
important for diverse, protective immunity.  Knowledge of the antibody repertoire diversity and B-cell receptor 
repertoire will give us insights into anti-malarial adaptive immune responses and enhance our understanding of 
the complex mechanisms underlying the induction and maturation of adaptive B-cell immune responses 
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towards Plasmodium parasites. Additionally, it would improve our understanding of human anti-parasite 
antibody repertoires that are evoked by natural infection or vaccination and the specific clones responsible for 
protective anti-malarial immunity, further guiding the development and improvement of malaria vaccines 
(170). 
 
Plasmodium parasite and human genetic diversity and their implications for vaccine development 
For future clinical vaccine development, antigenic targets of both (functional) humoral and cellular immune 
responses require to be identified. However, anti-malarial vaccine development is impacted by two genetic 
restrictions: the great genetic diversity of Plasmodium falciparum parasite strains in the field and human 
genetic diversity. Parasite genetic diversity may be a major hurdle in the identification of immunogenic 
antigens. Co-infection with multiple species occur in the field (171), which may impact the efficiency of immune 
responses induced towards one or more of these Plasmodium species. Data in the present thesis show that 
functional antibody-mediated immunity induced to one strain is not necessarily as efficient against another 
strain, most likely due to genetic differences in parasite antigens targeted by these antibodies (Chapter 4). The 
extreme genetic diversity of Plasmodium parasites makes it hard to identify those immunogenic antigens that 
can induce protection against a broad range of parasite clones, since this will be restricted to antigens that are 
relatively conserved across parasite strains, leaving only a few suitable candidate antigens for clinical vaccine 
development. Conserved malaria antigens are often less immunogenic than highly polymorphic antigens, 
although they have shown to induce strong immune responses in Ghanaian children (172). Besides, most 
candidate antigens have been based on laboratory parasite strains that have been in culture for a long period 
of time, while it is important to select antigenic variants that best represent strains circulating in natural 
parasite populations (173). Further characterization of the genetic diversity of immune epitopes of Plasmodium 
candidate vaccine antigens by whole genome sequencing is important. Next to Plasmodium genetic diversity, 
human genetic diversity may also impact the efficacy of vaccination. Human leukocyte antigen (HLA) 
polymorphism in the human population causes differences in recognition of epitopes and the induction of 
immune responses amongst individuals: only a small fraction of the human population may induce an effective 
immune response upon recognition of one single epitope. Parellel sequencing of full-length BCR sequences 
reveals that shaping of the peripheral BCR repertoire is HLA-dependent in healthy individuals, and most likely 
mediated by T-cell mediated recognition of BCR peptides (174). 
 
Together, these genetic restrictions in both parasites and humans suggest that an effective pre-erythrocytic 
subunit vaccine requires the inclusion of multiple immunogenic sporozoite and liver-stage antigens from 
different Plasmodium parasite strains, thereby increasing the induction and acquisition of effective strain-
transcending pre-erythrocytic immune responses and protection following exposure to different parasite 
clones. Additionally, it would be beneficial to include antigens that will be boosted by natural exposure to 
Plasmodium falciparum as well.  
 
Correlates of protection to Plasmodium falciparum malaria pre-erythrocytic stages 
So far, it has been difficult to identify correlates of protection to Plasmodium falciparum malaria pre-
erythrocytic stages. Both cellular and humoral immune responses are known to play a role in anti-malarial 
immunity. Cytotoxic CD8+ T-cells recognize and eliminate infected human hepatocytes (175), while CD4+ T-cells 
support the induction and maintenance of B- and CD8+ T-cell responses and might contribute to cytotoxic 
killing responses as well (15, 176). T-cell support to B-cells is an important aspect of adaptive immunity and the 
induction of immunological memory. B-cells interact with follicular CD4+ T helper cells that reside in secondary 
lymphoid organs, and support B-cell activation, affinity maturation and differentiation into high affinity 
antibody-producing plasma cells and memory B-cells (136, 177-184).  
 
The contribution of cellular and humoral immune responses to anti-malarial protection will likely differ per 
individual, for instance in the case of CPS-immunized volunteers: some individuals tend to be high functional 
antibody responders (Chapters 3-5), while others may rely more on the presence of cellular immune responses, 
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or a combination of both ((15) and Chapter 4). To further explore this, correlation analyses between functional 
antibody data and cellular T-cell subsets induced by CPS-immunization were conducted to determine whether 
low functional antibody responders might potentially be strong T-cell responders. However, analysis of 
unpublished in vitro traversal inhibition data and cellular readout data from 16 CPS-immunized volunteers (15) 
did not show associations between CPS-induced antibodies that are functionally active against sporozoite 
traversal and specific T-cell subsets, such as CD4+ and CD8+ T-cells expressing  CD107a, IFN-ƴ or granzyme B 
markers (Behet et al, unpublished; Figure 1). Similarly, no associations were found between invasion inhibitory 
antibodies in the presence or absence of active complement, and CPS-induced T-cell subsets (as described in 
Chapters 4 and 5), including CD4+, CD8+, natural killer (NK), natural killer T-cells (NKT) or ƴδ T-cells, expressing 
CD107a, granzyme B or IFN-ƴ. Taken together, there are no associations between the induction of functional 
antibody reactivity and the presence of specific T-cell subsets, suggesting that individuals differ in the 
acquisition of anti-malarial immune responses (Behet et al, unpublished; Figure 1).  
 
Likewise for antigen recognition, some protected CPS-immunized individuals recognize a broad range of 
antigens, while others only recognize a few antigens. Importantly, CPS-induced protective efficacy could be 
predicted with 83% sensitivity and 88% specificity in immunized individuals (Obiero et al, unpublished). The 
observed variations in functional antibody responses and antigen recognition by CPS-immunized volunteers 
support the hypothesis that individuals may differ in the acquisition and maintenance of humoral immune 
responses. A full-scale integrated analysis of cellular and humoral immune responses, both on the level of 
antigen recognition and functionality, might help further unraveling the markers that are most predictive of 
protective or rapid immune acquisition and provide potential immune correlates of sterile protection at group 
level. Remaining questions are why some individuals are protected from homologous and heterologous malaria 
sporozoite infection and how it comes that some individuals are already protected after only one single CPS-
immunization while others require more immunizations to achieve sterile protection from malaria challenge 
infection. Possible reasons for these differences could not only be at the level of antibody responses (e.g. 
antibody isotype, affinity or functionality), but also at the level of antigen-presenting cells (e.g. dendritic cells), 
regulatory T-cells, innate immune cells (e.g. platelet aggregation, NK-cells, monocytes) or T-cell mediated 
immune responses. 
 
Conclusions and future perspectives  
The work in this thesis contributes to an improved understanding of functional pre-erythrocytic humoral 
immune responses induced by whole sporozoite immunization under chemoprophylaxis and natural exposure 
to Plasmodium falciparum malaria sporozoites. We show that despite low antibody titers, individuals living in 
malaria-endemic areas acquire sporozoite-specific antibodies that are capable of neutralizing sporozoite 
infectivity in vitro. Additionally, CPS-immunization induces functional antibodies that are capable of 
neutralizing homologous and heterologous sporozoite infectivity in vitro. These antibodies interact with the 
complement system and can further reduce homologous and heterologous sporozoite infectivity in vitro.  
Interestingly, we show that the complement system plays a crucial role in further inhibiting sporozoite 
infectivity when antibodies are less efficient in neutralization, e.g. due to genetic differences between 
Plasmodium falciparum species. Taken together, the findings of this thesis suggest that multiple antibody-
mediated mechanisms likely contribute to protective pre-erythrocytic immunity, and it will be important to 
focus future research on the identification of pre-erythrocytic antigenic targets of functional antibodies, 
exploration of other antibody-mediated mechanisms such as ADCC or phagocytosis, and the identification of 
immune signatures of humoral protection. Exploration of these future research lines will provide new 
knowledge that is essential for the development of a more effective malaria vaccine. 
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Figure 1. Correlation analysis of functional anti-sporozoite inhibitory antibodies and the presence of cellular T-cell 
subsets after completed CPS-immunization. 
Correlation analysis for the percentage of (A) CD4+CD107a+ or (B) CD4+IFN-y+ T-cells and in vitro  traversal inhibition by CPS-
induced antibodies in the absence of active complement was conducted with samples from 16 CPS-immunized volunteers. 
Additionally, correlation analyses of in vitro invasion inhibition by CPS-induced antibodies in the absence and presence of 
active complement with the percentage of (C; D) CD4+CD107a+ or (E; F) CD4+IFN-y+ T-cells is shown for 16 CPS-immunized 
volunteers. Correlation analyses were conducted with Spearman correlation analysis (Spearman r: Spearman’s rank 
correlation coefficient). A p-value of <0.05 was considered statistically significant. 
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Summary 
 
Malaria remains one of the most common and severe infectious diseases worldwide with more than 3 billion 
people at risk. Roughly 200 million clinical cases and nearly half a million deaths annually are attributed to 
malaria. The disease is a mosquito-borne infectious disease and caused by Plasmodium parasites, with 
Plasmodium falciparum being the deadliest species. When P. falciparum sporozoites are deposited in the 
human skin via bites of infected female Anopheles mosquitoes, sporozoites enter the blood circulation and 
subsequently travel to the liver, where they migrate through hepatocytes before invading a final hepatocyte. 
After a maturation and replication step of approximately seven days, thousands of merozoites are released in 
the blood, followed by invasion and replication inside red blood cells. The blood-stage cycle is responsible for 
the clinical symptoms of malaria, such as fever, headache, fatigue and myalgia. More advanced complications 
caused by malaria infection include neurological deficits, cerebral malaria, organ failure, which may ultimately 
lead to death.  
 
A significant decrease in malaria mortality rates has been observed in the last decades amongst others due to 
widespread use of artemisinin-based combination treatments, indoor residual spraying, increasing availability 
and use of insecticide-treated bed nets. However, the emergence of drug-resistant parasites and insecticide-
resistant mosquitoes are threatening malaria control efforts, underscoring the need for a highly effective 
vaccine. A major stumble block for the development of an effective anti-malarial vaccine is our incomplete 
understanding of protective immune responses to malaria. This thesis aims to address the role of functional 
antibodies in protective antibody-mediated immunity against P. falciparum malaria sporozoites and liver-stage 
parasites. To this end, we use a controlled human malaria infection model: healthy human individuals are 
inoculated with malaria sporozoites by exposure to P. falciparum NF54-infected mosquito bites while receiving 
chloroquine prophylaxis (ChemoProphylaxis and Sporozoites immunization regimen). This immunization 
regimen has shown to induce long-lasting and sterile protection against a homologous challenge infection in 
controlled settings. CPS-induced protective immunity is mediated by immune responses targeting sporozoites 
and liver-stage parasites rather than blood-stage parasites. This model is therefore an invaluable tool to 
systematically delineate functional effector mechanisms of antibodies targeting Plasmodium sporozoites and 
liver-stage parasites. Additionally, we use samples from schoolchildren from Burkina Faso who are naturally 
exposed to Plasmodium infection(s) to characterize the acquisition of (functional) antibodies against 
sporozoites and liver-stage parasites in malaria-endemic settings. 
 
In Chapter 2, we describe an optimized flow cytometry-based human hepatocyte traversal assay to assess the 
inhibitory effect of antibodies to interfere with Plasmodium sporozoite traversal. Different parameters were 
tested to improve this assay. We observe that traversal efficiency of Plasmodium falciparum sporozoites 
depends on the host hepatocyte cell line used, with higher P. falciparum traversal rates for the HC-04 cell line 
which is permissive for Plasmodium falciparum sporozoites, hereby further confirming the high selectivity of 
this parasite species for its host cell. This improved version of the traversal assay has shown to be highly 
reliable, simple and it is a quick read-out to characterize the functional activity of antibodies on Plasmodium 
sporozoite traversal. 
 
This flow-cytometry-based approach has been further explored in Chapter 3, where CPS-induced antibodies 
from protected volunteers efficiently neutralize homologous P. falciparum NF54 sporozoite traversal in vitro. 
This neutralizing effect has shown to be dose-dependent with higher neutralizing efficiency of sporozoite 
traversal in the presence of 10 mg/ml than 1 mg/ml IgG antibodies. Physiological IgG levels in the human host 
are normally about 5-15 mg per milliliter blood and therefore, it is very likely that 1-2 mg/ml IgG is below the 
threshold that is required for functional antibody activity. This might also explain why neutralization of 
sporozoite gliding motility in the presence of 2 mg/ml IgG CPS-induced antibodies could only be observed in a 
very limited number of volunteers. Additionally, we show that CPS immunization-induced antibodies have a 
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much stronger inhibitory effect on in vivo liver-stage infection in passively immunized liver-chimeric mice, 
compared to in vitro sporozoite infectivity assays. This may be explained by antibodies immobilizing 
sporozoites in the skin or interfering with gliding motility, migration or invasion of human hepatocytes, 
however, they may also potentially interact with human complement proteins to further enhance the 
inhibitory effect on sporozoite infectivity. 
 
Given the large genetic diversity of Plasmodium falciparum parasites, it is essential to know whether protection 
against heterologous parasite strains can be achieved. In Chapter 4, we explore whether the CPS-immunization 
regimen can induce cross-species protection following a primary challenge infection with two geographically 
and genetically distinct P. falciparum parasite strains. We observe that NF54 CPS-immunization induces sterile 
protection against a homologous NF54 challenge infection, but only modest protection against NF135.C10 and 
NF166.C8 challenge infection. We further dissect CPS-induced antibody-mediated immune responses against 
homologous and heterologous sporozoite invasion of primary human hepatocytes, and find that CPS-induced 
antibodies are less efficient in inhibiting heterologous sporozoite infectivity in vitro.  
 
In Chapter 5, we further investigate whether there are any differences in recognition, neutralization and 
complement activation of homologous NF54 and heterologous NF135.C10 sporozoites by CPS-induced 
antibodies. CPS-immunization induces sporozoite-recognizing IgM and IgG antibodies with complement-fixing 
activity. Homologous NF54 sporozoite lysis, traversal and invasion inhibition by CPS-induced antibodies are 
enhanced in the presence of active complement. Although IgM binding to heterologous NF135.C10 sporozoites 
is reduced, CPS-induced antibodies similarly fix complement, lyse sporozoites and reduce heterologous 
sporozoite infectivity in vitro in the presence of active complement. Taken together, we demonstrate that CPS-
induced antibodies further enhance functional inhibition of in vitro homologous and heterologous sporozoite 
infectivity in the presence of active complement. This highlights the importance of the complement system as 
an additional immune effector mechanism in whole parasite immunization-induced anti-malarial immunity. 
 
Plasmodium falciparum circumsporozoite protein (CSP) is a major sporozoite surface protein and the basis of 
the most advanced subunit vaccine candidate to date, the RTS,S subunit vaccine (Mosquirix, GlaxoSmithKline). 
However, phase III clinical trials with the RTS,S subunit vaccine have only provided partial, rapidly waning 
protection against clinical disease in individuals in malaria-endemic areas. Identification of immunological 
antigenic targets other than CSP that are capable of preventing liver-stage infection and induce sterile 
protection against malaria, is required for the development of a more effective malaria vaccine. CPS-induced 
antibodies recognize a broad array of sporozoite and liver-stage antigens, and antigens other than CSP might 
play a role in CPS-induced immunity. In Chapter 6, we use the CPS model as a tool to investigate whether non-
CSP-specific antibodies can potentially prevent liver-stage infection in vitro and in vivo in a humanized mouse 
model. We find that antibodies in the absence of CSP-specific antibodies are still able to inhibit liver-stage 
infection in vivo, and recognize sporozoites and liver-stage parasites. These data argue for further identification 
of novel sporozoite and liver-stage proteins as potential vaccine candidate antigens. 
 
In Chapter 7, we investigate whether malaria-exposed schoolchildren from Burkina Faso can acquire 
(functional) antibody-mediated responses towards Plasmodium sporozoites. We find that naturally acquired 
antibodies significantly reduce in vitro sporozoite gliding motility and invasion in human hepatocytes, despite 
low antibody titers to pre-erythrocytic antigens, relative to asexual blood-stage lysate. Children with high anti-
CSP antibody levels and functional gliding inhibitory activity develop Plasmodium infection later compared to 
children with lower anti-CSP antibody levels and less efficient functional antibodies. In conclusion, we show 
that malaria-exposed schoolchildren acquire functional anti-sporozoite antibody responses, that likely also 
influence infection risk in malaria-endemic areas. 
 
In Chapter 8, we further explore the contribution of the complement system to naturally acquired antibody-
mediated immunity targeting Plasmodium sporozoites. We find that antibodies recognizing CSP are 
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predominantly IgG1, IgG3 and IgM, and interact with complement proteins via C1q recruitment and activation 
of the antibody-dependent classical pathway. Additionally, we demonstrate that naturally acquired antibodies 
fix complement on P. falciparum sporozoites and further enhance in vitro hepatocyte traversal inhibition and 
sporozoite death in the presence of active complement. We show that the acquisition of complement-fixing 
antibodies in malaria-exposed populations is age-dependent, and that high levels of complement-fixing 
antibodies are associated with a reduced risk of clinical malaria. These data further confirm the importance of 
the complement system as an additional immune effector mechanism in naturally acquired antibody-mediated 
anti-malarial immunity targeting Plasmodium sporozoites. 
 
In conclusion, this thesis improves our understanding of functional anti-sporozoite antibody-mediated immune 
responses induced by whole parasite immunization under chemoprophylaxis or natural exposure to 
Plasmodium malaria sporozoites. We show that immunization-induced and naturally acquired antibodies 
recognize sporozoites and are capable of reducing Plasmodium sporozoite infectivity and/or liver-stage 
infection. These antibodies interact with the complement system and further reduce in vitro sporozoite 
infectivity in the presence of active complement. Multiple antibody-mediated mechanisms likely contribute to 
protective anti-malarial immunity targeting sporozoites and liver-stage parasites. Further exploration of other 
antibody-mediated immune effector mechanisms, identification of sporozoite/liver-stage antigenic targets of 
functional antibodies and immune signatures of humoral protection will be essential for future research and 
provide new knowledge that is essential for the development of a more effective malaria vaccine. 
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Samenvatting 
 
Malaria is wereldwijd een van de meest voorkomende en ernstige infectieziekten. Meer dan 3 biljoen mensen 
lopen risico op het krijgen van malaria. Malaria veroorzaakt jaarlijks 200 miljoen klinische gevallen en bijna een 
half miljoen sterfgevallen. Deze infectieziekte wordt overdragen door muggen en veroorzaakt door 
Plasmodium parasieten, waarvan Plasmodium falciparum de dodelijkste variant is. Wanneer Plasmodium 
falciparum sporozoieten in de huid van een mens worden geïnjecteerd via muggenbeten van geïnfecteerde 
Anopheles vrouwtjesmuggen, verplaatsen de sporozoieten zich via de bloedbaan naar de lever. In de lever 
migreren ze door diverse levercellen, voordat ze uiteindelijk een levercel infecteren. Wanneer de 
malariaparasiet zich vermenigvuldigd heeft in de lever, komen er duizenden merozoieten in de bloedbaan 
terecht. Deze merozoieten infecteren en vermenigvuldigen zich in rode bloedcellen. Het bloedstadium van 
malaria is verantwoordelijk voor de klinische symptomen van malaria, zoals koorts, hoofdpijn, moeheid en 
spierpijn. Verder gevorderde complicaties die door malaria infectie veroorzaakt worden, zijn neurologische 
afwijkingen, cerebrale malaria, orgaan falen, wat uiteindelijk tot de dood kan leiden. 
 
De laatste decennia is er een significante afname van malaria mortaliteit te zien, onder andere door het 
wijdverspreid gebruik van combinatie behandelingen met het medicijn artemisinine, het binnenshuis sprayen 
met insecticiden, en een toename in de beschikbaarheid van en het gebruik van klamboes die geïmpregneerd 
zijn met insecticiden. Echter, de pogingen om malaria-infectie onder controle te houden worden ondermijnd 
door de opkomst van resistentie van parasieten tegen medicatie en muggen tegen insecticiden. Dit benadrukt 
de behoefte aan een efficiënt malariavaccin. Een groot struikelblok voor de ontwikkeling van een effectief 
malariavaccin is ons beperkte begrip van afweermechanismen die beschermen tegen malaria-infectie. Dit 
proefschrift streeft ernaar om de rol van functionele antilichamen in beschermende antilichaam-gemedieerde 
immuniteit tegen Plasmodium falciparum malaria sporozoieten en leverstadium parasieten te bestuderen. 
Hiervoor gebruiken we een gecontroleerde humane malaria infectie model: gezonde mensen worden 
geïnfecteerd met malaria sporozoieten door blootstelling aan Plasmodium falciparum NF54-geïnfecteerde 
muggenbeten, terwijl de mensen chloroquine profylaxe innemen (ChemoProfylaxe en Sporozoieten 
immunisatie regime). Dit immunisatie regime zorgt voor langdurige en steriele bescherming tegen een 
homologe NF54 infectie, onder gecontroleerde omstandigheden. CPS-geïnduceerde bescherming wordt 
voornamelijk gemedieerd door afweerreacties tegen sporozoieten en leverstadium parasieten. Dit CPS model is 
daarom een waardevol middel om systematisch de functionele immuun effectormechanismen van 
antilichamen tegen Plasmodium sporozoieten en leverstadium parasieten te kunnen uitzoeken. Daarnaast 
gebruiken we samples van kinderen uit Burkina Faso die op natuurlijke wijze worden blootgesteld aan 
Plasmodium infectie(s) om de acquisitie van (functionele) antilichamen tegen sporozoieten en leverstadium 
parasieten in malaria-endemische gebieden te bestuderen. 
 
In Hoofdstuk 2 beschrijven we een geoptimaliseerde flow cytometrie-gebaseerde humane levercel traversal 
assay om het remmende effect van antilichamen op Plasmodium sporozoieten migratie te meten. 
Verschillende parameters zijn getest om deze assay te verbeteren. We zien dat de migratie efficiëntie van 
Plasmodium falciparum sporozoieten afhankelijk is van de lever cellijn die gebruikt wordt voor de assay. De 
migratie door levercellen is efficiënter in de HC-04 lever cellijn, een cellijn die toegankelijk is voor Plasmodium 
falciparum sporozoieten. Dit bevestigt de hoge selectiviteit van deze parasieten voor zijn gastheer cel. Deze 
geoptimaliseerde versie van de migratie assay is betrouwbaar, simpel en de functionele activiteit van 
antilichamen op de migratie van Plasmodium sporozoieten kan snel worden uitgelezen. 
 
Deze flow cytometrie-gebaseerde aanpak is verder onderzocht in Hoofdstuk 3, waarin we laten zien dat 
homologe P. falciparum NF54 migratie door levercellen efficiënt kan worden geneutraliseerd door CPS-
geïnduceerde antilichamen van beschermde vrijwilligers. Dit neutraliserende effect is dosis-afhankelijk, met 
hogere neutraliserende efficiëntie van sporozoieten migratie in de aanwezigheid van 10 mg/ml dan 1 mg/ml 
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IgG antilichamen. Fysiologische IgG antilichaam niveaus in de mens zijn normaal rond 5-15 mg per milliliter 
bloed en daarom is het goed mogelijk dat 1-2 mg/ml IgG onder het niveau komt dat nodig is voor functionele 
antilichaam activiteit. Dit kan ook verklaren waarom neutralisatie van de motiliteit van sporozoieten in de 
aanwezigheid van 2 mg/ml IgG antilichamen alleen geobserveerd is in een erg klein aantal vrijwilligers. 
Daarnaast laten we zien dat CPS-geïnduceerde antilichamen een veel sterker remmend effect hebben op in 
vivo leverstadium infectie in passief geïmmuniseerde gehumaniseerde muizen, vergeleken met hun effect op in 
vitro  sporozoiet infectiviteit assays. Dit veel sterkere effect kan verklaard worden doordat antilichamen 
sporozoieten in de huid immobiliseren, interfereren met gliding motiliteit, migratie of invasie van levercellen. 
Het is echter ook mogelijk dat antilichamen samenwerken met humane complement eiwitten en zo het 
remmende effect van antilichamen op de infectiviteit van sporozoieten verder versterken.  
 
Gezien de grote genetische diversiteit van Plasmodium falciparum parasieten is het essentieel om te weten of 
er bescherming tegen andere, heterologe parasietenstammen bereikt kan worden. In Hoofdstuk 4 
onderzoeken we of het CPS-immunisatie regime ook bescherming geeft tegen infectie met twee geografisch en 
genetisch verschillende Plasmodium falciparum parasietenstammen. We observeren dat NF54 CPS-
immunisatie steriele- en complete bescherming induceert tegen een homologe NF54 infectie, maar echter 
alleen beperkte bescherming tegen infectie met de heterologe NF135.C10 en NF166.C8 parasietenstammen. 
We kijken tevens naar het effect van CPS-geïnduceerde antilichaamresponsen op invasie van levercellen door 
homologe en heterologe sporozoieten en vinden dat CPS-geïnduceerde antilichamen minder efficiënt zijn in 
het afremmen van de invasie van levercellen door heterologe sporozoieten. 
 
In Hoofdstuk 5 onderzoeken we of er mogelijke verschillen zijn in de herkenning, neutralisatie en complement 
activatie van homologe NF54 en heterologe NF135.C10 sporozoieten door CPS-geïnduceerde antilichamen. We 
vinden dat CPS-immunisatie sporozoieten-specifieke IgM en IgM antilichamen induceert, welke complement 
kunnen activeren. CPS-geïnduceerde antilichamen zijn beter in staat om homologe sporozoieten te lyseren en 
migratie en invasie van levercellen af te remmen in de aanwezigheid van actieve complement eiwitten. 
Ondanks dat heterologe NF135.C10 sporozoieten minder herkend worden door IgM antilichamen, zijn CPS-
geïnduceerde antilichamen nog steeds in staat om complement te activeren, sporozoieten te lyseren en de 
infectiviteit van heterologe sporozoieten af te remmen in de aanwezigheid van actief complement. In 
conclusie, we tonen aan dat functionele afremming van in vitro homologe en heterologe sporozoieten 
infectiviteit door CPS-geïnduceerde antilichamen verder versterkt wordt in de aanwezigheid van actief 
complement  
 
Plasmodium falciparum circumsporozoite protein (CSP) is een belangrijk eiwit dat het oppervlak van de 
sporozoite bedekt. CSP is de basis van de meest geadvanceerde subunit kandidaatvaccin tot dusver, het RTS,S 
subunit vaccin (Mosquirix, GlaxoSmithKline). Fase 3 klinische trials met het RTS,S subunit vaccin zorgen echter 
voor beperkte, snel verdwijnende bescherming tegen klinische ziekte in mensen die in malaria-endemische 
gebieden leven. Voor de ontwikkeling van een efficiënter malariavaccin is het van belang dat er andere 
immunologische antigen doelwitten dan CSP worden geïdentificeerd, welke in staat zijn om leverstadium 
infectie te voorkomen en complete bescherming tegen malaria te induceren. CPS-geïnduceerde antilichamen 
herkennen diverse sporozoieten en leverstadium antigenen; andere antigenen dan CSP zouden een rol kunnen 
spelen in CPS-geïnduceerde bescherming. In Hoofdstuk 6 gebruiken we het CPS model als een middel om te 
onderzoeken of niet-CSP-specifieke antilichamen mogelijk leverinfectie in vitro en in vivo in een gehumaniseerd 
muismodel kunnen voorkomen. We vinden dat antilichamen in de afwezigheid van CSP-specifieke antilichamen 
nog steeds in staat zijn om leverinfectie in vivo af te remmen en dat deze sporozoieten en leverstadium 
parasieten herkennen. Deze uitkomsten pleiten voor verdere identificatie van nieuwe sporozoieten en 
leverstadium eiwitten als mogelijke vaccinkandidaten. 
 
In Hoofdstuk 7 onderzoeken we of kinderen uit Burkina Faso die op natuurlijke wijze aan malaria worden 
blootgesteld, (functionele) antilichaamresponsen kunnen genereren tegen Plasmodium sporozoieten. We 
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vinden dat natuurlijk verkregen antilichamen de in vitro motiliteit van sporozoieten en invasie in humane 
levercellen kan reduceren, ondanks lage antilichaamlevels tegen pre-erythrocytaire antigenen vergeleken met 
aseksueel bloedstadium lysaat. Kinderen met hoge anti-CSP-specifieke antilichaamlevels en functionele 
remming van de motiliteit van sporozoieten, ontwikkelen later Plasmodium infectie vergeleken met kinderen 
die lagere anti-CSP-specifieke antilichaamlevels en minder efficiënte functionele antilichamen hebben. In 
conclusie, we laten zien dat kinderen die aan malaria worden blootgesteld, antilichamen verkrijgen die 
functioneel zijn tegen sporozoieten. Deze antilichamen kunnen mogelijk ook een invloed hebben op het 
infectierisico in malaria-endemische gebieden. 
 
In Hoofdstuk 8 bestuderen we de bijdrage van het complement systeem aan natuurlijk verkregen antilichaam-
gemedieerde immuniteit dat tegen Plasmodium sporozoieten gericht is. We vinden dat CSP-specifieke 
antilichamen hoofdzakelijk IgG1, IgG3 en IgM isotypes zijn, welke in interactie met complement eiwitten de 
antilichaam-afhankelijke klassieke pathway via rekrutie van C1q complement eiwitten. Daarnaast tonen we aan 
dat natuurlijk verworven antilichamen complement op P. falciparum sporozoieten kunnen fixeren. Deze 
natuurlijk verworven antilichamen remmen in de aanwezigheid van actief complement de migratie van 
sporozoieten door levercellen verder af en zijn meer efficiënt in het lyseren van sporozoieten. We laten zien 
dat de acquisitie van complement-fixerende antilichamen leeftijdsafhankelijk is in populaties die natuurlijk 
blootgesteld worden aan malaria. Daarnaast laten we zien dat hoge levels van complement-fixerende 
antilichamen geassocieerd worden met een verminderd risico op klinische malaria. Deze data bevestigen het 
belang van het complement systeem als een extra immuun effectormechanisme in natuurlijk verworden 
antilichaam-gemedieerde immuniteit die gericht is tegen Plasmodium sporozoieten. 
 
Tot slot, dit proefschrift zorgt ervoor dat we meer kennis krijgen over functionele anti-sporozoiet antilichaam-
gemedieerde immuunresponsen die geïnduceerd worden door immunisatie met levende parasieten terwijl 
mensen chemoprophylaxe innemen, of door natuurlijke blootstelling aan Plasmodium malaria sporozoieten. 
We laten zien dat antilichamen die door immunisatie en natuurlijke blootstelling aan malaria gegenereerd 
worden, in staat zijn om sporozoieten te herkennen en de infectiviteit van sporozoieten en/of leverinfectie 
kunnen neutraliseren. Deze antilichamen kunnen de in vitro infectiviteit van sporozoieten verder afremmen in 
de aanwezigheid van actief complement. Meerdere afweermechanismen die gemedieerd worden door 
antilichamen spelen mogelijk een rol in beschermende immuniteit tegen malaria sporozoieten en leverstadium 
parasieten. Het is essentieel om de mogelijke rol van andere antilichaam-gemedieerde immuun 
effectormechanismen te onderzoeken. Daarnaast is het belangrijk om de sporozoiet en leverstadium antigenen 
te identificeren, die worden herkend door functionele antilichamen. Tot slot zal het identificeren van 
immunologische kenmerken van humorale bescherming tegen malaria belangrijk zijn voor toekomstig 
onderzoek. Dit alles tezamen zal nieuwe kennis opleveren die van belang is voor de ontwikkeling van een 
efficiënter malariavaccin.  
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